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ABSTRACT
Although astrocytomas account for 40% of brain tumours in children, little is known about the 
genetics of these paediatric tumours. Indeed, 85% of low-grade (WHO grade I and II) and 50% 
of high-grade (WHO grade III and IV) paediatric astrocytoma have a normal karyotype. The 
aim of this study was to identify non-random genetic aberrations in different grades of 
paediatric astrocytoma at both the genomic and expression levels. Affymetrix genechip 
technology and array comparative genomic hybridisation (aCGH) have been used to generate 
gene expression profiles of 35 paediatric astrocytoma short-term cell cultures of all grades and 
19 pilocytic (PA, grade I) biopsies and identify copy number alterations (CNA) in 32 paediatric 
astrocytoma short-term cell cultures of all grades and 11 pilocytic biopsies.
The PAI biopsy samples have a distinct expression profile compared to normal brain with 1844 
genes being differentially expressed in all samples. The KEGG pathway most influenced by 
these genes is antigen processing and presentation, with the majority of genes being up- 
regulated. Addition pathways altered include PI3K signalling and MAPK signalling. Only 
single clone CNAs were detected in PAI including alterations at Ip36.32-p36.3, 14ql2 and 
22q33.33 which were lost or gained in the majority of samples. The clone at 14ql2 is located in 
a region of large-scale copy number alteration (LCV). Alterations at this site have been linked to 
increased risk of paediatric solid tumour development. No known genes are located within the 
clone site. However, FOXG1B is adjacent to the clone region and is significantly down- 
regulated in PAI compared to normal brain.
Hierarchical clustering of the short-term cultures according to expression profile similarity 
demonstrated that paediatric astrocytoma can be grouped into low and high-grade tumours by 
molecular signature. Furthermore, approximately half of paediatric glioblastoma multiforme 
(GBMIV, grade IV) clustered with 7 adult GBMIV cultures, suggesting that some paediatric 
GBMIV are genotypically similar to those arising in adults. KEGG pathways influenced by 
differential gene expression include Wnt signalling and the cell cycle pathway, with the finding 
that same pathways are being disrupted to varying extents in low and high-grade paediatric 
astrocytoma. The frequency of CNAs was similar to those previously reported, with gain of all 
or part of chromosome 7 as the most common alteration. Correlations between gene expression 
and CNAs were also identified in the short-term cultures.
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PI3K - phosphatidylinositol signalling system
PIP2 - phosphatidylinositol-4,5-diphosphate
PIP3 - phosphatidylinositol-3,4,5 -triphosphate
PXA - pleomorphic xanthoastrocytoma
Q-PCR - quantitative real-time polymerase chain reaction
RNA - ribonucleic acid
RT - radiotherapy
RT-PCR - reverse transcriptase polymerase chain reaction
siRNAs - small interfering RNAs
see - squamous cell carcinomas
SCLC - small cell lung carcinoma
SD - standard deviation
SNP - single nucleotide polymorphism
TAE - IX tris-acetate
uPAR - urokinase plasminogen activator receptor
VEGF - vascular endothelial growth factor
VEGFR - vascular endothelial growth factor receptor
WHO - World Health Organisation
WO - whole ovary
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CHAPTER 1 
INTRODUCTION
The initial goal of this study was to identify differentially expressed genes in different 
grades of malignancy of paediatric astrocytoma. As with the majority of studies, this 
study has evolved to include other aspects of brain tumour research such as the use of 
short-term cell cultures as a tool in the investigation of tumour cells, the use of normal 
controls in microarray experiments, the current and previous World Health Organisation 
(WHO) grading scheme, and chromosome alterations and methylation as mechanisms 
associated with tumour development and differential gene expression. The introduction 
of this thesis will focus on paediatric astrocytoma but where appropriate will refer to 
adult astrocytoma.
Astrocytoma histological classification and clinical parameters
Paediatric and adult astrocytomas are classified by WHO guidelines into four grades of 
malignancy according to histological criteria (Table 1.1). These criteria include nuclear 
atypia (enlarged, cigar-shaped or irregular hyperchromatic nuclei), mitosis, 
microvascular proliferation and/or necrosis. All astrocytomas consist of cells with 
phenotypical characteristics of astrocytes, although the true cell of origin of these 
tumours is unknown (Ichimura et al., 2004).
Table 1.1 Astrocytoma tumour sub-groups and grades according to WHO guidelines. Adapted from 
(Louis et al., 2007a).
Astrocytoma WHO Malignancy Grade
Pilocytic Astrocytoma I
Pilomyxoid II
Pleomorphic Xanthoastrocytoma II
Diffuse Astrocytoma 
Fibrillary 
Protoplasmic 
Gemistocytic
II
Anaplastic Astrocytoma III
Glioblastoma Multiforme 
Giant Cell Glioblastoma 
Gliosarcoma
IV
This report will use the terminology and definitions of the WHO classification of 2007 
throughout (Louis et al., 2007a).
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Pilocytic astrocytoma
Pilocytic astrocytoma are WHO grade I tumours (PAI). This tumour is the most 
frequent astrocytoma in children, commonly arising in the first two decades of life. PAI 
can arise in many regions of the central nervous system (CNS) including the 
cerebellum, cerebral hemispheres, thalamus and basal ganglia, optic nerve and chiasm, 
brain stem and spinal cord. These tumours are slow growing masses that can stabilise or 
regress but are rarely fatal. PAI of the hypothalamus or brain stem can be associated 
with poorer prognosis, prolonged clinical course and lesion recurrence. It has also been 
noted that a small number of both adult and paediatric PAI recur and in very rare cases 
transform into cellular mitotically active neoplasms (Rodriguez et al., 1990; Alshail et 
al., 1997; Broniscer et al., 2007).
The cells of PAI are pilocytes or hair cells that have long extensions and aggregate 
together forming a fibrillary background. The uniform nuclei of these cells appear 
elongated and the polar cells within the tumour are usually GFAP positive. Rosenthal 
fibres are common in dense regions of the lesion. Furthermore, microcysts are common 
and are usually uniformly spaced (Louis et al., 2007a). The typical biphasic pattern of 
these tumours can be seen in Figures 1.1a and 1.1b.
Figure 1.1 H&E stained paediatric pilocytic astrocytoma, a) x60 and b) x400 respectively.
All H&E stained pictures in this thesis are credited to Dr T. J. Jacques. These pictures illustrate the typical 
biphasic pattern of paediatric PAI.
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Pilomyxoid
This tumour is closely related to a pilocytic astrocytoma and corresponds to a grade II 
astrocytoma that is more aggressive, with local recurrence and cerebrospinal spread 
occurring more frequently. This tumour is typically seen in very young children (mean 
age 10 months), although it can occur in older children and commonly presents in 
hypothalamic/chiasmatic regions.
Pilomyxoid tumours have a prominent mucoid matrix consisting of bipolar cells with an 
angiocentric monomorphous arrangement. Rosenthal fibres and eosinophilic granular 
bodies are not commonly found in this tumour. However, the cells usually demonstrate 
strong reactivity for GFAP.
Pleomorphic xanthoastrocytoma
These grade II tumours account for less than 1% of all astrocytoma and have a 
favourable prognosis. The lesions occur most commonly in children and young adults, 
with most developing before 18 years of age. Pleomorphic xanthoastrocytoma (PXA) 
are often located in the cerebral hemispheres involving the meninges, preferentially in 
the temporal lobe. However, these tumours have also been found in the cerebellum and 
spinal cord.
The histopathology of this astrocytoma has many forms (pleomorphic). Spindly fibres 
are mixed with mono- or multinucleated cells, which themselves vary in shape and size. 
Mitotic activity is clearly visible, with progression to a more malignant form, usually in 
adults, being associated with increased mitotic activity (Kepes et al., 1989). The term 
xanthoastrocytoma is used to describe the intracellular accumulation of lipid droplets, 
which often pushes the intracellular structures to the periphery.
Diffuse infiltrating astrocytoma
Diffuse astrocytoma
Diffuse astrocytoma are classified as WHO grade II (DAII) and nuclear atypia is the 
only criterion required for this classification. These tumours have a high degree of 
cellular differentiation, are slow growing, usually supratentorial and infiltrate 
neighbouring brain structures (Perry, 2003). Only 10% of cases occur in patients below
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20 years of age. In adults, DAII commonly progress to a more malignant tumour (AAIII 
or GBMIV), but this is rarely seen in paediatric patients.
Several DAII sub-types are recognised including fibrillary, gemistocytic and 
protoplasmic astrocytoma. Fibrillary astrocytoma are the most common, consisting of 
fibrillary cells that show limited nuclear atypia and often resemble astrocytes. A scarce 
and poorly visible cytoplasm gives the appearance of ‘naked nuclei’. In addition to brain 
infiltration, these tumours may also contain multiple microcysts. GFAP expression is 
seen throughout the tumour, but not in all cells. Figure 1.2 illustrates the low cellularity 
and ‘naked nuclei’ associated with DAII.
Gemistocytic astrocytoma are composed of gemistocytic neoplastic cells which often 
have a plump, glassy, eosinophilic cell body appearance and are randomly distributed 
within a coarse fibrillary network. This variant progresses more rapidly to a higher 
grade tumour in adults (Watanabe et al., 1997b; Reis et al., 2001). The expression of 
GFAP is consistently seen in these cells.
Figure 1.2 H&E stained paediatric fibrillary diffuse astrocytoma, xl50.
ith minimal nuclear atypia
^ :__
paediatric DAII wis picture illustrates low cellularity.
Protoplasmic astrocytoma are composed of cells with an astrocytic phenotype. The cell 
bodies are small with a low content of glial filaments, the nuclei are round to oval in 
shape and microcysts are commonly seen. GFAP staining is scarce. This variant is rare, 
with few DAII being classed as pure protoplasmic DAII (Prayson and Estes, 1995). In 
the opinion of the pathologists at Great Ormond Street Hospital, protoplasmic
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astrocytoma may not exist as an astrocytoma subtype, but rather a feature of some 
tumours.
Anaplastic astrocytoma
Anaplastic astrocytoma are classified as WHO grade III (AAIII). Nuclear atypia and 
mitotic activity characterise these astrocytomas which have focal or dispersed anaplasia 
and show increased proliferation. Very few cases are seen below the age of 20 years. 
The common location of this tumour is very similar to that of other DAII, preferentially 
in the cerebral hemispheres.
Anaplastic astrocytoma have increased cellularity and complex nuclear morphology 
(Figure 1.3). The nucleus may appear enlarged and vary in shape or chromatin 
distribution. Multinucleation can also be seen, along with normal and abnormal mitoses. 
Inconsistent GFAP staining is often found in this tumour and gemistocytic cells may be 
present in small numbers.
Figure 1.3 H&E stained paediatric anaplastic astrocytoma, x400.
This picture illustrates a paediatric AAIII with high cellularity and cellular and nuclear anaplasia. 
Glioblastoma multiforme
Glioblastoma multiforme (GBMIV) are the most malignant astrocytoma and are 
classified as WHO grade IV. Any three of the four histological criteria, nuclear atypia, 
mitosis, microvascular proliferation and/or necrosis are required to diagnose this 
tumour, which is often composed of poorly differentiated neoplastic cells with an 
astrocytic phenotype (Figure 1.4).
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Figure 1.4 H&E stained paediatric glioblastoma multiforme, a) x50 and b) xlOO respectively.
These pictures illustrate a paediatric GBMIV with paeudopalisading necrosis (a) and microvascular 
proliferation (b).
As a group, the peak incidence of adult GBMIV is between 45 and 70 years of age. 
However, GBMIV may develop de novo (primary GBMIV) or from low-grade tumours 
(secondary GBMIV). Primary GBMIV are more common, manifesting after a short 
clinical history, usually during or after the sixth decade of life. Secondary GBMIV 
progress from low-grade tumours over a period of months or years and usually occur in 
the in the fourth decade of life (Kleihues and Ohgaki, 1999). Less than 3% occur in the 
first two decades of life, but this may be underestimated as resections are not 
necessarily carried out when the tumours are found in difficult locations in children, e.g. 
in the brain stem (Louis et al., 2007a).
GBMIV are most commonly located in the cerebral hemispheres, preferentially in the 
frontotemporal and parietal area. Infiltration of the tumour can reach the basal ganglia 
or contralateral hemispheres. On rare occasions, these tumours can be found in the 
cerebellum or spinal cord and whilst brain stem astrocytoma are less common in adults, 
they affect between 3-9% of children diagnosed with astrocytoma (Pollack, 1999a; 
Louis et al., 2007a).
Giant cell GBMIV are composed of multinucleated giant cells with a prominent stromal 
reticulin network. This is a rare variant, accounting for less than 5% of GBMIV. 
Furthermore, this characteristic may exist as a tumour feature rather than an overall 
diagnosis. The staining of GFAP is also sporadic in these cells.
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Gliosarcoma can be described as a GBMIV with sarcomatous components. Areas within 
the tumour often show gliomatous or mesenchymal differentiation, with glial regions 
displaying various degrees of GFAP staining and anaplasia. Spindle cells in long 
bundles and herringbone patterns of fibrosarcoma characterise the sarcomatous regions 
of the tumour. This variant accounts for approximately 2% of all GBMIV (Louis et al., 
2007a).
Incidence of paediatric astrocytoma and patient survival
It is difficult to determine the precise incidence and mortality of childhood brain 
tumours in the UK, particularly the various grades of astrocytoma. This is because the 
incidence and survival rate of astrocytoma grades in children below 15 years of age are 
not individually documented. The Office for National Statistics (www.statistics.gov) 
documents malignant neoplasms of the brain as a group and does not clarify the 
incidence of individual tumours or grades. Furthermore, the information provided by 
Cancer Research UK (www.cancerresearch.uk.org) regarding brain tumour incidence, 
sources the information provided by The Office for National Statistics. The Childhood 
Cancer Research Group also referenced by Cancer Research UK, combines astrocytoma 
incidence and survival data providing information that reflects astrocytoma tumours as a 
group and not PAI, DAII, AAIII and GBMIV as individual grades.
The Central Brain Tumour Registry of the United States (CBTRUS) provides an 
alternative source of childhood brain tumour incidence and mortality rates that is 
documented by grade. Between 1998 and 2002, the CBTRUS collected incidence and 
survival data for all newly diagnosed cases of non-malignant (benign and uncertain) and 
malignant primary brain and central nervous system tumours, from eighteen
collaborating state cancer registries. This data was complied into the “2005-2006 
Primary Brain Tumours in the United States Statistical Report”.
Brain tumours are the second most common malignancy among children after
leukaemia, but are the most common form of solid tumour. The most frequent
histologies in the 0-14 year age group include PAI and embryonal tumours
(medulloblastomas), which account for 21% and 17% of cases respectively (Figure 1.5).
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Figure 1.5 The distribution of brain tumours occurring in children between 0-14 years of age.
Other 31%
Germ Cell Tumours 
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Craniophamgioma 3%
Pilocytic Astrocytoma 21%
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Multiforme 3%
Diffue and Anaplastic 
Astrocytoma 11%
Ependymoma 7%
Oligodendroglioma 2%
Pituitary Tumours 1%
Embryonal Tumours including 
Medulloblastoma 17%
Adapted from the Central Brain Tumour Registry of the United States Report 2005-2006 (CBTRUS, 
2006).
The incidence of PAI peaks among children between 5-9 years of age with the broad 
glioma category accounting for 44% of tumours in children 0-14 years of age 
(CBTRUS, 2006).
The incidence of astrocytoma varies greatly between different age groups (Figure 1.6). 
The incidence rate of PAI in children between 0-14 years of age is 0.92 per 100,000 
population/year. This compares to the incidence of PAI in patients over 55 years of age 
of 0.06 per 100,000 population/year. DAII have a low incidence rate between 0-14 years 
of age of 0.05 per 100,000 population/year. This remains constant between 15-19 years 
of age but rises continuously with age, peaking between the ages of 65-74 years at a rate 
of 0.23 per 100,000 population/year. AAIII shows a similar pattern to DAII occurring at 
a rate of 0.08 per 100,000 population/year between the ages of 0-14 years and peaking 
between the ages of 65-74 years at a rate of 1.12 per 100,000 population/year. 
Moreover, GBMIV are most common in patients over 60 years of age with a peak 
incident rate of 13.45 per 100,000 population/year between 75-84 years of age.
23
Figure 1.6 The incidence of astrocytoma in the US population according to age.
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Adapted from the Central Brain Tumour Registry of the United States Report 2005-2006 (CBTRUS, 
2006).
Figure 1.7 The survival rates of children between the ages of 0-14 years diagnosed with
an astrocytoma.
□  Pilocytic astrocytoma
■  Diffuse astrcytoma
■  Anaplastic astrocytoma
■  Glioblastoma multiforme
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Years o f Survival
Adapted from the Central Brain Tumour Registry of the United States Report 2005-2006 (CBTRUS, 
2006).
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This compares to an incidence rate of 0.13 per 100,000 population/year in patients 
between 0-14 years of age (CBTRUS, 2006). This data does not distinguish primary and 
secondary adult GBMIV, which should be taken into consideration when viewing this 
data.
Tumour grade is the one of the most powerful predictive factors in astrocytoma 
prognosis. Prognosis for paediatric astrocytoma patients becomes increasingly poor with 
increasing grade of malignancy (Figure 1.7). Paediatric patients diagnosed with PAI or 
DAII have a good 10-year survival rate of approximately 90% and 80% respectively. 
However, children diagnosed with AAIII of the same age group have a poor 10-year 
survival rate of approximately 50% and GBMIV have a worse 10-year survival rate of 
just 14.6%. One year after diagnosis, only 50% of paediatric patients with a GBMIV 
remain alive.
Clinical manifestations of paediatric astrocytoma
In paediatric patients, the symptoms of astrocytoma are similar to those seen with other 
solid brain tumours and depend on tumour location and rate of growth. Seizures are a 
common presenting symptom, although more subtle changes in a patient may occur 
prior to this (Louis et al., 2007a). Clinical manifestations may include changes in 
sensation or vision, speech difficulties, irritability, vomiting, failure to thrive and 
progressive macrocephaly (Gilles et al., 1992; Pollack, 1994; Bos et al., 2002; Domer et 
al., 2007). These symptoms may occur due to increased intracranial pressure caused by 
the tumour itself or ventricular obstruction (Berger, 1996). Frontal lobe tumours may 
present with changes in personality or behaviour (Aitken and Luce, 1996). AAIII and 
GBMIV present with the same symptoms as PAI and DAII but usually have a much 
shorter clinical history (Louis et al., 2007a).
Treatment
Surgery
The primary treatment for the majority of paediatric brain tumours is surgery 
(Robertson, 2006). Initially, surgery provides tissue for tumour diagnosis, reduces 
tumour burden and may also restore the cerebrospinal fluid (CSF) pathway (Tomita, 
1998; Pollack, 1999b; Robertson, 2006). It has also been suggested that surgery may
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enhance tumour response to adjuvant irradiation and/or chemotherapy; the smaller the 
tumour the greater the response (Tomita, 1998).
Complete resection relies on a well-defined margin between tumour edge and normal 
brain, with tumour infiltration into normal tissue limiting surgery success (Pollack, 
1999b). In low-grade paediatric astrocytoma, particularly PAI, where infiltration rate is 
low, and a defined tumour edge can often be seen; complete resection is possible, with a 
high success rate. High-grade paediatric astrocytoma show increased infiltration and 
poorly defined tumour edge, therefore only a partial or majority removal of this tumour 
is usually possible (Pollack, 1999b; Robertson, 2006). Specific paediatric brain 
tumours, such as diffuse brain stem astrocytoma, are often unresectable, consequently 
diagnosis is carried out using MRI appearance and in certain cases biopsy alone 
(Albright et al., 1993).
The extent of paediatric tumour resection has been improved in recent years with the aid 
of new radiographical and electrophysiological methods (Robertson, 2006). Functional 
MRI allows examination of tumour proximity to functional brain regions. Image guided 
stereotactic techniques are now used during surgery to indicate tumour relationships 
with surrounding brain structures. Electrophysiological monitoring and awake 
craniotomy is also used during surgery to monitor the extent of tumour resection, 
reducing neurological morbidity (Rezai et al., 1997; Samdani et al., 2005). These 
techniques provide the surgeon with a ‘map’ of the tumour before and during surgery.
Data from clinical and retrospective studies suggests that the extent of astrocytoma 
resection (all grades of malignancy) in paediatric patients has a significant positive 
impact on patient survival, although this has never been proven prospectively. All 
patients who undergo a complete tumour resection, regardless of grade, show a 
significant increase in 5-year survival compared to patients that undergo an incomplete 
or partial resection (Wisoff et al., 1998; Finlay and Wisoff, 1999; Fisher et al., 2001).
Radiation therapy
When a complete tumour resection is not possible, radiotherapy (RT) is the primary or 
adjuvant treatment for paediatric patients. However, RT is associated with several 
disadvantages and side effects including, cognitive impairment caused by RT damage to
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the CNS, vasculopathies, stroke and neuroendocrine deficits. Radiosensitivity is also 
considerably higher in children below 2 years of age as the CNS is still developing. The 
long term effects of irradiating such young children include lower IQ, estimated at 25 
points per whole body irradiation, smaller stature and endocrine problems including 
damage to the thalamus and pituitary gland (Duffner et al., 1986; Robertson, 2006). The 
Paediatric Oncology Group completed a phase II clinical study in which postoperative 
chemotherapy was given to 198 paediatric malignant brain tumour patients under 36 
months of age until the age of 4 years or disease progression, in order to delay radiation 
to the developing brain. The study concluded that chemotherapy was an effective 
primary postoperative treatment for malignant brain tumours in young children, 
achieving disease control for one or two years in some patients. In patients who had 
total surgical resection or a complete response to chemotherapy, subsequent radiation 
therapy was not needed (Duffner et al., 1993). RT is often delayed in this age group but 
remains the adjuvant treatment in older children for all grades of astrocytoma that have 
recurred or show extensive growth (Pollack et al., 1995; Robertson, 2006).
The use of RT in paediatric oncology is a balance between the effects on tumour cells 
versus normal tissue within the irradiated volume, particularly in high-grade infiltrative 
tumours. RT is usually administered at a cumulative dose over several weeks to a target 
tumour volume, as normal tissue can tolerate several small doses of irradiation much 
better than one large dose (Larson et al., 1993; Swift, 2002). Advances in this field have 
been possible due to technology which administers the maximum therapeutic dose to a 
tumour mass whilst minimising the dose to surrounding normal brain. Three- 
dimensional conformal RT and intensity-modulated RT have been possible through 
advancements in computer modelling and RT delivery via multiple portals (Swift, 
2002). Gamma knife and stereotactic radiosurgery are precise RT approaches used to 
treat paediatric tumours that require imaging (CT and MRI) and head immobilisation. A 
single large fraction of radiation is delivered to a discrete volume of tumour with 
accuracy using a large number of intersecting beams. These methods are used to treat 
small, well defined, unresectable tumours, in regions where possible damage to normal 
tissue is acceptable (Kida et al., 2000; Hodgson et al., 2001; Suh and Barnett, 2003; 
Marcus et al., 2005).
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Chemotherapy
Chemotherapy was first used to treat paediatric astrocytoma in the 1970s, when 
vincristine was shown to have a significant effect on recurrent low and high-grade 
astrocytoma with minimal toxicity (Rosenstock et al., 1976). The use of 
chemotherapeutic agents alone, in combination and combined with RT have 
significantly improved outcome in children with astrocytoma (Robertson, 2006).
Several studies have investigated the treatment of high-grade astrocytoma in children 
with chemotherapy and RT in various combinations. A clinical trial carried out by the 
Society of Pediatric Oncology in 1991 reported the outcome of pre-irradiation 
chemotherapy for high-grade paediatric astrocytoma. Patients received maintenance 
chemotherapy involving lomustine, vincristine and cisplatin (irradiation followed by 
chemotherapy) or sandwich chemotherapy (chemotherapy followed by irradiation) 
involving ifosfamide, etoposide, methotrexate, cisplatin and cytosine arabinoside. 
Patients who had extensive chemotherapy, via the sandwich arm of the study, had a 
better overall survival (median 5.2 years) compared to those patients in the maintenance 
arm (median 1.9 years). However, the extent of tumour resection was the most 
significant prognostic factor. Median survival was 5.2 years for patients who underwent 
a greater than 90% tumour resection, compared to 1.3 years for patients who had an 
incomplete tumour resection. This study revealed that intensive chemotherapy prior to 
RT, increases survival rates in patients with high-grade astrocytoma that underwent total 
resection (Wolff et al., 2002a). A further phase I clinical study carried out by the 
Society of Pediatric Oncology also established that sandwich chemotherapy in 
paediatric patients with high-grade astrocytoma increased survival compared to surgery 
and RT alone (Wolff et al., 2002b).
A phase II study of different high-dose chemotherapy regimens prior to RT suggests 
that survival rate is increased in paediatric patients with high-grade astrocytoma 
receiving chemotherapy, but that no specific combination of agents provides further 
advantage. Three chemotherapeutic regimens were used; carboplatin/etoposide (regimen 
A), ifosfamide/etoposide (regimen B) and cyclophosphamide/etoposide (regimen C) 
(MacDonald et al., 2005).
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Furthermore, in a phase I study, carboplatin, an alkylating agent with reduced toxicity, 
was shown to increase survival in paediatric low-grade astrocytoma patients when used 
as a single agent, or in combination with vincristine (Packer et al., 1993).The Society of 
Pediatric Oncology and Hematology showed that carboplatin and vincristine 
chemotherapy could effectively defer RT in a treatment strategy for low-grade 
chiasmatic-hypothalamic astrocytoma in children and adolescents. In this phase II 
clinical study, children under 1 year did significantly worse than older children 
(Gnekow et al., 2004). Furthermore, a phase II trial showed that chemotherapeutic 
treatment with ifosfamide, carboplatin and etoposide combined with RT increased 
patient survival and reduce tumour size in patients with AAIII and GBMIV (Lopez- 
Aguilar et al., 2003).
The use of many individual chemotherapeutic agents has been investigated in the 
treatment of paediatric astrocytoma. Temozolomide is an imidazotetrazine derivative 
(alkylating agent) that has low toxicity and has been shown to increase survival in adult 
patients with GBMIV. Resistance to this agent has been found in tumours of patients 
that express MGMT (methylguanine DNA methyl transferase), a DNA repair protein. 
This has been important in identifying patients that will respond to temozolomide 
treatment (Friedman et al., 2000; Hegi et al., 2005). Temozolomide has been 
investigated as a treatment for high-grade astrocytoma and unfavourable low-grade 
astrocytoma in children. Boniscer et al. (2006) evaluated the efficacy of temozolomide 
alone given after RT in a multi-institutional study involving 31 paediatric patients. The 
study concluded that temozolomide treatment after RT did not increase patient survival. 
However, this may have been influenced by variations in patient prognostic factors such 
as tumour location and patient age at diagnosis. Furthermore, MGMT methylation status 
was not investigated in this study. Gururangan et al. (2007) carried out a phase II study 
of temozolomide in 32 children with recurrent low-grade glioma. Disease stabilisation 
was possible in more than 50% of patients for a prolonged period, without significant 
toxicity. A retrospective study by Donson et al. (2007) concluded that MGMT promoter 
methylation in paediatric GBMIV correlates with a survival benefit and sensitivity to 
temozolomide.
The blood-brain barrier impermeability limits the efficacy of chemotherapy, as does the 
over-expression of multidrug resistance proteins in tumours and/or endothelial cells.
29
Despite high response rates, development of intra-arterial chemotherapy remains limited 
because of frequent acute brain and eye toxicity. High-dose intravenous chemotherapy 
rescued by autologous hemopoietic stem cell transplantation is an alternative. This 
approach may increase drug delivery through the blood-brain barrier, whilst overcoming 
the myelosuppresion of elevated chemotherapeutic agent doses (Kalifa et al., 1999; 
Linassier et al., 2001). A phase I study involving twenty children with resistant or 
recurrent brain tumours, investigated the efficacy of high dose cyclophosphamide and 
carboplatin with peripheral stem cell rescue. Six patients showed a complete response, 
two showed a partial response, four had stable disease and disease progression was seen 
in six cases (two could not be assessed). This treatment approach was tolerated and 
showed reasonable success (Foreman et al., 2005). Martinez et al. (2007) completed a 
retrospectively study over 7 years of 35 children with recurrent brain tumours who 
underwent high dose chemotherapy with autologous stem cell rescue. It was also 
concluded that this approach may be effective in specific histological groups, including 
high-grade astrocytoma and very young children.
Alternative therapies
Identification of molecular variations between normal brain and tumour cells has 
allowed therapeutic approaches to exploit these properties, specifically targeting 
replicative cells. Targeting therapies include inhibition of tumour growth through 
immunotherapy, inhibition of signal transduction pathways, anti-angiogenic therapy, 
and gene expression manipulation (Robertson, 2006).
Immunotherapeutic approaches include tumour vaccines or monoclonal antibodies for 
tumour-specific receptors that are linked to tumour toxins or radioisotopes. Dendritic 
antigen presenting cells sensitised to specific tumour antigens induce a cell-mediated 
immune response towards tumour cells. This has been shown to inhibit the overall 
growth of astrocytoma in adults and children (De et al., 2004; Yamanaka et al., 2005). 
Radiolabeled monoclonal antibodies targeting tumour growth factors, such as epidermal 
growth factor and its receptor, have been shown to induce tumour cell anti-proliferation 
activity in vitro and in animal models (Schechter et al., 2003). Phase I and II clinical 
trials in adults investigating these antibodies have produced promising results, showing 
disease stabilisation and prolonged survival (Boskovitz et al., 2004).
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The inhibition of molecular pathways responsible for brain tumour growth, have also 
been investigated as a tumour treatment method. Growth factor receptors are linked to 
downstream molecular pathways involved in tumour cell proliferation and have been 
used as targets for monoclonal antibodies. The antibodies directed against specific 
receptors can inhibit signal transduction pathways inducing tumour cell apoptosis 
(Robertson, 2006). Recent monoclonal antibodies developed include, gefitinib (Iressa), 
which targets the epidermal growth factor receptor (EGFR) tyrosine kinase (Tremont- 
Lukats and Gilbert, 2003), imatinib (Gleevec), which targets the platelet derived growth 
factor-alpha receptor (PDGFRa) (MacDonald et al., 2001a) and erlotinib (Tarceva) 
targeting the ERBB2 receptor tyrosine kinase (Tremont-Lukats and Gilbert, 2003).
In addition, Rapamycin (Sirolimus) and a derivate (Everolimus) have been shown to 
inhibit the PTEN/PI3K/Ras/AKT/mTOR pathway in high-grade gliomas and are now 
undergoing phase II clinical trials in adult patients (Chang et al., 2005; Galanis et al., 
2005). Furthermore, phase II clinical trials in paediatric and adult brain tumours are now 
being carried out for Tipifamib (Zamestra), a famesyl transferase inhibitor which 
impairs proRas processing inhibiting the Ras signalling pathway (Tremont-Lukats and 
Gilbert, 2003; Cloughesy et al., 2006).
Angiogenesis is required for tumour growth. In brain tumours, several factors including 
a and (3 fibroblast growth factors (FGF), vascular endothelial growth factor (VEGF) and 
angiogenin promote angiogenesis. These growth promoters are thought to be 
synthesised either by the tumour cells themselves, or cells in the tumour 
microenvironment such as macrophages or endothelial cells (Kerbel and Folkman, 
2002; Robertson, 2006). Targets for anti-angiogenic agents include, endothelial cell 
proliferation, angiogenic factors or matrix metalloproteinases and vascular smooth 
muscle or integrin signalling (Puduvalli and Sawaya, 2000; Kerbel and Folkman, 2002). 
The cyclic peptide antagonist pentapeptide EMD 121974 (an integrin receptor 
antagonist) is currently in a phase I trial involving children with recurrent brain 
tumours. Preliminary results are promising with brain tumours showing responses to 
this agent (MacDonald et al., 2001b; Robertson, 2006).
Gene therapy is also being investigated as a treatment for adult and paediatric brain 
tumours. Prodrug activation (also known as “suicide therapy”) delivers a gene to a
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tumour cell which encodes a protein that sensitises the cell to a specific drug. Izquierdo 
et al. (1996) investigated the use of a modified herpes virus vector to treat malignant 
astrocytoma in 5 adult patients who had failed standard therapy and were expected to 
survive only a few weeks. The vector expressed the enzyme thymidine kinase which 
converts gangcyclovir to a toxic metabolite capable of killing tumour cells. Stereotactic 
intratumoural injection was used to administer the vector to the patient and this was 
followed by systemic gangcyclovir. Success was poor mainly due to transfection 
efficiency. However, this approach is now involved in phase I and II clinical trails in 
adults with recurrent high-grade GBMIV (Germano et al., 2003; Prados et al., 2003).
Tumour suppressor gene therapy is a similar approach in which mutated or deleted 
tumour suppressor genes are replaced with fully functional copies. MMAC1/PTEN is a 
tumour suppressor gene candidate commonly mutated in adult GBMIV. Following 
transduction of MMAC1 into U87MG glioblastoma cells using adenovirus (MMCB), 
proliferation and anchorage-independent growth in soft agar was inhibited. MMCB- 
infected U87MG cells were also found to be non-tumorigenic in nude-mice. This 
suggests a strong in vivo tumour suppression activity of MMACl/PTEN  and that in vivo, 
gene transfer with this recombinant adenoviral vector has a potential use in cancer gene 
therapy (Cheney et al., 1998). More recently, infection with a combination of antisense- 
hTERT and wild-type-PTEN adenoviruses significantly inhibited human U251 GBMIV 
cell proliferation in vitro and glioma growth in a xenograft mouse model, providing 
further evidence that gene therapy could be a successful treatment approach for 
astrocytoma (You et al., 2007).
Anti-sense gene therapy inhibits the expression of genes involved in tumour 
development. An “anti-sense” gene is designed, which when synthesised, is a single­
stranded RNA molecule complementary to the mRNA produced by the tumour target 
gene. If the gene is then expressed inside a tumour cell, the single-stranded RNA binds 
to the mRNA of the target gene, inhibiting ribosome apparatus function and preventing 
translation of the target gene. Urokinase plasminogen activator receptor (uPAR) and 
cathepsin B are over-expressed during astrocytoma progression. A study by Gondi et al. 
(2004) simultaneously down-regulated uPAR and cathepsin B in SNB19 glioma cell 
monolayers and spheroids, using an adenoviral vector carrying antisense uPAR and 
cathepsin B. The Ad-uAR-Cath B-infected cells showed a marked reduction in tumour
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growth and invasiveness. These results indicate that this type of gene therapy could be 
used to inhibiting tumour growth, invasion, and angiogenesis.
Prognostic indicators in paediatric astrocytoma
Tumour histology
Tumour grade is the most important prognostic factor in paediatric astrocytoma, with a 
more malignant tumour being associated with reduced survival expectancy as 
previously discussed (Figure 1.7). Low tumour grade has been confirmed by several 
studies as a good prognostic indicator in children, with a 10-year survival expectancy of 
80% or above(Lopez-Aguilar et al., 1997; Desai et al., 2001). Some sub-types of 
astrocytoma have been associated with a poorer prognosis. The presents of fibrillary 
histology has been shown to be a negative prognostic indicator in paediatric DAII 
(Smoots et al., 1998). Furthermore, poor prognosis has been associated with the 
gemistocytic DAII variant in adults but this is yet to be confirmed in paediatric 
astrocytoma (Watanabe et al., 1997b; Reis et al., 2001; Avninder et al., 2006; Martins et 
al., 2006; Geranmayeh et al., 2007).
Tumour location
Tumour location can impact paediatric patient prognosis and survival expectancy as 
only limited resection may be possible for tumours in difficult locations. Furthermore, 
variations in brain structure can allow rapid tumour infiltration promoting tumour 
growth and development (Robertson, 2006).
Total resection for PAI in the posteria fossa is possible in most cases and patients have a 
greater than 90% survival rate. Low-grade paediatric astrocytomas of the cerebral 
hemispheres often infiltrate surrounding areas and total resection is not always possible. 
When total resection is achieved, 10-year survival rates exceed 80% (Hirsch et al., 
1989). Midline optic pathway or hypothalamic astrocytomas are rarely resectable as 
they often infiltrate critical structures. Further treatment for these paediatric tumours, 
including radiotherapy or chemotherapy, is dictated by other prognostic factors 
including, patient age and tumour histology. However, long term survival is 
approximately 75% (Petronio et al., 1991). Brain stem astrocytomas in children are 
extremely difficult to treat, as the location prevents surgical intervention and patients 
have a median survival of less than a year (Hargrave et al., 2006). High-grade paediatric
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supratentorial astrocytomas are initially treated with surgery and maximum tumour 
resection is associated with prolonged survival (Wisoff et al., 1998). However, the 2- 
year survival rate of paediatric patients with high-grade tumours in this location is only 
approximately 20% (Broniscer and Gajjar, 2004).
Age
Young infants diagnosed with an astrocytoma have a worse prognosis compared to 
older children diagnosed with a similar tumour. Studies investigating the difference in 
prognosis depending on patient age have grouped patients as below 3, 2 or 1 years of 
age compared to older children (Raimondi and Tomita, 1983; Duffner et al., 1986; 
Ambrosino et al., 1988; Asai et al., 1989; Haddad et al., 1991; Duffner et al., 1993; 
Cohen et al., 1993; Jovani et al., 1998; Duffner et al., 1999; Sala et al., 1999; Rivera- 
Luna et al., 2003; Rivera-Luna et al., 2007). Moreover, Desai et al. (2001) investigated 
prognostic factors for cerebellar astrocytoma in 102 children and found that patient age 
did not affect outcome. However, the youngest patient in the study was 10 months old, 
consequently the younger age group was not sufficiently represented in this study. As 
previously discussed, neurotoxicity from RT is more frequent and severe in very young 
children, in some cases contributing to poor prognosis and quality of life (Jenkin et al.,
1998).
Molecular genetic markers
Predictive genetic markers in paediatric astrocytoma are limited. However, a number of 
studies have investigated the association between copy number alterations (CNAs) and 
outcome. Reduced survival was associated with gain of lq  in 30% of paediatric AAIII 
and 54% of paediatric GBMIV, p < 0.001 and p < 0.05 respectively (Rickert et al.,
2001). A study of CNAs in low-grade paediatric astrocytoma suggested that patients 
with tumours that had aberrations survived longer, although this was not significant (Orr 
et al., 2002). Furthermore, loss of 17p has also been associated with reduced survival in 
paediatric astrocytoma (Cogen, 1991)
Mutations or over-expression of TP53 in paediatric astrocytoma has been associated 
with reduced patient survival (Drach et al., 1996; Pollack et al., 2002; Ganigi et al.,
2005). Pollack et al. (2002) found that there was a significant association between TP53 
over-expression and shorter progression-free survival (PFS) and overall survival (OS).
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PFS and OS were 5.5 months and 14 months respectively, compared to 25 months and 
>4 years for those patients with tumours without TP53 over-expression. In addition, 
there was a significant association between TP 5 3 mutation, reduced PFS and shorter 
OS. Median PFS and OS for patients with 77*55-mutated tumours were 6 months and 16 
months respectively, versus 16 months and 25 months for those patients with tumours 
that did not have TP53 mutations (Pollack et al., 1997). A further study found a 
significant association between increased TP53 immunopositive tumour cells and 
reduced survival in paediatric GBMIV (Drach et al., 1996). Moreover, an investigation 
of TP53 immunoreactivity in DAII and AAIII demonstrated a link between increased 
TP53 staining in AAIII and reduced survival, but this was not found to be significant 
(Ganigi et al., 2005).
Increased EGFR and bcl-2 immunoreactivity was observed in 25.9% and 33.3% of 
paediatric GBMIV respectively, but this was not significantly associated with survival. 
However, combined increased TP53 and bcl-2 immunoreactivity was associated with 
reduced survival (Ganigi et al., 2005). Moreover, PTEN  deletions have also been 
associated with poor prognosis in paediatric AAIII and GBMIV (Raffel et al., 1999).
The methylation status of MGMT is a good predictive marker of response to alkylating 
agents (Esteller et al., 2000a; Soejima et al., 2005). The relationship between MGMT 
methylation status, chemotherapy response and patient survival has been studied in 
paediatric GBMIV patients. A randomized trial comparing radiotherapy alone and 
radiotherapy combined with concomitant or adjuvant treatment with temozolomide, 
demonstrated that MGMT promoter methylation conferred a survival benefit to 
paediatric GBMIV patients treated with temozolomide and radiotherapy. However, a 
strong association was also seen between MGMT promoter methylation and overall 
survival regardless of treatment (Donson et al., 2007).
Genetics and chromosomal alterations of astrocytoma
The study of paediatric astrocytoma is hindered by several factors, the first being the 
rarity of this tumour, especially high-grade tumours. Secondly, the location of many 
paediatric astrocytoma prevents resection, limiting the amount of tissue available for 
study. Furthermore, patient consent is given in fewer cases for the study of paediatric 
astrocytoma compared to adults. This is an understandable parental choice. Moreover,
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in the experience of our laboratory and collaborators, it is often difficult to generate 
good chromosome metaphase spreads for tumour cytogenetic analysis. Paediatric 
astrocytoma often have a low mitotic index and reduced doubling time compared to 
adults, decreasing the number of mitoses for metaphase spread preparation. This has 
hindered genetic investigation of paediatric astrocytoma compared to that of their adult 
counterparts.
Genetics and chromosome alterations in adult astrocytoma
Phenotypic characteristics of all tumour cells include increased proliferation, increased 
invasion, angiogenic properties and evasion of apoptosis. A number of molecular 
mechanisms have been identified in cellular transformation and malignancy that can be 
linked to these characteristics including 1) inactivation of Rb and TP53 cellular 
pathways; 2) activation of Ras and/or other growth promoting pathways; 3) evasion of 
apoptosis; 4) telomerase activation or alternative mechanisms of cellular 
immortalisation; 5) angiogenic activity (Bocchetta and Carbone, 2004).
Oncogenes are generally mutated forms of normal cellular genes (proto-oncogenes), 
which usually influence cell proliferation. They are genes that code for growth factor 
receptors, proteins involved in signal transduction or transcription factors (Bocchetta 
and Carbone, 2004). Mutations in proto-oncogenes can give rise to cellular genes that 
are constitutively active and behave like viral oncogenes. For example, substitution of 
the glycine at codon 12 of the K-ras proto-gene produces a constitutively active 
oncogenic ras allele, that is a marker in pancreatic carcinoma (Daus et al., 1995). 
Failure of cellular mechanisms to respond to this differential expression promotes 
tumour formation.
Genes that can promote tumour development through loss of function are termed 
tumour suppressor genes. These can be transcription factors such as TP53, proteins that 
interact with other proteins to inhibit kinase activity involved in cell cycle progression 
such as CDKN2A and CDKN1A, or proteins that affect cellular localisation of other 
proteins (Malumbres and Barbacid, 2001).
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Rb and TP53 pathways
The cell cycle can be arrested by tumour suppressor genes of the TP53 and Rb pathways 
that are activated by aberrant proliferative stimuli or DNA damage. After cell arrest, 
there is an opportunity to rectify DNA damage where necessary. If this is not possible or 
damage is irreparable, the cell enters senescence or undergoes apoptosis, preventing 
replication of the damaged genome (Bocchetta and Carbone, 2004). The role of the 
TP53 and Rb pathways is to maintain low levels of inactive TP53 in the absence of 
genomic damage allowing normal cell cycle function (Rathore et al., 1999; Kohn, 1999; 
Besson and Yong, 2001; Collins, 2002; Mirza et al., 2003). The majority of tumours 
have mutations in multiple tumour suppressor genes causing major disruptions to the 
TP53 and Rb pathways (Hahn and Weinberg, 2002). The basic role of TP53 in 
astrocytoma is discussed here, although the known multiple gene interactions have not 
been included. Current detailed information regarding this gene can be found at 
http://www-p53.iarc.fr/p53resources.html.
Primary and secondary adult GBMIV have different genetic profiles and chromosomal 
alterations (Figure 1.8). However, it is apparent that the TP53 and Rb pathways are 
disrupted in both through different mechanisms. Figures 1.8 and 1.9 illustrate genomic 
aberrations and differential gene expression identified in primary and secondary adult 
GBMIV (Konopka and Bonni, 2003; Ichimura et al., 2004). Furthermore, these two 
distinct pathways are now recognised by the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database. This database is a collection of manually drawn pathway 
maps representing current knowledge of molecular interactions and reaction networks 
(Kanehisa and Goto, 2000) (Figures 1.10 and 1.11).
The activation of TP53 transactivates many genes with varied functions. The 
transcription of CDKN1A is activated by TP53 and inhibits the Rb pathway. MDM2 
transcription is also initiated by TP53, which itself acts as a negative regulator of TP53. 
Cell cycle progression is also regulated through the release of E2F transcription factors 
by Rb phosphorylation, which initiates p l4 ARF transcription. This protein inhibits 
MDM2 preventing TP53 degradation, consequently increasing TP53 cellular 
concentration and inducing cell cycle arrest or apoptosis (Rathore et al., 1999; Kohn, 
1999; Besson and Yong, 2001; Collins, 2002; Mirza et al., 2003).
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Figure 1.8 The genetic differences between primary and secondary adult glioblastoma.
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The Rb pathway controls cell cycle progression from G1 to S phase. The release of E2F 
transcription factors through pRb phosphorylation initiates the transcription of S phase 
genes. Mitogenic stimuli up-regulates CCND1, CCND2 and CCND3, which bind 
CDK4 or 6. This complex phosphorylates the Rb protein, causing the release of E2F 
transcription factors. Phosphorylated Rb also modulates chromatin structure (Zhang and 
Dean, 2001). CDK inhibitors, CDKN2B and CDKN2A,compete with the cyclins to bind 
CDK4 or 6, blocking complex formation and the Rb pathway (Rathore et al., 1999; 
Kohn, 1999; Besson and Yong, 2001; Collins, 2002). The loss or mutation of TP53 is 
found in 60% of adult DAII, AAIII and secondary GBMIV (Frankel et al., 1992; 
Rasheed et al., 1994; Nozaki et al., 1999; Ichimura et al., 2000). This promotes cell 
proliferation, as does the over-expression or amplification of MDM2. MDM2 is located 
on chromosome 12ql3-15, a common region of gain in these tumours (Reifenberger et 
al., 1996; Ichimura et al., 2000; Ranuncolo et al., 2004).
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Figure 1.9 TP53 and Rbl cell cycle pathways
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The chromosomal region 9p21 is homozygously deleted in 30-40% of adult primary 
GBMIV and 10% of AAIII, but not in DAII. This region contains the CDKN2A locus 
encoding both CDKN2A and p l4 ARF. The deletion of CDKN2A, promotes cell 
proliferation through the disruption of the Rb and TP53 pathways (Jen et al., 1994; Ueki 
et al., 1996; Ichimura et al., 2000; Ranuncolo et al., 2004). Hypermethylation of the 
promoter region of these genes, has also been found in astrocytoma (Fueyo et al., 1996; 
Nakamura et al., 2001a; Gonzalez-Gomez et al., 2003a). Furthermore, Rb loss or 
promoter hypermethylation has been found in approximately 25% of astrocytoma (Ueki 
et al., 1996; Nakamura et al., 2001b).
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Figure 1.10 Adult primary GBMIV pathway recognised by KEGG.
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Figure 1.11 Adult secondary GBMIV pathway recognised by KEGG.
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Activation o f  Ras and growth promoting pathways
Over-expression of growth factor receptors is a frequent occurrence in cancer and has 
been observed in adult astrocytoma. Both PDGFRa and EGFR dimerise once activated 
by ligand binding. This initiates autophosphorylation of cytoplasmic domains 
stimulating the Ras/Raf/Map pathway and activating PI3-kinase. PI3-kinase then 
phosphorylates phosphatidylinositol-4,5-diphosphate (PIP2) to phosphatidylinositol- 
3,4,5-triphosphate (PIP3). The cellular levels of PIP3 are regulated by PTEN. PIP3 is 
bound to the intracellular cytoplasmic membrane, where it recruits proteins with 
pleckstring homology domains, including Akt, a well-known anti-apoptotic and survival 
factor (Kohn, 1999; Besson and Yong, 2001; Collins, 2002; Pandita et al., 2004).
Adult secondary GBMIV commonly show over-expression of PDGFRa or platelet 
derived growth factor alpha (PDGFa) (Hermanson et al., 1996; Kleihues and Ohgaki,
1999). Over-expression of this gene or the receptor has been shown to promote tumour 
self growth via autocrine or paracrine stimulation in astrocytoma (Lokker et al., 2002).
Primary GBMIV show amplification or over-expression of EGFR in approximately 
50% of cases (Tohma et al., 1998; Kleihues and Ohgaki, 1999). The most common 
EGFR gene mutation, found in GBMIV, results in an mRNA molecule lacking 801 
bases that encode amino acids 6-273 of the receptors extracellular domain. This 
transposes a receptor mutant, that is constitutively activated and no longer requires 
ligand binding for activation, leading to constant pathway stimulation (Ekstrand et al., 
1994; Nishikawa et al., 1994). It was also demonstrated that when cells expressing 
mutant EGFR were implanted into nude mice, tumourigenesis was increased 
(Nishikawa et al., 1994). The up-regulation of either EGFR or PDGFRa in some DAII 
has been linked to reduced patient survival (Varela et al., 2004).
PTEN, located at 10q23.4, shows loss in 80% of adult primary GBMIV. Loss of this 
gene promotes cell survival through reduced dephosphorylation of PIP3 to PIP2 
allowing PIP3 to be continuously available (Daido et al., 2004). Loss of heterozygosity 
(LOH) at lOq was reported in 70% of adult primary GBMIV, with PTEN  mutations 
occurring in approximately 25% of the cases (Ohgaki and Kleihues, 2005). A further 
study found PTEN  mutations in approximately 60% of GBMIV also showing lOq LOH 
(Wang et al., 1997). Other studies have confirmed PTEN  alterations in adult primary
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GBMIV and associated the disruption of this gene with reduced patient survival (Kato 
et al., 2000; Krex et al., 2003; Roversi et al., 2006; Homma et al., 2006).
Cell immortalisation
Cell immortalisation is a further event that contributes to malignant growth of 
astrocytoma. In most cases, this is thought to be achieved through the maintenance of 
chromosome telomeres. These regions are 5-15Kbp in length and consist of 5’- 
TTAGGG-‘3 tandem repeats at the end of each chromosome. The 3’ overhang of the 
repeat is arranged in a T-loop structure that protects the individual chromosome ends 
from end to end chromosome fusion and prevents the single strand being recognised as 
a double strand break, triggering the cell DNA repair system (Griffith et al., 1999). 
Under normal cell division and chromosome replication, the telomere region shortens 
because DNA polymerase uses RNA primers that are degraded after elongation (Moyzis 
et al., 1988). Once a telomere has shortened beyond the critical threshold, the DNA ends 
become structurally unstable. This leads to TP53 activation resulting in either 
replicative senescence or crisis. Deletion of TP53 significantly attenuates cellular 
effects of telomere dysfunction, but only during the earliest stages of genetic crisis. 
(Chin et al., 1999).
Germinal cells and tumour cells evade this mechanism that restricts cellular replication, 
through the activation of telomerase. This enzyme is a ribo-protein complex that adds 
TTAGGG repeats to the telomeres preventing shortening (Bocchetta and Carbone,
2004). It has been suggested that over 85% of human cancers have measurable levels of 
telomerase activity allowing indefinite proliferation (Shay and Bacchetti, 1997). 
Tumours without telomerase activity are thought to maintain telomere length through a 
process known as alternative lengthening of telomeres (ALT). This involves 
nonreciprocal recombination between telomeres of different chromosomes (Bryan et al., 
1997). Telomerase activity has been found in both primary and secondary adult 
GBMIV, and associated with increased TP53 mutation (Harada et al., 2000). 
Furthermore, a study by Chen et al. (2006) found an association between TP53 mutation 
and the ALT mechanism and between wild-type TP53 and telomerase activity, 
suggesting that regardless of TP53 mutation status, a mechanism promoting telomere 
maintenance is active.
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Angiogenesis
Angiogenesis is the formation of new blood vessels from those that already exist and is 
controlled through a balance of pro-angiogenic and anti-angiogenic factors. High levels 
of angiogenesis occur during embryonic development compared to that found in adults 
where the process is limited to the menstrual cycle and tissue repair and remodelling. 
This complex physiological process has been investigated in astrocytoma since the early 
1970’s and is now recognised as an essential mechanism involved in tumour 
development and progression (Folkman, 1971; Brem, 1976). Moreover, during tumour 
development the angiogenic signal balance is pushed towards new vessel growth to 
create a blood vessel network that facilitates nutrient and waste product exchange and 
allows tumour growth to exceed l-2mm (Folkman, 1990). Tumour cells that are more 
than ten cell layers from a vessel are hypoxic and it is this lack of oxygen that inhibits 
tumour growth (Evans et al., 2001). Low-grade astrocytoma are ‘non-angiogenic 
tumours’ as they utilise normal brain vasculature as a blood supply. Furthermore, the 
extent of tumour vascularity correlates with increasing tumour malignancy and adult 
GBMIV have been shown to be the most vascularised astrocytoma (Korkolopoulou et 
al., 2002). These tumours also show areas of necrosis linked to extensive tissue hypoxia. 
Moreover, WHO classification grading criteria for astrocytoma includes microvascular 
proliferation and necrosis (Louis et al., 2007a).
In order to quantify angiogenesis in astrocytoma, specific vessel parameters have been 
investigated including microvessel density and microvessel size and shape according to 
branching (Folkerth, 2000; Sharma et al., 2006). Increased microvessel density and 
branching has been associated with poor prognosis in adult astrocytoma (Leon et al., 
1996; Abdulrauf et al., 1998). Furthermore, a sub-group of low-grade adult astrocytoma 
with shorter patient survival showed increased numbers of microvessels at diagnosis, 
suggesting that a number of low-grade adult astrocytoma may have increased malignant 
potential (Abdulrauf et al., 1998). In a small group of six paediatric GBMIV, vascular 
hyperplasia was also associated with reduced patient survival (Germano et al., 2001). 
Moreover, “sprouting” of new capillaries and an immature vascular system was linked 
to paediatric AAIII compared to PAI and proposed as a rationale for anti-angiogenic 
treatment approaches in this patient group (Gesundheit et al., 2003).
A plethora of growth factors, cytokines and respective receptors are involved in
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angiogenesis causing basement membrane degradation, endothelial cell migration, 
proliferation and tubular formation (Folkman, 1992). These include, VEGF, FGF, 
PDGF, EGF, TGFa, TGFp, HGF, CYR61, CTGF, IGF-1, IL-6, IL-8, TNFa, 
angiopoietins and ephrins. The most prominent factor is VEGFa, an endothelial cell 
mitogen that binds to the tyrosine kinase receptors VEGFR-1 and VEGFR-2 and 
initiates endothelial cell proliferation, migration and development of new blood vessels 
(Kanno et al., 2000; Yancopoulos et al., 2000). Moreover, the expression of this factor 
is mediated by hypoxia-inducible factor-1 (HIF-1), a factor stabilised under hypoxic 
conditions (Forsythe et al., 1996). VEGF expression was found in adult astrocytoma 
cells but markedly increased in GBMIV cells. In the same study, the expression of the 
VEGF-1 receptor was shown to be up-regulated in tumour endothelial cells compared to 
normal brain epithelium (Plate et al., 1992). The importance of the VEGF-1 receptor in 
vasculogenesis has since been confirmed (Fong et al., 1995; Shalaby et al., 1995) 
Furthermore, the expression of VEGF is affect by the PI3K signalling pathway under 
both hypoxic and normoxic conditions and by the MAPK/ERK pathway during 
normoxia (Jiang et al., 2000; Woods et al., 2002). This suggests that genetic mutations 
common to adult GBMIV may influence VEGF expression. The loss or mutation of 
PTEN frequently found in primary GBMIV activates the PI3K signalling pathway, 
inadvertently up-regulating VEGF expression and promoting angiogenesis. Moreover, 
the VEGF promoter region contains transcription factor binding sites for SP1, a target of 
wild-type TP53. Loss or mutation of TP53 in secondary GBMIV may promote VEGF 
transcription via SP1 activity (Zhang et al., 2000).
Angiopoietins are recognised as partners of VEGF in angiogenesis. Angiopoietin-1 
(Ang-1) and its tyrosine kinase receptor, Tie-2, play a complementary role to VEGF and 
the VEGF-1 receptor by ensuring vascular stability and correct vessel formation (Suri et 
al., 1996; Zadeh et al., 2004). Furthermore, transgenic mice over-expressing VEGF and 
Ang-1 show hypervascularity with an increase in both vessel number and size (Thurston 
et al., 1999). Ang-2 has been proposed as both an agonist and antagonist, inhibiting the 
actions of Ang-1 and the Tie-2 receptor but promoting angiogenesis, compared to Ang- 
1 that promotes vascular stability. It is thought that Ang-2 inhibits this action, returning 
already mature vessels of the brain to a plastic, destabilised state, sensitive to 
angiogenesis and further vessel formation (Holash et al., 1999).
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In adult GBMIV, increased immunohistochemical staining of Tie-2 was found in 
tumour endothelium compared to normal human brain. Ang-1 staining was shown in all 
tumour cells compared to Ang-2, which was restricted to a small number of GBMIV 
blood vessel endothelial cells. Immature capillaries with few periendothelial support 
cells showed increased Ang-2 staining, compared to larger vessels with many 
periendothelial support cells that showed reduced staining (Stratmann et al., 1998).
Angiogenesis is a complex process involving a large number of growth factors only 
named here. All levels of tissue and cellular organisation are involved, as well as 
secreted ligands, receptors, ECM proteins, transcription factors and intracellular 
signalling molecules. Moreover, tumour microenvironment including, tissue oxygen 
level also plays a significant role (Kargiotis et al., 2006). Furthermore, common genetic 
alterations that occur in adult astrocytoma and to a greater extent in GBMIV, promote 
angiogenesis allowing tumour growth and infiltration (Kaur et al., 2004).
Copy number alterations
Genomic alterations involving chromosome copy number gains and losses impact 
differential gene expression and adult astrocytoma development. Many altered regions 
are thought to be the location of novel candidate tumour suppressor genes and 
oncogenes. Although PAI are most common in children, they do occur in adults. The 
majority of PAI found in adults show normal karyotypes, as reported by Sanoudou et al 
(2000a). In this study normal karyotypes were identified in 5 of 7 adult PAI, with the 
remaining 2 tumours exhibiting multiple complex aberrations.
The most common chromosomal alterations found in adult DAII include gain of part or 
all o f chromosome 7, an increase in 8q copy number (whole arm or specific regions) 
and loss of a single sex chromosome (Schrock et al., 1996; Perry et al., 1997; Nishizaki 
et al., 1998; Hirose et al., 2003). Other regions of chromosome or arm alterations 
reported in this tumour include -lp, -4q, +5p, +9, +12, -19q, +19p (Schrock et al., 1996; 
Nishizaki et al., 1998). Furthermore, loss of chromosome 10 or regions on 6q are 
uncommon but have been identified (Perry et al., 1997; Nishizaki et al., 1998; 
Miyakawa et al., 2000). Allelic loss of 17p has also been detected in adult DAII and 
correlates with TP53 mutations in the same tumour (von Deimling et al., 1992).
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In adult AAIII, gain of part or all of chromosome 7 is also the most common 
chromosome alteration, as seen in adult DAII (Nishizaki et al., 1998; Kunwar et al., 
2001; Koschny et al., 2002). The loss of 17p, Xq and regions on 6q have also been 
found in this tumour (von Deimling et al., 1992; Miyakawa et al., 2000). Additional 
chromosome gains and losses reported in adult AAIII include -lp, -4q, -8q, +1 Op, -11 q, 
- lip , -12q and -13q and -9p, -lOq, -13q and + 19q, more common in adult GBMIV 
(Nishizaki et al., 1998; Kunwar et al., 2001). Furthermore, alterations involving -4q, 
+7p, -10 and +19 were more common in patients above 45 years of age, compared to - 
lip , which was more common in patients below 45 years of age (Kunwar et al., 2001).
The most common chromosome alterations found in adult GBMIV include the loss of 
chromosomes 9p, 10, 13, 14, 17p and 22q and gain of chromosomes 7, 19 and 20. 
Overall, chromosomal loss is more common than gain (Schrock et al., 1994; Mohapatra 
et al., 1998; Harada et al., 1998; Nishizaki et al., 1998; Koschny et al., 2002). Multiple 
regions of deletion on 6q have also been reported in this tumour (Mohapatra et al., 
1998; Miyakawa et al., 2000). Furthermore, defined regions frequently altered in adult 
GBMIV include +7pl3-pl2, +7p31, +8q24.1-q24.2, -9p21, -10pl2-p ll, -10q22-qter, - 
13q21-13q22 and 20ql3 .1-13.2 (Harada et al., 1998; Nishizaki et al., 1998).
Many of these regions contain genes known to play a role in adult astrocytoma 
development or tumour progression including GAC1 at lq32, PDGFRa at 4ql2, 
PDGFR/3 at 5q34, EGFR at 7pl2, CDK6 and MET at 7q21-7q31, C-MYC at 8q24.1, 
PBX3, VAV2 and ABL at 9q34, PTEN at 10q23.3, MXI-1 at 10q25-q26, CCD1 at l lq l3 , 
CDK4 and MDM2 at 12ql3-ql5, Rb at 13ql4.2, TP53 at 17pl3, DCC at 18q21-q22 and 
ERCC1, ERCCC2 and BAX  at 19ql3 (Koschny et al., 2002). A less documented region 
at 3q25.3 contains the VHL gene reported to be lost in 40% of adult astrocytoma (Kanno 
et al., 1997). The lp  arm has also been studied in high-grade adult tumours with 20% of 
cases showing loss (Smith et al., 1999). Moreover, the TP73 gene, homologous to TP53, 
is located in this region. TP 73 promoter hypermethylation has been found in some adult 
GBMIV as an alternative mechanism for gene expression loss (Watanabe et al., 2002).
The deletion of chromosome 10 is the most common aberration found in adult GBMIV, 
occurring in 80% of cases. The tumour suppressor gene, PTEN, was identified at 10q23 
and is most frequently lost in these tumours. Furthermore, DMBT1, located at 10q25-26
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the region most frequently deleted on chromosome 10, was also shown to be lost in 
50% of tumours (Suzuki et al., 2004). Other genes have been suggested as tumour 
suppressors lost due to lOq deletions including, MXI1 and LGI1 (Wechsler et al., 1997; 
Mollenhauer et al., 1997; Fujisawa et al., 1999; Chernova et al., 2001; Wessels et al.,
2004).
Epigenetics
In normal cells, epigenetics can be defined as the mechanisms that preserve inheritable 
gene expression patterns and functions without altering the genome sequence. The 
epigenetic network is complex but can be summarised into four layers; DNA 
methylation, chromatin remodelling, histone modification, and non-coding RNAs. In 
tumours and cancer it is evident that major disruptions often occur in the epigenetic 
network (Esteller, 2006). Moreover, promoter hypermethylation is the most common 
epigenetic alteration in tumours causing loss or down-regulation of tumour suppressor 
gene expression. Hypermethylation describes an increase in the number of methylated 
CpG dinucleotides in a CpG island compared to normal levels.
The methylation of cytosine residues located within the dinucleotide CpG do not occur 
randomly within the genome, but cluster in CpG rich regions known as CpG islands that 
are primarily located at the 5’end of genes. These islands often span the promoter, 
untranslated region and exon 1, indicating the beginning of a gene sequence. In the 
DNA of normal cells, 5-methylcytosine (5mC) constitutes 0.75%-1% of all nucleic acid 
bases and 3-4% of methylated cytosines (Paz et al., 2002). Furthermore, in normal cells, 
methylation controls the gene expression of imprinted genes, X-chromosome genes in 
the female, germ line specific genes and tissue-specific genes (Feinberg et al., 2002). In 
comparison, CpG dinucleotides are often unmethylated in normal cells and 
hypermethylated in tumour cells, silencing gene expression (Esteller, 2005).
Hypomethylation has also been documented in tumour cells and has been attributed to 
tumourigenesis. In such cases, tumour cells have been found to have 20% to 60% less 
genomic 5mC than normal cells, occurring mainly at coding regions and introns, 
compared to hypermethylation, that is usually found at promoter regions. Reduced 
levels of 5mC are thought to invoke chromosome instability, reactivation of 
transposable elements and loss of imprinting, promoting mitotic recombination and loss
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of heterozygosity (Esteller, 2005).
Genes that control global genome methylation have been investigated in many tumours 
and cancer. A family of genes with DNA methyltransferase activity including DNMT1, 
DNMT2, DNMT3a, DNMT3b and DNMT3L, are thought to play a role in the 
maintenance of promoter region methylation. Differential expression of only DNMT1 in 
colon cancer cells was shown to have little effect on global methylation. However, 
when both DNMT1 and DNMT3a were down-regulated, methyltransferase activity was 
lost and methylation was reduced to less than 5% of the original level (Rhee et al., 
2002).
Tumour suppressor genes are frequently hypermethylated in tumours with significant 
consequences that provide cells with a selective advantage (Table 1.2). The cell cycle 
inhibitor CDKN1A is hypermethylated in a variety of cancers allowing cells to 
proliferate and escape senescence (Merlo et al., 1995). Other genes involved in tumour 
cell cycle control found to be hypermethylated include the Rb gene and CDKN2B. 
Regulation of Rb gene methylation status has also been linked to chromatin 
conformation at the promoter region, suggesting that several epigenetic mechanisms are 
simultaneously involved (De La Rosa-Velazquez IA et al., 2007). Several genes in the 
TP53 network including CDKN2A and TP73 have been found to be hypermethylated. 
Methylation, and consequent silencing of CDKN2A, allows uninhibited MDM2 to 
induce TP53 degradation (Esteller et al., 2001). Furthermore, genes of the APC/p- 
catenin, E-cadherin and Wnt signalling pathways are often methylated in tumours 
including APC, E-cadherin, H-cadherin, FAT and SFRP1 (Graff et al., 1995; Esteller et 
al., 2000b; Toyooka et al., 2001; Paz et al., 2003).
Alterations in methylation patterns also affect DNA repair mechanisms in tumours. 
Silencing of the mismatch DNA repair gene hMLHl, has been found in colorectal, 
endometrial and gastric tumours in conjunction with microsatellite instability (Herman 
et al., 1998; Esteller et al., 1999; Fleisher et al., 1999). The methylation of this gene in 
adult GBMIV has also been linked to a positive response in patients given nitrosoureas 
as part of a chemotherapy regime (Fukushima et al., 2005). Furthermore, the 
methylation status of MGMT is a good predictive marker of response to alkylating 
agents as previously discussed (Esteller et al., 2000a; Soejima et al., 2005; Hegi et al.,
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2005) The same relationship has recently been documented in paediatric GBMIV 
patients, but a strong association was also seen between MGMT promoter methylation 
and overall survival, regardless of treatment (Donson et al., 2007).
Table 1.2 Genes hypermethylated in specific tumours and cancers and the molecular consequences.
Gene Function Location Tumour Profile Consequences
CDKN2A Cyclin-dependent kinase inhibitor 9q21 Multiple types Entrance in cell cycle
pi 4 ^ MDM2 inhibitor 9q21 Colon, stomach, kidney Degradation of p53
CDKN2B Cyclin-dependent kinase inhibitor 9q21 Leukaemia Entrance in cell cycle
hMLHl DNA mismatch repair 3p21.3 Colon, endometrial, stomach, glioblastoma Frameshift mutations
MGMT DNA repair of 06-alkyl- guanine 10q26 Multiple types
Mutations,
chemosensitivity
GSTP1 Conjugation to glutathione 1 lql3 Prostate, breast, kidney Adduct accumulation
BRCA1 DNA repair, transcription 17q21 Breast, ovary Double strand breaks
p73 P53 homolog 1P36 Lymphoma Unknown
LKB1/STK11 Serine/threonine kinase 19pl3.3 Colon, breast, lung Unknown
ER Estrogen receptor 6q25.1 Breast Hormone sensitivity
PR Progesterone receptor i iq22 Breast Hormone sensitivity
AR Androgen receptor Xqll Prostate Hormone sensitivity
PRLR Prolactin receptor 5pl3-pl2 Breast Hormone sensitivity
RARp2 Retinoic acid receptor 3p24 Colon, lung, head and neck Vitamin sensitivity
RASSF1A Ras effector homolog 3p21.3 Multiple types Unknown
NORE1A Ras effector homolog lq32 Lung Unknown
VHL Ubiquitin ligase component 3p25 Kidney,hemangioblastoma Loss of hypoxic response
Rb Cell cycle inhibitor 13ql4 Retinoblastoma Entrance in cell cycle
THBS-1 Thrombospondin-1 antiangiogenic 15ql5 Glioma Neovascularisation
CDH1 E-cadherin, cell adhesion 16q22.1 Breast, stomach, leukaemia Dissemination
CDH13 H-cadherin, cell adhesion 16q24 Breast, lung Dissemination
FAT Cadherin, tumour suppressor 4q34-35 Colon Dissemination
HIC-1 Transcription factor 17pl3.33 Multiple types Unknown
APC Inhibitor of P-catenin 5q21 Aerodigestive tract Activation of p-catenin route
SFRP1 Secreted frizzled-related protein-1 8pl2-pl 1 Colon
Activation WNT 
signalling
COX-2 Cycooxygenase-2 lp25 Colon, stomach Anti-inflammatoryresistance
SOCS-1 Inhibitor of JAK/STAT pathway 16pl3.13 Liver, myeloma JAK2 activation
SOCS-3 Inhibitor of JAK/STAT pathway 17q25 Lung JAK2 activation
GATA-4 Transcription factor 8p23-p22 Colon, stomach Silencing of target genes
GATA-5 Transcription factor 20ql3 Colon, stomach Silencing of target genes
SRBC BRAC-1 binding lpl5 Breast, lung Unknown
SYK Tyrosine kinase 9q22 Breast Unknown
RIZ1 Histone/proteinmethyltransferase lp36 Breast, liver Aberrant gene expression
DAPK Pro-apoptotic 9q34.1 Lymphoma, lung, colon, glioblastoma Resistance to apoptosis
TMS Pro-apoptotic 16pl 1 Breast, glioblastoma Resistance to apoptosis
TPEF/HPP1 Transmembrane protein 2q33 Colon, bladder Unknown
Taken from Manel Esteller 2005 (Esteller, 2005).
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Few studies have investigated methylation in paediatric astrocytoma. In adult GBMIV, 
methylation of DAPK and TMS1 has been found at low frequencies and THBS1 
methylation has been shown in both low and high-grade astrocytoma (Li et al., 1999; 
Gonzalez-Gomez et al., 2003a). A detailed investigation of the methylation status of 34 
genes in 54 adult astrocytomas of various grades identified methylation of RASSF1A, 
TP73, AR, MGMT, CDH1, OCT6, MT1A, WT1, and IRF7 that were methylated in 
69.8%, 47.2%, 41.5%, 35.8%, 32%, 30.2%, 30.2%, 30.2% and 26.4% of cases 
respectively (Yu et al., 2004).
Transcription at methylated sites can also be affected by methyl-CpG binding domain 
proteins (MBD) that are recruited and act as adaptor proteins between methylated DNA 
and chromatin modifying enzymes (Hendrich and Tweedie, 2003). The role of 
chromatin remodelling and histone modification as mechanisms involved in tumour and 
cancer development is only just emerging. Chromatin consists of approximately 2m of 
DNA coiled around a series of nucleosomes and is parcelled into the nucleus. 
Surprisingly, in this form chromatin retains a large degree of functionality (Richmond,
2006). The nucleosome consists of histones H2A, H2B, H3 and H4 as hetero-dimers 
that form a core unit. Histone tails carry a positive charge and are capable of interacting 
with the poly-anionic back bone of DNA contributing to nucleosome stability (Yap and 
Zhou, 2006). The regulation of chromatin structure and transcription is often influenced 
by post-translational modification of histone tail residues, affecting the accessibility of 
transcription factors to DNA. This includes methylation, acetylation, phosphorylation 
and ADP-ribosylation (Vitolo et al., 2000).
A specific group of transcription factors are involved in chromatin structure remodelling 
allowing other transcription factors access to DNA regions (Thomas and Chiang, 2006). 
Alterations in chromatin structure can also occur through ATP-dependent nucleosome 
remodelling (Johnson et al., 2005). Histone acetyltansferases (HATs), histone 
methyltransferases (HMTs) and histone deacetylases (HDACs) are all involved in a 
proposed aberrant histone modification signature for cancer (Fraga and Esteller, 2005). 
A large study by Ozdag et al. (2006) illustrated that six different cancer types, including 
adult GBMIVs, had a unique pattern of histone modifier gene expression compared to 
that of the corresponding normal tissue or other cancers.
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The extent of non-coding RNA (ncRNA) involvement in epigenetics is largely 
unknown. Small regulatory ncRNAs include microRNAs (miRNAs) and small 
interfering RNAs (siRNAs) that are approximately 22 nucleotides in length and 
suppress translation in two ways. miRNAs undergo non-perfect pairing with target 
mRNA preventing translation and siRNAs pair perfectly with target mRNA causing 
degradation by the RNA-induced silencing complex. siRNAs are also involved in the 
silencing of chromatin and chromosome dynamics (Mattick and Makunin, 2006).
Recent discoveries suggest that the role of ncRNAs in disease is broader than initially 
understood, involving the control of gene expression through chromatin architecture and 
transcription (Mattick and Makunin, 2006). miRNA expression profiles have been used 
to classify human cancers (Lu et al., 2005) and disrupted miRNA target genes have been 
characterised in pituitary adenomas (Bottom et al., 2007). Furthermore, miRNAs have 
been found to be disrupted in adult GBMIV through microarray analysis (Ciafre et al.,
2005). In the primary GBMIV investigated, nine miRNAs were significantly up- 
regulated and four were significantly down-regulated. When the tumours were clustered 
according to the expression profile similarity of the miRNAs, a clear distinction could 
be seen between normal controls and GBMIV samples, suggesting a role for miRNAs in 
GBMIV development (Ciafre et al., 2005).
Control o f  transcription, translation and protein activation
The regulation of gene expression controls the amount of functional gene product 
available at a given time and when synthesis occurs. This process is modulated at all 
levels from transcription of mRNA to post-translational modification of proteins. This is 
essential, increasing the versatility and adaptability of cells, allowing specific proteins 
to be expressed in response to environmental change. Furthermore, gene regulation 
allows a multicellular organism to exist, utilising different transcriptomes each 
governed by different controls to influence cellular differentiation and morphogenesis.
The regulation of transcription controls when and how much RNA is synthesised. 
Specific mechanisms including DNA methylation, chromatin remodelling, histone 
modification and non-coding RNAs and their role in cancer have previously been 
discussed. Briefly, gene transcription by RNA polymerase is regulated by at least five
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factors and mechanisms including, specificity factors that alter the specificity of RNA 
polymerase for a given promoter, repressors that bind to non-coding sequences on the 
DNA strand impeding the progression of RNA polymerase, general transcription factors 
that position RNA polymerase at the start of a protein-coding sequence and then release 
the polymerase to initiate transcription, activators that enhance the interaction between 
RNA polymerase and a particular promoter, facilitating gene expression and enhancers 
that are DNA sites bound to by activators that alter DNA structure, in order to join a 
specific promoter and initiation complex (Quivy et al., 2004; Wilusz and Wilusz, 2004; 
Valencia-Sanchez et al., 2006). The regulation of transcription involves several 
interactions between many transcription factors that allows for complex responses to 
multiple conditions in the environment. This permits spatial and temporal differences in 
gene expression.
Once DNA is transcribed additional mechanisms known as capping, splicing and the 
addition of a poly(A) tail control the amount of protein translated from the mRNA. 
Capping adds a 7-methylguanosine (m7G) group to the 5’ end, which protects the 
mRNA from 5' nuclease degradation. The cap also aids ribosomal binding. Splicing 
removes introns from the mRNA to ensure that only coding regions are translated into 
proteins and the addition of poly(A) tails to the 3' end increases the half life of mRNA 
(Mata et al., 2005; Wek and Cavener, 2007).
Posttranslational modification is the chemical modification of a protein after translation. 
This modification of amino acids include attaching the protein to other biochemical 
functional groups such as acetate, phosphate, various lipids and carbohydrates, changing 
the chemical nature of an amino acid or by making structural changes. Many alterations 
govern protein degradation influencing half life, enzyme affinity and efficacy and 
whether a protein is active or inactive (Mata et al., 2005; Wek and Cavener, 2007).
Disruption at any stage of transcription or translation impacts cellular pathways and is 
involved in tumourigenesis. Understanding the complex control mechanisms governing 
these processes will identify those pathways disrupted in specific tumours including 
astrocytoma, providing targets for new therapies (Lo et al., 2005).
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Genetics and chromosomal alterations in paediatric astrocytoma 
Histopathologically, paediatric astrocytoma are similar to adults. However, studies have 
shown that their biological behaviour is different to that of their adult counterparts. This 
suggests that these tumours have a different molecular pathogenesis. Studies 
investigating chromosomal aberrations in paediatric astrocytoma have identified 
alterations that also occur in adult astrocytoma and further changes that are common to 
paediatric astrocytoma alone. Furthermore, some paediatric high-grade astrocytoma 
show a normal karyotype, a characteristic uncommon in adult astrocytoma (Bigner et 
al., 1997; Warr et al., 2001; Rickert et al., 2001).
Cytogenetic analysis of paediatric PAI has shown that the majority of these tumours 
(>70%) have a normal karyotype (Bhattachaijee et al., 1997). Numerical and structural 
abnormalities of chromosomes 5, 6, 7, 8 and 9 have been reported, although definitive, 
non-random aberrations have not yet been identified (White et al., 1995; Zattara- 
Cannoni et al., 1998; Shlomit et al., 2000; Sanoudou et al., 2000b; Rickert and Paulus, 
2004). Loss of the locus on chromosome 17p has been reported in some paediatric PAI 
studies but not consistently (von Deimling et al., 1993; Phelan et al., 1995; Willert et al., 
1995). Whole chromosome alterations have been observed in paediatric PAI arising in 
patients above 10 years of age. The most common alterations were gain of 
chromosomes 5 and 7, present in 13% and 17% of cases, respectively. Whole 
chromosome alterations of chromosomes 4, 6, 9, 10, 11, 12 and 20 were present in 3% 
of cases and chromosome 15 in 6% of cases (Jones et al., 2006). Single nucleotide 
polymorphic (SNP) allelic arrays have also been used to identify regions of allelic 
imbalance in low-grade paediatric gliomas including 6 PAI. However, no detectable 
LOH was found at any of the 11562 SNP loci investigated in the PAI (Wong et al.,
2006).
A study by Addo-Yobo et al. (2006) identified over-expression of ErbB3 and Sox 10 in 
paediatric PAI. The ErbB family of proteins are thought to be involved in the growth 
and development of the normal nervous system. This study suggests that the up- 
regulation of ErbB3 via Sox 10 in paediatric PAI, drives cell growth and proliferation, as 
previously seen in embryonic astrocytes (Britsch et al., 2001). PAI sensitivity to the 
tyrosine kinase inhibitor gefitinib is thought to occur via ErbB3.
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The risk of developing PAI is increased in neurofibromatosis type 1 (NF1) patients. 
These patients have a mutation and functional loss of the NF1 gene. Some sporadic 
paediatric PAI show LOH on chromosome 17q in the region of the NF1 gene (Willert et 
al., 1995). Consequently, loss of NF1 was expected to be a common event in these 
tumours, however this is yet to be established (Platten et al., 1996; Wimmer et al.,
2002). At this time it is unknown why the loss of NF1 increases the risk of PAI in NF1 
patients.
In paediatric DAII, AAIII and GBMIV of patients below 15 years of age there is a 
correlation between karyotype complexity and tumour grade. DAII often have a normal 
karyotype or show simple chromosome changes compared to high-grade astrocytoma 
that show multiple complex chromosome aberrations frequently displaying hyperdiploid 
or polypoid karyotypes (Agamanolis and Malone, 1995; Bigner et al., 1997; 
Bhattachaijee et al., 1997; Roberts et al., 2001). Studies investigating diffuse 
astrocytoma in children show inconsistent findings. Specific studies describe 
chromosome alterations that are common in adult astrocytoma including -17p, +7, -10 
and -22 (Schrock et al., 1996; Bhattacharjee et al., 1997). Other studies describe 
different alterations to those seen in adults (Neumann et al., 1993; Agamanolis and 
Malone, 1995; Cheng et al., 1999).
Chromosomal regions that have shown copy number aberrations in malignant 
astrocytoma from patients below 25 years of age include -16p, -17p, -19p, -22, +2q, 
+12q, +13, +4q, +5q and +8q. Seven regions of high copy number amplification were 
observed in the same study at 8q21-22 (three cases), 7q22-23 (two cases) and lp21-22, 
2q22, 12ql3-pter, 12ql5-21, and 13ql 1-14 (one case each) (Warr et al., 2001). Rickert 
et al. (2001) also identified gain of lq, 3q and 16p and loss of 8q and 17p in paediatric 
GBMIV. Furthermore, in paediatric AAIII different aberrations have been reported 
involving gain of 5q and loss of 6q, 9q, 12q and 22q (Rickert et al., 2001). Moreover, 
LOH on 22q was found to occur at the same frequency in paediatric astrocytomas as 
seen in adults (Nakamura et al., 2007). Interestingly, the same study found a higher 
frequency of TP53 mutations and LOH on chromosomes 19q and 22q in tumours from 
children above 6 years of age at diagnosis, compared with those from younger children 
(Nakamura et al., 2007).
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Amplification of EGFR is not commonly found in paediatric astrocytoma as seen in 
adults (Kraus et al., 2002; Khatua et al., 2003; Pollack et al., 2006). However, protein 
over-expression has been reported in 80% of paediatric astrocytoma (Bredel et al.,
1999). Moreover, a recent study investigating a small number of high-grade paediatric 
astrocytoma identified up-regulation of EGFR expression and other genes linked to 
angiogenesis (Khatua et al., 2003).
TP53 mutations have been found in paediatric astrocytoma at varying levels and at a 
much lower frequency than in adult astrocytoma (Sure et al., 1997; Cheng et al., 1999; 
Hayes et al., 1999; Pollack et al., 2002). However, in a study by Pollack et al. (2002) 
TP53 mutations were found in paediatric GBMIV at the same rate as previously found 
in adults. The same study also correlated TP53 protein over-expression with increasing 
paediatric astrocytoma grade. Furthermore, high-grade astrocytomas in children above 3 
years of age showed a TP53 mutation rate comparable to malignant astrocytoma from 
young adults (Pollack et al., 2001). This positive correlation between increasing TP53 
mutation rate and paediatric astrocytoma patient age has also been identified by 
Nakamura et al. (2007) High-grade astrocytoma from children above 6 years of age 
showed an increase in TP53 mutation frequency compared to those below 6 years of 
age. Although no amplification of the MDM2 gene has been reported, over-expression 
has been found in 67% of paediatric GBMIV (Sung et al., 2000).
In paediatric GBMIV, homologous deletion of the CDKN2A locus at 9p21 was found in 
10% of tumours and mutations of this gene were also found in 8% and 13% of AAIII 
and GBMIV respectively (Sure et al., 1997; Raffel et al., 1999; Newcomb et al., 2000) 
Furthermore, loss of CDKN2A expression was found in 60% of paediatric GBMIV 
(Sure et al., 1997). It has been reported that disruption of the TP53 pathway through one 
or more of these mechanisms occurs in 95% of paediatric GBMIV, a figure similar to 
that of adult astrocytoma. However, the Rb pathway is only disrupted in 25% of 
paediatric GBMIV, a much lower frequency than that seen in adult GBMIV (Sung et al.,
2000). Mutation of the PTEN gene has been linked to poor prognosis in paediatric 
astrocytoma, but this has been reported in only a few cases (Raffel et al., 1999; Kraus et 
al., 2002; Pollack et al., 2006).
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Stem cells and brain tumours
Tumours do not consist of a single cell type, but are composed of a variety of cells with 
different phenotypic and genotypic characteristics (Nakano and Komblum, 2006). 
Traditional thinking suggests that many cells within a tumour are capable of giving rise 
to another tumour cell (Reya et al., 2001). In contrast, the cancer stem cell hypothesis 
suggests that tumours arise from a minority cell type with self renewing properties, 
which are capable of giving rise to other more differentiated cell types. This hierarchy 
of cell origin has been well documented in leukaemia (Bonnet and Dick, 1997). From 
this hypothesis it was proposed that cancer stem cells originate from normal adult or 
tissue specific stem cells that have acquired mutations. Although this has not been 
proven, there is some evidence to suggest this in leukaemia. The implications of these 
suggestions are that target therapies would need to be aimed at cancer stem cells and not 
cellular derivatives to have any chance of success (Nakano and Komblum, 2006).
Several studies have investigated the cancer stem cell hypothesis in adult GBMIV. A 
sub-population of cells have been characterised with increased tumorigenic potential 
and expression of CD133, a marker of neural precursor cells (Singh et al., 2004). The 
CD133+ population of cells showed consistent stem cell characteristics including 
expression of stem cell markers CD133, Sox2, Musashi and Nestin, multi-lineage 
differentiation, with expression of GFAP and SI 00/3 (astrocytes), Map-2 and TUJ1 
(neurons) or 04  and GalC (oligodendrocytes) and neurosphere formation. The cells 
were also found to be highly tumorigenic in immunocompromised mouse brains 
compared to CD 133' cells (Bao et al., 2006).
Furthermore, the CD133+ adult GBMIV cells were found to be highly resistant to 
ionizing radiation compared to the CD 133’ GBMIV cells. This was attributed to the 
efficiency of DNA repair mechanism induction in the CD133+ cells. Moreover, after 
radiation, the CD133+ fraction of the tumour was increased. Ionising radiation has been 
the primary treatment for GBMIV for the last 40 years, but has become a temporary 
solution, reducing tumour size rather than a cure. These results provide an explanation 
for GBMIV response to ionising radiation and suggests that future therapies may need 
to target the CD133+ tumour cell population (Bao et al., 2006).
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A second study by Piccirillo et al. (2006) identified bone morphogenetic proteins 
(BMPs), specifically BMP4, as factors that can reduce the stem-like, tumour initiating 
CD133+ tumour cell population. BMPs play a role in promoting the differentiation of 
adult stems to astrocytes (Panchision and McKay, 2002). CD133+ adult GBMIV cells 
expressing BMP4 showed reduced proliferation in response to mitogens, increasing the 
number of cells in the G0/G1 phase of the cell cycle and simultaneously decreasing the 
number of cells in the S phase. In addition, morphological changes were seen in the 
cells including increased GFAP expression, decreased MAPS and pHI-tubulin 
expression (neuronal markers) and decreased GalC expression. Overall, BMP4 
expression was shown to promote differentiation in adult GBMIV CD133+ cells, 
reducing the pool of tumour initiating cells (Piccirillo et al., 2006). These results also 
imply that GBMIV cell populations may retain stem cell hierarchy and the ability to 
respond to the normal signals that induce them. This also fuels interest in developing 
therapies that promote tumour cell differentiation (Dirks, 2006).
Expression microarray studies investigating astrocytoma
Several microarray studies have been carried out on astrocytoma (Huang et al., 2000; 
Rickman et al., 2001; Fuller et al., 2002; Kim et al., 2002b; Nutt et al., 2003; Shai et al., 
2003; van den et al., 2003; Godard et al., 2003; Mischel et al., 2003; Rorive et al.,
2006). The studies are difficult to compare for several reasons. Initially, various array 
platforms have been used to generate gene expression profiles, consequently different 
probes and numbers are used to detect the same gene. Secondly, data analysis 
programmes for each platform are varied, as are the statistical tests and bioinformatic 
approaches. The studies use different types and numbers of astrocytoma, as well as 
control tissues or samples. Overall, more studies are needed and standards need to be 
introduced to allow comparisons between different data sets and results.
The studies involving adult astrocytoma have revealed that tumour tissue expression 
profiles significantly differ from that of normal tissue. Sub-groups of astrocytoma 
grades have also been recognised and distinct genetic profiles may be used to aid 
diagnosis and predict tumour behaviour. Eventually, this could lead to new tailored 
treatments determined by astrocytoma sub-type and expression profile.
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Results collected from these studies correlated with previous findings in adult 
astrocytoma. A study by Mischel et al. (2003) highlighted increased VGF and/or 
receptor expression in high-grade tumours as expected. Furthermore, larger studies have 
highlighted a number of novel genes aberrantly expressed in astrocytoma. A study of 
adult DAII highlighted novel differentially expressed genes including AAD14, SPARC, 
LRP, PTN, hBAP and IFI9-2 that were up-regulated, whilst CLK, TDGF1, BIN1, GAB1, 
TYR03, LDH-A, adducing 3, GUK1, CDC10, and KRT8 were down-regulated. 
Furthermore, TIMP3, MYC, EGFR, DR-nm23, nm23H4 and GDNPF were only 
expressed in the tumour samples compared to controls (Huang et al., 2000). 
Quantitative real-time polymerase chain reaction (Q-PCR) was used in the majority of 
cases to validate aberrant expression results found in the microarray studies.
Only three microarray studies have investigated paediatric astrocytoma, with two 
focusing on PAI (Khatua et al., 2003; Wong et al., 2005; Sharma et al., 2007). The 
study by Wong et al. (2005) analysed 21 paediatric PAI using the Affymetrix 
GeneChip® U133A array. A total of 428 genes showed a 3-fold and significant change 
in expression from the normal; 192 up-regulated and 236 down-regulated. Of the 428 
genes that showed differential expression, 96 were sub-grouped according to biological 
processes. A total of 23 genes were involved in neurogenesis; 20 genes in cell adhesion; 
14 genes in synaptic transmission; 11 genes CNS development; 10 genes in potassium 
ion transport; 10 genes in protein amino acid dephosphorylation; and 8 genes in cell 
differentiation. This study also identified two sub-groups of paediatric PAI within the 
21 samples. A group of 89 genes were differentially expressed between the two sub­
groups. The sub-groups were further distinguished by immunohistochemical staining of 
myelin basic protein (MBP). Paraffin sections of 8 of 10 PAI in one sub-group revealed 
fewer positively stained cells which correlated with increased disease progression in 
these PAI. The study suggests that MBP may be used as a marker to distinguish PAI 
with increased risk of disease progression.
A second study focused on 41 PAI ranging in age between 1 and 53 years, which were a 
mixture of sporadic PAI and those arising in patients with NF1. In this investigation, the 
Affymetrix GeneChip® U133 Plus 2 array was used to investigate differential gene 
expression. No gene expression signature was identified which could discriminate those
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PAI that were clinically aggressive, recurred, occurred sporadically or were from 
patients with NF1. Whole-genome expression analysis could not segregate the tumours 
based on tumour or patient parameters. However, a group of 36 genes were shown to be 
differentially expressed between supratentorial tumours and those located in the 
posterior fossa (Sharma et al., 2007).
Khatua et al. (2003) distinguished low and high-grade paediatric astrocytoma using 
genes involved in angiogenesis. The EGFR/FKBP12/HIF-2a pathway was found to be 
over-expressed in high-grade tumours. This study used the Affymetrix GeneChip 
U95Av2 array containing 12000 genes and selected 133 genes involved in angiogenesis 
for detailed analysis. In total, 44 genes were differentially expressed between low and 
high-grade astrocytoma. Hierarchical clustering using these genes, showed that the 
tumours clustered according to grade. This study showed that the over-expression of 
specific EGFR/FKBP12/HIF-2a pathway genes in high-grade paediatric astrocytoma 
promotes angiogenesis and could be used as target genes for new therapies.
aCGH studies investigating astrocytoma
Analogue CGH (comparative genomic hybridisation) has previously been used to 
identify common chromosome CNAs in paediatric astrocytoma. However, this 
technique is less sensitive than the 1MB resolution of aCGH (array comparative 
genomic hybridisation). Several aCGH studies have recently defined genome wide 
aberrations at a resolution of 1Mb in adult malignant astrocytoma (Cai et al., 2002; 
Nigro et al., 2005; Rossi et al., 2005; Misra et al., 2005; Korshunov et al., 2006; Ruano 
et al., 2006; Vranova et al., 2007; Wrensch et al., 2007). Only one study investigated 
paediatric astrocytoma, specifically PAI in children and young adults (Jones et al., 
2006). An additional study used SNP allele arrays to investigate genome-wide allelic 
imbalances in low and high-grade paediatric astrocytoma (Wong et al., 2006).
Potential genetic sub-groups were identified in two studies investigating adult GBMIV 
(Misra et al., 2005; Korshunov et al., 2006). The sub-groups did vary, but both studies 
identified loss of chromosome 10 and gain of chromosome 7 as the most common 
chromosome aberrations in adult GBMIV. Other single clone alterations were identified 
by the studies, which mapped to regions containing putative oncogenes and tumour
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suppressors. These clones were also used to define the genetic sub-groups, providing a 
more detailed and specific characterisation of adult GBMIV and the key regions and 
genes disrupted in this tumour. The study by Misra et al. (2005) included 50 primary 
GBMIV biopsy samples that clustered into 3 distinct groups according CNAs. Group A 
contained 23 GBMIVs with no consistent aberrations compared to groups B and C that 
consisted of 9 GBMIV with loss of chromosome 10 and 18 GBMIV with loss of 10 and 
gain of 7 respectively. The authors propose that the tumours of each group would show 
varying responses to different treatment regimes given the diverse CNAs identified in 
each cluster. No correlations were made between survival and specific CNAs or groups 
but only 3 patients involved in the study were considered to be long term survivors, 
which prevented this approach (Misra et al., 2005).
In comparison Korshunov et al. (2006) investigated 70 GBMIV and identify 46 CNAs 
that were associated with patient outcomes, 26 were associated with shortened survival 
and 20 correlated with good prognosis. Hierarchical cluster analysis distinguished two 
genetically distinct groups of GBMIV consisting of 56 (group 1) and 14 (group 2) 
tumours, respectively that showed a significant difference in survival. The 5-year 
survival rate was 0% for group 1 and 63% for group 2. The authors suggest that aCGH 
screening of GBMIV could provide clinically useful information and potentially 
improve the quality of treatment (Korshunov et al., 2006). Both of these studies consist 
of large sample numbers that have allowed hypotheses to be statistically proved. 
However both studies could benefit from addition sample numbers with broader tumour 
and patient parameters including varied survival rates.
Jones et al. (2006) investigated 32 PAI in patients below 15 years of age and 12 PAI in 
patients above 15 years of age. Overall, 64% of tumours had a normal karyotype, with 
32% of tumours showing gain of whole chromosomes. Whole chromosome alterations 
were only observed in tumours arising in patients above 10 years of age, the most 
common of which were gain of chromosomes 5 and 7, occurring in 13% and 17% of 
cases respectively. Alterations of chromosome 15 was present in 6% of cases followed 
by chromosomes 4, 6, 9, 10, 11, 12 and 20 that were seen in 3% of cases. Loss or gain 
of single BAC clones are still to be confirmed in this study.
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Short-term cell cultures and the study of astrocytoma
The use of short-term cell cultures and established cell lines in the study of cancer has 
been constantly criticised. Difficulties have been encountered when characterising cell 
lines due to the changes in cellular environment including the promotion of proliferation 
in vitro compared to in vivo, reduction in cell -  cell and cell -  matrix interactions due to 
purified culture fractions and loss of three-dimensional architecture and alterations in 
nutrient and hormonal availability. The culture environment promotes spreading, 
migration and proliferation and consequently these factors will induce changes in gene 
expression within in vitro cells compared to those in vivo.
A recent study by Camphausen et al. (2005) used microarray analysis to characterise 
two human glioma cell lines (U251 and U87) when grown in vitro and in vivo 
subcutaneously or as intracerebral xenografts. For each cell line, the gene expression 
profiles generated from each approach were significantly different suggesting that the in 
vivo growth environment modulates gene expression compared to orthotropic growth 
conditions, which induce different gene expression changes (Camphausen et al., 2005). 
These data also suggests that tumour cells respond to the environment in which they are 
grown consistently, inducing similar gene expression changes. Moreover, a study by 
Ross et al. (2000) characterised systematic variation in gene expression in 60 human 
cancer cell lines originating from 9 different types of solid tumour. Classification of the 
cell lines highlighted an association to the tumours of origin from which the cell lines 
were derived. Specific features of the gene expression profile also correlated with 
physiological properties of the cell lines including doubling time in culture, drug 
metabolism or the interferon response. Furthermore, a branch of the hierarchical 
clustering tree included all GBMIV, renal cell carcinoma and carcinoma derived cell 
lines. Those genes that specifically characterised this group of cultures included many 
involved in stromal cell functions. It was also noted that the GBMIV cell lines showed 
mesenchymal characteristics and may explain the ease of establishing these cell lines 
(Ross et al., 2000).
Both studies highlight that changes in gene expression do occur in tumour derived cell 
cultures but that the gene expression changes are different depending on the growth 
environment yet consistent. The clustering of cultures from the same tumour of origin 
confirms that the cultures do maintain characteristics of the tissue of origin. This also
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suggests that providing that the culture environment is maintained, comparisons could 
be made between cultures derived from different grades of the same tumour, or specific 
tumour types in order to study specific tumour characteristics or specific grades.
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AIMS
Little is known about the genetics of paediatric astrocytoma. The majority of these 
tumours have normal karyotypes and few common genomic alterations have been 
recognised. A number of studies have included the investigation of gene or protein 
expression but show conflicting results. Furthermore, the common genomic and 
expression alterations seen in adult astrocytoma are comparatively rare in paediatric 
astrocytoma.
The initial aim of this study was to identify differentially expressed genes in different 
grades of malignancy in paediatric astrocytoma biopsy samples. The samples for this 
study were frozen biopsy tissues collected from consenting patients at Great Ormond 
Street Hospital between 1980 and 2005. Unfortunately, it was not possible to obtain 
total RNA from paediatric DAII, AAIII and GBMIV tissues of sufficient quality for 
expression microarrays, due to tissue storage procedures in the 1980’s and early 1990’s. 
However, short-term cell culture samples were available from the same tumours and 
consequently this sample source was used as an alternative to investigate differentially 
expressed genes in paediatric astrocytoma.
As a result the aims of this study were to;
❖ Identify differentially expressed genes in paediatric astrocytoma using
microarray technology and identify expression profiles unique to paediatric 
astrocytoma that may correlate with tumour or patient parameters.
❖ Correlate differentially expressed genes with cellular pathways that may be
involved in tumour development.
❖ Identify copy number alterations in paediatric astrocytoma using aCGH and
correlate these with differential gene expression as a mechanism of gene 
expression alteration.
❖ Investigate methylation as a mechanism causing differential gene expression in
paediatric astrocytoma.
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Compare the use of biopsy and short-term cell cultures in the study of paediatric 
astrocytoma and the possible influence of short-term cell culture on gene 
expression.
Investigate the use of control samples in microarray experiments and the study 
of paediatric astrocytoma with regards to biopsy and short-term cell culture 
tumour samples and microarray experimental approaches.
Investigate the accuracy of single microarray chips for individual tumour sample 
study, by comparing chip replicates of a small number of samples.
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CHAPTER 2 
MA TER1ALS AND METHODS
The Local Research Ethics Committee at the Institute of Child Health and Great 
Ormond Street Hospital gave approval for this study (Study REC number 
04/Q0508/98).
Additional work not directly required for the understanding and interpretation of the 
results can be found in the Appendix or on the Supplementary Data CD included at the 
back of this thesis.
MATERIALS
Information regarding reagent suppliers and buffer preparations are detailed in 
Appendix I. Plastics were all purchased from Scientific Laboratory Supplies or Triple 
Red and all chemicals were obtained from Sigma Aldrich unless otherwise stated.
Samples
Astrocytoma biopsy samples were collected from consenting patients at Great Ormond 
Street Hospital between 1980 and 2005. The samples were obtained from tissue 
removed during surgery, surplus to diagnosis. The surgeons carrying out this procedure 
were Mr W. Harkness, Professor R. Hayward and Mr D. Thompson. All tumour 
samples were directly adjacent to tumour tissue processed for routine histological 
evaluation and were first examined macroscopically to ensure that no frankly normal 
tissue was present. They were diagnosed according to the WHO classification and 
reviewed by two neuropathologists Dr B. Harding and Dr T. Jacques (Kleihues and 
Cavenee, 2000).
In 2007, the fourth edition of the WHO Classification of Central Nervous System 
Tumours was published. In this edition, the WHO grading scheme has been up-dated to 
include new entities and histological variants where appropriate, as well as tumour 
genetic profiles (Louis et al., 2007b). A new astrocytoma variant was included in the 
edition, termed pilomyxoid astrocytoma, as previously described in the Introduction. 
The new grading scheme for astrocytomas was described by Louis et al. This account
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states that WHO defines diffusely infiltrating astrocytic tumours with cytological atypia 
alone as grade II, those showing anaplasia and mitotic activity as grade III and tumours 
additionally showing micro vascular proliferation and/or necrosis as WHO grade IV. 
Furthermore, this account also states that the finding of a solitary mitosis in a sample 
specimen does not confer grade III behaviour and that separation of grade II and III 
tumours may be more reliably achieved by determination of MIB-1 labelling indices. 
For grade IV, some authors accept only the criterion of endothelial proliferation, i.e. an 
apparent multi-layering of endothelium (Louis et al., 2007b).
The initial diagnoses of tumours included in this study, have been reviewed in light of 
the 2007 WHO classification grading scheme. It was not possible to review all cases 
and some cases could only be reviewed from case notes and pathology reports. 
Consequently, caution should be taken when acknowledging the new diagnoses in these 
cases. Interestingly, the majority of initial diagnoses that were PAI and GBMIV 
remained the same according to the 2007 WHO grading scheme. However, all initial 
diagnoses of DAII were altered under the new scheme, the majority of which were 
deemed PAI. As this review was completed at the end of the study, initial diagnoses and 
those made in 2007 are referred throughout the report. If two conflicting diagnoses have 
been reported for a tumour, the diagnosis shown in bold corresponds to the WHO 
grading scheme of 2007.
Short-term cell culture preparations were set up in the laboratory from biopsy tissue 
immediately after receipt. At the time of this study, the majority of tumour biopsy and 
short-term cell culture samples had already been collected and stored in liquid nitrogen. 
Details of all samples and patients used in this study are given in Tables 2.1, 2.2 and 
2.3.
Normal human adult and foetal brain total RNA from whole brain and specific brain 
regions were obtained as pooled samples where possible from several commercial 
companies including AMS Biotechnology, United States Biologicals and BD 
Biosciences. Foetal astrocytes were obtained from Cambrex Bio Sciences and Professor 
G. Pilkington, at Portsmouth University (Table 2.1).
67
Table 2.1 Data of the normal control samples in this study.
Ref4 Origin2 Location3 Number of 
pooled donors 4
Sex5 Age range6
A TB Young Adult Total Brain 5 M 24-30 yrs
A TB 34 Young Adult Total Brain 3 M 21-27 yrs
A TB 35 Young Adult Total Brain 3 M 23-29 yrs
A TB 36 Young Adult Total Brain 3 M 22-28 yrs
A Cere Adult Cerebellum 24 M & F 16-70 yrs
A CorC Adult Corpus Callosum 24 M & F 24-68 yrs
F TB Foetus Total Brain 21 M & F 26-40 wks
F Cere L Foetus Cerebellum (Left) 1 F 37 wks
F Cere R Foetus Cerebellum (Right) 1 F 33 wks
F CorC Foetus Corpus Callosum 3 M & F 22-36 wks
GP-9 Foetal Astrocytes - - - -
NHA Foetal Astrocytes - - - -
Ref4: Reference name and number; Origin2: Origin of RNA; Location3: Region of brain tissue used for 
RNA isolation; Number of Pooled Donors4: Number of donors pooled in each sample; Sex 5: M = male F 
= female; Age Range6: Age range of patients pooled in each sample.
Characterisation of short-term cell cultures
Short-term cell cultures were derived from tumour tissue directly adjacent to that 
processed for routine histological evaluation and examined macroscopically to ensure 
that no frankly normal tissue was present. Cell morphology was monitored throughout 
cell culture to ensure cells maintained an astrocytic phenotype. This included small 
rounded cells and spindle dendritic-like cells as characterised by Wang et al. (2007). 
During early passage, cells of some of cultures showed cytoplasmic processes that 
contacted each other as seen by Ishiwata et al. (2004).
CNAs were also investigated in each culture, as discussed in Chapter 5, as genetic 
instability and abnormal karyotypes are common in tumorigenic cells. However, not all 
paediatric astrocytoma exhibit CNAs as previously discussed in the Introduction. The 
gene expression profile of each short-term culture was also investigated and deemed to 
be significantly different from the normal as discussed in Chapter 5. Doubling times and 
TP 5 3 and P73 mutations have previously been investigated in these short-term cultures 
although the data is not discussed in this study. Cell surface markers were not 
investigated during or prior to this study. All short-term cultures investigated in the 
study were considered to be tumorigenic.
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Table 2.2 Clinical and pathological data of the astrocytoma in this study.
IN1 Age2 Sex3 Grade at Grade as Location6 Survival7
diagnosis4 of20075
1350 4.3 M PAI - Posterior Fossa Unknown
1520 7 M PAI PAI L. Temporal Parietal DIS 112 (A)
1524 13 M PAI PAI L.Cerebellum 13(A)
1591 2 F PAI PAI Frontoparietal 60(D)
1740 8 M PAI PAI Posterior Fossa 160 (A)
2017 7 M PAI PAI Posterior Fossa 124 (A)
2110 2.7 M PAI PAI Posterior Fossa DIS 125 (A)
2122 10 F PAI PAI Supraseller Optic Chiasm DIS 78 (A)
2356 4 M PAI PAI Cerebellum 142 (A)
2368 8 F PAI PAI Posterior Fossa DIS 87 (A)
2524 4 F PAI PAI Midline-Posterior Fossa DIS 39 (A)
2604 6 F PAI - Optic Chiasm Unknown
2631 4 F PAI PAI Cerebellum 21(A)
2674 5 M PAI PAI L.Cerebellum 112(A)
2688 5 M Low PAI Cerebellum 55 (A)
2788 9 M PAI PAI Posterior Fossa 45 (A)
2825 2.75 F PAI PAI Posterior Fossa 104 (A)
2921 3 M PAI PAI Posterior Fossa 48 (A)
2940 1.75 M PAI PAI Posterior Fossa 74 (A)
2969 3.5 F PAI PAI Posterior Fossa 57(A)
3013 11.5 M PAI PAI Posterior Fossa 58 (A)
3017 8.25 F PAI PAI Posterior Fossa 59(A)
3115 3.5 F PAI PAI Optic Pathway 33 (A)
3126 9 M PAI PAI Posterior Fossa 31(A)
3156 1.9 F PAI PAI Posterior Fossa 1(A)
380 1.8 F DAII - Posterior Fossa 92 (D)
1145 11 M DAII - Midline Cerebellar 60 (A)
1751 6 F DAII PAI R. Temporal 63 (A)
1869 15 F DAII PAI Posterior Fossa 139(A)
1930 13 F DAII AAIII Temporal 53 (A)
2012 7 F DAII PAI L. Temporal 145 (D)
2044 9 M DAII PAI Posterior Fossa DIS 18(A)
2102 8 M DAII PAI Brainstem 67 (A)
3032 9.5 F GA AAIII L.Thalamic 12(D)
2003* 9 F DAII PAI R. Temporal 117(A)
2591* 12 F DAII PAI Supratentorial 117(A)
178” 13 M GBMIV - L.Temporal 3(D)
179” 13 M GBMIV - Base of Skull 3(D)
699 15 M GBMIV - R.Thalamus Unknown
1163 0.2 M GBMIV - R. Parietal DIS 153 (A)
1262 14 M GBMIV - L. Parietal 12(A)
1419** 8.5 F GBMIV GBMIV Supratentorial 12(D)
1495 6 F GBMIV GBMIV Supratentorial 80 (A)
1523 10 F GBMIV GBMIV L.Parietal 33(D)
1566 6.4 F GBMIV GBMIV Posterior Fossa 7(A)
2087 3 M GBMIV GBMIV Brainstem (D)
2675 14 M GBMIV GBMIV Brainstem 16(D)
3046 15.9 M GBMIV AAIII L.Frontal 14(D)
IN1: Institute of Neurology assigned number; Age2: Age in years at diagnosis; Sex3: M = Male; F = 
Female; Grade475 PAI = pilocytic astrocytoma; DAII = diffuse astrocytoma; GA = gemistocytic 
astrocytoma; AAIII = anaplastic astrocytoma; GBMIV = glioblastoma multiforme; Low = low grade 
tumour. It was not possible to review all cases in this study. Furthermore, it was only possible to review 
the case notes and pathology report for specific cases and not slides (these tumours are shown in bold). 
Location6: L = left; R = right; Survival7: survival in months from the date of diagnosis, A = alive; D = 
deceased. DIS = Patient has been discharge; * and “ = tumours from the same patient; ** = patient 
diagnosed with Turners Syndrome (partial or complete loss of chromosome X ) .  Biopsy tissue was 
available from tumour samples highlighted blue. Short-term cell culture preparations were available from 
tumour samples highlighted green. Both biopsy and short-term cell culture preparations were available for 
samples highlighted red.
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Table 2.3 Clinical and pathological data of the adult astrocytoma in this study.
IN1 Age Sex Grade4 Location5 Survival6
2435 57 F GBMIV R. Parietal Lobe Unknown
2731 51 M GBMIV R. Occipital Parietal Mass Unknown
2810 66 M GBMIV L. Frontal Intrinsic Lesion Unknown
1760 57 F GBMIV R. Parietal Lobe 12(D)
1265 70 F GBMIV R. Parietal Lobe 15(D)
1528 61 M GBMIV R. Occipital 7(D)
2234 61 F GBMIV Temporal Lobe Unknown
IN1: Institute of Neurology assigned number; Age2: Age in years at diagnosis; Sex3: M = Male; F = 
Female; Grade4: GBMIV = glioblastoma multiforme; Location5: L = left; R = right; Survival6: survival in 
months from the date of diagnosis, A = alive; D = deceased. Short-term cell culture preparations were 
available from tumour samples highlighted green. Both biopsy and short-term cell culture preparations 
were available for samples highlighted red. All tumours are adult primary GBMIV.
METHODS
Biopsy tissue preparation
Excess tumour biopsy tissue for research purposes was immediately transferred into 
Hams F10 nutrient mix (Invitrogen Ltd) containing additional antibiotics, 
penicillin/streptomycin (lOOIC/ml / lOOpg/ml), kanamycin (50pg/ml) and amphotericin 
(2.5pg/ml). The biopsy tissue was stored at 4°C for immediate collection from the 
operating theatre. Rapid collection and processing was essential to obtain suitable tissue 
for short-term cell culture preparations and DNA and RNA extractions.
A sterile class II laminar flow cabinet (ICN Pharmaceuticals) was used for biopsy tissue 
preparation. Initially, the tissue was removed from the media and placed in a sterile petri 
dish. Where possible, lOOmg of tissue was prepared in RNAlater™ (Qiagen) and frozen 
in liquid nitrogen for RNA extraction. Approximately lOmg of tissue was used for 
short-term cell culture preparations and the remaining tissue was frozen in liquid 
nitrogen for DNA extraction.
Tissue for short-term cell culture preparations was diced using crossed sterile scalpels 
and transferred to a sterile 30ml sterile universal tube containing 2ml media (Hepes 
buffered Hams F10 nutrient mix and 10% foetal calf serum (FCS) (Invitrogen Ltd)) and 
lml of collagenase solution (2000U/ml). The tissue was incubated at 37°C for a 
minimum of 1 hour to allow collagenase breakdown of the tissue structure. Next, 7ml of 
media was added and the preparation and centrifuged (Wifug 500E, DJB Labcare) at 
l,000rpm for 5 minutes. The supernatant was removed, the remaining pellet re-
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suspended in 10ml of media and placed in a 25cm cell culture flask. The sample was 
incubated in a non-CC>2 incubator at 37°C and checked regularly for growth.
Cell culture
All cell culture procedures took place in a sterile class II laminar flow cabinet. During 
cell culture procedures, 70% methanol was used to clean the cabinet and wipe any 
objects entering the cabinet. Details of media, serum, antibiotics and trypsin can be 
found in Appendix I.
Maintaining cells in culture
Cells in culture were fed once a week or when the media changed from pink to yellow. 
This change indicates a reduction in nutrient content, an increase in cell waste products 
due to cell growth and a drop in pH. Media was aspirated from the culture flask and
9 9replaced; 25cm flasks with 10ml of media, 75cm flasks with 13ml of media and 
150cm flasks with 35ml of media.
Passaging cells
Once cells were confluent they were passaged to a larger flask or flasks according to the 
subcultivation guidelines below. This maintained sufficient tumour cell density allowing 
population expansion. Upon each passage using trypsin (Invitrogen Ltd), the cell 
passage number was increased by one. Initially, the media was aspirated and the cells
washed at least once with hanks buffered saline solution (HBSS) (Invitrogen Ltd). To
detach the cells from the flask, 3ml of trypsin was added and the flask incubated at 37°C 
for approximately 10 minutes. After incubation, 7ml of media was added to inactivate 
the trypsin and the flask contents transferred to a sterile universal. The universal was 
centrifuged at l,000rpm for 5 minutes in order to pellet the cells. Following removal of 
the supernatant, the cell pellet was re-suspended in 10ml of fresh media and transferred 
to the necessary flask or flasks.
1 x 25cm2 flask to 1 x 75cm2 flasks 
1 x 75cm2 flask to 3 x 75cm2 flasks or 1 x 150cm2 flask 
1 x 150cm2 flask to 3 x 150cm2 flasks
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Freezing cells in liquid nitrogen
Freezing of cultured cells in liquid nitrogen creates a stock of each tumour sample. 
Once the cells were trysinised and re-suspended in 10ml of fresh media, as previously 
described, 0.4ml of the suspension was added to 19.6ml of Isoton II (Beckman Coulter 
UK Ltd) and counted using a Coulter Counter (Beckman Coulter). The remaining 
suspension was centrifuged at l,000rpm for 5 minutes to pellet the cells. The 
supernatant was removed and the cells re-suspended in a volume of FCS containing 
10% dimethylsulphoxide (DMSO) to reach a final concentration of 1 million cells per 
lml. Finally, 1ml of the suspension was transferred to a cryovial and stored at -70°C for 
24 hours. The vials were then placed in liquid nitrogen storage.
Thawing frozen cell stocks
Initially, a vial of cells was taken from liquid nitrogen, placed in warm water at 
approximately 37°C and allowed to thaw. The cell suspension was removed from the 
vial and pipetted very slowly into a universal containing 10ml of media. The universal 
was then centrifuged at l,000rpm for 5 minutes and the supernatant removed leaving a
* •  9cell pellet. This was re-suspended in 10ml of fresh media and transferred to a 25cm 
flask. The flask was placed in an incubator at 37°C to allow the cells to attach to the 
flask surface. The media was then changed after 24 hours.
Mycoplasma testing and treatment
The MycoAlert™ mycoplasma detection assay (Cambrex Bio Science) was used to test 
all short-term cell cultures for the presence of the prokaryote mycoplasma. If a short­
term cell culture was found to be contaminated, a treatment regime was completed prior 
to any further work, to remove the prokaryote. Subsequent cultures were kept separate 
from initial cultures until the contamination had been removed.
To complete the MycoAlert™ test, 5ml of media was removed from cultures that were 
80% confluent. This was centrifuged at l,000rpm for 5 minutes to remove any cell 
debris. From this media, 0.1ml was pipetted into a 96 well plate. The addition of the test 
reagent initiated mycoplasma lysis, releasing specific enzymes which reacted with the 
test substrate, converting ADP to ATP. Luminometry based detection of this ADP-ATP 
conversion, using the Mediators PhL plate luminometer (Auren Biosystems GmbH),
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indicated mycoplasma infection. Mycoplasma contaminated cultures were treated with 
Plasmocin™ (Autogen Bioclear UK Ltd) at 25pg/ml for 2 weeks.
Mycoplasma contaminated cell cultures show altered gene expression profiles, 
compared to uncontaminated cultures of the same cells. This is temporary and once the 
contamination is removed gene expression returns to the original level (Miller et al., 
2003). As this study involved the investigation of paediatric astrocytoma gene 
expression profiles it was essential that any cultures used were free of mycoplasma.
RNA
All equipment and surfaces were cleaned with RNase AWAY (Molecular BioProducts 
Inc.) prior to any RNA work. All tubes and pipette tips were RNase/DNase free and any 
water used was either RNase/DNase free (supplied with most Qiagen Kits) or DEPC- 
treated.
RNA extraction from biopsy tissue
All RNA extractions were competed in a sterile Astecair 5000E hood (Bioquell UK 
Ltd). Between 50-100mg of tissue was used for each extraction depending on the initial 
tissue size. The biopsy samples were taken from liquid nitrogen storage and allowed to 
thaw on ice. Once thawed the tissue was weighed, cut and transferred to a sterile glass 
pestle and mortar containing 1ml of TRIzol® Reagent (Life Technologies). The tissue 
was homogenised and incubated to ensure all nucleases had been denatured. Phase 
separation was used to isolate the RNA using chloroform according to the 
manufacturer’s instructions. The resulting RNA pellet was re-suspended in 0.1ml of 
RNase DNase-free water.
The RNeasy® Mini Column Kit (Qiagen) was used to clean the extracted RNA 
following the manufacturer’s instructions. Briefly, 0.35ml of RLT buffer (containing P- 
mercaptoethanol at 0.01ml per 1ml of RLT) was added to the re-suspended RNA and 
mixed by gentle vortexing. A further 0.25ml of absolute ethanol was added and mixed 
via pipetting. The total mixture was transferred to an RNeasy® mini column and 
centrifuged for 15 seconds at 10,000rpm. Two wash steps were completed, the column 
transferred to a new collection tube and 30pl of RNase/DNase-free water added to the
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membrane. The column was then incubated at room temperature for 1 minute prior to 
centrifugation at 10,000rpm for 1 minute. The quantity and quality of the eluted RNA 
was assessed before storage at -80°C.
RNA extraction from cell cultures
Initially, cells that were 70% confluent in three 150cm flasks were detached using
trypsin and counted using the Coulter Counter as previously described. Qiagen 
• • •RNeasy Midi Kits were used to extract RNA from the cells following the 
manufacturer’s instructions. Briefly, the cell pellet was re-suspended in a volume of 
buffer RLT (containing (3-Mercaptoethanol at 0.01ml per 1ml buffer RLT) depending 
on the number of cells harvested; 5xl06-3 x l0 7 cells: 2ml; 3xl07-5 x l0 7
cells: 2ml; and 5xl07- lx l0 8 cells: 4ml.
The lysate was passed through an 18-20 gauge needle to homogenise the cells, an equal 
volume of 70% ethanol added and the sample vigorously shaken. The sample was 
applied to the midi column and centrifuged at 5000rpm for 10 minutes. A series of wash 
steps was then completed, the column placed in a new collection tube and 70pl of 
RNase/DNase-free water was pipetted onto the membrane. The column was incubated 
at room temperature for 1 minute and centrifuged. The elution was then transferred from 
the collection tube back to the membrane and centrifugation repeated. The quality and 
quantity of the RNA was assessed before being stored at -80°C.
RNA precipitation procedure
When the concentration of RNA obtained from an extraction was not sufficient for 
further work, the RNA was precipitated as a pellet and re-suspended in a smaller 
volume of DEPC-treated water. Initially, a tenth of the sample volume of 3M sodium 
acetate (NaOAc) pH 5.2 was added to the RNA sample, followed by two and a half 
times the sample volume of absolute ethanol. The sample was then gently vortexed. 
Prior to incubation overnight at -20°C, 5 fig of glycogen was added to increase the 
sample pellet visibility. Once incubated, the sample was centrifuged at 15,000rpm for 
20 minutes, the resulting pellet washed in 80% ethanol and centrifuged at 10,000rpm for 
7 minutes. This step was repeated. The ethanol was then removed and the pellet air-
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dried. Finally the pellet was re-suspended in the desired volume of DEPC-treated water 
and stored at -80°C.
DNA
DNA extraction from biopsy tissue
All DNA extractions were completed in a sterile Astecair 5000E hood (Bioquell UK 
Ltd). Approximately 25mg of tissue was used for each extraction depending on the 
initial tissue size.
DNA was extracted from the biopsy tissue using the QIAamp® DNA Mini Kit (Qiagen) 
following the manufacturer’s instructions. All buffers were supplied with the kit. 
Briefly, 25mg of tissue was diced and placed in a 1.5ml microcentrifuge tube containing 
180pl of buffer ATL and 20pl of proteinase K (0.6AU/ml). The sample was vortexed 
and incubated at 56°C for 3 hours or until the tissue was completely lysed. To remove 
any RNA contamination, 4pl of RNase A (lOOmg/ml) was then added to the sample 
followed by 200pl of Buffer AL. The sample was pulse-vortexed and incubated at 70°C 
for 10 minutes. 200pl of ethanol (96%-100%) was added, the mixture transferred to the 
QIAamp Spin Column and centrifuged at 800rpm for 1 minute. A series of wash steps 
was then completed, the column placed in a new collection tube and 200pl of DEPC- 
treated water added to the column. The column was centrifuged at 800rpm for 1 minute 
to elute the DNA. DNA quality and quantity was assessed before being stored at -80°C.
DNA extraction from cell cultures
Initially, cells that were 70% confluent in three 150cm3 flasks were detached using 
trypsin and counted using the Coulter Counter as previously described. Qiagen 
Genomic-tips were then used to extract DNA from the cells once they had been 
homogenised. All buffer preparations can be found in Appendix I.
Cells were resuspended in 2ml of ice cold PBS (lx  phosphate buffered saline) at xlO 
cells per ml. An equal volume of ice cold buffer Cl was added to the suspension, the 
tube inverted several times and incubated on ice for 10 minutes. The sample was 
centrifuged at 4°C for 15 minutes at 900rpm to pellet the cells. The supernatant was 
removed and the pellet resuspended in 1ml ice cold buffer C l and 3ml of ice cold
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DEPC-treated water. The sample was then vortexed and centrifuged as previously 
described. The supernatant was discarded, 5ml of buffer G2 was used to resuspend the 
pellet and the sample was vortexed for 10-30 seconds. To digest any denatured proteins, 
95pi of protease (lAU/ml) was added to the sample which was then incubated at 50°C 
for 45 minutes or until the lysate became clear.
Gravity allowed all solutions to pass through the genomic-tip 100/G. Initially, the tip 
was equilibriated with 4ml of buffer QBT. Once vortexed for 10 seconds, the lysate was 
applied to the tip, this was followed by a wash step using 7.5ml of buffer QC. The 
genomic DNA was then eluted by applying 5ml of buffer QF to the tip. DNA 
precipitation was achieved by adding 3.5ml of room temperature isopropanol to the 
elution, vortexing briefly and centrifuging at 4°C for 15 minutes at max speed. The 
supernatant was removed leaving the DNA pellet which was then washed in 2ml of ice 
cold 70% ethanol and centrifuged at 4°C for 10 minutes at max speed. The ethanol was 
removed and the pellet allowed to air dry before resuspension in lOOpl of DEPC-treated 
water. Finally, the DNA was dissolved overnight at 55°C. DNA quality and quantity 
was assessed before being stored at -80°C.
RNA and DNA quantification and assessment
Agilent Bioanalyser 2100
The Agilent Bioanalyser 2100 and RNA 6000 NanoChip® assay (Agilent Technologies) 
were used to assess RNA quality and quantity. High quality total RNA samples were 
characterised by an electropherogram with two well-defined peaks corresponding to 18S 
and 28S ribosomal RNAs, with peak ratios between 1.9 and 2.1. A lower ratio and 
distorted peaks indicates RNA degradation.
The priming station and initial RNA 6000 NanoChip® preparations were carried out 
according to manufacturer’s instructions. For sample analysis, 5pi of RNA 6000 Nano 
marker and 1 pi of sample were added to each well. The chip was vortexed for 1 minute 
and inserted into the Bioanalyser. The running of the chip was controlled through the 
Agilent Bioanalyser 2100 software.
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Figure 2.1 The eletropherograms illustrate degraded RNA (a) and high quality RNA (b).
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Spectrophotometer analysis
DNA and RNA quality and quantity was also assessed using a spectrophotometer 
(GeneQuant, Pharmacia Biotech, Amersham Bioscience). An absorbance measurement 
at 260nm of 1 is equivalent to 40pg/ml of RNA or 50pg/ml of DNA and these values 
were used to calculate RNA or DNA concentrations. An additional measurement at 
280nm was also taken and the ratio (260nm/280nm) calculated. Good quality RNA and 
DNA should have a ratios between 1.9 and 2.1 or 1.7 and 1.9 respectively. A value 
lower indicates nucleotide degradation and a value higher indicates protein 
contamination.
Affymetrix GeneChip® Human Genome U133A array
The Affymetrix GeneChip® U133A array allows the analysis of genome-wide gene 
expression in a single experiment. The array encompasses 22000 probes sets including 
18400 transcripts and variants that correlate with 14500 well-characterised genes. The 
array platform is divided into a series of ‘spots’. Oligonucleotide probe pairs 
complementary to corresponding gene sequences are synthesised in situ to each spot. 
The probe pairs are 25 bases in length and designed to be a match and a mismatch to the 
target cRNA. On every array, each probe set consists of 11-16 oligonucleotide probe 
pairs. This multi-detection method increases the sensitivity and specificity of transcript 
detection in the presence of complex background signals. This is particularly important 
when looking at low abundance genes. The gene sequences used in the array design 
were selected from GeneBank®, dbEST and RefSeq. The sequence clusters were created 
from the UniGene database (Build 133, April 20, 2001) and then refined by analysis and
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comparison with other public databases. Samples used for Affymetrix GeneChip® array 
technology need to be of the highest quality in order for the system to function 
efficiently and generate reliable results.
RNA preparation and completion to the Affymetrix GeneChip® Human Genome 
U133A array
Recommended manufacturer’s protocols were followed at all times for RNA 
preparation and completion to Affymetrix GeneChip ® U133A arrays. Figure 2.2 
illustrates each stage of the protocol.
Figure 2.2 cRNA synthesis from total RNA for microarray analysis.
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cDNA synthesis from total RNA
Initially, 8pg of total RNA was required for cDNA synthesis. Table 2.4 indicates the 
reagents, volumes and concentrations used for one cDNA synthesis reaction per sample. 
All reagents were purchased as the Superscript Choice System (Invitrogen Ltd). To 
initiate first strand cDNA synthesis, DEPC-treated water, T7-oligo (dT) primer and total 
RNA were added to a 0.5ml tube. Each tube was flick mixed, briefly spun and incubated 
at 70°C for 10 minutes. To complete the primer hybridisation, the tubes were placed on 
ice for a minimum of 2 minutes. The 5X first strand buffer, DTT and dNTP mix were 
added, the tubes flick mixed, briefly spun and incubated at 42°C for 2 minutes. 
Superscript II was then added, the tubes mixed, spun and incubated at 42°C for 1 hour 
(Table 2.4).
Table 2.4 The reagent mix for first strand cDNA synthesis.
Reagents Volume Final Concentration
DEPC-treated Water To a total volume of 20pl -
T7-oligo(dT) primer 1 pi (from stock) 100 pmol
Total RNA for 8pg of sample
5X first strand buffer 4pl IX
0.1MDTT 2pl lOmM
lOmM dNTP mix lpl 500pM each
Superscript IIRT (200U/ul) lp l 200U
Total Volume 20 pi -
After incubation, the tubes were placed on ice for a minimum of 2 minutes and briefly 
spun. The reagents for second strand cDNA synthesis were added to each tube in the 
order stated in Table 2.5.
Table 2.5 The reagent mix for second strand cDNA synthesis.
Reagents Volume Final Concentration
DEPC-treated Water To a total volume of 150pl
5X second strand buffer 30pl IX
lOmM dNTP mix 3 pi 200pM each
lOU/pl E.Coli DNA ligase lpl 10U
lOU/pl E.Coli polymerase I 4pl 40U
2U/pl E.Coli RNase H lpl 2U
Total Volume 150pl
The tubes were flick mixed, briefly spun and incubated at 16°C for 2 hours. The tubes 
were then spun, 2 pi of T4 DNA polymerase (10U) added and the tubes incubated at
79
16°C for a further 5 minutes. Finally, 1 Ojj.1 of EDTA (0.5M) was added to each tube and 
the samples cleaned.
Clean-up o f  double-stranded cDNA
cDNA clean-up was completed using the Sample Clean-up Module (Affymetrix Inc.) 
according to the manufacturer’s instructions. To each sample, 0.6ml of cDNA binding 
buffer was added and vortexed for 3 seconds. The colour of the mixture was always 
yellow indicating correct pH. The sample was applied to the cDNA clean-up column 
and centrifuged at 10,000rpm for 1 minute. A wash step was then completed and the 
column centrifuged with the cap open at maximum speed for 5 minutes to dry the 
membrane. The columns were transferred to a new 1.5ml collection tube and 14pl of 
cDNA elution buffer pipetted directly onto the membrane. The column was incubated at 
room temperature for 1 minute and centrifuged at maximum speed for 1 minute to elute 
the cDNA. The cDNA was stored at -20°C.
To ensure cDNA synthesis had been successful, a reverse transcriptase polymerase 
chain reaction (RT-PCR) was completed for the gene (3-actin. The forward and reverse 
primer sequences used are as follows; forward: 5’-AATCTGGCACCACACCTTCTAC­
S’ and reverse: 5’-CTCCTTAATGTCACGCACGAT-3 ’. The RT-PCR reaction mix 
was made up as shown in Table 2.6 and the cDNA synthesis reaction diluted 1:20.
Table 2.6 RT-PCR reaction mix.
Reagent Concentration Volume
RNase/DNase Free Water - 13.8pl
Buffer Without MgCL2 lOx 2 pi
MgCL2 Buffer 25mM 1.2pl
dNTP Mix lOmM 0.5pl
Forward Primer lOmM 0.5pl
Reverse Primer lOmM 0.5pl
cDNA Template (1:20) lp l
Taq DNA Polymerase 5U/pl 0.5pl
Total Volume - 20pl
The reaction cycle parameters, included an initial denaturation step at 94°C for 2 
minutes, followed by denaturation phase at 94°C for 30 seconds, an annealing phase at 
60°C for 30 seconds and extension phase of 72°C for 45 seconds. This was repeated 30 
times followed by a final step of 72 °C for 4 minutes. Once the reaction was completed
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the tubes were placed on ice for a minimum of 2 minutes and spun to collect any 
condensation.
Gel electrophoresis was performed to view the amplified p-actin product. A 3% agarose 
gel was made using 60ml of IX tris-acetate (TAE) buffer and ethidium bromide 
(lOpg/ml). 2pi of DNA loading-dye was added to each 20pl cDNA sample reaction mix 
and a lOObp DNA ladder (MBI Fermentas) was used as a marker for the 350bp p-actin 
product. Products were then visualised using a UV transilluminator. A previously 
successful cDNA sample was included in this RT-PCR reaction as a positive control.
Biotin labelled cRNA synthesis
The Bio Array High Yield RNA Transcript Labelling Kit (Affymetrix Inc.) was used to 
generate biotin-labelled cRNA using lOpl of the cDNA synthesis reaction. The reaction 
for each sample was set up as shown in Table 2.7. The tubes were flick mixed, spun and 
incubated at 37°C for 5 hours. At 30 minute intervals, the samples were gently mixed 
via pipetting. Once complete, the samples were placed on ice for a minimum of 2 
minutes and cleaned.
Table 2.7 Reagent mix for cRNA synthesis reaction.
Reagent Volume
Template cDNA lOpl
RNase/DNase Free Water 12pl
10X HY Reaction Buffer 4pl
10X Biotin-Labelled Ribonucleotides 4pl
10X DTT 4pl
10X RNase Inhibitor Mix 4pl
20X T7 RNA Polymerase 2pl
Total Volume 40pl
Clean-up o f  biotin labelled cRNA
Buffers were made in the laboratory according to the manufacturer’s instructions 
(Sample Clean-up Module, Affymetrix Inc). Initially, 60pi of RNase/DNase free water, 
350pl of IVT cRNA binding buffer and 250pl of absolute ethanol were added to each 
cRNA reaction and vortexed for 3 seconds. The mixture was then transferred to an IVT 
cRNA clean-up column and centrifuged at 10,000rpm for 15 seconds. A wash step was 
then completed followed by a second involving 0.5ml of 80% ethanol. The column was
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then centrifuged with the cap open at max speed for 5 minutes to dry the membrane. 
The columns were then transferred to a new 1.5ml collection tube and 11 pi of 
RNase/DNase free water pipetted directly onto the membrane. The column was 
incubated at room temperature for 1 minute and centrifuged at maximum speed for 1 
minute. This step was repeated with lOpl of RNase/DNase free water. cRNA quality 
and quantity was assessed by spectrophotometer and gel electrophoresis analysis. The 
samples were then stored at -80°C.
Correction calculation
The yield of cRNA was adjusted to reflect the carry over of unlabelled total RNA. The 
spectrophotometer analysis result was corrected using the following calculation.
Adjusted cRNA yield = RNAm-(total RNAj) (y)
RNAm = amount of cRNA measured after IVT (pg) 
total RNAj = starting amount of total RNA (pg) 
y = fraction of cDNA reaction used in IVT
Fragmentation o f  biotin labelled cRNA
The fragmentation mix shown in Table 2.8 was used for each sample followed by an 
incubation step at 94°C for 35 minutes. The samples were placed directly on ice for a 
minimum of 2 minutes and briefly spun to collect any condensation. To ensure 
fragmentation had been successful, 2pl of mixture was removed and assessed via gel 
electrophoresis. The samples were then stored at -20°C.
Table 2.8 The reaction mix required for fragmentation.
Component Volume
15pg cRNA Sufficient for 15pg
5X Fragmentation Buffer 8 pi
RNase/DNase Free Water To a total volume of 40 pi
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cRNA assessment
Gel electrophoresis was used to asses the quality of both the cleaned cRNA and the 
fragmented cRNA. This was carried out as previously described using a 1% agarose gel 
and a lkb RNA Century Marker (Ambion Ltd) (Figure 2.3).
The lkb marker was located in the first well (the second well is empty) and the samples IN3013, IN2044, 
IN2003, IN2591, IN2102, IN 1751 and IN2921 are located in wells 3-16; cleaned cRNA followed by 
fragmented cRNA for each sample.
cRNA hybridisation
The hybridisation cocktail assembled for each fragmented cRNA sample was composed 
of the reagents shown in Table 2.9 including the GeneChip® Eukaryotic Hybridisation 
Control Kit (Affymetrix Inc.), Herring Sperm (Invitrogen) and BSA (Promega). The 
samples were flick mixed, briefly spun and incubated at 99°C for 5 minutes. The 
samples were the transferred to 45°C for 5 minutes before being spun at maximum 
speed for 5 minutes.
Figure 2.3 The gel electrophoresis image illustrates cleaned and fragment cRNA.
Table 2.9 Reaction mix required for each hybridisation cocktail.
Component Volume
15pg Fragmented cRNA sufficient for 15pg 
5 pi 
15pl
Control Oligonucleotide B2 3nM
20X Eukaryotic Hybridisation Controls 
(bioB, bioC, bioD, ere)
Herring Sperm DNA (lOmg/ml) 3 H-l 
3 pl 
150jnl 
15pl
Bovine Serum Albumin (BSA) (50mg/ml) 
2X Hybridisation Buffer
DMSO 
RNase/DNase Free Water 
Total Volume
to final volume 300pl 
300pl
The Affymetrix GeneChip® U133A probe array was allowed to reach room temperature 
before use. The array was primed using 200pl of IX hybridisation buffer via the septa 
on the probe array reverse and incubated at 45°C for 10 minutes. The hybridisation
buffer was then removed and 200pl of the treated hybridisation cocktail pipetted into 
the probe array. The array was then placed into the hybridisation oven at 45 °C for 16 
hours.
U133A probe array washing and staining
The fluidics Station 450 was used to wash and stain the probe arrays. This was set up 
and primed according to Affymetrix protocol guidelines prior to this stage of the array 
protocol. All buffer synthesis protocols can be found in Appendix I.
After hybridisation, the cocktail was removed and 200pl of non-stringent wash buffer 
was added to the probe array. The array was inserted into the primed fluidics station and 
the EukGE-WS2v4 450 washing and staining protocol carried out (Table 2.10).
Table 2.10 Washing and staining protocol for Affymetrix GeneChip®.
____________________________________ EukGE-WS2v4 450 wash protocol_________
Post Hybridisation Wash #1 10 cycles of 2 mixes/cycle with wash buffer A at 25°C
Post Hybridisation Wash #2 4 cycles of 15 mixes/cycle with wash buffer B at 50°C
Stain Stain the probe array for 10 minutes in SAPE
solution at 25°C
Post Stain Wash 10 cycles of 4 mixes/cycle with wash buffer A at 25 °C
2nd Stain Stain the probe array for 10 minutes in antibody
solution at 25°C
3rd Stain Stain the probe array for 10 minutes in SAPE
solution at 25°C
Final Wash 15 cycles of 4 mixes/cycle with wash buffer A at 30°C.
_____________________________________ The holding temperature is 25°C.__________
Wash Buffer A = Non-Stringent Wash Buffer; Wash Buffer B = Stringent Wash Buffer 
U133A probe array scanning
Once the wash and staining protocol was complete the probe arrays were scanned using 
the Affymetrix GeneChip® Scanner 3000 following manufacturer’s guidelines. Before 
the probe array was inserted into the scanner, Tough-Spots™ were placed over the two 
septa to prevent fluids leaking during scanning. The array was then scanned at a pixel 
resolution of 3pm and wavelength of 570nm.
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The raw data the intensities of each probe set collected by the scanner dictated the 
expression measurement. This measurement is described both qualitatively and 
quantitatively and compared to a baseline line measurement to gauge the relative change 
in transcript abundance. Using the probe pair intensities and a detection algorithm, a 
detection p-value is generated that indicates the reliability of transcript detection. This 
can be either present, marginal or absent. A further algorithm uses the probe pair 
intensities to calculate a signal value which assigns a relative measure of abundance of 
each transcript. These expression results can then be analysed using a variety of 
software programmes.
GeneSpring® - Affymetrix GeneChip® Human Genome U133A array data analysis
GeneSpring® allows the analysis of all 22000 gene expression results generated by the 
Affymetrix GeneChip® Human Genome U133A array. Samples were grouped into 
specific experiments to answer the different questions laid out in the aims of this 
project. Only 1 array chip was completed per sample and therefore the cross-genes error 
model was applied when the samples were not grouped according to a common 
parameter. The cross-gene error model assesses sample and measurement variation as a 
function of the control strength within all the measurements taken for a single sample, 
compared to the usual method of sample replicates to assess variation. This is achieved 
by ordering the probe sets by their control strengths and calculating the median variance 
and median control strength for each non-overlapping set of eleven. The error for each 
probe set is approximated by using the median deviation from 1.0. This approach can be 
used with general purpose arrays where the majority of genes have little biological 
variability.
Normalizations were then carried out to standardize all data in an experiment. This 
reduces the affects of background noise and experimental variation enabling biological 
variation in gene expression to be more easily identified. This also allows data scaling 
so that relative gene expression comparisons can be made between samples. Initially, a 
data transformation normalisation was completed for an experiment. Any measurements 
less than 0.01 (set as a standard cut-off) were readjusted to 0.01. This removed any 
negative values given as a gene expression level and replaced it with a level equivalent 
to 0 (i.e. no expression). Per chip normalisations were then completed, dividing all the
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measurements on each array by the 50th percentile. This corrected for chip-wide 
variations in intensity, possibly due to inconsistent washing, sample preparation or array 
production. The resulting expression levels were therefore centred on 1 for each chip. 
Measurements for this normalisation step were limited to those that were called as 
present or marginal.
Finally, per gene normalisations were completed. In this approach, the expression level 
of each gene was divided by either the mean expression of the same gene in several 
control samples or the mean expression of the gene in all samples. Normalisations were 
carried out in sequence using the corrected gene values from the previous 
normalization. The choice of normal control samples is most important when using this 
approach to normalise an experiment. The reliability and number of control samples 
was considered when experiment analysis was completed.
Once the raw expression data for a given experiment had been normalised, various 
filters were applied to remove unwanted or unnecessary results from the final stage of 
analysis. Using the tool, Filter On Flags, gene expression results were removed from the 
experiment according to detection reliability on the chip; absent, marginal or present. 
Expression results flagged absent in every sample were removed from an experiment. 
Removal of further gene expression data depended on the number of present calls per 
number of samples in the experiment. Genes that were identified as being constant in all 
samples and Affymetrix GeneChip® standard genes were also removed from further 
analysis.
Allowing genes that are present in a proportion of samples, for example 50%, into an 
experiment permits those genes that are not expressed due to sample biology rather than 
an experimental error to be analysed. Moreover, this allows those genes that are not 
expressed in a control group compared to a sample group or not expressed in a sample 
group compared to a control group to be investigated. This approach does allow more 
false positives into an experiment but at the same time provides a more accurate 
assessment of gene expression profiles with regard to genes that are expressed and not 
expressed. Few microarray studies using GeneSpring® software for analysis state the 
‘present’ criteria included in the study. However, one study stated that ‘the magnitude
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of difference between two groups was defined using the following criteria; (i) greater 
than 2-fold difference, (ii) statistical significance (p < 0.05), and (iii) classification as 
‘present’ in at least one of the tumours’ (Sowar et al., 2006). Furthermore, Wong et al. 
(2005) removed genes that were called ‘absent’ in 5 of the 21 tumours investigated.
From the final group of reliable gene expression results, those genes that showed a 
statistically significant difference between groups were identified. This was completed 
using a Student’s t-test or a one-way ANOVA and variances were assumed to be equal. 
A p-value cut-off of p = 0.05 was used in each test. In order to reduce the false 
discovery rate, the Benjamini and Hochberg false discovery rate multiple test correction 
was also applied. In addition, the tool Filter On Fold was used to find those genes that 
showed a greater than 2-fold up or down-regulated between groups. Genes identified by 
both methods were used in further analysis approaches. When investigating one sample, 
statistical analysis was not always possible. Consequently, a gene fold change greater 
than 2 was used to identify differentially expressed genes. The functional significance 
of those genes deemed to be differentially expressed between groups could only be 
determined by further analysis approaches discussed below. The expression fold change 
and level of significance limits used in this study reduced the overall gene list to a 
manageable number for these approaches. Furthermore, genes outside these limits may 
also show differential expression and play a biological role in astrocytoma development 
or progression. The separation of genes according to a 2-fold change in expression 
between groups may exclude some genes with biological significance. However, this 
fold change was chosen as it was felt that fewer genes below this cut-off would have 
functional significance compared to higher changes of 3 or 4-fold often used. 
Consequently, all genes within pathways of interest that were identified using this fold 
change and statistical limits, were investigated for changes in gene expression.
Unsupervised hierarchical clustering approaches were used to cluster the samples and 
controls according to expression profile similarity. This method establishes samples 
with similar gene expression patterns, highlighting groups and sub-groups regardless of 
any sample or patient parameter. Separation ratios determine the similarity between two 
samples or groups of samples, with a ratio of 0 indicating identical expression profiles. 
This approach allows sample and patient parameters to be correlated with sample gene 
expression patterns (Eisen et al., 1998). This clustering approach was also used to
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cluster the genes according to expression profile similarity and where appropriate k- 
means clustering was used to identify sets of genes with similar expression patterns.
K-means clustering groups genes into sets that show a high degree of expression 
similarity within each set but a low degree of similarity between sets. The clustering 
algorithm divides genes into a user-defined number of groups. To do this, centroids (in 
expression space) are created at the average location of each set of genes and each 
algorithm iteration assigns genes to the set with the closest centroid. After each 
iteration, the location of the centroid is recalculated and the process repeated. This 
results in the average expression profile for each set being distinct from that of others 
(Shai et al., 2003; Datta and Datta, 2006; Steinley, 2006).
Aberrantly expressed genes were investigated in detail using the internet based software 
Onto-tools (Draghici et al., 2003; Khatri et al., 2005). This software generated 
functional profiles of the differentially expressed genes and assessed the impact of 
alterations upon biological processes and pathways. The pathways used by Onto-tools 
originate from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database 
(Kanehisa and Goto, 2000). A list of the pathways involved in this approach can be 
found on the Supplementary Data CD included with this thesis. Gene functions, 
pathway involvements, chromosomal locations and links with other tumours or cancers 
were the main factors studied.
Q-PCR
To validate the Affymetrix GeneChip® U133A array results, Q-PCR analysis was 
completed for a number of genes using QuantiTect Reverse Transcription Kit (Qiagen). 
All buffers were supplied with the kit and a genomic DNA elimination step was 
completed for each sample prior to Q-PCR. cDNA synthesis was completed using 1 pg 
of total RNA according to manufacturer’s instructions. A reverse transcription master 
mix was prepared for each sample using the kit components, which included an RT 
buffer, an RT primer mix and reverse transcriptase. The master mix was divided into 
individual reactions, the genomic DNA-free total RNA for each sample was added to 
each reaction, the mixture flick mixed, briefly centrifuged and incubated at 42°C for 15 
minutes. To inhibit the reaction, the mixture was incubated for 3 minutes at 95°C. The
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cDNA was then diluted 1:10 using DEPC-treated water and lp l of the resulting mixture 
was used for Q-PCR.
Q-PCR was carried out using Assays-on-Demand™ (Applied Biosystems). Gene- 
specific oligonucleotide probes and primer pairs for the genes of this study can be found 
in Appendix I. All probes were designed across exon-exon boundaries. Taqman 
Universal Mix No AmpErase UNG was used in a 25 pi reaction volume following 
cycling conditions recommended by the manufacturer. These involved an initial 
denaturation step of 10 minutes for 95°C followed by forty cycles of 95°C for 15 
seconds and 60°C for 1 minute.
All reactions were completed as single well reactions using the ABI prism 7000 
Sequence Detection System. The comparative Cj method (PE Applied Biosystems) was 
used to determine the relative ratio of the gene expression for each gene in the tumour 
samples compared to the normal controls, p-actin was used as an endogenous control.
Xtest = 2 AACt  =  (C t, X-Ct, R)control -  (C t, x -C t, R)test
^control 2
Cj, x, is the cycle threshold of the gene of interest and Ct, r, is the cycle threshold of the 
endogenous control. Test, refers to the tumour cDNA sample and Control, refers to the 
normal brain cDNA control sample.
Methylation specific PCR assay and sequencing
DNA bisulfite treatment
All buffer preparations can be found in Appendix I.
DNA was treated with sodium bisulfite to convert all unmethylated cytosines to uracil 
as described previously (Herman et al., 1996). Briefly, lpg  of genomic DNA was 
diluted in 40pl of RNase/DNase free water, lOpl of NaOH added, the sample flick 
mixed, briefly centrifuged and incubated at 37°C for 10 minutes. To this mixture, 30pl 
of lOmM hydroquinone and 520pl of 3M sodium bisulfite were added, the tube 
inverted, briefly centrifuged and mineral oil (Sigma) layered over the contents. The 
sample was then incubated at 50°C for 16-20 hours. Once incubated the sample was
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transferred from beneath the oil to a new eppendorf tube and cleaned using the Wizard® 
DNA Clean-Up System (Promega) following manufacturer’s instructions.
Initially, a 3ml disposable syringe was attached to the Wizard® DNA mini column. 1ml 
of Wizard® DNA clean-up resin was added to each sample, the sample inverted and the 
slurry added to the syringe barrel of the Wizard® column. Pressure was applied to move 
the slurry through the column. A wash step was completed using 2ml of 80% 
isopropanol, the syringe was removed and the column transferred to a 1.5ml eppendorf 
tube. The column was centrifuged at maximum speed for 2 minutes to dry the 
membrane. To elute the DNA, 30pl of warmed DEPC-treated water was added to the 
membrane, the column incubated for 1 minute at room temperature and centrifuged at 
maximum speed for 20 seconds. This step was repeated with 25pi of warmed DEPC- 
treated water.
To pellet the DNA, 6.lpl of 3M NaOH was added to each elution, the mixture flick 
mixed and incubated at room temperature for 5 minutes. Two volumes of ice cold 
absolute ethanol were added to the sample, the tube inverted and incubated on ice for 1 
hour. The sample was then centrifuged at 13,000rpm for 15 minutes. The supernatant 
was removed, 300pl of ice-cold ethanol added to the visible pellet, the sample 
centrifuged as previously described and the step repeated. The supernatant was then 
removed and the pellet allowed to air dry. The DNA was resuspended in 25 pi of TE 
buffer and stored at -20 °C.
Methylation specific PCR
The methylation specific PCR (MSP) and sequencing primer pairs for this study were 
either adopted or designed according to MSP principles (Olek et al., 1996a; Wamecke 
et al., 1997) with the aid of the CpG island identification web server 
(http://www.uscnorris.com/cpgislands2/), primer design web server and software 
packages (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and Primer 
Express (Table 2.11). A blank control containing all MS-PCR components except 
sample DNA and two positive controls (normal DNA and commercially purchased 
universally methylated DNA (CpGenome™) both of which were bisulphite-treated) 
were included in each experiment.
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Table 2.11 MSP primer sequences, annealing temperatures and product sizes for all genes investigated.
Genes Sense Annealing 
Temperature (°C)
PCR Product 
Size
CCNA1 Sense (M) tcgtcgcgttttagtcgt 
Sense (U) gggtagttttgttgtgttttagtt
54.3 200
Antisense (M) cgttctcccaacaaccg 
Antisense (U) ccattctcccaacaaccac
55.1 200
CDKN1C Sense (M) gggttcgcgcgtataaa 
Sense (U) gggtggggtttgtgtgtat
54.7 200
Antisense (M) atacgaaaaacgcgacgac 
Antisense (U) aaaacacaacaactacctaactatcc
53.7 200
DAPK1 Sense (M) gtcggatcgagttaacgtcg 
Sense (U) gtttgtgagtgagtgtttagtttg
56.9 70
Antisense (M) aaacgccgaccccaaa 
Antisense (U) tctaattacctaaaaccaaattcatca
57.6 70
PRDM2 Sense (M) cgacggcgtagggttaagg 
Sense (U) ggtgatggtgtagggttaagggt
58.7 150
Antisense (M) ctatttcgccgaccccg 
Antisense (U) cactatttcaccaaccccaaca
58.7 150
REPRIMO Sense (M) tgcgagtgagcgtttagttc 
Sense (U) gtttgtgagtgagtgtttagttgg
55.1 100
Antisense (M) ttacctaaaaccgaattcatc 
Antisense (U) tctaattacctaaaaccaaattcatca
55.7 100
SPINT2 Sense (M) cgagaaggtcgggcg 
Sense (U) gttgagaaggttgggtgtttt
55.7 150
Antisense (M) caaccgttaaaatctcgcg 
Antisense (U) caccaaccattaaaatctcac
54.3 150
MSP was carried out in a 25pl volume (Table 2.12) with Qiagen Hot Start Taq using 
1.5 pi of bisulfite treated DNA. The initial denaturation step at 95 °C for 15 minutes was 
followed by an annealing step for 1 minute at the desired primer pair temperature. 
Thirty five amplification cycles were completed at 95°C for 30 seconds, varying primer 
pair temperatures for 30 seconds and 72°C for 30 seconds. A final extension step at 
72°C for 5 minutes was then completed.
Table 2.12 Components, concentrations and volumes of the MSP reaction.
Component Concentration
Modified DNA Sample 50-100ng
MSP Buffer 10X
12.5mM dNTP 0.25mM
lOpM Forward Primer 0.2pM
lOpM Reverse Primer 0.2pM
Hot Start Taq 1U
DEPC-treated water -
Polyacrylamide gel electrophoresis was used to separate MSP products due to their 
small size. A 10ml gel mix consisting of 10% glycerol was prepared using 2ml of 29:1 
Accugel and 1ml of 10X TBE. To initiate polymerisation, lOOpl of 10% APS
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(ammonium sulphate) and 10pl of TEMED were added to the glycerol mix. This was 
allowed to polymerise at room temperature for 20 minutes. Electrophoresis was carried 
out in IX TBE at 90V for 1.5 hours. The gel was incubated in 50ml of IX TBE 
containing ethidium bromide (0.5pg/ml), for approximately 20mins. The products were 
visualised by UV light.
Sequencing o f  bisulfite treated DNA
PCR for sequencing was carried out in a 50pl volume with Qiagen Hot Start Taq using 
the primers in Table 2.13. After an initial incubation at 95°C for 15 minutes, 38 cycles 
of 94°C for 15 seconds, varying primer temperatures for 30 seconds and 72°C for 45 
seconds were completed. This was followed by a final extension step at 72°C for 5 
minutes. Products were separated using a 1.5% gel and TBE buffer. The products were 
visualised by UV light.
Table 2.13 Sequencing primers, annealing temperatures and product sizes for all genes studied.
Genes Sense Annealing Temperature (°C)
PCR Product 
Size
CCNA1 Sense (Setl) ggggaagattttttgtggg 
Antisense (Setl) tcaaacccctaaaaacccaac
56 525
Sense (Set2) tatagttggagttggagggt 
Antisense (Set2) caaaacctacctaaacccc
54 490
CDKN1C Sense (Setl) gtggtgttgttgaaattga 
Antisense (Setl) cactaatactaaaaaaatcccac
49 420
Sense (Set2) gtgggatttttttagtattagtg 
Antisense (Set2) accaaaacactaaacaactactc
49 375
DAPK1 Sense (Setl) ggaaggtagggatttaaaaa 
Antisense (Setl) accaataaaaaccctacaaac
49 380
Sense (Set2) gtttgtagggtttttattggt 
Antisense (Set2) ccttaaccttcccaattact
49 450
Sense (Set3) gagtaattgggaaggttaagg 
Antisense (Set3) tcactaaaaacaatctctctcca
52.5 380
PRDM2 Sense (Setl) tgggaatagtaagttttttaaggg 
Antisense (Setl) caataaccaccacccaacc
55 420
Sense (Set2) ggttgggtggtggttatt 
Antisense (Set2) aaaaccccaaataacccca
55 600
REPRIMO Sense (Setl) gggtttgtttttggttaatagtag 
Antisense (Setl) caaatttacttcacccaatctc
52.5 390
SPINT2 Sense (Setl) aggaaggaatttataggaaagttg 
Antisense (Setl) ccaaataccaaaaccccc
53.5 575
Sense (Set2) gggggttttggtatttgg Antisense 
(Set2) attctccctactcaaacccc
57 320
The products were excised from the gel and cleaned for sequencing using the 
PureLink™ Quick Gel Extraction Kit (Invitrogen) following manufacturer’s 
instructions. Excised bands were placed in a 1.5ml eppendorf tube and weighed. For
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every lOmg of gel, 30pl of stabilisation buffer was added and the solution incubated at 
50°C for 15 minutes. The mixture was vortexed every 3 minutes to promote gel 
dissolution. The mixture was loaded into a Quick Gel Extraction column and 
centrifuged at 12,000rpm for 1 minute. A series of wash steps were then completed. To 
elute the DNA, 50pl of warmed TE buffer was added to the membrane and the column 
incubated at room temperature for 1 minute. The column was then centrifuged at 
12000rpm for 2 minutes.
Individual sequencing reactions using both forward and reverse primers was completed 
for each gene in 2 tumour samples and 1 normal control. The reaction was carried out 
using the sequencing PR-100 buffer and 5X reaction buffer from Applied Biosystems in 
a 20 pi total volume following manufacturer’s guidelines. An initial denaturation step 
was completed at 96°C for 30 seconds. This was followed by 25 cycles at 50°C for 15 
seconds and 60°C for 4 minutes.
The sequencing reaction was cleaned using the Millipore Montage™ Single Sample 
PCR Kit (Montage). Briefly, 380pl of DEPC-treated water and the sequencing reaction 
mixture was added to the Millipore column and centrifuged at l,000rpm for 15 minutes. 
To elute the sequencing product, the column was turned upside-down, placed into a 
clean eppendorf tube, 20pl of TE buffer added to the membrane and the column 
centrifuged at l,000rpm for 2 minutes. Finally, lOpl of the sequencing product was 
transferred to a 96 well plate and sequence analysis completed by the 3730 DNA 
Analyser. Raw data analysis and sequence viewing was completed using the ABI 
SeqScape software.
SpectralChip™ 2600 array
The SpectralChip™ 2600 is a human BAC array that generates a molecular profile of 
each chromosome allowing quantitative analysis. Each 2600-element BAC array is 
printed on a glass slide and evaluates genome wide regions of gain and loss at a 
resolution of 1Mb.
DNA preparation and completion to the SpectralChip™ 2600 array
The SpectralChip™ 2600, Spectral hybridisation buffers and Cy5-dCTP and Cy3-dCTP 
dyes were purchased from GE Healthcare. The male and female reference DNAs were
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purchased commercially and are composed of multiple anonymous donors according to 
the manufacturer’s description (Promega). All additional buffers for this protocol were 
made in the laboratory and can be found in Appendix I.
Differential labelling o f  DNA with Cy3-dCTP and Cy5-dCTP
Initially, lpg  of tumour DNA and lpg of reference DNA were each made up to a 
volume of 25pi using DEPC-treated water. To each sample, 25pi of 2.5X random 
primer solution (Bioprime Labelling Kit, Invitrogen) was added and the samples heated 
at 100°C for 5 minutes. The samples were then placed into an ice slurry for 5 minutes 
and briefly centrifuged. A dye master mix including labelling buffer, klenow fragment 
and either Cy5-dCTP or Cy3-dCTP was made up following manufacturer’s instructions, 
according to the number of samples being processed. The dye was kept in the dark at all 
times and was not used in direct sunlight or artificial lighting.
Once the master mix had been made, 5 pi of the Cy5 dye mix was added to the tumour 
sample and 5pi of the Cy3 dye mix was added to the corresponding reference sample. 
The samples were then flick mixed, briefly centrifuged and incubated at 37°C for 1 
hour. This was followed by an incubation at 100°C of 5 minutes before being placed in 
an ice slurry. 5 pi of the same dye as previously used was added to each sample, the 
samples flick mixed and incubated at 37°C for 1 hour. To stop the reaction, 5pi of 0.5M 
EDTA was added, the samples incubated at 37°C for 10 minutes and placed in an ice 
slurry. The experiment was completed in duplicate and the opposing dyes used for 
reference and tumour sample labelling.
DNA hybridisation to the SpectralChip™ 2600 array
The tumour and reference DNA labelled with the opposite dye were mixed together as 
illustrated in Figure 2.4. The reference DNA combined with each tumour sample was 
the opposite sex to that of the tumour patient. In the first arm of the experiment, the 
tumour DNA was labelled with Cy5 and the reference DNA with Cy3. In the second 
arm of the experiment, the tumour and reference DNAs were labelled with the opposing 
dye.
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Figure 2.4 Experiment work flow for aCGH DNA preparation. 
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To each sample mix, 45pl of spectral hybridization buffer I, 12.9pl of NaCl and 130pl 
of isopropanol were added, the samples flick mixed and incubated at room temperature, 
in the dark, for 20 minutes. The samples were centrifuged at 5,000rpm for 20 minutes. 
The supernatant was removed leaving the DNA pellets that appeared purple. A pink or 
blue pellet suggests DNA labelling was not completely successful or unequal amounts 
of tumour and reference DNA were used in the initial stages of the experiment. These 
pellets were not used. Successful pellets were then washed using 500pl of 70% ethanol, 
flick mixed and centrifuged at max speed for 3 minutes. The supernatant was removed 
and the pellets allowed to air dry at room temperature, in the dark, for 10 minutes. The 
pellets were resuspended in lOpl of DEPC-treated water and incubated at room 
temperature, in the dark, for 10 minutes.
Once completely resuspended, 30pl of spectral hybridization buffer II was added, the 
samples flick mixed, briefly centrifuged, incubated at 72°C for 10 minutes and then at 
37°C for 30 minutes. The SpectralChip™ 2600 array was placed onto a clean work 
bench with powder free gloves and the sample was pipetted as a single line down the
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centre of the glass slide. Using forceps, a 22 X 600mm coverslip was laid over the slide 
from top to bottom ensuring no air bubbles were visible. The slide was placed into a 
hybridization chamber, which was then wrapped in foil and sealed a small plastic bag 
containing a damp paper towel. This was then placed into a humidified chamber and 
incubated at 37°C for 16 hours.
Post hybridisation washes
The slides were removed from the hybridization chambers and placed in a coplin jar 
containing 2X SSC-0.5% SDS at room temperature for 10 minutes. The coverslips were 
removed without peeling or applying force. The slides were then washed in 2X SSC- 
50% formamide at 50°C for 20 minutes, 2X SSC-0.1% igepal at 50°C for 20 minutes 
and 0.2 SSC at 50°C for 10 minutes with agitation. After washing, each slide was 
dipped in 80% ethanol 5 times before being placed in 80% ethanol for 2 minutes. The 
slides were then blown dry using nitrogen gas and stored in a desiccator in the dark at 
room temperature until scanning.
Scanning and analysis
The arrays were scanned using the GenePix Personal 4100A Microarray Scanner 
(Molecular Devices, CA, USA). Once scanned, images were analysed using GenePix 
Pro version 6 (Molecular Devices). Image spots were defined by an automatic grid 
feature that correlated the BAC clone position on the array, with the clone details 
including genomic locations. The spots were adjusted where necessary and the dye 
intensities calculated. Further analysis was completed using Formatter Software (Digital 
Scientific, Cambridge, UK and MIDAS Team (Saeed et al., 2003)). This software 
programme has previously been used to generate genomic profiles of chronic 
myelogenous leukaemia and characterize imbalances associated with disease 
progression (Brazma et al., 2007). Preliminary analysis involved the removal of 
defective spots and those without a signal. Any spot with an intensity value less than 
10000 in one or both channels was discarded. Furthermore, if the background corrected 
signal intensity was greater than or equal to the background intensity for both channels 
of a spot, the spot was considered reliable and included in further analysis. A flip-dye 
consistency check involving the cross-log-ratios of each signal from the duplicated 
clone spots on each array and from the dye swap experiment was also completed and
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those signals that showed a greater than ± 2 SD variation between replicates were 
discarded (Quackenbush, 2002; Yang et al., 2002).
Iterative linear regression global (whole array) normalisations were completed for each 
sample reducing the SD of spot log2 ratios. In this approach, the SD of a given sample 
was continuously recalculated, removing outliers, until the correlation coefficients 
converged to a constant value. The final value is referred to as the modified standard 
deviation (MSD). The outlier range used for this was ± 2 SD (Finkelstein et al., 2002).
In order to identify those clones that showed gain or loss in the tumour samples, 
Formatter displays the log2 ratios that are in excess of a predetermined bar threshold (± 
3 MSD was used here). This level assumes that variations in the data are random and 
constant non-changing results form the majority of data. Theoretically only 0.7% of data 
values will occur outside the threshold, therefore any deviations exceeding the threshold 
are considered as true positives (Quackenbush, 2002; Yang et al., 2002). Only results 
that exceeded the threshold in both arms of the experiment were considered as true, 
reliable results (Figure 2.5). The effectiveness and reliability of this approach is 
influenced by the extent of aberrations found in a given sample. Multiple large 
chromosomal aberrations are excluded during the MSD calculation, therefore fewer 
constant non-changing results are available for the overall MSD calculations. As a 
result, the MSD may be unusually large in samples with multiple aberrations and a 
threshold of 3 SD may not be appropriate.
Figure 2.5 The profile illustrates true chromosome gains and losses compared to experiment artefacts.
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The log2 ratio of the X chromosome was also taken into consideration in each sample 
analysis. Previous studies have compared the XX and XY log2 ratio of normal male and 
female DNA as a marker of copy number alterations. Two studies stated that genomic 
CNAs in autosomal chromosomes were ± 0.3 log2 ratios compared to ± 0.68 log2 ratios 
for the X chromosome. Consequently threshold values were set at gain > 0.3 log2 ratio, 
loss < 0.3 log2 ratio, amplification > 0.68 log2 ratio and deletion < 0.3 log2 ratio (Park et 
al., 2006; Lee et al., 2007b). An additional study found that the male/female X 
chromosome log2 ratio was ± 0.69 (0.05 SD) (Pinkel et al., 1998). The difference in log2 
ratios between autosomes and the X chromosome is thought to be due to cross­
hybridisation between some X-chromosome genes and homologous sequences on 
autosomes (Pollack et al., 1999). A comparison of male and female reference DNA was 
completed in this study (Figure 2.6). The mean log2 ratio for the X chromosome was 
1.41 (0.15 SD) and no clones showed a greater than ± 0.3 log2 ratio. A cluster of clones 
at Xpter show loss in the male/female normal DNA comparison. This alteration is not 
associated with tumour development and therefore was not considered during analysis. 
As the X chromosome alterations were taken into consideration when analysing specific 
tumour profiles, the chromosome was not investigated for aberrations associated with 
tumour development. However, if the X chromosome log2 ratio in any tumour 
experiment showed a significant difference from the control male/female experiment, 
the chromosome was considered to be altered.
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Figure 2.6 This Figure illustrates the aCGH profile comparison of the male and female reference DNA.
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CHAPTER 3
THE USE OF BIOPSY AND SHORT-TERM CELL CULTURE SAMPLES IN THE 
STUDY OF PAEDIATRIC ASTROCYTOMA AND CHOICE 
OF EXPERIMENTAL CONTROLS
INTRODUCTION
Prior to the investigation of differential gene expression in paediatric astrocytoma, 
aspects of the microarray experiment required validation to ensure that the results were 
reliable and not due to experimental design, errors or artefacts. Microarray experiments 
often have complex designs with aspects that can influence experimental variation 
including, sample pooling, biological and technical replicates, sample pairing and dye- 
swapping (Altman, 2005; Zakharkin et al., 2005). Technical variations can arise from 
several experimental steps including sample preparations, labelling and hybridisation 
(Brown et al., 2004; Han et al., 2004). Biological variations include tissue or cell 
heterogeneity, genetic polymorphisms and cellular mRNA level variations due to sex, 
age, race or genotype (Spruill et al., 2002; Oleksiak et al., 2002; Whitney et al., 2003). 
Moreover, technical replicates have a consistently higher correlation in gene expression 
than biological replicates (Altman, 2005).
MICROARRAY TECHNICAL REPLICATES
INTRODUCTION
The majority of microarray studies use one array per sample and if sufficient biological 
replicates are included in the study, a level of sensitivity and specificity can be achieved 
for statistical power. In microarray experiments, this is a balance between cost, 
biological replicates and being able to correctly reject the null hypothesis (Pavlidis et 
al., 2003; Han et al., 2004; Dobbin and Simon, 2005; Jorstad et al., 2007). Pavlidis et al. 
(2003) suggested that in a simple experiment with the goal of identifying differentially 
expressed genes between two sample groups, 10-15 biological replicates are sufficient 
to achieve good statistical power and data stability. This does not take into account 
appropriate sample pooling. RNA extracted from specific samples of the same origin 
(e.g. RNA extracted from individual normal brain tissues) can be pooled together onto a
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single array or a smaller number of arrays to reduce experimental costs, overcome the 
difficulty of limited RNA from individual tissues and reduce gene expression variability 
between individuals. This approach has been shown to have little effect on statistical 
power (Peng et al., 2003).
In this study only one microarray chip was to be completed for each sample. This was 
due to cost and the number of samples included in the study. For this reason it was 
necessary to confirm that one microarray chip could accurately assess the gene 
expression profile of a sample and technical replicates were not necessary. Duplicates of 
3 short-term cell culture samples were completed using the Affymetrix GeneChip® 
U133A array. The samples were taken from the same extracted RNA, but the 
experiments were carried out on different days following the same protocol. This 
approach was used to assess the impact of technical variation on microarray tumour 
expression profiles.
The data from the duplicated samples and an additional 29 samples was grouped in one 
experiment to assess the reproducibility of the microarray chip. The experiment analysis 
was carried out as previously described and the mean expression of each gene in all 
samples was used for the per gene normalisation. Only gene probe sets present in all 35 
samples were used for the unsupervised hierarchical clustering approach, a total of 6123 
probe sets. This ensured only reliable expression results were used to assess the 
reproducibility of the arrays.
RESULTS
The replicates of each sample grouped together with a high degree of expression profile 
similarity (Figure 3.1). The separation ratios were 0.203, 0.178 and 0.177 for the 
replicates of samples A, B and C respectively (at a separation ratio of 0, gene expression 
profiles are regarded as identical). This compared to a separation ratio of 0.354 for two 
tumours that showed the highest expression profile similarity. Furthermore, these 
tumours are both PAI and therefore can be considered as biological replicates. A similar 
number of genes showed a 2-fold change in expression between the replicates of 
samples A and B. However, this was higher than that altered between the replicates of
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sample C (Table 3.1). Moreover, 704 probe sets showed a 2-fold difference in 
expression between the most similar biological replicates, a larger number than that 
seen between any of the technical replicates.
Figure 3.1 Unsupervised hierarchical clustering of the sample replicates and 29 additional samples.
The replicates of samples A, B and C cluster together with a higher degree of expression profile similarity 
compared to the remaining samples. The expression profiles of the biological replicates are shown in red.
Table 3.1 The separation ratio and number of genes with a greater than 2-fold change in gene expression 
between the technical replicates and the biological replicates.
Separation
Ratio
Number of probe sets with a 
2-fold difference in expression 
between replicates
Percentage of 
genes investigated 
(%)
Technical replicates of sample A 0.203 417 6.8
Technical replicates of sample B 0.178 481 7.9
Technical replicates of sample C 0.177 99 1.6
Biological replicates of PAI 0.354 704 11.5
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DISCUSSION
Unsupervised hierarchical clustering demonstrated that the tumour expression profiles 
of the technical replicates of 3 samples show a high degree of similarity and most 
importantly cluster together. These replicates were completed from the same extracted 
RNA to chip hybridisation on different days following the same protocol. This approach 
also highlighted that the percentage of probe sets showing a 2-fold difference in gene 
expression between technical replicates ranged from 1.6-7.9%. This compared to 11.5% 
of probe sets that showed a 2-fold difference in expression between the most similar 
biological replicates (two samples from different tumours of the same grade). Variation 
in the number of genes showing differential expression between the technical replicates 
is expected and can be explained by technical variations in mRNA preparation 
including, labelling, hybridisation and scanning. Although these stages of the protocol 
are carried out under the same conditions as far as possible, small experimental 
differences do occur, due to day or time of processing, scanning order, temperature, 
experiment duration and pipetting, amongst others (Zakharkin et al., 2005).
This experiment confirmed that one microarray chip can accurately assess the 
expression profile o f a tumour sample and technical replicates were not necessary in this 
study.
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COMPARISON OF BIOSPY AND SHORT-TERM CELL CULTURE GENE 
EXPRESSION PROFILES FROM THE SAME TUMOUR 
INTRODUCTION
Biopsy tissue, cell lines and short-term cell cultures have been used in the study of 
tumours and specific studies have directly compared tumour biopsies and short-term 
cell cultures or cell lines. It is important to recognise that these two tumour cell growth 
environments, inside the brain or artificial culture conditions, are not equal and this will 
have some influence on gene expression. It has been shown that the expression profiles 
of biopsy tissue and cell lines from specific tumours vary greatly, with some cell lines 
showing profiles that are more similar to the tumour of origin than others. Moreover, 
several studies have found fewer differences between primary tumour tissue and short­
term cell cultures (Ross and Perou, 2001; Virtanen et al., 2002; Sandberg and Emberg, 
2005; Bignotti et al., 2006; Miller et al., 2006; Olsavsky et al., 2007). Two separate 
studies have compared gene expression profiles from GBMIV tumour tissues and cell 
lines or derived cultures. Each showed that the cell culture gene expression profiles 
varied when compared to the tumour tissues and unsupervised hierarchical clustering 
grouped the cell culture samples independently of the tumour tissues (Hess et al., 2001; 
Mehrian et al., 2005). Moreover, cellular pathways have been identified in cell lines that 
show differential gene expression compared to normal and tumour tissues. Pathways up- 
regulated include ATP synthesis, cell communication pathways, cell cycle, oxidative 
phosphorylation, purine, pyrimidine and pyruvate metabolism and proteosome pathways 
and pathways down-regulated include cell adhesion and ECM-receptor interaction 
(Ertel et al., 2006).
The heterogeneity of tumours and the diversity of short-term cell cultures and cell lines 
are two elements well recognised in the study of tumours (Nicolson, 1984; Rubin, 
1990). Tumours consist of a heterogeneous cell population with various cellular 
phenotypes existing within an individual tumour and a number of tumours with the 
same diagnosis. It is this diversity which challenges the study and understanding of 
tumour growth and development. Furthermore, when tumour cells are cultured, changes 
are inevitably induced, due to artificial culture conditions. There is also the added
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complication of only being able to culture specific tumour cell populations that are able 
to survive within the artificial environment.
The use of biopsy and short-term cell cultures in the study of paediatric astrocytoma 
raises several questions:
• Can biopsy and short-term cell culture samples from tumours of the same grade 
or different grades be compared in the same microarray experiment?
• Can the same sample controls be used for biopsy and short-term cell cultures 
from the same tumour?
To investigate the use of biopsy and short-term cell cultures in the study of 
astrocytomas and the most appropriate experiment design when studying these different 
samples, comparisons were made between the gene expression profiles of 6 paired PAI 
biopsy and short-term cell culture samples from the same tumour mass and 3 paired 
adult GBMIV biopsy and short-term-cell culture samples from the same tumour mass.
Two experiments were used in this investigation, the first containing the paediatric PAI 
samples and the second containing the adult GBMIV samples. The experiment analysis 
was carried out as previously described and the mean expression of each gene in all 
samples of each individual experiment was used for the per gene normalisation. Gene 
probe sets present in 6 of 12 paediatric PAI samples, which corresponded to 11433 
probe sets and probe sets present in 3 of the 6 adult GBMIV samples, which 
corresponded to 12076 probe sets were used for an unsupervised hierarchical clustering 
approach in each experiment. This allowed those genes that were not expressed in either 
the biopsy or corresponding short-term cell culture samples to be included in the overall 
analysis. To compare the biopsy and short-term cell culture samples in this study with 
those of other studies, further analysis approaches were also completed.
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RESULTS
In the experiment containing the 12 paediatric PAI biopsy and short-term cell culture 
samples, 3157 probe sets showed a 2-fold and significant change in expression between 
the biopsies and short-term cell cultures (Figures 3.2 and 3.3). An unsupervised 
hierarchical clustering approach using the 11433 reliable gene expression results clearly 
demonstrates the clustering of these two sample groups. Moreover, the branching 
pattern of the dendrogram is different in each group (Figure 3.3).
Figure 3.2 The expression profile of six paired paediatric pilocytic astrocytoma
biopsies and short-term cell cultures. 5
IN1740 IN2110 IN2356 IN2368 IN2921 IN3013 IN1740 IN2110 IN2356 IN2368 IN2921 IN3013
BIOPSY TISSUE CELL CULTURE
The profile illustrates the 3157 probe sets that show a 2-fold and significant change in expression between 
the paired samples.
In the experiment containing the 6 adult GBMIV biopsy and short-term cell culture 
samples, 2629 probe sets showed a 2-fold and significant change in expression between 
the biopsies and short-term cell cultures (Figures 3.4). The unsupervised hierarchical 
clustering approach using the 12076 reliable gene expression results, again clearly 
demonstrates the clustering of these two sample groups. Furthermore, the branching 
pattern of the dendrogram is different in each group (Figure 3.4).
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Figure 3.3 The dendrogram illustrates two clear groups between the six paired paediatric pilocytic
astrocytoma biopsies and short-term cell cultures.
B io p s y
The dendrogram is coloured by 11433 probe sets that show a 2-fold and significant change in expression 
between the two groups. The dendrogram colour saturation is proportional to the magnitude of the 
difference from the experiment median.
Figure 3.4 The dendrogram illustrates two clear groups between the six paired adult glioblastoma 
multiforme biopsies and short-term cell cultures.
Biopsy
The dendrogram is coloured by 12076 probe sets that show a 2-fold and significant change in expression 
between the two groups. The dendrogram colour saturation is proportional to the magnitude of the 
difference from the experiment median.
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Mehrian et al. (2005) identified the 40 most differentially expressed genes between 
glioma tissues and derived cell lines. In order to compare the results to those of this 
study, the 40 most differentially expressed genes were identified between the paediatric 
PAI biopsy and short-term cell culture samples and the adult GBMIV biopsy and short­
term cell culture samples. Tables 3.2 and 3.3 list the identified genes.
Reliable data was not available for 5 of the genes in both the paediatric PAI experiment 
and the adult GBMIV experiment (.MYH11, PHYHIP, SHC3, MOBP and KCNQ2). No 
change in gene expression was found for 5 genes in the paediatric PAI experiment 
0UM2, MLC2, ACTB, KCNQ2 and SCL1A3) and 9 genes in the adult GBMIV 
experiment (UM2, MLC2, ACTB, KCNQ2, SCL1A3, ADM, CD151, D2S448 and 
TAGLN2).
Miller et al. (2006) demonstrated that a large number of genes were expressed at the 
same level in malignant peripheral nerve sheath tumour (MPNST) tissues and cell lines, 
but were expressed at a different level when compared to controls, which were human 
Schwann cells (HSC). In order to make the same comparisons between the primary 
tumours, derived short-term cell cultures and normal controls of this study, genes that 
showed no differential expression between the biopsies and short-term cell cultures 
were identified in the paediatric PAI and adult GBMIV experiments and the expression 
levels of these genes were investigated in the normal brain controls. No differential 
expression was characterised as those genes that did not show a greater than 2-fold 
variation in expression from the normalised experiment median in the biopsies and 
short-term cell cultures.
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Table 3.2 Differentially expressed genes between paediatric pilocytic astrocytoma
biopsy and short-term cell culture samples.
Ordered position Fold Gene Description
from 3157genes Change Name
1 265.8 stanmocalcin 2
2 207.7 GREM1 cysteine knot superfamily 1, BMP antagonist 1
3 150.2 COL1A1 collagen, type I, alpha 1
4 120.2 FBN1 fibrillin 1 (Marfan syndrome)
5 116.0 MYL9 myosin, light polypeptide 9, regulatory
6 114.6 GPR49 G protein-coupled receptor 49
7 104.3 COL1A2 collagen, type I, alpha 2
8 94.2 CNN1 calponin 1, basic, smooth muscle
9 89.4 ITGBL1 integral, beta-like 1 (with EGF-Iike repeat domains)
10 78.0 COL6A2 collagen, type VI, alpha 2
11 76.6 MYOID myosin ID
12 75.7 COL3A1 collagen, type III, alpha 1
13 69.7 FN1 fibronectin 1
14 66.0 LOX Human lysyl oxidase (LOX) gene, exon 7.
15 65.3 KRT7 keratin 7
16 64.9 CALD1 caldesmon 1
17 64.2 SERPINH1 serine (or cysteine) proteinase inhibitor
18 63.4 THBS1 thrombospondin 1
19 63.1 HSPG2 heparan sulfate proteoglycan 2 (perlecan)
20 60.2 SERPINE1 serine (or cysteine) proteinase inhibitor
23 55.8 PHLDA2 tumour suppressing subtransferable candidate 3
81 19.7 NID2 nidogen 2 (osteonidogen)
83 19.4 ACTG2 actin, gamma 2, smooth muscle, enteric
116 15.3 ADM adrenomedullin
261 7.4 TRAM2 TRAM-like protein
341 5.7 ANXA2 annexin A2
480 4.4 PFKP phosphofructokinase, platelet
521 4.1 CD151 CD151 antigen
549 3.9 NBL1 neuroblastoma, suppression of tumorigenicity I
5% 3.7 S100A11 S100 calcium binding protein All (calgizzarin)
665 3.3 D2S448 Melanoma associated gene
693 3.2 TAGLN2 transgelin 2
695 3.2 STATI Homo sapiens transcription factor ISGF-3 mRNA
711 3.2 MAP2K3 mitogen-activated protein kinase kinase 3
740 3.1 CNN2 calponin 2
1650 -2.2 ARL6IP ADP-ribosylation factor-like 6 interacting protein
2176 -3.3 SYT11 synaptotagmin XI
2432 -4.7 CNP 2'rJ'-cyclic nucleotide 3' phosphodiesterase
2459 -4.8 RNASE1 Homo sapiens ribonuclease, RNase A family, 1
2689 -7.9 CCND2 cyclin D2
2824 -12.7 CRMP1 collapsin response mediator protein 1
2915 -17.5 OLFM1 olfactomedin 1
2934 -19.9 RASSF2 Ras association (RalGDS/AF-6) domain family 2
2964 -24.8 SPOCK2 sparc/osteonectin,
3016 -37.6 CLDN5 claudin 5 (deleted in velocardiofacial syndrome)
3065 -68.5 SNAP25 synaptosomal-associated protein, 25kDa
3138 -219.3 PTPRZ1 protein tyrosine phosphatase
3139 -220.3 PLP1 proteolipid protein 1
3140 -222.7 CHL1 cell adhesion molecule with homology to LI CAM
3141 -224.7 GFAP glial fibrillary acidic protein
3142 -228.3 SNX10 sorting nexin 10
3143 -228.3 GPM6A glycoprotein M6A
3144 -231.5 ASCL1 achaete-scute complex-like 1 (Drosophila)
3145 -241.0 m6bl glycoprotein M6B
3146 -243.3 FABP7 fatty acid binding protein 7, brain
3147 -260.4 PMP2 peripheral myelin protein 2
3148 -272.5 NKX2-2 NK2 transcription factor related, locus 2 (Drosophila)
3149 -288.2 PDZK3 PDZ domain containing 3
3150 -306.7 CX3CR1 chemokine (C-X3-C motif) receptor 1
3151 -312.5 S100B SI00 calcium binding protein, beta (neural)
3152 -341.3 GAD1 glutamate decarboxylase 1 (brain, 67kDa)
3153 -366.3 HLA-DRA major histocompatibility complex, class 11, DR alpha
3154 -370.4 GRIA2 glutamate receptor, ionotropic, AMPA 2
3155 -387.6 RGS1 B cell activation gene
3156 -401.6 C3 complement component 3
3157 -574.7 TU3A TU3A protein
This Table illustrates the 40 most differentially expressed genes between PAI biopsies and short-term cell 
cultures and lists the genes and fold changes of those genes found to be differentially expressed by 
Mehrian et al. (shown in bold) (Mehrian et al., 2005). Genes highlighted in red are differentially 
expressed between both paediatric PAI and adult GBMIV biopsy and short-term cell culture samples.
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Table 3.3 Differentially expressed genes between adult glioblastoma multiforme
biopsy and short-term cell culture samples.
Ordered position Fold Gene Name Description
from 2969 genes Change
1 209.1 GREM1 cysteine knot superfamily 1, BMP antagonist 1
2 62.5 PTPLA protein tyrosine phosphatase-like member a
3 57.5 PTGFR prostaglandin F receptor (FP)
4 57.2 GATA6 GATA binding protein 6
5 55.7 MET met proto-oncogene (hepatocyte growth factor receptor)
6 50.4 BST1 bone marrow stromal cell antigen 1
7 43.7 DSP desmoplakin (DPI, DPI1)
8 40.8 STC2 stanniocalcin 2
9 39.0 RGS4 regulator of G-protein signalling 4
10 38.4 INHBA inhibin, beta A (activin A, activin AB alpha polypeptide)
11 37.1 WNT5B wingless-type MMTV integration site family, member 5B
12 36.6 FBN1 fibrillin 1 (Marfan syndrome)
13 34.4 NGFB nerve growth factor, beta polypeptide
14 34.0 ABLIM3 K.IAA0843 protein
15 33.4 GPR49 G protein-coupled receptor 49
16 33.2 PAPPA pregnancy-associated plasma protein A
17 32.4 THBS1 thrombospondin 1
18 31.9 CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1
19 30.5 ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains)
20 30.2 PTGDS prostaglandin D2 synthase 21kDa (brain)
48 16.4 CNN1 calponin 1, basic, smooth muscle
167 6.5 NID2 nidogen 2 (osteonidogen)
202 5.6 TRAM2 TRAM-like protein
238 4.9 NBL1 neuroblastoma, suppression of tumorigenicity 1
298 4.2 PHLDA2 tumor suppressing subtransferable candidate 3
311 4.0 S100A11 S100 calcium binding protein All (ealgizzarin)
371 3.5 ACTG2 actin, gamma 2, smooth muscle, enteric
420 3.2 MAP2K3 mitogen-activated protein kinase kinase 3
512 2.8 STAT1 signal transducer and activator of transcription 1, 91kDa
590 2.6 CNN2 calponin 2
645 2.5 ANXA2 annexin A2
670 2.4 SERPINH1 serine (or cysteine) proteinase inhibitor
874 2.2 PFKP phosphofructokinase, platelet
1362 -2.4 ARL6IP ADP-ribosylation factor-like 6 interacting protein
1535 -2.7 CNP 2\3'-cyclic nucleotide 3' phosphodiesterase
2166 -6.6 SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2
2170 -6.7 RNASE1 Homo sapiens ribonuclease, RNase A family, mRNA.
2184 -6.9 CCND2 cyclin D2
2231 -7.9 SYT11 synaptotagmin XI
2234 -7.9 CRMP1 collapsin response mediator protein 1
2235 -8.0 OLFM1 olfactomedin 1
2372 -12.9 SNAP25 synaptosomal-associated protein, 25kDa
2413 -17.6 RASSF2 Ras association (RalGDS/AP-6) domain family 2
2528 -52.1 CLDN5 claudin 5
2610 -143.5 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1
2611 -147.7 BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1
2612 -152.0 ASCL1 achaete-scute complex-like 1 (Drosophila)
2613 -155.0 PMP2 peripheral myelin protein 2
2614 -159.7 GDF1 Homo sapiens growth differentiation factor 1 (GDF1), mRNA.
2615 -165.3 CD74 CD74 antigen
2616 -165.6 FCGBP Fc fragment of IgG binding protein
2617 -176.1 SERPINA3 serine (or cysteine) proteinase inhibitor, clade A, member 3
2618 -187.6 CXCR4 Homo sapiens CXCR4 gene encoding receptor CXCR4.
2619 -190.5 PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1
2620 -192.7 GFAP glial fibrillary acidic protein
2621 -210.1 GPM6A glycoprotein M6A
2622 -236.4 S100B SI00 calcium binding protein, beta (neural)
2623 -240.4 C3 complement component 3
2624 -243.3 HLA-DRA major histocompatibility complex, class II, DR alpha
2625 -248.8 m6bl glycoprotein M6B
2626 -251.9 FABP7 fatty acid binding protein 7, brain
2627 -263.9 TU3A TU3A protein
2628 -300.3 RGS1 B cell activation gene
2629 -325.7 TTYH1 tweety homolog 1 (Drosophila)
This Table illustrates the 40 most differentially expressed genes between adult GBMIV biopsies and 
short-term cell cultures and lists the genes and fold changes of those genes found to be differentially 
expressed by Mehrian et al. (shown in bold) (Mehrian et al., 2005). Genes highlighted in red are 
differentially expressed between both paediatric PAI and adult GBMIV biopsy and short-term cell culture 
samples.
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In the 12 paediatric PAI tumour samples and 6 adult GBMIV tumour samples, 403 and 
2652 probe sets respectively, showed no change in expression. The difference in the 
number of genes that showed no change in expression between these 2 groups is likely 
to be influenced by the variation in n number. From these gene lists, those genes that 
showed a 2-fold and significant change in expression between the tumour sample 
groups and 4 normal total brain controls were identified. (Refer to Control Samples in 
this Chapter for the use of this specific normal control). Only 25 probe sets showed 
differential gene expression between the controls and the paediatric PAI samples and 
353 probe sets showed differential gene expression between the controls and the adult 
GBMIV samples. A hierarchical clustering approach was then used to cluster each 
tumour group and normal controls, according to the expression profile similarity using 
these gene probe sets (Figures 3.5 and 3.6).
Figure 3.5 The dendrogram illustrates differential gene expression between paediatric pilocytic 
astrocytoma tumour samples (biopsies and short-term cell cultures) and normal controls.
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The 25 probe sets differentially expressed between the paediatric PAI tumour samples (biopsies and 
short-term cell cultures) and the normal controls were used for this dendrogram. Red branches indicate 
biopsy samples, both tumour and normal controls and yellow branches indicate short-term cell culture 
samples. The dendrogram colour saturation is proportional to the magnitude of the difference from the 
experiment median.
In the dendrogram comparing the 25 probe sets differentially expressed between the 
normal controls and the paediatric PAI, a distinction can still be seen between the 
biopsy and short-term cell culture groups although some integration has occurred.
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Moreover, 1 biopsy sample clusters with the normal control samples. In the dendrogram 
comparing the 353 probe sets differentially expressed between the normal controls and 
the adult GBMIV, a clear distinction can still be seen between the biopsy and short-term 
cell culture groups.
Figure 3.6 The dendrogram illustrates differential gene expression between adult glioblastoma 
multiforme tumour samples (biopsies and short-term cell cultures) and normal controls.
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The 353 probe sets differentially expressed between the adult GBMIV tumour samples (biopsies and 
short-term cell cultures) and the normal controls were used for this dendrogram. Red branches indicate 
biopsy samples, both tumour and normal controls and yellow branches indicate short-term cell culture 
samples. The dendrogram colour saturation is proportional to the magnitude of the difference from the 
experiment median.
Several studies have compared the expression profile of specific cell lines with the 
tumour of origin and investigated the cellular pathways altered in cultured tumour cells. 
The cell cycle has been identified as one of the most altered pathways in cell lines 
compared to the primary tumour and normal controls (Ertel et al., 2006). In order to 
investigate the cell cycle in the tumour and short-term cell cultures studied here, all 
reliable gene expression data for the cell cycle was isolated. In total, 407 cell cycle 
probe sets were common to both the paediatric PAI and adult GBMIV biopsy and short­
term cell culture experiments. A 1-WAY ANOVA statistical significance test (p = 0.05) 
followed by a Benjamini and Hochberg multiple correction test was used to identify 
those genes that were significantly differentially expressed between the 4 groups 
comprising; adult GBMIV biopsies, paediatric PAI biopsies, adult GBMIV short-term 
cell cultures and paediatric PAI short-term cell cultures. In total, 126 probe sets were
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significantly differentially expressed between the 4 sample groups. The sample groups 
and gene expression similarities are illustrated in the dendrogram of Figure 3.7.
Figure 3.7 The dendrogram illustrates 126 differentially expressed cell cycle genes between paediatric 
pilocytic astrocytoma and adult glioblastoma multiforme biopsies and short-term cell cultures.
The 126 probe sets that were differentially expressed between the paediatric PAI and adult GBMIV 
biopsies and short-term cell cultures are clustered (branches to the left of the dendrogram) according to 
gene expression similarity. The dendrogram colour saturation is proportional to the magnitude of the 
difference from the experiment median. Several clear cell cycle gene groups can be observed and are 
indicated by the green lines.
Moreover, although the biopsy and short-term cell culture samples cluster together and 
it is clear that a large number of genes are differentially expressed between these sample 
types, all 4 profiles show similarities and differences (indicated by the positioning of the 
green lines in Figure 3.7). The genes that cluster at the bottom of the dendrogram show 
higher expression in the adult GBMIV biopsies compared to the remaining 3 groups, 
with some of these genes showing a slightly higher expression in the adult GBMIV
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short-term cell cultures. A small cluster of genes in the middle of the dendrogram show 
a higher expression in the PAI biopsies compared to the remaining 3 groups and a 
cluster of genes towards the top of the dendrogram show reduced expression in the 
paediatric PAI biopsies compared to the remaining 3 groups. Together these 126 genes 
show a molecular signature that can distinguish biopsy and cell culture samples. The 
details of the cell cycle genes involved in this dendrogram can be found in Appendix III.
DISCUSSION
The paired tumour biopsy and short-term cell culture samples investigated here show 
extensive variation in gene expression. There are several explanations for this and 
tumour heterogeneity plays a role. The biopsy samples were taken from a tumour tissue 
mass and consequently the sample consists of a variety of cell populations. The majority 
of these are heterogeneous tumour cells but normal cells (neurons and invading immune 
cells amongst others) are also present in small numbers. The expression profile of the 
tumour biopsy sample represents the mean expression of genes from all cells within the 
region of the tumour from which the sample was taken. A study by Van et al. (2006) 
investigated microarray analysis of MRI-defined GBMIV regions and identified 
regional intratumoural differences in tumour periphery and core areas. Multiple 
therapeutic targets significant to glioblastoma including matrix metalloproteinases, 
AKT1, EGFR and VEGF showed significant differences in regional expression that may 
affect treatment response. This study highlights the important intratumoural regional 
differences in the molecular phenotype of GBMIV and the need for multiple tumour 
biopsies. In the present study it was not possible to obtain multiple biopsies or clarify 
the tumour region from which the biopsy samples were taken. Consequently, this is a 
source of variation within the biopsy samples investigated here.
The short-term cell culture samples studied here were grown from the tumour biopsy 
tissue, as previously described in Chapter 1. The heterogeneity of tumour tissue and the 
artificial growth environment does select for cell sub-populations that are able to grow 
under artificial culture conditions. The gene expression profile of the short-term cell 
culture samples investigated in this study represents a cell population of the paediatric 
PAI or adult GBMIV tumours. However, the profile may not represent the majority cell 
population of the heterogeneous tumour tissue. This introduces variation between the
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cell culture samples, which is reflected in the biopsy and short-term cell culture clusters 
illustrated in the dendrograms of Figures 3.3 and 3.4. The clusters do not show the same 
branching patterns and different samples group together, highlighting the variation 
between the samples of each group. Furthermore, it is also well known that long-term 
cell culture induces further expression and genomic changes in the cultured cell 
population (Band et al., 1990; Sen et al., 1995). For this reason, all cultures in this study 
are short-term cell cultures below passage 8.
Two previous studies have compared the gene expression profiles of GBMIV tissues 
and cell lines. The study by Hess et al. (2001) compares GBMIV tissue expression 
profiles with well established GBMIV cell lines. The study by Mehrian et al. (2005) 
investigates the expression profiles of glioma tissues and derived cell lines of 
approximately passage 10. The results found by these two studies are similar to those 
found here. In each study, the tumour tissue and cell culture samples group 
independently when clustered according to expression profile similarity. O f the 40 
genes identified by Mehrian et al. that showed the most differential gene expression 
between the glioma tissues and derived cell lines, thirty showed a similar expression 
pattern between the paediatric PAI and adult GBMIV biopsy and short-term cell 
cultures studied here (Tables 3.2 and 3.3).The genes found to be up-regulated in this 
group are associated with nucleotide and nucleic acid metabolism, cell proliferation and 
signal transduction. Those down-regulated include genes involved in development, 
signal transduction, and transporter activity. Mehrain et al. (2005) suggested that 
GBMIV tumour cells selected during culture have a more rapid proliferation rate and a 
more undifferentiated phenotype compared to the primary tumour cells. In both the 
paediatric PAI biopsy and short-term cell culture comparisons and the adult GBMIV 
biopsy and short-term cell culture comparisons of this study, the 40 most differentially 
expressed genes were involved in nervous system development, cell differentiation and 
G-protein coupled receptor signalling in. Furthermore, genes involved in immune 
response were only differentially expressed between the adult GBMIV biopsies and 
short-term cell cultures and genes involved in cell adhesion and phosphate transport 
were only differentially expressed in the paediatric PAI biopsies and short-term cell 
cultures.
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Moreover, the majority of the 40 genes that were most differentially expressed genes 
between the paediatric PAI and adult GBMIV biopsy and short-term cell cultures of this 
study were different to those found by Mehrian et al. (2005). This may be because the 
samples investigated here are short-term cell cultures of approximately passage 8. 
Moreover, although not stated in the analysis protocol used by Mehrian et al., those 
genes present in all tissue samples and absent in all short-term cell culture samples or 
vice versa, do not appear to be included in the analysis. Consequently, the experiment 
approach of this study used a larger number of genes for further analysis. This would 
explain the differences found by each study as well as the correlations. It was also noted 
that GFAP expression was significantly down-regulated in the short-term cell culture 
samples compared to the tumours tissue. This has previously been documented in short­
term cell cultures by approximately passage 5/6, derived from 50 astrocytomas (Lolait 
et al., 1983).
A further study compared the expression profiles of HSC, MPNST and cell lines. A 
molecular signature o f 209 probe sets was characterised that distinguished MPNST 
primary tumours and cell lines from normal HSC (Miller et al., 2006). This is not a 
complete profile of global gene expression as two different Affymetrix GeneChips® 
were used in this study and only those genes common to both arrays could be compared. 
Of the 209 probe sets, 159 genes clustered into 3 groups that validated the use of 
MPNST cell lines as an in vitro model of MPNST primary tumours. The first cluster 
contained 10 genes that were up-regulated in the MPNST cell lines compared to the 
primary tumours. The protein products of the majority of these genes are involved in 
cell cycle progression. The authors suggest that this is not unexpected and can be 
attributed to the fact that the cell lines are exposed to non-physiological growth- 
promoting conditions in vitro. Cluster two contained 13 genes that were up-regulated in 
both the cell lines and primary tumours compared to the HSC and have been implicated 
in other tumour systems. The remaining 146 genes clustered in the third group and 
showed a common down-regulation in the MPNST samples compared to the HSC. A 
number of these genes are reported to be Schwann cell differentiation markers 
suggesting that the MPNST cells do not show characteristics of differentiated Scwann 
cells. (Miller et al., 2006). Furthermore, although the 159 genes showed differential 
gene expression between the tumour samples as a group and the HSC, hierarchical
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clustering distinguished the cell lines and primary tumours and no tumour integration 
was observed.
Using a similar approach to the study carried out by Miller et al. expression signatures 
of 25 and 353 probe sets were identified in paediatric PAI and adult GBMIV 
respectively that showed a significant difference in expression between the tumour 
samples, regardless of biopsy or short-term cell culture origin and normal brain. In total, 
11 genes were common to both experiments. In the paediatric PAI, 7 genes were down- 
regulated compared to the normal controls and 18 were up-regulated. In the adult 
GBMIV, 136 probe sets were up-regulated compared to the normal controls and 217 
down-regulated. KEGG pathway analysis of the 353 probe sets revealed that genes 
involved in phosphatidylinositol signalling, MAPK signalling, apoptosis, tight 
junctions, notch signalling and hedgehog signalling were down-regulated in the adult 
GBMIV compared to normal controls. Furthermore, genes also involved in 
phosphatidylinositol signalling and MAPK signalling showed up-regulation as well as 
genes involved in calcium signalling, gap junctions and VEGF signalling. This 
approach was not completed for the 25 differentially expressed genes in paediatric PAI 
compared to normal controls as the gene list was not large enough.
Although the adult GBMIV biopsy and short-term cell culture samples clustered 
together, sub-branches within this cluster group clearly distinguished the two sample 
types, as seen in the MPNST tissue, cell line and HSC comparison. Moreover, this was 
not seen in the hierarchical clustering approach involving the paediatric PAI tumour 
samples and normal controls, in which tumour biopsies and short-term cell culture 
samples showed some integration. This biopsy and short-term cell culture integration is 
most likely due to the small number of genes involved in the genetic signature used for 
this approach. However, it should be acknowledged that biopsy sample contamination 
with a small amount of normal tissue may influence gene expression results. 
Consequently when small numbers of genes are used for hierarchical clustering, specific 
tumour samples may cluster with normal controls as seen in Figure 3.5.
Other studies have compared the expression profiles of specific tumour tissues and 
either cell lines or derived short-term cell cultures to investigate the impact of cell 
culture on gene expression. A study investigating 44 different lung tumours and 38
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corresponding cell lines found that hierarchical clustering grouped the lung tumour 
tissue samples and cell lines independently. Within the tissue branch of the dendrogram, 
all small cell lung carcinoma (SCLC) tissues clustered on one branch and the non-small 
cell lung carcinoma tissues (NSCLC) clustered on a different branch. The NSCLC 
branch of the dendrogram showed sub-branches, separating adenocarcinomas (AC), 
squamous cell carcinomas (SCC) and large cell carcinomas. In the cell line branch of 
the dendrogram, the cell lines generally clustered according to tumour type and 
separation of SCLC and NSCLC cell lines was observed. However, within the NSCLC 
branch of the dendrogram only the SCC cell lines showed a distinct cluster. In order to 
promote integration of tumour tissues and cell lines when clustered, a filtering algorithm 
was used to remove genes from the analysis that showed a significant differential 
expression between the two groups. Moreover, when hierarchical clustering was 
repeated, the lung tumour and cell line samples did integrate to some extent. Of the 38 
cancer cell lines, 24 integrated with the tissue samples and the remaining 14 formed an 
independent cell line cluster. Within the dendrogram, no particular pathological type 
clustered independently. However, overall the SCLC and NSCLC tumour and cell line 
samples did cluster separately (Virtanen et al., 2002).
When this approach was applied to the tumours of the present study and genes 
significantly differentially expressed between the astrocytoma biopsy and short-term 
cell culture samples were removed from the hierarchical clustering approach, the 
paediatric PAI biopsy and short-term cell culture samples did not integrate (data not 
shown). However, some integration was observed between the biopsy and short-term 
cell cultures of the adult GBMIV samples (Figure 3.8).
It is possible that the cells derived from the primary adult GBMIV tissues are the 
majority cell in the tumour and are consequently more representative of the tumour 
tissue, than those cultured from the PAI biopsies. Furthermore, the tumour induced 
changes within these cells may result in cells that are more amenable to in vitro 
conditions and less expression changes are consequently induced. Moreover, in the 
experience o f this laboratory, the culture of adult GBMIV cells is more successful than 
paediatric PAI cells and the doubling times for these tumour cells are higher. These 
explanations describe possible factors that may influence the integration of adult 
GBMIV samples compared to paediatric PAI samples.
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Figure 3.8 The dendrogram illustrates integration of the adult glioblastoma multiforme
biopsies and short-term cell cultures.
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The 9447 probe sets that were not differentially expressed between the biopsy and short-term-cell cultures 
were used for this hierarchical clustering approach and colour the dendrogram. The dendrogram colour 
saturation is proportional to the magnitude of the difference from the experiment median. Yellow 
dendrogram branches indicate short-term cell culture samples and red branches indicate biopsy samples.
Several studies have identified cellular pathways that are differentially expressed 
between cell lines and primary tumours. A study by Sandberg et al. (2005) compared 60 
tumour cell lines from 9 tissue origins with 135 human tissues and 176 tumour samples. 
The study found that approximately 30% of investigated genes showed a significant 
difference in expression between the cell lines, tumour and normal tissues, the majority 
of which were involved in cell cycle progression, macromolecule processing, ATP 
synthesis, cell adhesion and membrane signalling. Furthermore, a smaller study also 
identified ATP synthesis, cell communication pathways, cell cycle, oxidative 
phosphorylation, purine, pyrimidine and pyruvate metabolism and proteosome pathways 
as pathways up-regulated and cell adhesion molecules and ECM-receptor interaction as 
pathways down-regulated (Ertel et al., 2006).
This study compared the impact of short-term cell culture on cell cycle gene expression 
in adult GBMIV and paediatric PAI with the results from the two previous studies as it 
was the most altered pathway. Ertel et al. (2006) showed that in a common molecular 
signature of 6 cell lines compared to 6 tumour tissues, the majority of cell cycle genes
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were up-regulated. The results the present study found that in a common molecular 
signature between the biopsies and short-term cell cultures, approximately the same 
number of cell cycle genes were up-regulated as down-regulated. Furthermore, although 
a large number of cell cycle genes showed differential gene expression between the 
biopsy and short-term cell culture samples as two groups, differences were also 
observed between the paediatric PAI and adult GBMIV biopsy samples. The up- 
regulation of different clusters of cell cycle genes was clearly seen in the adult GBMIV 
biopsies compared to the paediatric PAI biopsies. Furthermore, this was not reflected in 
the paired short-term cell cultures, although a number of genes that showed up- 
regulation in the adult GBMIV biopsy samples, also showed slightly higher expression 
in the corresponding short-term cell cultures, but this was not significant.
Moreover, a number of genes that showed higher expression in the short-term cell 
culture samples also showed high expression in the adult GBMIV biopsies but not the 
paediatric PAI biopsies. Although paediatric PAI and adult GBMIV cells grow equally 
well in culture once established, these results highlight the fact that in vitro culture 
changes the phenotype of paediatric PAI cells to a greater extent compared to adult 
GBMIV cells, by promoting their growth above that of in vivo cells which are relatively 
slow growing. Adult GBMIV cells are already proliferating at a high rate in vivo, 
therefore the growth promoting effects of in vitro culture are less obvious.
A study by Wang et al. (2006a) compared 59 cell lines with the presumed tumour of 
origin. This study defined a cell line as being representative of its tumour of origin if 
there was no other tumour type that had a gene expression profile with a significantly 
higher correlation to the cell line than the presumed tumour of origin (p < 0.05). Using 
this approach 51 of the 59 cell lines were representative of the tumour of origin. In the 
study carried out here, only the expression profiles of short-term cell cultures and 
astrocytoma biopsy tissues have been compared. If other tumour types had also been 
included in this study, along with the astrocytoma, a distinction may have been seen 
between the short-term cell cultures and primary tumours of astrocytoma compared to 
other tumour types, as seen in the previous study.
It is clear that biopsies and short-term cell cultures from the same tumour mass show 
different gene expression patterns. There is also no doubt that cells in culture undergo
120
associated changes in gene expression and this should be recognised when studying 
tumour short-term cell cultures. The variation in clustering patterns of the specific 
biopsy and short-term cell culture groups is likely to be a reflection of different tumour 
cell clones grown from the tumour tissue and the variation in the tumour region used 
when obtaining the tumour biopsy sample. Moreover, this evidence suggests that it is 
inappropriate to include a mixture of biopsy and cell culture samples as a representation 
of astrocytoma in the same experiment, but that the each sample type may be used for 
the study of paediatric astrocytoma, taking into account the merits and shortcomings in 
each case.
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CONTROL SAMPLES
INTRODUCTION
The choice of normal control samples for microarray experiments investigating gene 
expression in brain tumours is difficult and sometimes limited. Normal tissue from 
adjacent normal brain regions of a tumour is not available from most patients, as tumour 
tissue is usually obtained for diagnosis during resection and it would be inappropriate to 
sample normal brain at this time. The options available are then reduced to normal brain 
from other individuals. This introduces variation between tumour samples and normal 
controls due to variations in the human population and tumour locations (Oleksiak et al., 
2002; Morley et al., 2004).
An individual study has investigated the choice of normal ovarian controls and the 
influence this may have on the determination of differentially expressed genes in 
ovarian cancer expression profiling studies (Zorn et al., 2003). The study compared five 
normal control sources (two or three replicates) including, whole ovary samples (WO), 
ovarian surface epithelium (OSE) and immortalised OSE cell lines with a group of 24 
serous ovarian carcinoma samples. The gene lists produced by the comparison of each 
normal group with the tumour samples were unique to that normal-carcinoma 
comparison. No gene appeared in all five lists. The study concluded that the OSE 
brushings were the most appropriate control sample for serous ovarian carcinoma 
analysis, as they were not cultured and provided the purest samples of OSE (Zorn et al., 
2003). The study also recognised that although OSE brushings were felt to be the most 
appropriate control there was not a perfect control.
Aside from these findings, the study makes two important statements; (i) controversy 
surrounds the decision to collect normal tissue from the same patient as the tumour or 
from a different patient thought to be disease free. The adjacent normal approach limits 
the inclusion of genes that are differentially expressed due to interpatient variability but 
have little impact on malignant transformation, where as the normal donor approach 
recognises that even normal-appearing tissue in a diseased individual may exhibit gene 
expression changes from truly normal tissue; (ii) studies whose aim is to establish 
overall molecular profiles, such as comparison of tumour profiles with clinical
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outcomes, would be less affected by these concerns because referring to a normal 
control is unnecessary (Zom et al., 2003).
It is also important to recognise that normal tissue has a different cellular content, 
morphology and function compared to tumour tissue in the same environment. 
Although tumour tissue is heterogeneous, normal tissue is a balanced mixture of cell 
types, each contributing to normal tissue function. This again highlights the question: Is 
there a good control for the study of tumours?
The normal controls used in previous microarray studies of brain tumours vary greatly. 
Studies investigating differential gene expression between tumour grades or primary 
and recurrent tumours have not necessarily included any normal brain samples in the 
experiments (Kim et al., 2002b; Nutt et al., 2003; van den et al., 2003; Mischel et al., 
2003; Sharma et al., 2006). Other studies comparing tumour expression profiles to 
normal brain have used extracted total RNA from tissue samples obtained from normal 
brain regions including tissue from a lobectomy after edema, hippocampus tissue from 
an epileptic patient, subcortical white matter, cortical brain, the cortex of temporal lobe 
and post-mortem cortex and medulla tissues (Huang et al., 2000; Rickman et al., 2001; 
Khatua et al., 2003; Shai et al., 2003; Godard et al., 2003). Groups who have not had 
direct access to normal brain have also commercially purchased total RNA samples of 
adult and foetal normal brain for use as controls (Godard et al., 2003; Wong et al., 
2005).
The use of a variety of normal controls in microarray experiments raises several 
questions:
• Is it appropriate to compare the expression profile of a tumour located in a 
specific brain region to a normal brain control taken from another region?
• Should every tumour be individually compared to a normal control from the 
same location?
• Which normal control is most appropriate for a tumour spanning several brain 
regions?
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• Is age important when comparing controls and tumours from different age 
groups?
From the previous investigation it was clear that paediatric astrocytoma biopsies and 
short-term cell cultures cannot be combined in the same experiments in order to study 
this tumour. Consequently, different controls are necessary for each experiment. Several 
controls were investigated to ensure that the most appropriate control was selected for 
each experiment.
It was not possible to obtain normal brain samples from adjacent normal brain regions 
to the tumour. As an alternative, normal human adult and foetal brain total RNA from 
total and specific brain regions were purchased as pooled samples from several 
commercial companies, AMS Biotechnology, United States Biologicals and BD 
Biosciences. Normal samples were not available from individuals of a closer age to the 
patient group, therefore both foetal and adult normal brain were investigated as possible 
controls. These included adult and foetal total brain, corpus callosum and cerebellum.
Foetal astrocytes were obtained as normal controls for the short-term cell culture 
samples of this study from Cambrex Bio Sciences and Professor Geoff Pilkington at 
Portsmouth University. No adult astrocytes were available. All controls were compared 
to six paired paediatric PAI biopsy and short-term cell culture samples and three paired 
adult GBMIV biopsy and short-term cell culture samples. These tumours were used to 
investigate the controls as paired tumour biopsy and short-term cell culture samples 
were available.
Analysis was carried out as previously described and the mean expression of each gene 
in all samples of the experiment was used for the per gene normalisation. The same 6 
paediatric PAI paired biopsy and cell culture samples and 3 adult GBMIV paired biopsy 
and cell culture samples used in the previous analysis comparing biopsy and short-term 
cell cultures were included in this analysis. Gene probe sets present in all samples were 
used for an unsupervised hierarchical clustering approach, a total of 5304 probe sets.
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RESULTS
Figure 3.9 illustrates the unsupervised hierarchical clustering approach and gene 
expression profile similarity between all controls, biopsy and short-term cell culture 
samples and clearly demonstrates independent sample grouping. Within the biopsy 
group, the normal brain controls and 6 paediatric PAI biopsies branch independently of 
the adult GBMIV biopsies. However, the clustering of the 6 paediatric PAI biopsies is 
separate from the normal brain control samples as a group. Furthermore, within the 
normal brain control cluster, sub-groups of adult and foetal controls exist, 
demonstrating that the adult and foetal normal tissue parameter influences the clustering 
of these samples to a greater extent than the brain region of origin. Variation can also 
been seen between the expression profiles of tissues from different brain regions.
Within the cell culture group, clustering of the short-term cell cultures is not 
independent of the normal controls and the paediatric PAI and adult GBMIV short-term 
cell cultures do not cluster into distinct groups. Moreover, the expression profiles of the 
short-term cell culture samples as a group (normal astrocytes, paediatric PAI and adult 
GBMIV short-term cell cultures) are more similar, compared to the corresponding 
samples in the biopsy group.
The gene expression profiles of the adult and foetal normal brain samples were 
compared to determine the most suitable control for the tumour biopsies of this study. 
Those genes that showed a greater than 2-fold and significant change in expression 
between the six paediatric PAI biopsies and the adult normal controls, the six paediatric 
PAI biopsies and the foetal normal controls and the foetal and adult normal controls 
were identified; 3088, 3240 and 2527 probe sets respectively (Figure 3.10). The adult 
GBMIV biopsies were not combined in this approach in order to reduce variation within 
the tumour biopsy group. However, a separate approach was completed for the adult 
samples comparing the three adult GBM GIV biopsies and the adult normal controls 
and the three adult GBM GIV biopsies and the foetal controls. The data from this 
approach is not shown as the findings and conclusions made were comparable to those 
found using the PAI biopsies.
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IFigure 3.9 The dendrogram illustrates the expression profile similarity between the investigated controls, six paired paediatric pilocytic astrocytoma biopsies and short-term
cell cultures and three paired adult glioblastoma multiforme biopsies and short-term cell cultures.
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The dendrogram is coloured by 5304 genes that were present in all samples and used for this unsupervised hierarchical clustering approach. The samples with red branches
are biopsy samples or controls, those with yellow branches are short-term cell culture samples or controls. The dendrogram colour saturation is proportional to the magnitude 
of the difference from the experiment median. The abbreviations in the diagram are as follows; Cer = cerebellum, Cor Cal = corpus callosum, TB = total brain, NHA = 
normal human astrocytes. Tumour samples highlighted purple are paediatric PAI. Tumour samples highlighted green are adult GBMIV.
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In total, 1345 probe pairs were identified that showed common differential expression in 
the PAI when either the foetal or adult normal controls were used (turquoise segment of 
the Venn diagram; representing 44% and 41% of the probe pairs when the foetal normal 
controls and adult normal controls were used respectively). In addition, probe sets that 
showed differential gene expression in the PAI when using the adult or foetal normal 
controls that were not identified when using the opposing control, did show a similar 
expression trend but did not show a greater than 2-fold change (the dark blue and green 
segments of the Venn diagram representing 698 (22%) and 609 (20%) probe sets 
respectively). A number of probe sets showed differential gene expression in PAI when 
using a specific control that did not show any expression alterations when using the 
opposing control (the pink (adult controls) and yellow (foetal controls) segments of the 
Venn diagram representing 770 (24%) and 707 (23%) probe sets respectively). These 
probe sets also showed differential gene expression between the adult and foetal normal 
controls.
Figure 3.10 Genes that show a 2-fold change in expression between the adult normal controls, the foetal 
normal controls and the six pilocytic astrocytoma biopsies are correlated in this Venn diagram.
Total
5179
Genes with a 2 fold 
difference between adult 
normal controls and foetal 
normal controls: 2527
Genes with a 2 fold 
difference between foetal 
normal controls and 6 PA 
biopsies: 3088
The impact on cellular pathways of differentially expressed genes between PAI and 
specific controls was assessed using the Onto-tools software. Table 3.4 shows the 
pathway rankings for each comparison. 53 pathways were included in this analysis but
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only those of interest are shown in the table (a list of all pathways in this approach can 
be found on the Supplementary Data CD included with this thesis). Overall pathway 
rankings are similar when using either foetal or adult normal controls. Moreover, of the 
top ten ranked KEGG pathways using either control group, eight were the same. These 
included antigen processing and presentation, cell adhesion molecules, 
phosphatidylinositol signalling system, MAPK signalling pathway, ECM receptor 
interaction, focal adhesion, regulation of actin cytoskeleton and calcium signalling. 
Figures 3.11, 3.12, 3.13 and 3.14 illustrate the gene expression pattern for each 
comparison in antigen processing and presentation, colorectal cancer, the cell cycle and 
Wnt signalling respectively. These pathways were investigated specifically as antigen 
processing and presentation was ranked first using both controls. The colorectal cancer 
pathway is the only characterised KEGG pathway for a specific cancer involved in this 
analysis approach and it was felt that this would be of specific interest. Disruption of the 
cell cycle is well characterised in astrocytomas and control of Wnt signalling is 
involved in foetal development.
The use of adult or foetal normal controls for analysis does not alter the results found 
for antigen processing and presentation (Figures 3.11a and 3.11b). However the genes 
of the MHC II pathway are down-regulated in the foetal normal controls compared to 
the adult normal controls (Figure 3.11c). The genes involved in colorectal cancer show 
up-regulation when foetal or adult normal controls are used (Figures 3.12a and 3.12b). 
Moreover, the genes of this pathway are up-regulated in the foetal normal controls 
compared to the adult normal controls (Figure 3.12c). A larger number of genes 
involved in the cell cycle show down-regulation when foetal normal controls are 
compared to adult normal controls (Figures 3.13a and 3.13b). The differential gene 
expression found in the Wnt signalling follows a similar pattern (Figures 3.14a and 
3.14b).
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Table 3.4 Comparison of KEGG pathways Onto-tool rankings between pilocytic astrocytoma biopsies 
and adult normal controls (green), pilocytic astrocytoma biopsies and foetal normal controls (blue) and 
foetal and adult normal controls (red). The genes used for this ranking approach showed a 2-fold and 
significant difference in expression between the selected groups (Figure 3.10). Of the 53 pathways 
investigated only those of interest are shown.
PAI biopsies compared to adult PAI biopsies compared to foetal Foetal normal controls compared to
________ normal controls_________________ normal controls________________adult normal controls_______
Rank Pathway Impact %Pathway Rank Pathway Impact %Pathway Rank Pathway Impact %Pathway
Name Factor Genes in Name Factor Genes in Name Factor Genes in
_____________________In pul____________________________ Input__________________________ Input
1 Antigen 112.08 26.7
processing
and
presentation
2  Cell adhesion 24.04 32.6
molecules
3 Phosphatidyli 19.97 30.4
nositol
signalling
system
4 MAPK 13.78 28.9
signalling
pathway 
6 ECM- 12.32 36.8
receptor 
interaction
8 Focal 11.03 29.9
adhesion
9 Regulation of 9.22 27.2
actin 
cytoskeleton 
11 Calcium 8.35 26.1
signalling 
pathway
14 Toll-like 7.56 30.8
receptor
signalling
pathway
15 Neurodegene 6.84 40.0
rative
disorders
16 Apoptosis 6.35 29.8
2 0  Gap junction 5.41 27.3
2 1  B cell 5.32 30.2
receptor 
signalling 
pathway
23 Adherens 5.16 29.9
junction
2 8  Natural killer 4.13 23.4
cell mediated 
cytotoxicity
1 Antigen 734.27 30.2 
processing
and
presentation
2  Cell adhesion 31.93 35.6
molecules
5  Calcium 10.95 28.4
signalling
pathway
6 MAPK 9.46 25.3
signalling
pathway
8 Phosphatidyli 9.35 27.8
nositol
signalling
system
9 ECM- 9.19 32.2
receptor
interaction
1 0  Gap junction 8.60 31.3
11 Focal 8.60 
adhesion
1 2  Regulation of 7.04
actin
cytoskeleton
24.3
1 3  Apoptosis 6.71 29.8
15 Toll-like 5.65 26.4
receptor
signalling
pathway
1 6  Natural killer 5.55 24.2
cell mediated 
cytotoxicity
2 0  B cell 4.61 22.2
receptor 
signalling 
pathway
2 3  Cytokine- 4.14 19.9
cytokine 
receptor 
interaction
2 5  Neurodegene 3.96 31.4
rative 
disorders
1 Antigen 119.33 14.0
processing
and
presentation
2 ECM- 13.57 31.0
receptor
interaction
3 Phosphatidyli 12.18 24.1
nositol
signalling
system
4 Focal 10.54 24.2
adhesion
5 Axon 10.53 25.4
guidance
6 Wnt 8.47 23.1 
signalling
pathway
7 Cell adhesion 8.04 22.7
molecules
26.8 8 Gap junction 7.20 25.3
1 0  Colorectal 5.54 24.7
cancer
1 3  Tight 5.09 21.0 
junction
1 4  Regulation of 4.53 18.0
actin
cytoskeleton
1 6  B cell 3.98 17.5
receptor 
signalling 
pathway
1 9  Insulin 3.82 19.3
signalling 
pathway
23 MAPK 3.40 16.5
signalling 
pathway
26 Calcium 2.96 16.5
signalling 
pathway
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30 Neuroactive 
ligand- 
receptor 
interaction
32 Colorectal
cancer
33 Cell cycle
34 T cell 
receptor 
signalling 
pathway
35 TGF-beta 
signalling 
pathway
36 Tight 
junction
37 Wnt
signalling
pathway
38 VEGF 
signalling 
pathway
41 Cytokine- 
cytokine 
receptor
interaction
42 Jak-STAT 
signalling 
pathway
47 SNARE 
interactions 
in vesicular
transport
48 Insulin 
signalling 
pathway
49 mTOR 
signalling 
pathway
51 Hedgehog 
signalling 
pathway
52 Notch 
signalling 
pathway
3.97 18.9
3.71 24.7
3.62 23.2
3.55 24.7
3.37 23.8
3.05 21.0
2.99 20.4
2.72 20.8
2.45 18.4
2.35 18.3
1.71 19.4
1.38 17.8
1.19 16.3
0.95 7.0
0.71 10.9
26 Cell cycle
30 Adherens 
junction
31 Colorectal
cancer
32 Neuroactive
ligand-
receptor
interaction
33 VEGF 
signalling 
pathway
35 Jak-STAT 
signalling 
pathway
39 T cell
receptor 
signalling 
pathway
42 Tight 
junction
43 Hedgehog 
signalling 
pathway
44 SNARE 
interactions 
in vesicular
transport
45 Wnt 
signalling 
pathway
48 TGF-beta 
signalling 
pathway
49 Notch 
signalling 
pathway
50 Insulin 
signalling 
pathway
52 mTOR
signalling 
pathway
3.87 23.2
2.86 23.4
2.71 22.1
2.47 17.2
2.45 18.1
2.09 16.3
1.77 17.2
1.68 15.1
1.55 15.8
1.48 16.7
1.43 15.6
1.23 14.3
1.18 15.2
0.95 14.8
0.67 10.2
27 TGF-beta 
signalling 
pathway
30 Hedgehog 
signalling 
pathway 
32 Adherens 
junction 
36 Cell cycle
39 Apoptosis
40 VEGF 
signalling 
pathway
42 Neuroactive
ligand-
receptor
interaction
43 Natural killer 
cell mediated 
cytotoxicity
44 T cell 
receptor 
signalling 
pathway
45 mTOR 
signalling 
pathway
46 Notch 
signalling 
pathway
47 Regulation of
autophagy
48 Jak-STAT 
signalling 
pathway
49 Toll-like 
receptor 
signalling 
pathway
50 Cytokine- 
cytokine 
receptor
interaction
51 SNARE 
interactions 
in vesicular
 transport
2.79 14.3
2.60 15.8
2.43 18.2
2.16 14.3
1.91 14.3
1.88 13.9
1.79 9.6
1.67 12.5
1.67 14.0
1.60 14.3
1.55 13.0
1.19 9.8
1.12 9.9
1.09 6.6
1.03 8.353 Regulation of 0.49 6.9
autophagy
53 Regulation of 0.60 3.4
autophagy
1.38 10.3
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The 4 adult normal total brain samples showed a very high degree of expression profile 
similarity, as seen by in the tight clustering of these samples in the dendrogram of 
Figure 3.9. Moreover, the adult cerebellum and corpus callosum samples clustered with 
the foetal total brain, and showed variations between expression profiles. Only samples 
from these brain regions were available for investigation and although some tumours 
involved in this study are located in these regions, others are located in regions aside 
from the cerebellum or corpus callosum. Consequently adult total brain samples were 
used as normal controls for further analysis.
As a comparison between the biopsy and short-term cell culture experiments, those 
differentially expressed genes between the tumour and control samples were compared. 
From the 3240 differentially expressed probe sets between the 4 adult normal total brain 
controls and the 6 paediatric PAI biopsies and the 1695 differentially expressed probe 
sets between the 2 foetal astrocyte controls and the 6 paediatric PAI short-term cell 
cultures, only 556 probe sets were common to both analyses.
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Figure 3.11 This Figure illustrates differential genes expression found in the KEGG pathway antigen processing and presentation. Genes shown in blue are down-regulated, 
genes shown in red are up-regulated and those genes in green are either normally expressed or no reliable data was available (those in white were not included in this 
approach).
a) Pilocytic astrocytoma biopsies compared to adult normal controls.
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b) Pilocytic astrocytoma biopsies compared to foetal normal controls.
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c) Foetal normal controls compared to adult normal controls.
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IFigure 3.12 This Figure illustrates differential genes expression found in the KEGG pathway colorectal cancer. Genes shown in blue are down-regulated, genes shown in red 
are up-regulated and those genes in green are either normally expressed or no reliable data was available (those in white were not included in this approach).
a) Pilocytic astrocytoma biopsies compared to adult normal controls.
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Ib) Pilocytic astrocytoma biopsies compared to foetal normal controls.
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c) Foetal normal controls compared to adult normal controls.
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Figure 3.13 This Figure illustrates differential genes expression found in the KEGG pathway cell cycle. Genes shown in blue are down-regulated, genes shown in red are up- 
regulated and those genes in green are either normally expressed or no reliable data was available (those in white were not included in this approach).
a) Pilocytic astrocytoma biopsies compared to adult normal controls.
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Ib) Pilocytic astrocytoma biopsies compared to foetal normal controls.
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Ic) Foetal normal controls compared to adult normal controls.
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IFigure 3.14 This Figure illustrates differential genes expression found in the KEGG pathway Wnt signalling. Genes shown in blue are down-regulated, genes shown in red 
are up-regulated and those genes in green are either normally expressed or no reliable data was available (those in white were not included in this approach).
a) Pilocytic astrocytoma biopsies compared to adult normal controls.
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b) Pilocytic astrocytoma biopsies compared to foetal normal controls.
Canonical pathway
Adherens junction
Alsheimer's MAPK signaling 
path-waydisease
TAK1 1 NLK
| c-mycDuplin
Scaffold
| | [3-cateninj-
DNASMAD4
Axam ] ICAT1 1 U terineAxin G roue ho
■ Phosphorylation 
,+P dependence
p53 1 -------------------Siah-1 I j [3-TtCP
' Skpl
L  [ TGF-(3 signaling
path-wayUhiquitin mediated 
proteolysisPAR-1 || Nkd 1
Phosphorylation
independence Proteolysis
Focal adhesion
Prickleto
—H  RhoA f-— ROCK21—
Wnt 11
Knypek
MAPK signaling 
pathway
Cell
cycle
Planar cell polarity (PCP) 
pathw ay
Cytoskeltal change 
Gene transcription
Wnt/ Ca2+ pathway
Wnt5 | ►HBlilil-----------
G protein?
HFAT ] — O -
DNA
142
c) Foetal normal controls compared to adult normal controls.
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DISCUSSION
The majority o f control samples investigated for this study were pooled samples 
(Pavlidis et al., 2003; Peng et al., 2003). Variations in expression due to individual 
diversity could have been reduced if normal tissue had been available from tumour 
patients. As this was not possible, all control samples were pooled to mask variation in 
gene expression due to individuals and reduce cost. Tumour samples were not pooled in 
this experiment, or any of the experiments of this study as valuable data regarding to 
tumour heterogeneity would be lost or masked (Pavlidis et al., 2003; O'Sullivan et al., 
2005; Lusa et al., 2006).
Clustering of adult and foetal normal controls independently of the tumour biopsies 
suggested that either foetal or adult normal controls were suitable for the study of 
tumour biopsy samples (Figure 3.9). The identification of 1345 common, differentially 
expressed genes in PAI biopsies when using either adult or foetal normal controls 
strengthened this view (Figure 3.10). Furthermore, the overall similarity of the KEGG 
pathway ranking when comparing the PAI biopsies to either adult normal controls or 
foetal normal controls also suggested that either control group was suitable for the study 
of tumour biopsies. However, on investigation of the cellular pathways influenced by 
differential gene expression in the PAI biopsies when adult or foetal normal controls 
were used and in the normal foetal controls when compared to adult normal controls, it 
became apparent that the adult normal samples were more appropriate controls (Figures 
3.11-3.14).
As illustrated by Figures 3.11, 3.12, 3.13 and 3.14, the adult and foetal normal controls 
do have similar expression profiles. However, when considering controls for this study 
it was noted that foetal brain is in an exponential or linear growth phase and that this 
may have an impact on gene expression and signalling pathways (Samuelsen et al., 
2003). Furthermore, increased proliferation, cell signalling and reduced apoptosis are 
associated with foetal development and are also characteristics of tumour cells. The 
investigation of embryonic CNS cell migration has also provided clues as to how 
tumour cell migration may occur (Dirks, 2001). Moreover, the down-regulation of MHC 
class II mediated cell immunity has previously been identified in foetal tissue and is
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thought to be linked to a high success rate when transplanting foetal tissue 
(Bhattacharya, 2004).
The genes of the Wnt signalling pathway and cell cycle are clearly up-regulated in the 
foetal normal controls compared to the adult normal controls. It was hypothesised that 
the gene expression profile of foetal normal controls may mask aspects of the tumour 
profile when used as controls. This was seen in the tumour expression profile of the Wnt 
signalling pathway, the cell cycle and to a lesser extent the colorectal cancer pathway 
when foetal normal controls were used. Moreover, the Wnt signalling pathway has been 
implicated in foetal development (McMahon and Bradley, 1990; Parr et al., 1993; 
Hoang et al., 1998; Smalley and Dale, 1999; Katoh et al., 2000). For this reason the 
adult normal controls were chosen as controls for this study.
In addition, it was also decided to use only the adult total brain samples as controls. 
Significant variation was seen between the expression profiles of total brain, cerebellum 
and corpus callosum from both adult and foetal origin. Furthermore, the tumours of this 
study are located in brain regions aside from the cerebellum and corpus callosum and it 
was felt inappropriate to compare tumour samples from different locations to normal 
controls taken from these regions. Consequently, to standardise the normal control 
group and reduce sample heterogeneity, four pooled total brain samples from between 3 
and 5 individuals were chosen as controls.
The expression profiles of biopsy and short-term cell culture samples from the same 
tumour show variations when compared. This is not unexpected given sampling and cell 
culture conditions as previously discussed. Furthermore, the biopsy and cell culture 
samples clearly cluster into 2  groups regardless of sample origin, highlighting cell 
culture as the most important parameter in this experiment. Consequently, it was not 
possible to use normal brain samples as the control for tumour short-term cell culture 
experiments. Astrocytes are the proposed cell of origin of astrocytomas and the tumours 
are often positive for astrocytic markers. Consequently, foetal astrocytes were chosen as 
normal controls for the tumour short-term cell cultures of this study. Adult astrocytes 
were not available for additional comparisons and consequently no comparisons were 
possible when selecting this control. Due to a sample number of only 2, the foetal
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astrocyte controls have been included in further experiments with caution and have not 
been directly used for experiment normalisations.
The dendrogram of Figure 3.9 illustrates the grouping of all biopsy and short-term cell 
culture samples separately, suggesting that regardless of sample type the most 
dominating sample parameter influencing gene expression is cell culture. This confirms 
the need for independent normal controls for each sample type. Furthermore, the 
comparison of those genes showing differential gene expression between tumour 
biopsies and adult total brain and tumour short-term cell cultures and foetal astrocytes 
highlights the differences between these sampling approaches and the influences this 
has on paediatric astrocytoma study.
Short-term cell cultures are a valuable tool in the study of astrocytoma and other 
tumours and cancer. They represent a resource that increases the availability of tumour 
RNA and DNA for study. Moreover, short-term cell cultures provide a means to 
investigate cell characteristics such as cell surface markers, proliferation rate, cell 
motility, chemoresistance and response to stimuli including growth factors, extracellular 
matrix components, proteases and adhesion molecules. The manipulation of gene 
expression through a variety of mechanisms including RNA interference, target 
antibodies and gene therapy allows investigators to study cell response. This provides a 
working platform to assess the efficacy of target therapies and validate further 
investigation in in vivo studies.
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CHAPTER 4
DIFFERENTIAL GENE EXPRESSION AND COPY NUMBER ALTERATIONS IN  
PAEDIATRIC PILOCYTIC ASTROCYTOMA BIOPSIES
INTRODUCTION
PAI are the most common brain tumour in children (Louis et al., 2007a). Cytogenetic 
analysis of paediatric PAI has shown that the majority of these tumours (>70%) have a 
normal karyotype (Bhattachaijee et al., 1997). Numerical and structural abnormalities of 
chromosomes 5, 6 , 7, 8  and 9 have been reported, although definitive, non-random 
aberrations have not yet been identified (White et al., 1995; Zattara-Cannoni et al., 
1998; Shlomit et al., 2000; Sanoudou et al., 2000b; Rickert and Paulus, 2004). It has 
been suggested that epigenetic events in low-grade astrocytoma such as aberrant 
promoter hypermethylation are more common than genetic alterations and that they may 
have a greater impact on tumour development (Costello et al., 2000).
Few individual studies have focused on differentially expressed genes in paediatric PAI. 
However, two microarray studies have investigated paediatric PAI. The study by Wong 
et al. (2005) analysed 21 paediatric PAI using the Affymetrix GeneChip® U133A array. 
A second study focused on 41 PAI ranging in age between 1 and 53 years which were a 
mixture of sporadic PAI and those arising in patients with NF1 (Sharma et al., 2007). 
These studies have previously been discussed in detail in Chapter 1.
The aim of this chapter was to identify differential gene expression in paediatric PAI 
biopsies compared to 4 adult normal total brain controls and investigate genomic CNAs 
and methylation as a mechanism for these alterations to characterise disrupted cellular 
pathways that could be involved in tumour development and growth. The Affymetrix 
GeneChip® U133A array validated by Q-PCR was used to generate gene expression 
profiles and identify aberrantly expressed genes in 19 paediatric PAI biopsies and 4 
normal adult total brain controls. Six of these paediatric PAI biopsies are the same 
samples as those used in Chapter 3 including IN I740, IN2110, IN2356, IN2368, 
IN2921 and IN3013. The aCGH SpectralChip™ 2600 array was also used to define 
genomic aberrations in 11 of the 19 paediatric PAI biopsies. Limited tumour biopsy
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material was available for this study, consequently priority was given to RNA extraction 
and expression analysis as it was felt that this would prove to be the most significant in 
the study of PA
To further investigate mechanisms that may induce transcriptional silencing in PAI, 
MSP was used to investigate the promoter region methylation status of six genes 
comprising CDKN1C, PRDM2, SPINT2, REPRIMO, CCNA1 and DAPK1, that showed 
a 2-fold and significant down-regulation in the PAI compared to the normal controls 
(Olek et al., 1996b; Wamecke et al., 1997; Grunau et al., 2001). As well as showing 
down-regulation in the PAI, these genes had previously been reported as being 
methylated in astrocytoma or other tumours or cancer. Furthermore, hypermethylation 
of these 6  genes has been detected in more than 30% of several tumours types including 
gastric carcinoma, lung cancer and renal cell carcinoma Moreover, CCNA1 was 
hypermethylated in 100% of colorectal adenoma (Kikuchi et al., 2002; Toyooka et al., 
2003; Xu et al., 2004; Oshimo et al., 2004; Morris et al., 2005; Takahashi et al., 2005). 
Only one previous study has investigated hypermethylation in paediatric PAI involving 
MGMT, GSTP1, DAPK1, p l4 ARF, THBS-1, TIMP-3, p73, CDKN2A, RB-1 and TP53. 
Hypermethylation of CDKN2A was most frequent, occurring in 46% of cases. However, 
5 of the remaining genes were hypermethylated in less than 8 % of cases (Gonzalez- 
Gomez et al., 2003b). In total, 17 PAI were included as sufficient DNA was not 
available from the 2  remaining tumours.
PAI tumour biopsy tissue was available from 19 paediatric patients, details of which can 
be found in Table 2.2. The mean patient age at diagnosis was 5.8 years, (range, 1.75 to 
11.5 years) with a female/ male ratio of 8/11. At the time of this study patient survival 
ranged from 1-160 months from diagnosis. The initial diagnosis of all 19 tumours in this 
Chapter remained the same according to the 2007 WHO grading schemes.
The experiment analysis was carried out as previously described and the mean 
expression of each gene in all samples was normalised to that of the control samples for 
the per gene normalisation. The control samples used here were 4 adult normal total 
brain controls, details of these samples and their use as a control is documented in 
Chapter 3. Normalising to the control samples centres the experiment about the average 
expression level of each gene in the control samples. Gene probe sets present in 19 of
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the 23 samples (10554) were included in the experimental analysis as well as probe sets 
that were called as present in all 4 normal controls but absent in all 19 PAI (99). This 
allowed those genes that were down-regulated in either sample group and consequently 
detected as absent on the array to be included in further analysis.
RESULTS 
Paediatric pilocytic astrocytoma biopsy clustering, sub-groups and molecular 
signatures
Unsupervised hierarchical clustering using 10653 reliable gene expression results was 
used to generate a dendrogram illustrating the similarity in expression profiles of the 19 
paediatric PAI biopsies compared to 4 adult normal brain controls (Figure 4.1). The 
tumours do not group or order according to patient age, sex or tumour location and no 
further sub-groups were clearly defined, contradictory to that previously shown by 
Wong et al., 2005.
Wong et al. (2005) described a molecular signature of 89 genes that distinguished two 
subgroups of PAI representing tumours with different potentials of progression. A list of 
the 89 genes was not available. However, 16 of the 89 genes were described by Wong et 
al. (2005) and involved in biological processes significantly altered between the two 
sub-groups. These 16 genes were investigated in the PAI of this study. Only 13 of the 
16 genes showed reliable data and were used to cluster the 19 PAI. The PAI did not 
cluster into sub-groups and Figure 4.2 illustrates a continuous increase or decrease in 
the expression of these 13 genes between tumours that are least similar.
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Figure 4.1 Unsupervised hierarchical clustering of 19 paediatric pilocytic astrocytoma and 4 normal brain 
controls using 10653 reliable gene expression results.
The dendrogram colour saturation is proportional to the magnitude of the difference from the mean 
relative to controls, ranging from red (over-expressed) to blue (under-expressed). Patient ages are in years 
at diagnosis, tumour labels coloured green indicate a male patient and pink a female patient and location 
abbreviations are as follows: OP = optic pathway; PF = posterior fossa; CHI = chiasmatic; CERE = 
cerebellum.
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Figure 4.2 The profile of 13 reliable expression results from this study, also used by Wong et al. (2005) 
to distinguish two possible sub-groups in paediatric pilocytic astrocytoma.
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The 19 PAI are ordered according to the hierarchical clustering results of this study.
Expression profiles of paediatric pilocytic astrocytoma biopsies
From 10653 reliable expression results, 1844 genes showed a 2-fold and significant 
change in expression in PAI compared to the normal controls. Of these, 1002 were up- 
regulated and 842 were down-regulated. Table 4.1 illustrates the percentage of genes 
disrupted in specific Gene Ontology (GO) biological processes (Thomas et al., 2007). 
Approximately 5-10% of genes in each GO group showed differential gene expression. 
The cell homeostasis GO showed the highest number of altered genes (11%), compared 
to chemi-mechanical coupling which was the lowest (3%). The GO of those genes 
investigated using Q-PCR and MSP are also shown in Table 4.1.
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In order to investigate those gene that were most differentially expressed, genes that 
showed a greater than 1 0 -fold change in expression and were either involved in a 
KEGG pathway or have been well-characterised were identified (Table 4.2). SERPINA3 
a protease inhibitor, showed the largest up-regulation in gene expression with an 80.89- 
fold change in the tumour samples compared to normal brain. FOXG1B, a member of 
the forkhead family of transcription factors, showed the largest down-regulation in gene 
expression with a 325.73-fold change.
To identify cellular pathways involved in PAI development, Onto-tools was used to 
investigate the 1844 genes that showed a 2-fold and significant change in expression 
(Table 4.3). The software ranked the KEGG pathways according to the extent of 
differential gene expression and the impact on the pathway overall. Of the 53 pathways 
that were ranked, only those of interest are displayed in Table 4.3.
To further investigate the correlations between differential gene expression and the 
impact this may have on specific pathways, those gene involved in 5 pathways or more 
were also identified (Table 4.4).
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Table 4.1 Gene ontologies of specific genes differentially expressed between pilocytic astrocytoma and
normal controls.
Biological process GO ID Number o f genes Number of genes differentially
in GO group expressed between paediatric 
astrocytoma and normal controls
Amino acid and derivative metabolism 0006519 180 13 (7%)
Behaviour 0007610 83 8 (10%)
Biosynthesis 0009058 885 52 (6%)
Carbohydrate metabolism 0005975 1696 134 (8%)
Catabolism 0009056 426 27 (6%)
Cell cycle 0007049 1161 78 (7%) (MAPK1, CDKN1C, 
CCNA1, MATK, REPRIMO)
Cell death 0008219 863 66 (8%) (MAPK1, DAPK1, 
MCL1)
Cell differentiation 0030154 1657 144 (9%) (TIMP1, MATK, 
MCL1)
Cell growth 0016049 3993 288 (10%) (TIMP1, CDKN1C, 
MATK, MCL1)
Cell homeostasis 0019725 90 10(11%)
Cell proliferation 0008283 1067 82 (8%) (TIMP1, CDKN1C, 
MATK)
Cell recognition 0008037 1820 161 (9%)
Cell-cell signalling 0007267 2582 220 (9%) (SPINT2)
Chemi-mechanical coupling 0006943 102 3 (3%)
Co-enzyme and prosthetic group 0006731 1163 64 (6%)
metabolism
Cytoskeleton organisation and biogenesis 0007010 1536 131 (9%) (MAPK1)
DNA metabolism 0006259 1470 75 (5%)
Electron transport 0006118 3286 210(6%)
Embryonic development 0009790 779 44 (6%)
Energy pathways 0006091 1497 71 (5%) (DAPK1)
Growth 0040007 1405 123 (9%) (SPINT2)
Host-pathogen interactions 0030383 4051 301 (7%) (CCNA1, MATK)
Ion transport 0006811 2474 193 (8%)
Lipid metabolism 006629 859 82 (10%)
Mitochondria organisation and biogenesis 0007005 1273 66 (5%) (DAPK1)
Morphogenesis 0009653 301 11 (4%)
Protein biosynthesis 0006412 1060 53 (5%)
Protein modification 0006412 307 24 (8%)
Protein transport 0015031 2031 203 (10%)
Regulation o f gene expression; epigenetic 0040029 3969 241 (6%) (TIMP1, CDKN1C, 
PRDM2, CCNA1, MATK)
Reproduction 0000003 141 8 (6%)
Response to endogenous stimuli 0009719 103 9 (8%)
Response to stress 0006950 427 31 (7%) (MAPK1, MCL1)
Signal transduction 0007165 4158 330 (8%) (MAPK1 ,DAPK 1)
Transcription 0006350 3697 185 (5%) (PRDM2)
Unknown biological processes 0000004 11034 379 (3%)
The percentage o f genes in each ontology group that shows differential expression between the PAI and 
normal controls is shown in brackets. The GO of those genes investigated using Q-PCR and MSP are 
indicated in column 4.
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Table 4.2 Genes identified from the 1844 differentially expressed genes that show a greater than 10-fold 
change in expression and are involved in specific pathways or are well-characterised with functions that
can be linked to tumour development.
Rank Gene symbol Gene description Fold change in Chromosome
___________________________________________ ===========______  expression location
1 SERPINA3 serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 3
80.89 14q32.1
2 CHI3L1 chitinase 3-like 1 (cartilage 
glycoprotein-39)
56.98 lq32.1
4 CHAD 2 (4,11) chondroadherin 43.68 17q21.33
6 TIMP4 tissue inhibitor o f metalloproteinase 4 41.47 3p25
7 WEE1 1 (38) WEE1 homolog (S. pombe) 41.03 1 Ipl 5.3-p 15.1
11 T1A-2 lung type-I cell membrane-associated 
glycoprotein
35.21 lp36
12 ABCC3 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3
33.72 17q22
15 IL1RAP 2 (1,47) interleukin 1 receptor accessory protein 26.58 3q28
17 CSPG4 chondroitin sulfate proteoglycan 4 
(melanoma-associated)
23.77 15q23
19 AGTRL1 1 (32) angiotensin II receptor-like 1 22.36 11 q 12
22 CD44 Homo sapiens CD44 isoform RC 
(CD44) mRNA, complete cds
19.88 1 lp 13
24 MYT1 myelin transcription factor 1 18.49 20ql3.33
26 TAZ transcriptional co-activator with PDZ- 
binding motif (TAZ)
17.53 3q23-q24
31 TIMP1 tissue inhibitor o f metalloproteinase 1 
(erythroid potentiating activity, 
collagenase inhibitor)
16.23 X pll.3 -p ll.23
32 HLA-DPA1 3 (1 ,2 , 32) major histocompatibility complex, 
class II, DP alpha 1
15.79 6p21.3
36 S100A10 SI00 calcium binding protein A10 
(annexin II ligand, 
calpactin I, light polypeptide (pi 1))
15.27 1 q21
38 TLR2 1 (14) toll-like receptor 2 14.66 4q32
40 TFPI 1 (12) ESTs, Weakly similar to cytokine 
receptor-like factor 2; 
cytokine receptor CRL2 precusor 
[Homo sapiens] [H.sapiens]
14.09 2q32
44 POSTN osteoblast specific factor 2 
(fasciclin I-like)
12.60 13ql3.1
46 CHI3L2 chitinase 3-like 2 12.22 lp l 3.3
48 CCL3 chemokine (C-C motif) ligand 3 11.89 17qll-q21
49 MSR1 macrophage scavenger receptor 1 11.87 8p22
50 SRPX sushi-repeat-containing protein, 
X chromosome
11.29 Xp21.1
51 CSPG2 1 (2) chondroitin sulfate proteoglycan 2 
(versican)
10.86 5ql4.3
56 CD151 CD151 antigen 10.61 1 lp l 5.5
-74 FGF13 2 (5, 6) fibroblast growth factor 13 -10.34 Xq26.3
-72 MEF2C 1 (5) MADS box transcription 
enhancer factor 2, 
polypeptide C (myocyte 
enhancer factor 2C)
-10.48 5ql4
-70 WNT10B 2 (28,46) wingless-type MMTV integration site 
family, member 10B
-10.50 12ql3
-69 NPY1R 1 (32) neuropeptide Y receptor Y 1 -10.96 4q31.3-q32
-67 ATP2B2 1 (19) Homo sapiens, Similar to nuclear 
localization signals binding 
protein 1, clone IMAGE:4933343, 
mRNA
-11.22 3p25.3
-66 PRKCB1 15(3-5, 7, 
8, 10, 16-19, 22, 28, 
36,39,41)
protein kinase C, beta 1 -11.24 16pl 1.2
-65 MAL mal, T-cell differentiation protein -11.55 2cen-ql3
-62 CACNA2D3 1 (5) calcium channel, voltage-dependent, 
alpha 2/delta 3 subunit
-11.89 3p21.1
-60 GRIN1 3 (7,19, 32) glutamate receptor, ionotropic, N- 
methyl D-aspartate 1
-12.15 9q34.3
-59 HTR2A 3 (10,19, 32) 5-hydroxytryptamine 
(serotonin) receptor 2A
-12.22 13ql4-q21
-55 SNAP25 1 (43) synaptosomal-associated protein, 25kDa -13.04 20pl2-pl 1.2
-54 PTK2B 4 (8, 16, 17, 19) PTK2B protein tyrosine kinase 2 beta -13.42 8p21.1
-52 VIP 1 (32) vasoactive intestinal peptide -14.27 6q26-q27
-50 VAMP1 1 (43) vesicle-associated membrane 
protein 1 (synaptobrevin 1)
-15.17 12p
-48 NPY 2 (32, 35) neuropeptide Y -15.63 7pl5.1
-45 ENPP2 ectonucleotide pyrophosphatase/ 
phosphodiesterase 2 (autotaxin)
-17.09 8q24.1
-44 MBP myelin basic protein -17.48 18q23
-39 HTR2C 3(10, 1,32) 5-hydroxytryptamine (serotonin) 
receptor 2C
-19.23 Xq24
-37 P2RX5 2 (19,23) purinergic receptor P2X, ligand-gated 
ion channel, 5
-19.57 17pl3
-32 MATK 2 (6, 15) megakaryocyte-associated 
tyrosine kinase
-23.75 19pl3.3
-31 CRH 2 (22, 32) corticotropin releasing hormone -24.27 8ql3
-22 NEFH 2 (25,31) neurofilament, heavy 
polypeptide 200kDa
-27.40 22ql2.2
-21 ICAM5 intercellular adhesion molecule 5, 
telencephalin
-27.70 19pl3.2
-19 EGR4 early growth response 4 -28.90 2pl3
-15 CAMK2A 5 (7, 8, 19, 20, 
28)
calcium/calmodulin-dependent protein 
kinase (CaM kinase) II alpha
-36.76 5q33.1
-13 ATP2B2 1 (19) ATPase, Ca++ transporting, plasma 
membrane 2
-39.22 3p26-p25
-11 SST 1 (32) somatostatin -43.86 3q28
-10 ITPKA 2 (3, 19) inositol 1,4,5-trisphosphate 3-kinase A -49.50 15ql4-q21
-6 GABRA5 1 (32) gamma-aminobutyric acid (GABA) A 
receptor, alpha 5
-101.01 15ql 1.2-ql2
-3 CACNG3 1 (5) calcium channel, voltage-dependent, 
gamma subunit 3
-136.99 16pl2-p 13.1
-2 CCK 1 (32) cholecystokinin -146.63 3p22-p21.3
-1 FOXG1B forkhead box GIB -325.73 14q 12-q 13
The numbers outside the brackets after the gene symbol, indicate how many specific pathways the gene is 
known to be involved in. The numbers inside the brackets correspond to the specific pathways in Table 
4.3. Genes highlighted in red are involved in many pathways shown by Table 4.4.
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Table 4.3 The Onto-tools result ranking KEGG pathways disrupted by the 1844 
differentially expressed genes in pilocytic astrocytoma.
Rank Unique KEGG Database Pathway Name Impact Genes in Pathway Genes
Pathway-id Factor Pathway in Input
(percentage %)
1 1 04612 Antigen processing and presentation 76.6 86.0 24.4
2 1 04514 Cell adhesion molecules (CAMs) 24.1 132.0 25.8
3 1 04070 Phosphatidylinositol signalling system 23.2 79.0 27.8
4 1 04510 Focal adhesion 14.7 194.0 25.8
5 1 04010 MAPK signalling pathway 14.3 273.0 22.7
6 1 04810 Regulation of actin cytoskeleton 12.9 206.0 23.3
9 1 04210 Apoptosis 9.3 84.0 27.4
10 1 04540 Gap junction 9.3 99.0 25.3
11 1 04512 ECM-receptor interaction 9.1 87.0 26.4
12 1 04610 Complement and coagulation cascades 8.8 69.0 27.5
14 1 04620 Toll-like receptor signalling pathway 8.1 91.0 25.3
16 1 04670 Leukocyte transendothelial migration 7.8 117.0 23.1
17 1 04650 Natural killer cell mediated 
cytotoxicity
7.3 128.0 21.1
18 1 04662 B cell receptor signalling pathway 7.2 63.0 27.0
19 1 04020 Calcium signalling pathway 7.0 176.0 18.2
24 1 04910 Insulin signalling pathway 5.7 135.0 20.7
25 1 01510 Neurodegenerative disorders 5.7 35.0 28.6
26 1 05210 Colorectal cancer 5.6 77.0 23.4
28 1 04310 Wnt signalling pathway 5.5 147.0 18.4
32 1 04080 Neuroactive ligand-receptor 
interaction
4.7 302.0 11.3
33 1 04660 T cell receptor signalling pathway 4.4 93.0 20.4
35 1 04920 Adipocytokine signalling pathway 4.0 69.0 20.3
36 1 04530 Tight junction 3.9 119.0 16.8
37 1 04520 Adherens junction 3.8 77.0 20.8
38 1 04110 Cell cycle 3.5 112.0 16.1
39 1 04370 VEGF signalling pathway 3.0 72.0 16.7
42 1 04150 mTOR signalling pathway 2.6 49.0 18.4
43 1 04130 SNARE interactions in vesicular 
transport
2.5 36.0 13.9
44 1 04350 TGF-beta signalling pathway 2.3 84.0 15.5
45 1 04630 Jak-STAT signalling pathway 2.2 153.0 13.7
46 1 04340 Hedgehog signalling pathway 1.6 57.0 12.3
47 1 04060 Cytokine-cytokine receptor interaction 1.6 256.0 11.7
51 1 04140 Regulation of autophagy 0.8 29.0 3.4
52 1 04330 Notch signalling pathway 0.8 46.0 8.7
The pathways are ranked according to impact factor. This impact factor takes into account the fold change 
and number o f genes differentially expresses in a pathway and the influence each individually disrupted 
gene has on a pathway.
The pathway most affected by differential gene expression (rank 1) was antigen 
processing and presentation, in which the majority of genes are significantly up- 
regulated and located at 6p21.3 (Figure 4.3). Pathways expected to have a greater 
involvement in tumour development than indicated by their rank appear to have a lower 
percentage of pathway input genes. These include the calcium signalling pathway, 
WNT signalling pathway, the cell cycle, TGF-beta signalling pathway, Jak-STAT
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signalling pathway and the Notch signalling pathway that all have a gene input less than 
20%.
Figure 4.3 The KEGG pathway antigen processing and presentation ranked 
first by the Onto-tools software.
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This pathway illustrates the aberrantly expressed genes in paediatric PAI involved in antigen processing 
and presentation. Those genes showing up-regulation are red and those down-regulated are blue.
To investigate if particular differentially expressed genes could influence several 
pathways and have an overall impact on tumour development, those genes involved in 5 
or more pathways were identified (Table 4.4). Although MAPK1 is involved in 17 
pathways, this gene only showed a 2.01-fold down-regulation in expression. In contrast, 
genes with the largest fold changes are involved in fewer pathways. Only two genes, 
CAMK2A and PRKCB1, showed a greater than 10-fold change in expression and are 
involved in more than 5 pathways (Tables 4.2 and 4.4), suggesting that those genes with 
the highest degree of deregulation in paediatric PAI may not have the greatest impact on 
cellular pathways.
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Table 4.4 The Onto-tools result of differentially expressed genes involved in 5 pathways or more.
Gene Gene description Fold change in Number o f pathways Chromosome
symbol______________________________________ expression_____ gene involved in_______ location
MAPK1 mitogen-activated protein kinase 1
PIK3CB phosphoinositide-3-kinase, catalytic, 
beta polypeptide 
PIK.3R1 phosphoinositide-3-kinase, regulatory 
subunit 1 (p85 alpha)
PRKCB1 protein kinase C, beta 1
AKT3 v-akt murine thymoma viral
oncogene homolog 3 
(protein kinase B, gamma) 
MAP2K1 mitogen-activated protein
kinase kinase 1 
MAPK9 mitogen-activated protein kinase 9
MAPK10 mitogen-activated protein kinase 10
PRKACB protein kinase, cAMP-dependent, 
catalytic, beta 
PPP3CA protein phosphatase 3 (formerly 2B), 
catalytic subunit, alpha 
isoform (calcineurin A alpha) 
PPP3CB protein phosphatase 3 (formerly 2B), 
catalytic subunit, beta 
isoform (calcineurin A beta) 
PRKX protein kinase, X-linked
PPP3R1 protein phosphatise 3 (formerly 2B), 
regulatory subunit B, 19kDa, alpha 
isoform (calcineurin B, type I) 
IKBK.B inhibitor o f kappa light polypeptide 
gene enhancer in B-cells, kinase beta 
JUN v-jun sarcoma virus 17 oncogene
homolog (avian)
PAK.1 CDKN1A /Cdc42/Racl-activated
kinase 1 
(STE20 homolog, yeast)
TP53 tumor protein p53 (Li-Fraumeni
syndrome)
PLCB1 phospholipase C, beta 1
(phosphoinositide-specific) 
CALM1 calmodulin 1 (phosphorylase kinase, 
delta)
PDGFRA platelet-derived growth factor 
receptor, alpha polypeptide 
CALM3 calmodulin 3 (phosphorylase kinase, 
delta)
ITGB1 integrin, beta 1 (fibronectin receptor, 
beta polypeptide, 
antigen CD29 includes MDF2, 
MSK12)
ITPR1 inositol 1,4,5-triphosphate receptor, 
type 1
ITPR2 inositol 1,4,5-triphosphate receptor, 
type 2
ROCK1 Rho-associated, coiled-coil
containing protein kinase 1 
NFKBIA nuclear factor o f kappa light
polypeptide gene enhancer 
in B-cells inhibitor, alpha 
ROCK2 Rho-associated, coiled-coil
containing protein kinase 2
-2.01 17(4-8, 10,17,21,22, 24, 
26, 37, 39-42, 44)
22ql 1.21
-2.05 1 6 (3 ,4 , 6 ,9 , 14, 16-18, 
24, 26, 33, 39-42, 45)
3q22.3
-2.13 16(3, 4, 6, 9, 14, 16-18, 
24, 26, 33, 39-42, 45)
5q13.1
-11.24 15(3-5, 7, 8, 10, 16-19, 
22, 28, 36,39,41)
16pl 1.2
-2.54 14(4, 5, 9, 14, 18, 24, 
26,33, 35 ,36, 39,41, 
42, 45)
Iq43-q44
-4.17 1 2  (4 -8 ,1 0 ,1 7 ,2 2 ,2 4 , 15q22.1-q22.33 
26, 39, 41)
-3.48 11  (4, 5, 8, 14, 15, 24, 
26, 28, 35, 40 ,41)
5q35
-2.28 11  (4, 5, 8, 14, 15, 24, 
26, 28, 35, 40 ,41)
4q22.1-q23
-2.55 11 (5, 7-10, 19, 20, 24, 
28, 46, 48)
lp36.1
-4.13 11  (5, 7, 9, 17-19,21, 
28 ,3 1 ,3 3 , 39)
4q21-q24
-3.65 10(5, 7, 9, 17-19,21, 
2 8 ,3 1 ,3 3 ,3 9 )
10q21-q22
2.08 10 (5, 7, 8, 10, 19, 20, 
24, 28, 46, 48)
Xp22.3
-3.05 10(5, 7, 9, 17-19,21, 
28, 33, 39)
2pl5
2.75 9 (5 ,9 , 14, 15, 18, 24, 
33, 35, 40)
8pl 1.2
2.49 9 (4 , 5, 8, 14, 15, 18, 26, 
28, 33)
Ip32-p31
-7.87 7(4-6 , 15, 17 ,21 ,33) 1Iq l3-q l4
3.14 7 (5 , 9, 26, 28, 29,31, 
38)
17pl3.1
-2.73 7 (3 , 7, 8 ,,10 , 19, 22, 
28)
20pl2
-2.22 7 (3, 7, 8, 19, 20 ,24, 29) 14q24-q31
5.76 7 (4-6, 10, 19, 26, 47) 4 q ll-q l3
-2.31 7 (3, 7, 8, 19, 20, 24, 29) 19ql3.2-ql3.3
2.26 6 (2 , 4, 6, 11, 16,21) 10p ll.2
-8.62 6 (3 , 7, 8, 10, 19, 22) 3p26-p25
5.42 6 (3 , 7, 8, 10, 19, 22) 12pl 1
2.42 6 (4, 6, 16, 21 ,28 , 44) 18q 11.1
2.17 6 (9 , 14, 15, 18, 33,35) 14q 13
-2.40 6 (4, 6, 16, 21, 28, 44) 2p24
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CCNDl cyclin D1 3.77 5 (4, 26, 28, 38,45) 1 lq l3
CAMK2A calcium/ cal modul in-dependent 
protein kinase 
(CaM kinase) II alpha
-36.77 5 (7, 8, 19, 20, 28) 5q33.1
CAMK2B calci um/cal modul in-dependent 
protein kinase 
(CaM kinase) II beta
-8.77 5 (7 , 8, 19, 20, 28) 7pl4.3-pl4.1
GNAI3 guanine nucleotide binding protein 
(G protein), alpha 
inhibiting activity polypeptide 3
2.72 5 (10 , 16 ,21 ,22 , 36) 3p21
TGFB1 transforming growth factor, beta 
l(Camurati-Engelmann disease)
2.32 5 (5, 26, 38 ,4 4 ,4 7 ) 19ql3.1
ACTN1 actinin, alpha 1 2.26 5 (4, 6, 16, 36, 37) 14q22-q24
PAK2 CDKNIA-activated kinase 2 2.23 5 (4 -6 ,2 1 ,3 3 ) 3q29
FOS v-fos FBJ murine osteosarcoma viral 
oncogene homolog
5.10 5 (5 , 14, 18, 26 ,33) 14q24.3
ACTN2 actinin, alpha 2 -2.52 5 (4, 6, 16, 36 ,37) Iq42-q43
MAP2K4 mitogen-activated protein kinase 
kinase 4
-3.30 5 (5 , 8, 14, 15,41) 17pl 1.2
PLA2G6 phospholipase A2, group VI 
(cytosolic, calcium-independent)
-2.02 5 (5 , 8 ,2 ,3 9 ,4 1 ) 22ql3.1
PTPN6 protein tyrosine phosphatase, non­
receptor type 6
2.21 5 (17 , 18, 33 ,37 , 45) 12pl3
FAS Fas (TNF receptor superfamily, 
member 6)
5.90 5 (5 , 9, 13, 17, 47) 10q24.1
CCND2 cyclin D2 2.02 5 (4, 26, 28, 38,45) 12pl3
PLA2G12A phospholipase A2, group XIIA 3.99 5 (5 , 8, 22, 39,41) 4q25
GNAS GNAS complex locus -4.93 5 (8 , 10, 19, 22, 48) 20ql 3.3
GNAI1 guanine nucleotide binding protein 
(G protein), alpha 
inhibiting activity polypeptide 1
-2.25 5 (10 , 16 ,21 ,22 , 36) 7q21
CAMK2G calcium/calmodulin-dependent 
protein kinase (CaM kinase) II 
gamma
-3.40 5 (7 , 8, 19, 20 ,28) 10q22
The numbers in bold outside the brackets correspond to the specific pathways in Table 4.3 and the 
numbers inside the brackets are the pathway rankings. Genes highlighted in red are the most disrupted in 
PAI, with a greater than 10-fold change in expression. These genes are listed in Table 4.2.
Validation of array results using Q-PCR
To validate the expression results obtained from the Affymetrix GeneChip® 
experiments, the expression of 6  genes that showed a 2 -fold and significant difference in 
expression in PAI compared to the normal controls were assessed using Q-PCR in 16 of 
the 19 samples. Sufficient RNA was not available for the remaining 3 samples. The 
array data demonstrated that CCNA1, SPINT2, MAPK1 and MATK were significantly 
down-regulated and TIMP1 and MCL1 were significantly up-regulated. Q-PCR 
confirmed these changes in gene expression in PAI compared to normal brain (Table
4.5). Similar differential expression of these genes was also found when SAGE data was 
analysed (http:cgap.nci.nih.gov) (Boon et al., 2002b). Only data from paediatric 
astrocytoma tumours were included.
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Table 4.5 Q-PCR validation o f the microarray data.
Tumour
Sample
TIMP1 MCL1 SPINT2 CCN1A MAPK1 MATK
Array/Q-PCR Array/Q-PCR Array/Q-PCR Array/Q-PCR Array/Q-PCR Array/Q-PCR
IN1350 10.95/5.46 2.88/1.89 0.24/0.02 0.19/0.00 0.50/0.16 0.04/0.01
IN 1740 43.15/35.92 2.281.89 0.18/0.03 0.28/0.00 0.57/0.26 0.03/0.01
IN2110 12.11/9.60 2.33/1.39 0.31/0.03 0.03/0.00 0.43/0.20 0.03/0.01
IN2368 10.20/20.49 5.63/2.34 0.07/0.02 0.17/0.00 0.67/0.29 0.05/0.01
IN2524 13.52/9.54 6.42/1.53 0.24/0.03 0.17/0.00 0.68/0.26 0.03/0.00
IN2604 26.74/20.16 5.25/2.44 0.17/0.02 0.19/0.02 0.85/0.11 0.07/0.00
IN2631 18.05/5.58 6.15/0.78 0.25/0.02 0.32/0.01 0.72/0.17 0.02/0.00
IN2674 7.12/6.26 3.43/1.50 0.57/0.16 0.25/0.02 0.50/0.46 0.03/0.03
IN2825 27.41/32.00 5.43/3.19 0.17/0.03 0.40/0.05 0.46/0.22 0.06/0.01
IN2921 39.89/26.05 3.68/1.16 0.60/0.05 0.14/0.00 0.37/0.13 0.05/0.01
IN2940 17.56/7.78 4.93/1.30 0.28/0.04 0.22/0.00 0.38/0.17 0.03/0.01
IN2969 11.15/9.89 3.57/1.68 0.26/0.05 0.26/0.03 0.48/0.27 0.04/0.01
IN3013 14.69/13.42 3.95/1.33 0.33/0.05 0.14/0.00 0.49/0.17 0.05/0.00
IN3017 13.95/23.92 3.15/3.50 0.13/0.05 0.22/0.01 0.60/0.32 0.04/0.00
IN3126 11.68/11.69 7.56/1.00 0.38/0.08 0.31/0.00 0.67/0.26 0.05/0.01
IN3156 30.88/19.93 3.91/0.89 0.30/0.04 0.26/0.03 0.45/0.18 0.02/0.01
The comparative CT method was used to determine the relative ratio o f expression results for each gene 
using Q-PCR. In this approach p-actin was used as the endogenous control and adult normal total brain 
was used as the control. The relative quantitative value shown above is expressed as 2'AACt .
Genomic aberrations found in paediatric pilocytic astrocytoma biopsies
aCGH was carried out using the SpectralChip™ 2600 array to identify regions of 
chromosome gain and loss in 11 paediatric PAI. In total, 97 individual BAC clones 
were found to be either gained or lost in 1 or more tumours. Of these, 26 were gained, 
64 were lost and 7 were gained or lost in different tumours (Figure 4.4) (The raw data 
for this analysis can be found on the Supplementary Data CD included with this thesis). 
Several chromosome regions were frequently altered in PAI. BAC clones mapping to 
lp36.33, 14ql2, 19pl3.2 and 22ql3.33 showed either gain, loss or both in 91%, 82%, 
64% and 91% of tumours, respectively. A small region containing 2 adjacent clones at 
l p l3 was lost in 1 tumour and a region that varied in size containing up to 7 adjacent 
clones at 7ql 1.23 was lost in 7 tumours (Figure 4.5). Other regions less frequently 
altered included 7ql 1.2 and 8q21 in 45% of tumours, 7q34, 8q24.3, 10q21.3 and 17q21 
in 36% of tumours and 6ql2, 6ql3, 17q21.3 and 19pl3.3 in 27% of tumours.
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Reliable gene expression data was not available for all genes located in the same regions 
as the 97 altered clones. Overall, loss of six individual clones correlated with down- 
regulation of genes mapping to the same region, comprising BCL7B at 7q 11.23 in 7 
tumours (Figure 4.5); SH3GL2 at 9p21.2-p23 in 1 tumour; BCL7A at 12q24.33 in 1 
tumour; DRD1IP at 10q26.3 in 1 tumour; and TUBG2 and CNTNAP1 at 17q21.31 in 2 
tumours. Critically, although clone loss at these regions was not seen in every tumour, 
all tumours showed a 2 -fold and significant down-regulation in the specific genes at 
these loci (Table 4.6) No correlations were found between clone gain and gene over­
expression.
Large scale copy number variations (LCVs) in specific chromosome regions have been 
characterised in the normal population. Of the 97 clones that were involved in CNAs, 37 
are located in regions of known LCV, indicated by the green circles in Figure 4.4.
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Figure 4.4 aCGH results indicating regions of chromosome gain and loss in paediatric PAI.
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Circles to the right of each chromosome ideogram show the number of individual tumours with single 
clone gains (red) and losses (blue) among the 11 PAI studied. Clones in a region of LCV in the normal 
population are indicated by a green ring. Adjacent clones altered in the same tumour are indicated by a 
yellow box. Multiple clones in a region are indicated by two arrows. Cytogenetic band positions are 
shown to the left. Correlations between clone alterations and differential gene expression in the same 
region are indicated by a purple box.
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Table 4.6 The Table illustrates the correlation of BAC clone losses and differential gene expression in the same region in paediatric pilocytic astrocytoma.
Clone
Location Clone Name
Clone
Alteration
Gene Located 
in Clone Region
Fold
Change Description
7q 11.23 RP11-35P20, B315H11, CITB-51J22, B270D13, B39H04, RP11-137E8, RP11-89A20 Loss BCL7B -2.14 B-cell CLL/lymphoma 7B
9p21.2-p23 RP11-163F8 Loss SH3GL2 -6.94 SH3-domain GRB2-like 2
10q26.3 RP11-122K.13 Loss DRD1IP -35.09 dopamine receptor D1 interacting protein
12q24.33 RP11-87C12 Loss BCL7A -2.98 B-cell CLL/lymphoma 7A
14q 12 RP11-125A5 Loss FOXG1B -325.73 forkhead box G 1B
17q21.31 AC 100793.8 Loss TUBG2
CNTNAP1
-2.28
-2.99
tubulin, gamma 2 
contactin associated protein 1
Figure 4.5 Loss of between 2 and 7 BAC clones at 7ql 1.23 in seven pilocytic astrocytoma.
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T
The coloured rows of spots represent individual tumours with BAC clones losses at 7ql 1.23. The distance 
between each spot is representative of the BAC clone binding locations.
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Methylation specific PCR and sequencing in paediatric pilocytic astrocytoma
biopsies
MSP products were only generated by primer sets specific for unmethylated promoter 
regions, indicating that the promoter regions of CDKN1C, PRDM2, SPINT2, 
REPRIMO, CCNA1 and DAPK1 were not methylated in the 17 PAI analysed (Figure
4.6). A result was not achieved for CCNA1 in tumours IN2788, IN2825 and IN3017 
despite repeated attempts. Sequencing of each gene in IN3115 and IN2940 and normal 
brain confirmed that promoter region methylation was not present in either PAI or the 
normal samples. An example of this is shown in Figure 4.7.
F ig u re  4 .6  MSP results for CDKN1C, PRDM2, SPINT2, REPRIMO, CCNA1 and 
DAPK1 in paediatric astrocytomas.
2921 2788 2825 3156 3115 2361 2524 2940 2674 1740 3017 2110 2356 2368 3013 1350 2969 
M U M U A A U M U M U M U M U A A U M U M U M U A A U M U M U A A U M U A A U
CDK.N1
P R D M
SP1NT
REPRIM
CCNA
DAPK
These results show PCR products for primer sets designed to amplify unmethylated or methylated 
promoter regions. M indicates methylated products and U indicates unmethylated products for each 
tumour.
F ig u re  4 .7  Sequencing data for DAPK1 in PAI IN3115 and IN2940 and normal brain. 
Original Sequence D  'CpS site
66A C A 6^& A ^c3^6C C A ^f^e^C 6066A C TT T 6T TC (^ ^ C&&AG6G6^C^C&0CAAlTlcfC^CA&C&GCA6&&TC'{M^C&&C6CCT&G 
I____________Primer___________J  L ------ EdmfiC--------- 1
Bisulfate Treated Sequence
66 AT
Normal
Brain
6666A T TT66TAA inTTT6TA6T66TA 666TTT6666TT66T6TTT666A66
IN31I5
IN2940
CpG sites where methylation could occur are indicated in the original sequence by a blue box. 
Unmethylated cytosine residues are converted to uracil residues which during amplification become 
thymidine residues. The bisulfite treated sequence illustrates no methylation.
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1
DISCUSSION
This Chapter has focused on global differential gene expression in PAI and correlations 
between genomic CNAs at a 1MB resolution in order to identify and characterise 
cellular pathways that are involved in tumour development and growth. Genomic gain 
and loss and gene promoter region methylation are mechanisms that disrupt gene 
expression and play a significant role in the development of many tumours.
Using the Affymetrix GeneChip® U133A array, 10563 reliable gene expression results 
were generated for 19 paediatric PAI and 4 normal brain controls. From these, 1844 
differentially expressed genes were identified that showed a 2 -fold and significant 
change in expression; 1002 were up-regulated and 842 were down-regulated. An 
unsupervised hierarchical clustering approach using all reliable results showed that the 
tumour and control samples grouped separately. No GO biological process showed a 
significantly large difference in the percentage of differentially expressed genes in the 
PAI compared to normal controls.
Sub-groups and molecular signatures in paediatric pilocytic astrocytoma biopsies
Unsupervised hierarchical clustering of PAI in this study grouped tumours and control 
samples separately but further sub-groups within PAI were not identified. Wong et al. 
(2005) previously demonstrated that two sub-groups of PAI could be distinguished by a 
molecular signature of specific genes and suggested that these sub-groups represented 
PAI with different potentials of progression. While it has been documented that 
paediatric PAI that undergo partial excision may recur in the same location, malignant 
progression is very rare (Krieger et al., 1997; Fernandez et al., 2003). In the PAI 
included in this study, 13 of the 89 genes from the molecular signature showed a 
continuous change in expression rather than a significant differential expression 
between two PAI sub-groups. However, it is recognised that only a proportion of the 
genes could be investigated here, in a smaller sample group compared to that of Wong 
et al. (2005).
Sharma et al. (2007) also reported a molecular signature of 36 genes that showed 
differential expression between supratentorial PAI and posterior fossa PAI and
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suggested that glial tumours have an intrinsic, lineage specific signature, which reflects 
the region of the brain from which the non-malignant tumour cell precursors originate. 
In the present tumour group, the majority of tumours were located in the posteria fossa, 
consequently a comparison to this study was not possible. These studies emphasises the 
intrinsic genetic heterogeneity of PAI and the need for large sample numbers to identify 
true sub-groups with clinical or prognostic relevance.
Genes involved in paediatric pilocytic astrocytoma development
To investigate paediatric PAI development, those genes which showed a greater than 
10-fold change in expression and were either involved in a KEGG pathway or are well- 
characterised were identified. The most over-expressed gene, SERPINA3, is specifically 
expressed in astrocytes and is involved in the expression of astrocytic markers such as 
GFAP (Gopalan et al., 2006a; Gopalan et al., 2006b). In this study, GFAP was 1.98-fold 
up-regulated just missing the 2-fold cut-off for further analysis. These results support 
that the tumour cells are of astrocytic lineage. The second most over-expressed gene 
CHI3L1 (also known as YKL-40) is another astrocytic marker and has previously been 
used as a diagnostic marker in astrocytoma (Nutt et al., 2005; Rousseau et al., 2006).
CHAD and T1MP4 have been shown to be over-expressed in PAI compared to other 
grades of astrocytoma and normal brain in two other studies (Rickman et al., 2001; 
Rorive et al., 2006). Interestingly, the proteins of these genes inhibit migration and may 
contribute to the benign phenotype of PAI. Rickman et al. (2001) also found over­
expression of CSPG4, CPGS2 and FOS and under-expression of PRKACB as found in 
the PAI o f this study (Tables 4.2 and 4.4).
Several genes from Table 4.2 have already been investigated in other grades of 
astrocytoma. These include T1A-2, ABCC3, CD44, MYT1, TIMP1, HLA-DPA1, TFPI, 
CSPG2, CD151, WNT 10B, PTK2B, ENPP2, MBP, MATK, SST, CCK and FOXG1B. 
The expression of T1A-2 (also known as podoplanin) was found to be significantly 
higher in GBMIV compared to AAIII or DAII and is thought to be a marker of 
malignant progression (Mishima et al., 2006). The large fold change seen here 
compared to normal brain suggests that this gene is involved in promoting tumour 
development in PAI. ENPP2 also known as autotaxin is highly expressed in GBMIV 
and involved in the promotion of cell motility (Kishi et al., 2006). This gene is
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significantly down-regulated in the PAI of this study possibly hindering cell motility. 
Other genes from this group have functions associated with a range of tumour 
characteristics. For example, increased expression of ABCC3, from the multi-drug 
resistance protein family of ATP-dependent efflux pumps, may mediate drug resistance 
in PAI (Bronger et al., 2005). The up-regulation of TIMP1 and HLA-DPA1, immune 
defence-associated genes, may contribute to the benign biological behaviour of this 
tumour (Huang et al., 2005). There is evidence to suggest that CSPG2 (also known as 
versican) protects from oxidative-stress induced apoptosis and promotes tumour growth 
and angiogenesis (Zheng et al., 2004). Furthermore, CPGS4 from the same family was 
found to be up-regulated in diffuse and malignant astrocytoma in response to PDGF and 
increases tumour cell proliferation and invasion (Chekenya et al., 1999; Johansson et al.,
2005). In the present study, CSPG2 and CPGS4 demonstrated a 10.86 and 23.77-fold 
up-regulation in expression respectively, in addition to PDGFRa which was also over­
expressed by 5.84-fold.
The additional genes in Table 4.2 are either associated with the development of other 
tumours and cancers or have functions that could promote or inhibit tumour 
development. POSTN is over-expressed in more than 80% of human colon cancers and 
demonstrates the highest fold change expression in oral squamous-cell carcinoma 
(OSCC). POSTN enhances cancer growth by both preventing stress-induced apoptosis 
and augments endothelial cell survival to promote angiogenesis (Bao et al., 2004; 
Siriwardena et al., 2006). Furthermore, the homophilic interactions of CD151 have been 
shown to stimulate integrin-dependent signalling to c-Jun, enhancing cell motility in 
melanoma (Hong et al., 2006). CD151 is up-regulated in PAI and could increase cell 
motility through a similar mechanism. ITPKA is significantly down-regulated in the PAI 
studied here and OSCC cell lines. It is involved in the phosphorylation of inositol 1,4,5- 
trisphosphate that regulates the intracellular calcium (Ca2+) concentrations by releasing 
Ca2+ from intracellular stores. ITPKA is also responsible for regulating the levels of a 
large number of inositol polyphosphates that are involved in cellular signalling. 
Disruption of this gene and consequently intracellular signalling could be linked to PAI 
development (Kato et al., 2006).
The study by Wong et al. (2005) also identified 428 genes that showed a significant and 
3-fold change in expression from the normal, 192 up-regulated and 236 down-regulated.
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Of the 428 genes that showed differential expression, 96 were sub-grouped according to 
biological processes. A total of 23 genes were involved in neurogenesis, 7 of which 
have been identified in this study as showing a 2 -fold and significant change in 
expression; DLG4, GAS7, SEMA3E, HEY2, ASCL1, DPYSL3 and SEMA5A. A further 
20 genes were involved in cell adhesion and 3 were also identified in this study; 
COL9A1, ITGB2 and SEMA5A. 14 genes involved in synaptic transmission were 
identified and 4 corresponded with this study; GLG4, GRM3, SYT1 and GABRAG2. A 
group of 11 genes were involved in CNS development and only 2 were also identified in 
this study; DCAMKL1 and SH3GL3. 10 genes were involved in potassium ion transport 
and only 1 corresponded with this study; ATP1B1. Genes involved in protein amino 
acid dephosphorylation formed a group of 1 0  and 2  were also identified in this study; 
DUSP8 and PPP3CA. Finally 8  genes were involved in cell differentiation and only 1 
was also identified in this study; ASCL1.
Pathways with differential gene expression in paediatric pilocytic astrocytoma 
biopsies
The Onto-tool software ranked the KEGG pathways influenced by the 1844 
differentially expressed genes according to the extent of disruption. In PAI, the KEGG 
pathway antigen processing and presentation was most affected by differential gene 
expression. With the exception of HSP90A, all identified genes involved in this pathway 
were up-regulated, including CD74, HLA-DPA1, HLA-DRA, HLA-DMA, HLA-DRB1, 
HLA-DMB, HLA-DQB1, HLA-G, CTSS, HLA-B, KLRC3, HLA-F, HLA-A, PSME2, 
PDIA3, HLA-E, IFI30, TAPI, and B2M. A previous study observed an increase in the 
expression of genes involved in immune response in PAI compared to DAII, 
oligodendrogliomas and normal brain (Huang et al., 2005). An increase in HLA-DPA1 
expression in PAI compared to AAIII was also observed in a second study (Hunter et 
al., 2 0 0 2 ).
The major histocompatibility complex molecules also known as the HLA system have a 
crucial role in antigen processing and presentation regulating T lymphocytes and 
influencing immunosurveillance. The six HLA-D molecules are known as MHC class II 
and are classically expressed on specialised antigen presenting cells such as 
macrophages and dendritic cells. These cells present antigen to T (CD4+) lymphocytes 
activating an immune response. The increase of MHC class II expression in
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premalignant lesions of breast, colon, cervix and larynx appears to be independent of 
leukocytic infiltration (Garrido et al., 1993). This has also been previously documented 
in low-grade astrocytoma (Rossi et al., 1988). The biopsy samples of this study were 
directly adjacent to tumour tissue processed for routine histological evaluation, which 
were first examined macroscopically to ensure that no frankly normal tissue was 
present. However, increased numbers of immune cells may have been present in the 
tissue used. Moreover, astrocytes have also been shown to express class II major 
histocompatibility complex (MHC) antigens and costimulatory molecules (B7 and 
CD40) that are critical for antigen presentation and T-cell activation, suggesting that the 
up-regulation of the antigen processing and presentation pathway in these PAI maybe a 
response of the astrocytoma cells (Dong and Benveniste, 2001). Furthermore, HLA-DR 
over-expression has been associated with good prognosis in large bowel carcinoma and 
ovarian tumours (Lovig et al., 2002; Tamiolakis et al., 2003). The up-regulation of 
immune response genes in PAI may contribute to the benign behaviour of this tumour 
type.
The KEGG pathways phosphatidylinositol signalling (PI3K) and MAPK signalling 
were ranked as third and fifth respectively, according to the extent of differential gene 
expression in PAI (Table 4.3). Altered signalling in these pathways through increased 
receptor stimulation and disrupted tumour suppressor or oncogene function has been 
characterised in other grades of astrocytoma particularly primary and secondary adult 
GBMIV (Soni et al., 2005).
Of the 22 genes differentially expressed in the PI3K pathway, 19 (8 6 %) are down- 
regulated. Similarly in the MAPK signalling pathway, 58% (36/62) of genes are under­
expressed compared to normal brain. Of those genes involved in 10 or more pathways, 
85% (11/13) are involved in the MAPK signalling pathway and 91% (10/11) of these 
are down-regulated including MAPK1, PRKCB1, AKT3, MAP2K1, MAPK9 and 
MAPK10 (Table 4.4). Moreover, EGFR commonly over-expressed or amplified in adult 
primary GBMIV, showed a 5.21 down-regulation in expression. In contrast, several 
growth factors and corresponding receptors involved in the propagation and stimulus of 
the PI3K or MAPK signalling pathways are over-expressed, including PDGFRA, 
1TGB1, TGFB1, FAS, PDGFC, FGFR1,FGF2, TNF1A and IL1R1. Furthermore, three 
key target transcription factors JUN, FOS and TP53 activated by the MAPK signalling
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pathway are also up-regulated. AP-1 dimers are a group of proteins involved in the 
control of cell proliferation, neoplastic transformation and apoptosis. Jun and Fos are a 
group of transcription factors capable of forming the dimers of AP-1. Most evidence 
suggests that cell fate is influenced by AP-1 through the regulation of cell cycle 
components (Shaulian and Karin, 2001a). AP-1 is known to directly induce the 
transcription of cyclin D l, a gene found to be up-regulated 3.77-fold in this study. The 
growth factor and receptor up-regulation in the PI3K and MAPK signalling pathways is 
contradictory to the reduction of gene expression and overall pathway activity, 
suggesting that the up-regulation of target transcription factors may occur through a 
different mechanism or pathway.
Genomic loss in regions of large scale copy number variations in paediatric 
pilocytic astrocytoma biopsies
Of the 97 BAC clones found to be altered in PAI, 40% were located in regions of LCV 
present in the normal population (Iafrate et al., 2004; Sebat et al., 2004; Sharp et al., 
2005; Locke et al., 2006; Fiegler et al., 2006; Khaja et al., 2006; Redon et al., 2006; 
Conrad et al., 2006). The role of LCVs (which involve gain or loss of hundreds of 
kilobases of genomic DNA) in phenotypically normal individuals is not clear (Iafrate et 
al., 2004). However, LCV at 14ql2 was present in DNA from 50% of chronic myeloid 
leukaemia (CML) and paediatric solid tumours compared to an incidence of 10% in 
somatic DNA of healthy control individuals, suggesting that acquired or inherited LCVs 
at 14ql2 may be associated with the onset or progression of neoplasia (Braude et al.,
2006). In this study, the incidence of 14ql2 loss in PAI was 82%. Further investigations 
are necessary to establish the incidence of LCVs in somatic DNA of PAI patients in 
order to determine whether 14ql2 alterations are inherited or are acquired during 
tumour development.
It would be particularly valuable if the alterations located in regions of LCV could be 
characterised as either being present in somatic DNA or only found in tumour DNA. 
Additional aCGH experiments investigating the normal blood from the patients of these 
tumours 19 PAI could determine whether these alterations were inherited or acquired. 
Normal blood is available from these patients; however limited funding prevented 
further investigation of these regions.
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Correlation of copy number alterations and differential gene expression in 
paediatric pilocytic astrocytoma biopsies
Three genes are located in the exact region of loss at 14ql2, including RPL26P, 
BTF3P3 and LOC387978. FOXG1B is adjacent to the clone at 14ql2 and is the only 
gene with reliable gene expression data in this study. FOXG1B expression was 
significantly down-regulated in all PAI compared to normal controls (p = 0.01).
FOXG1B, also known as BF1, FKH2, FKHL1, FKHL4, HBF-1, HFK1 or QIN, has 
many functions. In the embryo, FOXG1B expression is localised in progenitor cells of 
telencephalic neuroepithelium where it modulates both progenitor cell proliferation and 
differentiation. FOXG1B is also found in the adult brain located in structures 
originating from the telencephalon including the cerebral cortex, hippocampus, 
olfactory bulbs and the basal ganglia (Dou et al., 1999; Hanashima et al., 2002). 
Furthermore, this gene is thought to act as an oncogenic transformer and transcriptional 
repressor through specific interactions with Groucho, Hes and Smad proteins (Yao et 
al., 2001; Rodriguez et al., 2001). More importantly, FOXG1B has been proposed as a 
major FoxO Forkhead transcription factor that acts as a signal transducer between the 
Smad, PI3K and FoxGIB pathways. The activity of these pathway interactions has been 
shown to be involved in the resistance to TGF-P mediated cytostasis during 
telencephalic neuroepithelium development and in glioblastoma brain tumour cells 
(Seoane et al., 2004).
TGF-P induced cytostasis requires the transcriptional activation of cyclin dependent 
kinase inhibitors CDKN1A and CDKN2B and repression of growth-promoting factors c- 
myc and Idl-Id3  to mediate cell cycle arrest. In this study, CDKN1A and Id l , Id2 and 
Id3 were significantly up-regulated and CDKN2B was significantly down-regulated (no 
data was available for c-myc). Seoane et al. have shown that FOXGIB  is an antagonist 
that suppresses CDKN1A induction by binding to and inhibiting the FoxO-Smad 
activator complex. Loss of this gene in PAI may therefore prevent CDKN1A 
transcriptional inhibition promoting TGF-p induced cytostasis (Seoane et al., 2004).
The involvement of FOXGIB in PI3K (the pathway most affected by differential gene 
expression in PAI) highlights the impact FOXGIB disruption may have on intracellular
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signalling. The location of this gene in a region of LCV at 14ql2 also suggests that 
some individuals may be predisposed to PAI development.
CNAs of individual clones at 9p21.2-p23, 10q26.3, 12q24.33, and 17q21.31 and a 
cluster of 7 clones at 7ql 1.23 correlated with differential gene expression. Two genes 
BCL7B and BCL7A located at 7ql 1.23 and 12q24.33 respectively are from the same 
family and share 90% homology. BCL7B maps to a region deleted in the congenital 
disorder Williams syndrome, although little is known about its function (Jadayel et al., 
1998). BCL7A is a putative tumour suppressor gene which is hypermethylated in 
primary cutaneous T-cell lymphoma (CTCL) (van Doom et al., 2005). Earlier studies 
have demonstrated the involvement of the BCL7A locus in a recurrent break point in B- 
cell lymphomas and a complex translocation and rearrangement in specific cell lines 
(Zani et al., 1996). Expression profiling of mycosis fungoides (MF), a common CTCL, 
and B-cell lymphoma identified the down-regulation of BCL7A as part of a molecular 
signature that could distinguish MF, inflammatory dermatoses (ID) and distinct types of 
diffuse large B-cell lymphoma (Alizadeh et al., 2000; Tracey et al., 2003). The loss of 
BCL7A has also been associated with disrupted NF-kappaB signalling and unfavourable 
prognosis in patients with B-cell lymphomas, suggesting that this gene has tumour 
suppressor properties (Martinez-Delgado et al., 2004).
Reduction of SH3GL2 expression correlated with loss at 9p21.2-p23. A recent study 
indicates that SH3GL2 is involved in the development and progression of laryngeal 
squamous cell carcinoma (LSCC), as expression levels correlate with pathological 
classification (Shang et al., 2007). The expression of SH3GL2 also correlates with 
distinct stages of intestinal-type gastric cancer, although a functional role in 
tumourigenesis has not yet been determined (Sun et al., 2006).
TUBG2, located at 17q21.31, shares 97.3% amino acid identity with TUBG1 and the 
two genes are co-expressed in a variety of tissues. This suggests that the functions of 
TUBG1 and TUBG2 are similar and both have a significant role in the organization of 
the microtubule cytoskeleton (Wise et al., 2000). CNTNAPJ, also located at 17q21.31, is 
transcribed predominantly in brain and the architecture of the protein extracellular 
domain is similar to that of neurexins. CNTNAP1 plays an important role in the creation 
and maintenance of the paranodal region of mylinated axons, enabling recruitment and
172
activation of intracellular signalling pathways in neurons (Geurts et al., 2003). DRD1IP 
maps to 10q26.3 and encodes a brain-specific dopamine receptor 1-interacting protein 
involved calcium signalling (Laurin et al., 2005). However, a role for these two genes in 
tumour development has yet to be established
Promoter hypermethylation in paediatric pilocytic astrocytoma biopsies
Down-regulation of gene expression through promoter hypermethylation is an important 
mechanism of transcriptional silencing in many tumours. Hypermethylation of the six 
genes investigated in this study has been detected in more than 30% of several tumour 
types including gastric carcinoma, lung cancer and renal cell carcinoma Moreover, 
CCNA1 was hypermethylated in 100% of colorectal adenoma (Kikuchi et al., 2002; 
Toyooka et al., 2003; Oshimo et al., 2004; Xu et al., 2004; Morris et al., 2005; 
Takahashi et al., 2005). All six genes showed a 2-fold and significant down-regulation 
in PAI compared to normal brain but hypermethylation of gene promoter regions was 
not found. Only one previous study has investigated hypermethylation in paediatric PAI 
involving MGMT, GSTP1, DAPK1, p l4 ARr, THBS-1, TIMP-3, TP73, CDKN2A, RB-1 
and TP53. Hypermethylation of CDKN2A was most frequent occurring in 46% of cases. 
However, 5 of the remaining genes were hypermethylated in less than 8 % of cases 
(Gonzalez-Gomez et al., 2003b). CDKN2A hypermethylation was not investigated in 
this study as this gene was not found to be significantly down-regulated in the 19 PAI 
investigated. It is possible that methylation is not the predominant mechanism of gene 
silencing in PAI development and other epigenetic processes such as histone 
modification and microRNAs may play a more significant role.
Overall, differential gene expression in PAI can be linked to functions promoting 
tumourigenesis. In the PAI studied here, the differential expression of several genes was 
also associated with functions that may hinder tumour progression and could be 
attributed to the benign behaviour of this tumour. CNAs of whole chromosomes or arms 
were not found in these tumours, suggesting that large CNAs are not involved in the 
development of paediatric PAI. However, specific correlations were identified between 
single clone alterations and differential expression. These alterations were often located 
in regions of LCVs, suggesting that small regions of alteration may predispose 
individuals to tumour development. The investigation of the methylation status of a
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small number of genes was completed in this study, but larger more extensive studies 
are needed to determine the involvement of this mechanism in PAI development.
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CHAPTER 5
DIFFERENTIAL GENE EXPRESSION AND COPY NUMBER ALTERATIONS IN  
PAEDIATRIC ASTROCYTOMA SHORT-TERM CELL CULTURES
INTRODUCTION
Histopathologically, paediatric astrocytoma resemble corresponding grades of adult 
astrocytoma. However, studies have shown that their biological and clinical behaviour 
is different to that of their adult counterparts, suggesting that these tumours have a 
different molecular pathogenesis.
Cytogenetic analysis of paediatric PAI has shown that the majority of these tumours 
(>70%) have a normal karyotype (Bhattacharjee et al., 1997). Numerical and structural 
abnormalities of chromosomes 5, 6 , 7, 8  and 9 have been reported, although definitive, 
non-random aberrations have not yet been identified (White et al., 1995; Zattara- 
Cannoni et al., 1998; Shlomit et al., 2000; Sanoudou et al., 2000b; Rickert and Paulus, 
2004).
In DAII, AAIII and GBMIV of patients below 15 years of age there is a correlation 
between karyotype complexity and tumour grade. DAII often have a normal karyotype 
or show simple chromosome changes compared to high-grade astrocytoma that show 
multiple complex chromosome aberrations frequently displaying hyperdiploid or 
polypoid karyotypes (Agamanolis and Malone, 1995; Bigner et al., 1997; Bhattacharjee 
et al., 1997; Roberts et al., 2001). Studies investigating diffuse astrocytoma in children 
show inconsistent findings. Specific studies describe chromosome alterations that are 
common in adult astrocytoma including -17p, +7, -10 and -22 (Schrock et al., 1996; 
Bhattacharjee et al., 1997). Other studies describe different alterations to those seen in 
adults (Neumann et al., 1993; Agamanolis and Malone, 1995; Cheng et al., 1999).
Various studies previously discussed have investigated the expression of specific genes 
in grades of paediatric astrocytoma or genome wide gene expression in individual 
grades of paediatric astrocytoma. No studies to date have included genome wide 
expression profile analysis of all grades of paediatric astrocytoma.
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The aims of this Chapter were to investigate genome wide gene expression in paediatric 
astrocytoma short-term cell cultures in order to identify cellular pathways affected by 
differential gene expression, correlate these changes with CNAs as a possible 
mechanism and identify any specific gene signatures that correspond to specific tumour 
or patient parameters including tumour grade, location, patient survival, age or sex. 
Moreover, the inclusion of 7 adult GBMIV short-term cell cultures has allowed a 
comparison to be made between the expression profiles of these tumours and those from 
paediatric patients. This chapter also aims to confirm that astrocytoma short-term cell 
cultures are representative of the tumour of origin and that conclusions drawn from 
these cultures regarding CNAs and gene expression are comparative to those made 
using biopsy samples.
The Affymetrix GeneChip® U133A array was used to generate gene expression profiles 
and identify differentially expressed genes in 35 paediatric astrocytoma short-term cell 
cultures derived from 19 PAI, 2 DAII, 3 AAIII and 11 GBMIV according to the 2007 
WHO grading scheme. It was not possible to review the diagnosis of every case 
according to the 2007 WHO classification guidelines including 2 DAII and 5 GBMIV 
(Refer to Table 2.2). In addition, 6  of these short-term cell culture samples were 
previously analysed in Chapter 3, IN1740, IN2110, IN2356, IN2368, IN2921 and 
IN3013. The aCGH SpectralChip™ 2600 array was used to define genomic CNAs in 32 
of these tumours; sufficient DNA was not available for tumours IN I740, IN I930 and 
IN2087.
The experimental analysis was carried out as previously described and the mean 
expression of each gene in all samples was used for the per gene normalisation. The 
controls included in this study were 2  cultured foetal astrocyte samples (details of these 
samples can be found in Table 2.1 and Chapter 3). Due to the small number of controls 
and the foetal origin as discussed in Chapter 3, the experiment was not normalised to the 
controls as previously carried out in Chapter 4. However, the normal foetal astrocytes 
were included in the study so that some comparisons could be made between the 
expression profiles of these samples and those of the paediatric astrocytomas short-term 
cell cultures. Gene probe sets present in 10 of the 37 samples (11491 after cleaning) 
were included in the experimental analysis. This sample number was felt to be
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appropriate given that 11 GBMIV (according to the 2007 WHO grading scheme) 
composed the smallest sample group categorised by grade. This allowed those genes 
that may have been down-regulated in a specific grade and consequently detected as 
absent on the array, to be included in further analysis.
To compare the paediatric short-term cell cultures to those derived from adult tumours, 
7 adult GBMIV short-term cultures were added to the experiment and the hierarchical 
approach repeated (details of these samples can be found in Table 2.3). Three of these 
samples were previously analysed in Chapter 3, IN2435, IN2731 and IN2810. All 
experiment parameters were kept the same and the foetal astrocytes were removed from 
the experiment, as the comparison was only between the tumour samples.
Patient details of the tumour derived short-term cell cultures can be found in Tables 2.2 
and 2.3. The mean paediatric patient age was 8.4 years, ranging from 0.2 years to 15.9 
years. At the time of this study 22 patients were alive. According to the 2007 WHO 
grading scheme, of the 19 PAI patients 2 are deceased (survival 12 and 60 months), 5 
had been discharged from hospital and were no longer being monitored (follow-up 
between 18-125 months) and 12 patients had a follow-up between 13-160 months. Of 
the 2 DAII patients 1 was deceased (survival 92 months) and 1 had a follow-up of 60 
months. Of the 3 AAIII patients, 2 were deceased (survival 12 and 14 months) and 1 
had a follow-up of 53 months. Of the 10 GBMIV patients 5 were deceased (survival 
between 3-33months), 1 had been discharged, 3 had a follow-up between 7-80 months 
and survival data for 1 patient was not available. Survival data and follow-up was 
limited for the adult patients, the mean patient age at diagnosis was 60.4 years and 
ranged from 51 years to 70 years. All adult short-term cell cultures were derived from 
adult primary GBMIV biopsies.
The survival data of patients in this study was considered to be unreliable as unform 
treatment regimes were not applied to the patients. Consequently, although survival was 
not statistically analysised is was considered with caution during some analysis 
approaches.
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RESULTS
Gene expression profiles of paediatric astrocytoma short-term cell cultures
Using the Affymetrix GeneChip® U133A array the expression pattern of approximately 
22000 genes were investigated in 35 paediatric astrocytoma short-term cell cultures of 
various grades and 2 normal human cultured foetal astrocytes. Unsupervised 
hierarchical clustering using 11491 reliable gene expression results was used to generate 
a dendrogram illustrating the similarity in expression profiles of the paediatric 
astrocytoma short-term cell cultures (Figure 5.1). The tumour cultures do not group or 
order according to tumour location or patient age or sex. However, the cultures do 
cluster into 3 clear groups. According to the 2007 WHO grading scheme, 2 groups are 
comprised of predominately PAI short-term cell cultures with several high-grade 
cultures and the third group consists of high-grade short-term cell cultures and 2 PAI 
cultures (Figure 5.1). The 3 culture cluster groups will be referred to as Group 1, Group 
2 and Group 3.
The PAI short-term cell cultures of this study appear to cluster into 2 clear groups as 
seen by Wong et al. (2005) and discussed in detail in Chapter 4. These cluster groups 
are Groups 1 and 2 according to the analysis completed in the rest of Chapter 5. The 
expression pattern of the 13 reliable gene expression results that correspond to 13 of the 
89 genes used by Wong et al. (2005) to characterise two PAI sub-groups was 
investigated in the tumour cultures of this experiment. Differential gene expression was 
not seen between the short-term cell culture Groups or normal controls (data not 
shown). Furthermore, Wong et al. (2005) identified the biological processes cell 
adhesion, regulation of cell growth, cell motility, nerve ensheathment and angiogenesis 
as showing significant differential gene expression between the two PAI sub-groups. In 
this experiment, only cell adhesion and angiogenesis showed a significant difference 
between the 2 PAI Groups.
From the group of 11491 gene probe sets, 4682 were identified that showed a 2-fold and 
significant difference in expression between the 3 Groups and the normal astrocyte 
controls. To generate molecular profiles of each tumour culture Group and identify 
genes that show similar and different expression patterns, the 4682 differentially
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expressed genes were studied using k-means clustering. The genes were clustered into 
10 sets according to expression pattern similarity (Figure 5.2 and Table 5.1).
Figure 5.1 Unsupervised hierarchical clustering of thirty-five paediatric astrocytoma short-term cell 
culture samples and two normal foetal astrocyte controls using 11491 reliable gene expression results.
,__________________________ i ..... - ...........................
Diagnosis according to the 2007 WHO grading scheme
In total, 4682 genes showed a 2-fold and significant change in expression between the 3 Groups and the 
normal astrocytes, these colour the dendrogram. The dendrogram colour saturation is proportional to the 
magnitude of the difference from the experiment median and ranges from red (high-expression) to yellow 
(low-expression). PAI = purple; DAII = yellow; Low-grade tumour = light-blue; AAIII = dark blue; 
GBMIV = red (according to the 2007 WHO grading scheme). The green and pink boxes below the 
dendrogram labels represent the patient sex; male and female respectively. The age of the patient at 
diagnosis and tumour location are given within the coloured boxes. The abbreviations used are as follows; 
Cere = cerebellum, Tern = temporal, Front = frontoparietal, Supra = supratentorial, PF = posteria fossa, 
OC = Optic Chiasm, Par = parietal, BS = brain stem, Thai = thalamus and BoS = base of skull.
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Figure 5.2 The dendrogram illustrates the expression pattern of the 4682 differentially expressed probe 
sets, between the 3 culture Groups and the normal control.
The dendrogram colour saturation is proportional to the magnitude of the difference from the experiment 
median, ranging from red (high-expression) to yellow (low-expression). The colour bar to the left of the 
dendrogram indicates the k-means cluster set for each gene.
Table 5.1 K-means clustering grouped the 4682 differentially expressed genes between the 3 tumour 
Groups into 10 sets according to expression pattern similarity.
Set No. No. of genes Group 1 Group 2 Group 3
1 723 High
2 443 High
3 362 Low Low
4 541 High High
5 665 High High
6 776 Low Low
7 298 Low Low Low
8 388 High High
9 250 Low
10 182 Low Low Low
The Table indicates high or low gene expression in specific tumour Groups compared to the remaining 
Groups and normal controls.
K-means cluster sets 4 and 5, and sets 7 and 10 show the same expression pattern 
between the 3 tumour Groups and the normal controls. The remaining sets show 
expression patterns that can be used to distinguish the 3 tumour Groups.
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To characterise the 4682 probe sets, those involved in specific biological processes were 
identified. Table 5.2 illustrates the percentage of gene probe sets disrupted in specific 
GO biological processes. Approximately 20% of gene probe sets in each GO group 
showed differential gene expression. The catabolism GO showed the highest number of 
altered probe sets (25%), compared to behaviour which was the lowest (8 %). A large 
number of gene probe sets were differentially expressed in each GO group.
Table 5.2 Gene ontologies of the specific gene probe sets differentially expressed between the short-term
cell culture Groups and normal controls.
Biological process GO ID Number of genes 
in GO group
Number of probe sets 
differentially expressed 
between the Groups
Amino acid and derivative metabolism 0006519 180 35 (19%)
Behaviour 0007610 83 7 (8%)
Biosynthesis 0009058 885 199 (22%)
Carbohydrate metabolism 0005975 1696 350(21%)
Catabolism 0009056 426 106(25%)
Cell cycle 0007049 1161 225(19%)
Cell death 0008219 863 144(17%)
Cell differentiation 0030154 1657 278(17%)
Cell growth 0016049 3993 673 (17%)
Cell homeostasis 0019725 90 18(20%)
Cell proliferation 0008283 1067 211 (20%)
Cell recognition 0008037 1820 301 (17%)
Cell-cell signalling 0007267 2582 443 (17%)
Chemi-mechanical coupling 0006943 102 11 (11%)
Co-enzyme and prosthetic group metabolism 0006731 1163 192(17%)
Cytoskeleton organisation and biogenesis 0007010 1536 314(20%)
DNA metabolism 0006259 1470 256(17%)
Electron transport 0006118 3286 560(17%)
Embryonic development 0009790 779 117(15%)
Energy pathways 0006091 1497 291 (19%)
Growth 0040007 1405 270(19%)
Host-pathogen interactions 0030383 4051 602(15%)
Ion transport 0006811 2474 428(17%)
Lipid metabolism 006629 859 183 (21%)
Mitochondria organisation and biogenesis 0007005 1273 262(21%)
Morphogenesis 0009653 301 43 (14%)
Protein biosynthesis 0006412 1060 231 (22%)
Protein modification 0006412 307 56(18%)
Protein transport 0015031 2031 456 (22%)
Regulation of gene expression; epigenetic 0040029 3969 698(18%)
Reproduction 0000003 141 17(12%)
Response to endogenous stimuli 0009719 103 21 (20%)
Response to stress 0006950 427 71 (17%)
Signal transduction 0007165 4158 647 (16%)
Transcription 0006350 3697 563 (15%)
Unknown biological processes 0000004 11034 950 (8%)
The percentage of gene probe sets in each ontology group that shows differential expression between the 
short-term cell culture Groups and normal controls is also shown in brackets.
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To further characterise the differences in expression profile between the 3 tumour 
culture Groups and normal controls, the 4682 probe sets were divided into clusters that 
showed a 2 -fold and significant difference in expression between each tumour culture 
Group and the normal control. In total, 1764 probe sets were differentially expressed 
between Group 1 and the controls, 3035 between Group 2 and the controls and 3375 
between Group 3 and controls. The biological processes influenced by differential gene 
expression in each Group were investigated using Onto-tools (Tables 5.3-5.5). The p 
value for each process is the probability that deregulated genes are associated with a 
function by chance and is based on a binomial probability distribution and GO 
annotations.
The most common biological processes significantly altered in the tumour cultures of 
Groups 1, 2 and 3 compared to the normal controls involve antigen processing and 
presentation. The biological processes of Group 3 involve more input genes compared 
to Groups 1 and 2. Furthermore, Onto-tools groups similar process under one title if all 
are significantly altered. For example, signal transduction is significantly altered in 
Group 3 compared to Groups 1 and 2, but this includes negative regulation of 
lipopolysaccharide-mediated signalling pathway, positive regulation of transforming 
growth factor beta receptor signalling pathway, negative regulation of Wnt receptor 
signalling pathway, Notch signalling pathway, positive regulation of I-kappaB 
kinase/NF-kappaB cascade and positive regulation of vascular endothelial growth factor 
receptor pathway, identified in Groups 1 and 2, as well as G-protein coupled receptor 
signalling and small GTPase signalling that were not significantly altered in Groups 1 
and 2. Furthermore, cell differentiation biological processes were frequently disrupted 
in the tumour cultures of Group 1 compared to Groups 2 and 3.
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Table 5.3 Significantly altered biological processes in the Group 1 short-term cell cultures.
Biological Process Gene input p value
Cell adhesion 101 (5.73%) 3.0 E-5
Organ morphogenesis 30(1.7%) 3.0 E-5
Antigen processing, endogenous antigen via MHC class I 17(0.96%) 1.6 E-4
Muscle development 25 (1.42%) 1.6 E-4
Antigen presentation, endogenous antigen 14 (0.79%) 4.7 E-4
Glutathione biosynthesis 6 (0.34%) 0.006
Germ cell migration 5 (0.28%) 0.006
Antigen presentation 13 (0.74%) 0.006
Cell growth 16(0.91%) 0.006
Prostaglandin biosynthesis 7 (0.4%) 0.006
Cell recognition 6 (0.34%) 0.008
Regulation of cell migration 8 (0.45%) 0.008
Regulation of cell shape 13 (0.74%) 0.008
Mevalonate transport 3 (0.17%) 0.012
Regulation of circadian sleep/wake cycle 3 (0.17%) 0.012
Actomyosin structure organisation and biogenesis 4 (0.23%) 0.014
Angiogenesis 15(0.85%) 0.027
mRNA stabilisation 3 (0.17%) 0.027
Negative regulation o f chemokines biosynthesis 3 (0.17%) 0.027
Sulfate assimilation 3 (0.17%) 0.027
Deoxribonuclease diphosphate metabolism 2(0.11%) 0.034
Fatty acid biosynthesis 11 (0.62%) 0.034
Leukocyte adhesive activation 2(0.11%) 0.034
Negative regulation of lipopolysaccharide-mediated signalling pathway 2(0.11%) 0.034
Neuron lineage restriction 2(0.11%) 0.034
Positive regulation o f calcium-independent cell-cell adhesion 2(0.11%) 0.034
Positive regulation o f transforming growth factor beta receptor signalling 2(0.11%) 0.034
pathway
Regulation of endothelial cell differentiation 2(0.11%) 0.034
Response to toxin 5 (0.28%) 0.034
Endothelial cell differentiation 3 (0.17%) 0.036
Fat cell differentiation 5 (0.28%) 0.036
Keratinocyte differentiation 5 (0.028%) 0.036
Positive regulation o f translation 3 (0.17%) 0.036
Regulation of innate immune response 3 (0.17%) 0.036
Vasculogenesis 5 (0.28%) 0.036
Myoblast differentiation 4 (0.23%) 0.037
Negative regulation o f transcription factor activity 4 (0.23%) 0.037
Negative regulation o f Wnt receptor signalling pathway 4 (0.23%) 0.037
Protein export from nucleus 4 (0.23%) 0.037
Positive regulation of cell proliferation 25 (1.42%) 0.038
Cell fate determination 5 (0.28%) 0.049
Cholesterol homeostasis 4 (0.23%) 0.049
Cortical actin cytoskeleton organisation and biogenesis 5 (0.28%) 0.049
Membrane protein ectodomain proteolysis 5 (0.28%) 0.049
Organic anion transport 6 (0.34%) 0.049
Phosphate transport 17(0.96%) 0.049
Regulation of cell proliferation 5 (0.28%) 0.049
Regulation of embryonic development 4 (0.23%) 0.049
Negative regulation of cell proliferation 32(1.81%) 0.049
Notch signalling pathway 9(0.51%) 0.049
The gene input percentage indicates the number of genes involved in the specific biological process as a
percent of the overall input, in this case 1764.
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Table 5.4 Significantly altered biological processes in the Group 2 short-term cell cultures.
Biological Process Gene input p value
Antigen presentation, endogenous antigen 20 (0.66%) 2.7 E -4
Antigen processing, endogenous antigen via MHC class I 23 (1.76%) 2.7 E -4
Cell Adhesion 135 (4.45%) 2.7 E -4
Lipid metabolism 71 (2.34%) 9.4 E -4
Antigen presentation 20 (0.66%) 0.001
Positive regulation o f I-kappaB kinase/NF-kappaB cascade 36(1.19%) 0.003
Superoxide metabolism 9 (0.3%) 0.010
Cell-matrix adhesion 25 (0.82%) 0.014
Germ cell migration 6 (0.2%) 0.014
Organ morphogenesis 34(1.12%) 0.014
Attachment of GPI anchor protein 5 (0.16%) 0.014
ER to golgi vesicle-mediated transport 30 (0.99%) 0.018
Electron transport 81 (2.67%) 0.018
Fatty acid desaturation 6 (0.2%) 0.020
Induction o f positive chemotaxis 6 (0.2%) 0.020
Barbed-ended actin filament capping 15 (0.49%) 0.026
Angiogenesis 22 (0.72%) 0.026
Positive regulation o f vascular endothelial growth factor receptor pathway 4(0.13%) 0.030
Phosphate transport 27 (0.89%) 0.039
Cell motility 42(1.28%) 0.046
Cell growth 20 (0.66%) 0.048
The gene input percentage indicates the number of genes involved in the specific biological process as a
percent of the overall input, in this case 3035.
Table 5.5 Significantly altered biological processes in the Group 3 short-term cell cultures.
Biological Process Gene input p value
ER to Golgi vesicle-mediated transport 42(1.24%) 4.0 E -5
Protein biosynthesis 100 (2.96%) 6.0 E -5
Nuclear mRNA splicing, via spliceosome 62(1.84%) 5.5 E-5
Antigen presentation, endogenous antigen 20 (0.59%) 0.001
Antigen processing, endogenous antigen via MHC class I 22 (0.65%) 0.002
Protein transport 91 (2.7%) 0.002
Tricarboxylic acid cycle 18(0.53%) 0.005
Antigen presentation 19(0.56%) 0.011
Signal transduction 200 (5.93%) 0.019
Ion transport 38(1.13%) 0.039
Protein targeting 20 (0.59%) 0.041
Cell redox homeostasis 6(0.18%) 0.044
Electron transport 86 (2.55%) 0.047
Mitochondrial electron transport, NADH to uniquinone 10 (0.3%) 0.047
Response to unfolded protein 20 (0.59%) 0.047
The gene input percentage indicates the number of genes involved in the specific biological process as a
percent of the overall input, in this case 3375.
To further investigate the overall gene expression profiles of each tumour culture Group 
and correlate changes in biological pathways to tumour development, the Onto-tools 
software was used to rank KEGG pathways using the 4682 differentially expressed gene 
probe sets. In total, 53 pathways were ranked, only those of interest are displayed in 
Table 5.6. The focal adhesion and extracellular matrix receptor interaction pathways
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were ranked first and second in all 3 tumour culture Groups. The Wnt signalling 
pathway and the cell cycle showed large differences in rank between the 3 Groups 
(Table 5.6). These pathways were investigated in more detail as disruption of the cell 
cycle is known to be involved in tumour development and Wnt signalling is involved in 
foetal development and control of stem cell differentiation (Clark et al., 2007). It was 
hypothesized that the disruption of these pathways through differential gene expression 
occurs in each Group, but to different extents. With the number of differentially 
expressed genes being greater in the more malignant tumour cultures of Group 3.
The genes involved in Wnt signalling pathway and cell cycle show significant changes 
in expression between the 3 tumour Groups (Figures 5.3 and 5.4). The Wnt signalling 
pathway in Group 1 tumour cultures has fewer differentially expressed genes compared 
to Group 2 and 3 tumour cultures. Furthermore, the majority of genes in the Wnt 
signalling pathway are up-regulated in Groups 2 and 3 compared to Group 1. The 
signalling of this pathway is further altered by the down-regulation of APC expression 
and up-regulation of P-catenin in Group 3 tumour cultures only (Figure 5.3).
The majority of genes involved in the cell cycle of Group 3 tumour cultures show up- 
regulation, including TP53, genes of the APC/C complex and mini chromosome 
maintenance (MCM) genes. In Group 2 tumour cultures TP53 is also up-regulated but 
genes of the APC/C complex are down-regulated. Key cell cycle components CCNE, 
CCNA and CDK2 also show down-regulation in Group 2 tumour cultures compared to 
Groups 1 and 3. Moreover, TP53 and genes of the APC/C complex are not differentially 
expressed in Group 1 tumour cultures (Figure 5.4).
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Table 5.6 The Onto-tools result ranking the KEGG pathways using the 4682 differentially expressed probe sets for each of the 3 tumour Groups.
Rank Pathway Name ImpactFactor
% Pathway 
Genes in 
Input
Rank Pathway Name ImpactFactor
% Path way 
Genes in 
Input
Rank Pathway Name ImpactFactor
% Pathway 
Genes in 
Input
1 Focal adhesion 13.24 21.65 1 ECM-receptor
interaction
12.70 35.63 2 ECM-receptor
interaction
8.57 34.48
2 ECM-receptor interaction 11.31 25.29 2 Focal adhesion 9.86 28.35 3 Focal adhesion 7.82 28.87
8 TGF-beta signalling 
pathway
6.35 17.86 4 Colorectal cancer 6.90 32.47 4 Colorectal cancer 6.96 33.77
14 Regulation of actin 
cytoskeleton
5.14 15.05 6 Wnt signalling 
pathway
5.51 24.49 5 Phosphatidyl inositol 
signalling system
6.74 16.46
20 Antigen processing 
and presentation
4.26 13.95 10 TGF-beta signalling 
pathway
4.85 23.81 6 Wnt signalling 
pathway
5.59 25.85
21 Phosphatidylinositol 
signalling system
4.22 12.66 11 Regulation of actin 
cytoskeleton
4.49 22.33 11 Cell cycle 4.79 25.00
22 Notch signalling 
pathway
3.63 17.39 17 Antigen processing 
and presentation
4.04 19.77 17 Antigen processing 
and presentation
3.98 23.26
23 MAPK signalling 
pathway
3.38 12.82 19 MAPK signalling 
pathway
3.83 20.88 22 mTOR signalling 
pathway
3.22 28.57
25 Wnt signalling 
pathway
3.31 13.61 21 Calcium signalling 
pathway
3.43 18.75 25 TGF-beta signalling 
pathway
3.01 22.62
30 Colorectal cancer 2.94 15.58 22 Notch signalling 
pathwav
3.38 23.91 28 Apoptosis 2.83 20.24
32 Calcium signalling 
pathway
2.76 11.93 31 Cell cycle 2.82 21.43 29 Regulation of actin 
cytoskeleton
2.81 20.39
36 Apoptosis 2.38 13.10 36 Jak-STAT signalling 
pathway
2.38 18.95 35 MAPK signalling 
pathway
2.32 19.41
40 Jak-STAT signalling 
pathway
2.19 11.11 37 mTOR signalling 
pathway
2.22 20.41 36 Notch signalling 
pathway
2.23 17.39
43 Hedgehog signalling 
pathway
2.01 10.53 39 Hedgehog signalling 
pathway
2.17 19.30 39 Hedgehog signalling 
pathway
1.98 14.04
46 mTOR signalling 
pathway
1.91 12.25 42 Phosphatidylinositol 
signalling system
2.07 20.25 43 Calcium signalling 
pathway
1.66 18.18
49 Cell cycle 1.70 11.61 43 Apoptosis 2.02 19.05 45 Jak-STAT signalling 
pathway
1.55 13.73
Group 1 = blue; Group 2 = green; Group 3 = red. The pathways are ranked according to impact factor, taking into account the fold change, the number of genes disrupted in a 
pathway and the influence each gene exerts on a pathway.
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IThese are reference KEGG pathways for Figures 5.3 and 5.4, as the gene names are not always clear in these Figures.
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Figure 5.3 The d ifferen tial gene expression found in the Wnt signalling pathway of Group 1, 2 and 3
tumour cultures.
Wnt signalling in G roup 1 tumour cultures
O protein?
Axam
HLK
|Oroucho|
Phosphorylation. 
1 dependence
Ubiquitin mediated 
proteolysisOil!
Wnt signalling in  Group 2 tumour cu
MAPK. agnail r« path-wy
TOP-P signaling 
pathwayUbiquitin mediated 
proteolysisOnll
Rbxl
Wnt signalling in  Group 3 tumour cultures
| Alzheimer*
I disease 1
Up-regulated genes are red, down-regulated genes are blue, those in green showed no differential 
expression and re lia b le  data was not available for genes indicated with a cross.
189
Figure 5.4 The differential gene expression found in the cell cycle signalling pathway of Group 1, 2 and
3 tumours.
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Comparison of adult GBMIV and paediatric astrocytoma short-term cell culture 
expression profiles
Expression profiles of 7 adult GBMIV short-term cell cultures were generated using the 
Affymetrix GeneChip® U133A array as previously described. A hierarchical clustering 
approach was completed to compare the adult GBMIV profiles with those of the 
paediatric astrocytoma short-term cell cultures of this study (Figure 5.5). Genes present 
in 10 of 42 of the short-term cell cultures were included, a total of 12377 reliable gene 
expression results.
Figure 5.5 Unsupervised hierarchical clustering of 35 paediatric astrocytoma and 7 adult GBMIV short­
term cell cultures using 12377 reliable gene expression results.
Subgroups
Diagnosis according to the 2007 WHO grading scheme
The dendrogram colour saturation is proportional to the magnitude of the difference from the experiment 
median, ranging from red (high-expression) to yellow (low-expression). The tumour grades shown 
correspond to the 2007 WHO grading scheme; paediatric PAI = purple; paediatric DAII = yellow; 
paediatric AAIII = dark blue; paediatric GBMIV = red; adult GBMIV = green.
Unsupervised hierarchical clustering showed that five of the adult GBMIV cultures 
clustered with the paediatric astrocytoma cultures of Group 3, dividing the group into 
two sub-groups. Three paediatric GBMIV cultures with whole chromosome alterations 
(IN699, IN I523 and IN 179) and a further 2 paediatric GBMIV cultures (INI566 and 
IN2675) clustered with 5 of the adult GBMIV cultures. The remaining 2 adult GBMIV 
cultures clustered with the paediatric astrocytoma of Group 2.
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From the group of 12377 gene probe sets, 4870 were identified that showed a 2-fold and 
significant difference in expression between the 3 Groups. Table 5.7 illustrates the 
percentage of gene probe sets disrupted in specific GO biological processes. 
Approximately 20% of gene probe sets in each GO group showed differential gene 
expression. The protein modification GO showed the highest number of altered genes 
(26%), compared to behaviour which was the lowest (7%).
Table 5.7 Gene ontologies o f specific genes differentially expressed between the short-term cell culture
Groups including the adult samples.
Biological process GO ID Number o f  genes 
in GO group
Number o f  genes 
differentially expressed 
between astrocytoma Groups
Amino acid and derivative metabolism 0006519 180 31 (17%)
Behaviour 0007610 83 6 (7%)
Biosynthesis 0009058 885 201 (23%)
Carbohydrate metabolism 0005975 1696 334 (20%)
Catabolism 0009056 426 97 (23%)
Cell cycle 0007049 1161 244 (21%)
Cell death 0008219 863 139(16% )
Cell differentiation 0030154 1657 255 (15%)
Cell growth 0016049 3993 659(17% )
Cell homeostasis 0019725 90 12(13% )
Cell proliferation 0008283 1067 185 (17%)
Cell recognition 0008037 1820 284(16% )
Cell-cell signalling 0007267 2582 377(15% )
Chemi-mechanical coupling 0006943 102 15 (15%)
Co-enzyme and prosthetic group metabolism 0006731 1163 203 (17%)
Cytoskeleton organisation and biogenesis 0007010 1536 340 (22%)
DNA metabolism 0006259 1470 291 (20%)
Electron transport 0006118 3286 605 (18%)
Embryonic development 0009790 779 112(14% )
Energy pathways 0006091 1497 279(19% )
Growth 0040007 1405 243(17% )
Host-pathogen interactions 0030383 4051 247(14% )
Ion transport 0006811 2474 453 (18%)
Lipid metabolism 006629 859 182 (21%)
Mitochondria organisation and biogenesis 0007005 1273 246 (19%)
Morphogenesis 0009653 301 40 (14%)
Protein biosynthesis 0006412 1060 248 (23%)
Protein modification 0006412 307 79 (26%)
Protein transport 0015031 2031 516(25% )
Regulation o f  gene expression; epigenetic 0040029 3969 685 (17%)
Reproduction 0000003 141 15(11% )
Response to endogenous stimuli 0009719 103 26 (25%)
Response to stress 0006950 427 87 (20%)
Signal transduction 0007165 4158 620(15% )
Transcription 0006350 3697 625 (17%)
Unknown biological processes 0000004 11034 1104(10% )
The percentage of genes in each ontology group that shows differential expression between the short-term 
cell culture groups and normal controls is also shown in brackets.
K-means clustering was used to investigate the expression patterns of the 4870 gene 
probe sets between the 3 tumour culture Groups. Due to the large number of genes 
investigated, the k-means approach was used to cluster the genes into 2 0  sets.
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Observations regarding the expression pattern for each set were then made (Table 5.8). 
Sets 1, 4 and 12 show similar gene expression patterns and could be grouped for further 
analysis, along with sets 9, 10 and 13; 5, 6 and 7; 14 and 17; and 3, 15, 16 and 18. Sets 
2, 8, 11,19 and 20 show specific expression patterns compared to any other set.
Table 5.8 K-means clustering of the 4870 differentially expressed genes between the 3 tumour Groups.
Set No. No. of genes Group 1 Group 2 Group 3
1 229 High High Low
2 308 Low Low High (sub group only)
3 299 High Low
4 173 High High Low
5 399 Low High High
6 371 Low High High
7 250 Low High High
8 549 Low (sub group only)
9 329 High Low Low
10 366 High Low Low
11 144 High
12 162 High High Low
13 155 High Low Low
14 163 Low High Low
15 239 High Low
16 130 High Low
17 199 Low High Low
18 349 High Low
19 89 Low High
20 123 High Low
The Table indicates high or low gene expression in specific tumour Groups compared to the remaining 
Groups and normal controls.
In the dendrogram of Figure 5.6, the 308 genes from k-means cluster set 2 are 
highlighted blue. This set of genes was the only group to show high-expression in the 
second sub-group of Group 3 tumours. In total, 94 probe sets are tightly clustered by 
expression pattern (main blue band in Figure 5.6). In total, 53 probe sets correlated with 
the 4682 probe sets that characterise the paediatric short-term cell culture Groups. The 
remaining 41 probes, representing 38 genes, were only found in the 4870 probe set list 
that characterise the Groups when the adult short-term cell cultures are added. As this 
group of genes showed a unique expression pattern and was a reasonably small number,
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the function of this set of genes was investigated by database mining to determine if a 
common biological function could be linked to the expression pattern (Table 5.9).
Figure 5.6 The dendrogram illustrates the clustering of the paediatric and adult short-term cell cultures 
and highlights the 308 genes from k-means cluster set 2 that show high-expression in the second sub­
group of Group 3 tumours (genes highlighted blue). In total, 94 probe sets are tightly clustered by 
expression pattern.
The dendrogram colour saturation is proportional to the magnitude of the difference from the experiment 
median, ranging from red (high-expression) to yellow (low-expression). The tumour grades are according 
to the 2007 grading scheme; PAI=purple; DAII=yellow; paediatric GBMIV=red; adult GBMIV=green. 
The genes highlighted blue in the dendrogram are the 308 probe sets for set 2 of the k-means clustering 
approach. The tight blue band consists of 121 probe sets.
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Table 5.9 The common names, functions and locations of the 38 genes that showed high-expression in 
the sub-group of Group 3 tumours compared to all other tumours.
Common
Name
M96
KIF2C
Description according to NCBI Locus Link Chromosome
Location
ANP32E
SFRS7
SMC4L1
RFC4
LSM6
KLIP1
TRIP 13 
CCNB1
HMMR
PTTG1
MCM3
NUP153
CBX3
PFTK1
Metal response element binding transcription factor 2 1 p22.1
Kinesin family member 2C - Proteins of this family are microtubule- lp34.1
dependent molecular motors that transport organelles and move 
chromosomes during cell division. KIF2C is important for anaphase 
chromosome segregation and may be required to coordinate the onset of 
sister centromere separation (Maney et al., 1998).
Leucine-rich acidic nuclear protein like 1 q21.2
Splicing factor, arginine/serine-rich 7, 35kDa 2p22.1
SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 3q26.1
Replication factor C (activator 1) 4 - The elongation of primed DNA 3q27
templates by DNA polymerase delta and DNA polymerase epsilon 
requires the accessory proteins proliferating cell nuclear antigen
(PCNA) and replication factor C (RFC). RFC is a protein complex
consisting o f five distinct subunits, this gene encodes the 37 kD subunit.
LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 4q31.21
Hypothetical protein FLJ23468 -  This gene is expressed in nucleated 4q35.1
hematopoietic cells, from early embryonic hematopoietic stem cells 
through to mature adult blood lymphoid lineages. Membrane KLIP-1 is 
also expressed by the fetal liver CD34(+) cells (Prost et al., 2002).
Thyroid hormone receptor interactor 13 5p 15.33
Cyclin B1 - The protein encoded by this gene is a regulatory protein 5ql2
involved in mitosis. The gene product complexes with cdc2 to form the 
maturation-promoting factor (MPF). Over-expression of CCNB1 is 
associated with astrocytoma and down-regulation by geldanamycin has 
been shown to induce G2 arrest. (Allan et al., 2000; Nomura et al.,
2007).
Hyaluronan-mediated motility receptor (RHAMM) - The receptor for 5q33.2-qter 
hyaluronan mediated motility has been reported to mediate migration, 
transformation, and metastasis. Increased RHAMM expression has been 
found in endometrial carcinomas (Rein et al., 2003) as well as other 
cancers. This protein can directly affect centrosomal structure and 
spindle integrity potentially modulating apoptosis and cell cycle 
progression (Maxwell et al., 2005).
Pituitary tumor-transforming 1 -  This protein prevents separins from 
promoting sister chromatid separation. It is an APC/C substrate that 
associates with a separin until activation o f the APC/C. The gene 
product has transforming activity in vitro and tumorigenic activity in 
vivo. This gene is highly expressed in various tumours and over­
expression in astrocytoma is a marker of poor prognosis (Genkai et al.,
20°6)
MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) - The 
protein encoded by this gene is one of the highly conserved MCM 
proteins that are involved in genome replication. The protein complex 
formed by MCM proteins is a key component of the pre-replication 
complex and is involved in the formation of replication forks and 
recruitment of other DNA replication proteins. Over-expression of 
MCM3 has been linked to reduced survival in DAII, AAIII and GBMIV 
(Soling et al., 2005).
Nucleoporin 153kDa 6p22.3
Chromobox homolog 3 (HP1 gamma homolog, Drosophila) - The 7pl5.2
protein encoded for by this gene binds DNA and is a component of 
heterochromatin.
PFTAIRE protein kinase 1 7q21 -q22
5q35.1
6pl2
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MTB
MELK
MKI67
CNAP1
RACGAP1
RFC 5
CKAP2
NUSAP1
BUB IB
CCNB2
AURKB
FLJ10156 
FLJ10534 
CDC6
JUNB
Hypothetical protein FLJ20311
Maternal embryonic leucine zipper kinase - MELK over-expression is 
thought to affect mammary carcinogenesis through the inhibition of the 
pro-apoptotic function of Bcl-GL (Lin et al., 2007).
Antigen identified by monoclonal antibody Ki-67 - A gradual increase 
in Ki-67 antigen expression was observed in agreement with mitotic 
index and histopathological classification of astrocytoma (Faria et al., 
2006).
Chromosome condensation-related SMC-associated protein 1 
Rac GTPase activating protein 1 -  This gene was found to be over­
expressed in epithelial ovarian cancer (Lu et al., 2004).
Replication factor C (activator 1 ) 5 -  Refer to RFC4; this gene encodes 
the 36.5kDa subunit.
Cytoskeleton associated protein 2 -  The protein encoded by this gene is 
linked to the microtubule network. CKAP2 was found to be over­
expressed in gastric adenocarcinomas (Bae et al., 2003).
Nucleolar protein ANKT -  The protein of this gene localises 
prominently to central spindle microtubules during mitosis. Gene 
expression is selective to proliferating cells (Raemaekers et al., 2003). 
BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) - 
This gene encodes a kinase involved in spindle checkpoint function. The 
protein has been localized to the kinetochore and plays a role in the 
inhibition of APC/C, delaying the onset of anaphase and ensuring proper 
chromosome segregation. Impaired spindle checkpoint function has 
been found in many forms of cancer, the over expression BUB1B is 
associated with chromosomal instability in bladder cancer (Yamamoto 
et al., 2007).
Cyclin B2 - Cyclin B2 is a member of the B-type cyclins. Cyclins B1 
and B2 associate with cdc2 and are essential components of the cell 
cycle regulatory machinery. Cyclin B1 co-localizes with microtubules, 
whereas cyclin B2 is primarily associated with the Golgi region. Cyclin 
B2 also binds to transforming growth factor beta RII and thus cyclin 
B2/cdc2 may play a key role in transforming growth factor beta- 
mediated cell cycle control. Over-expression o f Cyclin B2 was found in 
colorectal adenocarcinomas (Park et al., 2007).
Serine/threonine kinase 12 - Chromosomal segregation during mitosis is 
regulated by kinases and phosphatases. Aurora kinase B (AURKB) 
localizes to microtubules near kinetochores with over-expression of this 
gene inducing multicellularity and polyploidy. Over-expression of 
AURKB was correlated with a shortened survival in glioblastoma (Zeng 
et al., 2007).
Hypothetical protein FLJ 10156 
Hypothetical protein FLJ 10534
CDC6 cell division cycle 6 homolog (S. cerevisiae) - This protein 
functions as a regulator in the early steps of DNA replication. It 
localizes to the cell nucleus during the G1 phase o f the cell cycle, but 
translocates to the cytoplasm at the start of S phase. The subcellular 
translocation of this protein during the cell cycle is regulated through its 
phosphorylation by Cdks. Transcription o f this protein was reported to 
be regulated in response to mitogenic signals via transcriptional control 
mechanisms involving E2F proteins. Moreover, activation o f TP53 by 
DNA damage results in enhanced Cdc6 destruction by the APC/C 
complex (Duursma and Agami, 2005).
Ribonuclease H2, large subunit. JUNB is a proto-oncogene that 
functions as a regulator of erythroid cell survival, proliferation, and 
differentiation. It is one o f many DNA binding proteins that form AP-1 
dimers. Amongst the Jun proteins that are involved in this dimerisation, 
c-Jun positively regulates cell proliferation through the repression of 
tumor suppressor gene expression and function, and induction of cyclin 
D1 transcription. JunB antagonises these actions, by up-regulating tumor
7q36.3 
9p 13.1
10q25-qter
12p 13.3 
12ql3.12
12q24.2-q24.3
13ql4
15ql4
15ql 5
15q21.2
17pl3.1
17pl3.2
17pl3.3
17q21.3
19pl3.12
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suppressor genes and repressing cyclin D1 (Shaulian and Karin, 2001b).
ASF IB Anti-silencing function IB. This gene encodes a member o f the H3/H4
family o f histone chaperone proteins. The encoded protein is the
substrate o f the tousled-like kinase family o f cell cycle-regulated
kinases, and may play a key role in modulating the nucleosome structure 
of chromatin by ensuring a constant supply o f histones at sites of
nucleosome assembly.
KIAAO186 KIAAO186 gene product
TOPI Topoisomerase (DNA) I -  The protein of this gene is an enzyme that
adjusts the number of supercoils in DNA and altering topologic states 
during transcription Both type I and type II topoisomerases have been 
identified as clinically important targets for cancer chemotherapy and 
their inhibitors are central components in many therapeutic regimes 
(Giles and Sharma, 2005).
UBE2C Ubiquitin-conjugating enzyme E2C. This gene encodes a member of the
E2 ubiquitin-conjugating enzyme family and is required for the 
destruction o f mitotic cyclins and for cell cycle progression. 
Hepatocellular carcinomas with over-expression of UBE2C showed 
higher frequencies of tumor invasion and tumor de-differentiation. 
Furthermore, patients with tumours that showed high UBE2C expression 
also showed significantly worse disease-free survival rates compared to 
those with low UBE2C expression (Ieta et al., 2007).
C21 orf45 Chromosome 21 open reading frame 45.
KIF4A Kinesin family member 4A. Kinesins, such as KIF4A, are microtubule-
based motor proteins that generate directional movement along 
microtubules. They are involved in many crucial cellular processes, 
including cell division.
HMGB3 High-mobility group box 3. HMGB3 is a member of a family of
chromatin-binding proteins that can alter DNA structure to facilitate 
_____________ transcription factor binding._______________________________________
To investigate the expression pattern of those genes commonly differentially expressed 
in adult astrocytoma, as discussed in the introduction, in the paediatric astrocytoma of 
this study, the expression profile of specific genes including TP53, PDFRA, PDGFA, 
RB, PTEN, EGFR, CDKN2A, CDKN1A, CCND1, CDK4 and E2F1 were investigated in 
all short-term cell culture samples. No reliable expression data was available for CDK6 
or MDM2.
Figure 5.7 illustrates a dendrogram comparing the expression profile similarity of the 
short-term cell cultures from adult and paediatric tumours and 16 probe pairs 
representing the 11 genes previously described. According to the expression of these 11 
genes, the samples do not cluster by Group or grade and the adult short-term cell 
cultures integrate with the paediatric short-term cell cultures. However, 4 sample cluster 
groups can be seen.
19pl3.12
20pl 1.1 
20ql2-ql3.1
20ql3.11
21q22.11 
Xql3.1
Xq28
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Figure 5.7 The dendrogram illustrates the expression pattern of 11 genes commonly differentially expressed in adult
astrocytoma, in the short-term cell cultures of this study.
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The branches of the dendrogram represent each sample, green branches are adult GBMIV short-term cell cultures and black branches are paediatric short-term cell cultures. 
The tumour grades shown correspond to the 2007 WHO grading scheme; PAI = purple; DAII = yellow; AAIII = dark blue; paediatric GBMIV = red; adult GBMIV = green. 
The dendrogram colour ranges from red (high-expression) to yellow (low-expression).
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Genomic CNAs in paediatric astrocytoma short-term cell cultures
All of paediatric astrocytoma cultures studied here showed single clone alterations. An 
example of the raw data generated for each chromosome in every sample can be found 
in Figure 5.8. This illustrates single clone alterations that clearly exceed the threshold, 
as well as those that only just exceed the threshold.
Figure 5.8 Illustration of the raw data for chromosome 1 in tumour IN 1566.
Figures 5.9-5.40 display all CNA alterations for every short-term cell culture, ordered 
by tumour grade and numerical Institute Number. Table 5.10 displays 37 clone 
alterations that occur in 5 tumour cultures (16%) or more, that are single clone 
alterations in the majority of samples but may be part of whole chromosome or arm 
alterations in specific tumours.
199
Figure 5.9 aCGH profile of tumour IN 1520 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN 1520 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.10 aCGH profile of tumour IN 1524 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN 1524 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.11 aCGH profile of tumour IN 1591 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN 1591 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.12 aCGH profile of tumour IN 1751 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN 1751 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.13 aCGH profile of tumour IN 1869 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN 1869short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.14 aCGH profile of tumour IN2003 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2003 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.15 aCGH profile of tumour IN2012 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2012 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.16 aCGH profile of tumour IN2017 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2017 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.17 aCGH profile of tumour IN2044 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour FN2044 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.18 aCGH profile of tumour IN2102 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2102 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.19 aCGH profile of tumour IN2110 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN21 lOshort-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.20 aCGH profile of tumour IN2122 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2122 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.21 aCGH profile of tumour IN2356 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2356 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.22 aCGH profile  o f  tum our IN2368 short-term  cu ltu re  (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2368 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.23 aCGH profile of tumour IN2591 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2591 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.24 aCGH profile of tumour IN2688 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2688 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.25 aCGH profile of tumour IN2921 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN2921 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.26 aCGH profile of tumour IN3013 short-term culture (PAI).
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The Figure displays clone alterations across the entire genome of tumour IN3013 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.27 aCGH profile of tumour IN380 short-term culture (DAII).
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The Figure displays clone alterations across the entire genome of tumour IN380 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.28 aCGH profile of tumour INI 145 short-term culture (DAII).
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The Figure displays clone alterations across the entire genome of tumour IN 1145short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.29 aCGH profile of tumour IN3032 short-term culture (AAIII).
IN3032
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The Figure displays clone alterations across the entire genome of tumour IN3032 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.30 aCGH profile of tumour IN3046 short-term culture (AAIII).
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The Figure displays clone alterations across the entire genome of tumour IN3046 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.31 aCGH profile of tumour IN 178 short-term culture (GBMIV).
D M 1 7 8
| ♦ 1 ♦ 2 ♦ 3~*4 5 •  6 ♦ 7 ♦ 8 ♦ 9 ♦ 10 ♦ 11 ♦ 12 •  13 ♦ 14 ♦ 15 ■ 16 ■ 17 ■ 18 ■ 19 20 ■ 21 ■ 22 ■ X
1.0 -|
- 1.0
Chromosome Linear Location
The Figure displays clone alterations across the entire genome of tumour IN 178 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.32 aCGH profile of tumour IN 179 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 179 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.33 aCGH profile of tumour IN699 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN699 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.34 aCGH profile of tumour INI 163 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour INI 163 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
212
Figure 5.35 aCGH profile of tumour IN1262 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 1262 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.36 aCGH profile of tumour IN 1419 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 1419 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.37 aCGH profile of tumour IN 1495 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 1495 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.38 aCGH profile of tumour IN 1523 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 1523 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Figure 5.39 aCGH profile of tumour IN 1566 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN 1566 short-term cell culture. 
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
Figure 5.40 aCGH profile of tumour IN2675 short-term culture (GBMIV).
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The Figure displays clone alterations across the entire genome of tumour IN2675 short-term cell culture.
Each chromosome is represented by a different colour and the clones that are considered to be gained or
lost are those outside the red threshold lines.
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Table 5.10 Representation of the individual clone CNAs found in the paediatric astrocytoma short-term cell cultures.
Location
1 pl3.3-lp21.3 
14ql2-14ql2 
1 Op 15.3 
16pll.2-16pll.2  
19pl3.2-19pl3.2 
Ip35.1-lp36.21 
6ql2-6ql2 
10qll.22 
8q21 2-8q21.2 
13ql4.3-13q21.2 
16pll.2-16pl 1.2 
7p21 
15ql 3.1 
3pl4.1-3pl4.1 
6p25.3 
7qll.23-7q21.1 
Ip21.3-lp22.3 
2q21-2q22 
4pl3-4pl3 
5pl5.2d-5pl5.2 
9q32-9q33.3 
9q34.3 
19q 13.12-19q 13.12 
Ip34.2-lp36.11 
Ip34.3-lp36.11 
Ip31.1-lp31.3 
Iq24-lq24 
2ql2-2ql2 
6q25.1-6q25.3 
7qll.23-7qll.23  
7q21.1-7q21.1 
7q22.1-7q22.1 
7q35-7q35 
8q21.3-8q21.3 
12q24.2-12q24.2 
16pl2-16pl2 
16p 11.1-16q 11.1
1751 1591 2110 1419 178 1495 2044 1524 1520 2122 2921 1262 2003 2012 380 2591 2368 3013 1869 2102 23563032 15661163 3046 2017 2688 1523 2675 179 699
40 98 41 38 40 25 57 38 19 64 50 28 17 30 23 38 16 25 45 22 34 106 43 35 18 65 14 1031 21 276 372
-  -  I
The Table is ordered with the most frequently altered clones at the top; blue boxes represent clone loss and red boxes represent clone gain. The tumours are ordered according 
to the dendrogram in Figure 5.1.The number of total clones altered in each tumour is indicated in green. The most single clone alterations were found on chromosome 1.
216
Tumour culture IN2368 has the least number of CNAs, a total of 16 clones, compared to 
tumour culture IN 1523 that shows the most alterations (1031 clones). Between 19-98 
clone alterations were found in the tumour cultures of Group 1 , compared to 16-45 and 
14-1031 in the tumour cultures of Group 2 and 3 respectively. Furthermore, if  the 
tumour cultures are grouped or ordered according to patient age or sex, tumour location 
or grade, no non-random clone alterations were found (data not shown).
No consistent clone alterations found in 5 tumour cultures or more, are unique to 
Groups 1, 2 or 3 (as shown in Table 5.10). However, clone RP11-89C12, located at 
2pl2, was gained in 4 tumour cultures of Group 3, IN3032, IN2017, IN2675 and IN179. 
Furthermore, 4 different clone alterations were found in 3 tumour cultures of the same 
Group. Clone RP11-92014, located at lp33, was gained in tumour cultures INI 163, 
IN1523 and IN699 of Group 3. Clone RP11-90M13, located at 8p21.2, was gained in 
tumour cultures INI 566, IN 1523 and IN699 of Group 3. Clone RP11-88B18, located at 
10q21.1, was lost in tumour cultures IN1751,IN1419 and IN 1495 of Group 1 and clone 
RP11-88B2, located at 18q22, was lost in tumour cultures IN I566, IN I79 and IN699 of 
Group 3. No reliable expression data was available for the genes in the regions of these 
clones.
As well as single clone alterations, 9 tumour cultures showed CNAs of between 2-4 
adjacent clones, but no whole chromosomes or arms. Furthermore, the PAI tumour 
cultures, IN2044 and IN2017, that showed loss of 6 q and gain of 7q respectively, also 
showed alterations of small regions containing 2-3 adjacent clones. The majority of 
samples with these small regions of alteration clustered in Groups 1 and 2. Two single 
clone alterations at 7q 11.23 and 16pl 1.2 were also identified as small regions of 
alteration involving 2-3 adjacent clones in specific tumour cultures (Figure 5.41).
Only seven tumour cultures showed gain or loss of entire chromosomes or arms 
including 3 GBMIV (IN699, IN179 and IN1523 all clustering in Group 3), 1 AAII 
(IN3032 clustering in Group3) and 3 PAI (IN2044, IN2012 and IN2017 clustering in 
Groups 1, 2 and 3 respectively). The most common alteration was gain of part or all of 
chromosome 7, seen in 5 tumour cultures that clustered in Group 3.
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IFigure 5.41 Clone alterations at 16p 11.2 and 7ql 1.23 in the paediatric astrocytoma short-term cell cultures.
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Correlation of CNAs with differential gene expression in paediatric astrocytoma 
short-term cell cultures
Clones altered in 5 or more tumour cultures were investigated further for correlations 
with differential gene expression. The cut-off was drawn here because of the extensive 
amount of time each clone analysis required and because the clones altered in 4 or less 
tumours appeared to be random (except those previously mentioned). Genes located in 
the same regions as the significantly altered BAC clones were identified and the 
expression of these genes was investigated using the data from the Affymetrix 
GeneChip® array. BAC clone regions were defined as the direct binding region of the 
clone and the regions either side of the binding region, up to each adjacent clone. Any 
genes located in the same region as altered clones that showed a 2 -fold difference in 
expression between the normal astrocyte controls and all or some of the short-term cell 
culture Groups, were deemed to correlate with clone alterations. Figure 5.42 illustrates 
BAC clone RP11-259N12, located at Ipl3.3-lp21.3 (103-104K), as well as the genes 
located in the same region using the Database of Genomic Variants 
(http://projects.tcag.ca/variation/cgi-bin/gbrowse/hgl8 ). The NCBI nucleotide database 
was also used to confirm the genes located at Ipl3.3-lp21.3 
(http://www.ncbi.nlm.nih.gov/mapview/mapsearch.cgi?taxid=9606). This approach was 
used to investigate all CNAs.
In total, 37 single clones were altered in at least 5 tumour cultures (16%). Reliable data 
was not available for every gene in an altered region and consequently few correlations 
were identified between single clone alterations and differentially expressed genes 
located in the same region (Table 5.11).
A single clone in the region of Ipl3.3-lp21.3 was lost in 47% of tumour cultures and 
correlated with the down-regulation of COLLA1 in all cultures. A clone located at 
14ql2 was gained in 28% of tumour cultures and lost in 19% of cultures and the gene, 
FOXG1B, located in the region adjacent to this clone, was down-regulated in 91% of 
cultures. /D/7, ANXA8, EPHA2, TRJ1, ARHGEF4, COL8A2, TRIP6, G10, ARPC1A, 
SGCE, SLC25A13 and SHCBP1 also showed differential gene expression and correlated 
with single CNAs in the same regions.
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Figure 5.42 Location of BAC clone RP11-259N12 and the genes located in the clone binding site and adjacent regions.
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This was taken from the Database of Genomic variants, http://projects.tcag.ca/variation/cgi-bin/gbrowse/hgl8.
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ITable 5.11 Single clone CNAs that correlate with differential gene expression in paediatric astrocytoma short-term cell cultures.
BAC clone Location (iaincd Lost % Gained % Lost % Total Region size (Mbp) No. of genes in region Differentially expressed genes
RP11-259N12 Ipl3.3-lp21.3 4 15 12.50 -46.88 59.38 ~4 17 i C O L 1 1 A 1  100%
RP11-125A5 14ql2-14ql2 9 6 28.13 -18.75 46.88 -1.6 6 1 F O X G l B 9 \ %
RP11-38M7 10pl5.3 11 1 34.38 -3.13 37.50 -0.2 11 t ID I 1  Grps 2&3
RP11-499D5 16p 11.2-16p 11.2 3 9 9.38 -28.13 37.50 -4.3 70
RP11-79F15 19pl3.2-19pl3.2 5 6 15.63 -18.75 34.38 -2.8 84
RP1-163M9 Ip35.1-lp36.21 2 8 6.25 -25.00 31.25 -0.9 32 |  E P H A 2  100%
RP11-80L16 6ql2-6ql2 6 4 18.75 -12.50 31.25 -1.5 0
AL390716.27 lOql 1.22 0 10 0.00 -31.25 31.25 -4.1 85 i A N X A 8  100%
RP11-96G1 8q21.2-8q21.2 7 2 21.88 -6.25 28.13 -1.3 19
RP11-100C24 13ql4.3-13q21.2 9 0 28.13 0.00 28.13 -3 6
RP 11-488120 16pl 1.2-16p 11.2 5 4 15.63 -12.50 28.13 -1.9 36
C1TB-13P7 7p21 7 1 21.88 -3.13 25.00 -1.3 19
AC 102941.9 15q13.1 7 1 21.88 -3.13 25.00 -3.3 43 T T J P 1  Grps 2&3
RP11-89A12 3pl4.1-3pl4.1 7 0 21.88 0.00 21.88 -1.7 11
| AL035696.14 6p25.3 4 3 12.50 -9.38 21.88 -0.2 9
RP11-60N2 7ql 1.23-7q21.1 7 0 21.88 0.00 21.88 -1 3
RP11-335D10 Ip21.3-lp22.3 3 3 9.38 -9.38 18.75 -0.5 4
RP11-89B17 2q21-2q22 0 6 0.00 -18.75 18.75 -2.5 63 |  A R H G E F 4  100%
RP11-81N11 4pl3-4pl3 0 6 0.00 -18.75 18.75 -3.3 7
RP11-145B1 5pl 5.2 5 1 15.63 -3.13 18.75 -0.8 9
RP11-9H12 9q32-9q33.3 6 0 18.75 0.00 18.75 -2.1 33
RP1-112N13 9q34.3 4 2 12.50 -6.25 18.75 -0.2 5
RP11-118P21 19ql3.12-19ql3.12 5 1 15.63 -3.13 18.75 -4.6 154
RP5-893G23 Ip34.2-lp36.11 5 0 15.63 0.00 15.63 -2.5 20
RP1-34M23 1 p34.3-1 p36.11 4 1 12.50 -3.13 15.63 -2.7 38 t C O L 8 A 2  Grp 2
RP11-492C3 1 p31.1-1 p31.3 3 2 9.38 -6.25 15.63 -1 16
RP11-81H19 Iq24-lq24 5 0 15.63 0.00 15.63 -1.1 17
RP11-9009 2ql2-2ql2 2 3 6.25 -9.38 15.63 -1.4 11
RP11-535A9 6q25.1-6q25.3 1 4 3.13 -12.50 15.63 -1.7 11
RP11-89A20 7qll.23-7qll.23 5 0 15.63 0.00 15.63 -0.4 3
RP11-88D24 7q21.1-7q21.1 4 1 12.50 -3.13 15.63 -2.1 143 t T R I P 6  Grps 2&3, T G 1 0  Grps 2&3, 
|  A R P C 1 A  Grps 3
RP11-10D8 7q22.1-7q22.1 5 0 15.63 0.00 15.63 -7.7 143 t S G C E  1 0 0 % ,  t S L C 2 5 A 1 3  100%
RP11-79M8 7q35-7q35 5 0 15.63 0.00 15.63 -4.2 25
RP11-90015 8q21.3-8q21.3 3 2 9.38 -6.25 15.63 -1 10
RP11-3L23 12q24.2-12q24.2 3 2 9.38 -6.25 15.63 -3.1 44
RP11-79115 16p 12-16p 12 2 3 6.25 -9.38 15.63 -1.5 15
RP11-80F22 16pl 1.1-16pl1.1 3 2 9.38 -6.25 15.63 -4.3 17 t S H C B P 1  Grp 3
Boxed clones are located in regions of LCV in the normal population. In total 21/37 (57%) clones are located in regions of LCV.
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The size of the regions investigated in this approach varied between 0.2-7.7 Mbps. To a 
certain extent, this explains the variation in the number of genes found in each region 
(0-154). Furthermore, 21 of the 37 clones investigated were located in regions of LCV 
that occur in the normal population.
Several tumour cultures showed CNAs of 2 or more adjacent clones in regions that 
correlated with differential gene expression, including whole chromosome or 
chromosome arm alterations (Table 5.12). In these cases, those genes that were located 
in the regions of alteration and showed a 2 -fold difference in expression between the 
astrocyte controls and the tumour short-term cell cultures in which the alteration was 
seen, were deemed to correlate with clone alterations. Genes identified using this 
approach were then compared to the 4682 probe sets that were differentially expressed 
between the astrocyte controls, short-term cell culture Group 1, Group 2 and Group 3. 
Tumour culture IN699 showed the most CNAs that correlated with differential gene 
expression in the same regions. The majority of tumour cultures with alterations 
between 2 and 4 adjacent clones that correlated with differential gene expression were 
clustered in Group 1 or Group 2. Tumour cultures IN3032, IN2017 and IN 179 are an 
exception to this, but they also show whole chromosome or arm alterations.
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Table 5.12 The correlation o f 2 or more adjacent clones in specific paediatric astrocytoma short-term cell 
cultures with differential gene expression where possible.
Tumour Region No. of 
clones
Loss or Gain Region size 
(Mbp)
No. of genes in 
region
No. of differentially 
expressed genes
INI 145 2pl3.2 2 Gain -4.9 27 t P450RAI-2
IN2110 4q33-4q34 2 Gain -6.5 20 T FU 20035, t PALLD, \  NEK1
IN178 10pl5.3 2 Gain -0.4 13
16pl3.3 2 Gain -3.2 165 T RGSU, t PDIA2, t GNG13, f
ABCA3
22ql3.1 2 Gain -3.2 68 T TCF20, t SREBF2, f A4GALT
IN2044 3q24-3q25 2 Gain -3.3 43
9q33 2 Gain -3.5 42
6q 119 Loss -108 653 |  45 (15=33%)
IN2122 4q25-4q26 2 Loss -2.1 58 1 NOLA1, i  CASP6,1  ENPEP, |
RRH, i  EGF
IN 1262 3p26.3 2 Gain -2.4 7
10q26.3 2 Gain -0.2 20
6ql2 3 Gain -5.7 19
IN2003 12pl 3.3 2 Loss -4.2 21 i PLEKHA5
IN2012 7pl4-7p21 47 Loss -37 240 I 32 (22=68%)
IN2591 1 p21.3 2 Gain -1.8
16pl 1.2 2 Gain -4.4 58 | TP53TG3
IN3013 2ql4-2q22 3 Loss -3.9 67 i  ARHGEF4
16pl 1.2 2 Gain —4.4 58 T TP53TG3
IN 1869 6p22.3 2 Gain -1.2 13
IN3032 6q26 4 Loss -3.5 37
7q 71 Gain -97 980 t 68 (44=64%)
16pl 1.2 2 Gain -4.4 58 i  TP53TG3
17p 30 Loss -21 442 I 15(7=46%)
IN2017 7ql 1,23-7qter 71 Gain -80 980 t 65 (41=63%)
16pl 1.2 3 Gain -5.4 58 I TP53TG3
IN 1523 2 213 Loss -243 1888 i  170(69=40%)
4 203 Loss -192 1154 1 105 (46=43%)
6 184 Gain -171 1505 T 291 (148=51%)
7 136 Gain -160 1452 T 183(84=46%)
9 116 Gain -135 1148 t 147 (75=51%)
12 127 Loss -134 1370 i 161 (69=43%)
20ql3.2-20qter 10 Gain -15 79 t 10(4=40%)
1 p35.1 -1 pi 3.1 87 Gain -87 730 t 176(68=38%)
IN 179 7 136 Gain -160 1452 t 159(84=52%)
9 116 Gain -135 1148 T 159(78=49%)
16pl 1.2 2 Gain -4.4 58 t TP53TG3
17q 22 Gain -56 348 t 30 (18=60%)
21 26 Gain -47 352 t 32 (22=68%)
IN699 lq32-lqter 36 Loss -52 432 131 (9=29%)
2p23.2-2ql 1.2 56 Gain -74 640 t 128 (45=35%)
2q21-2q31.2 21 Gain -41 152 t 53 (19=36%)
3pl4.3-3ql2.2 31 Loss -45 181 1 29 (16=55%)
4 203 Loss -192 1154 1 123 (55=45%)
5pter-5pl5.2 18 Gain -36 91 T 19(6=32%)
5q33.3-5qter 14 Gain -20 227 T 44 (11=25%)
6pter-6p24 12 Loss -7.5 70 1 6 (4=67%)
7pl5-7q21.1 51 Gain -34.3 454 1 77 (34=44%)
7qll.22-7q21.1 18 Gain -14.9 124 T 26 (11=42%)
8 133 Gain -146 984 t 210 (96=46%)
9pter-9q21.1 29 Loss -26.5 145 1 14 (2=14%)
9q33-9qter 21 Gain -12.2 351 t 76 (24=32%)
1 lq23-l lqter 22 Loss -20 177 1 10(4=40%)
13ql 1-I3ql2.3 13 Loss -10.7 128 1 7 (1=14%)
13q14-13q21.1 14 Gain -19 116 t 16 (4=25%)
13q22-13q31.1 8 Loss -9.2 35 13(0)
13q31.2-13q31.3 7 Gain -9.4 15
13q32.1-13qter 26 Loss -20 214 130(11=37%)
15ql 2-15q22 40 Loss -38.5 463 1 73 (31=43%)
17pl 1.2-17pl3.2 15 Gain -18 236 t 48 (13=27%)
18 46 Loss -78 432 1 54 (23=43%)
20ql3.2-qter 9 Gain -15 79 T 24 (7=29%)
The tumours are ordered according to the hierarchical clustering approach in Figure 5.1 and the dotted 
lines indicate tumour Groups. The percentage o f genes differentially expressed in each region and also 
found to be differentially expressed between the astrocyte controls and the 3 tumour Groups are shown in 
brackets.
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Gain of part or all of chromosome 7 and correlation with gene over-expression in 
paediatric astrocytoma short-term cell cultures
Gain of part or all of chromosome 7 was the most common chromosomal alteration 
found in 5 paediatric astrocytoma short-term cell cultures, comprising 3 GBMIV 
(IN699, INI 523 and INI 79), 1 AAII (IN3032) and 1 PAI (IN2017). Gain of part or all 
of this chromosome correlated with a greater than 2-fold up-regulation of 103, 183, 159, 
68 and 65 genes in tumour cultures IN699, IN 1523, IN 179, IN3032 and IN2017 
respectively (Table 5.12). In total, 16 genes located on chromosome 7 showed a 
common 2-fold up-regulation in the 5 tumours (Figure 5.43). Furthermore, the 
expression profile of these 16 genes in all tumours shows a continuous increase in up- 
regulation from those tumours in Group 1 to those of Group 3.
Figure 5.43 The expression profile of the 16 genes that show a 2-fold increase in expression in all 
paediatric astrocytoma short-term cell cultures with gain of chromosome 7.
lotrt
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The tumours are ordered according to the hierarchical clustering diagram in Figure 5.1.
Table 5.13 details the 16 genes, including those highlighted red, which have functions 
previously investigated in astrocytoma or that have been linked to tumour or cancer 
development.
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Table 5.13 Details of the 16 genes that show a greater than 2-fold increase in expression in all samples
with gain of part or all of chromosome 7.
Location Common Name Description
Chr:7q 11.21 FLJ10099 hypothetical protein FLJ 10099
Chr:7q 11.23 POMZP3 POM (POM 121 homolog, rat) and ZP3 fusion
Chr:7q21.I SRI sorcin
Chr:7q21.2 FLJ20073 hypothetical protein FLJ20073
Chr:7q21.3 SLC25A13 solute carrier family 25, member 13 (citrin)
Chr:7q21-q22 SGCE sarcoglycan, epsilon
Chr: 7q22.1 PBEF1 pre-B-cell colony-enhancing factor
Chr:7q22.1 SYPL synaptophysin-like protein
Chr:7q31.1-q31.3 LSM8 LSM8 homolog, U6 small nuclear RNA 
associated (S. cerevisiae)
Chr: 7q31.2-q3I.3 CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2
Chr:7q31-q32 DLD dihydrolipoamide dehydrogenase
Chr:7q31-q32 GNG11 guanine nucleotide binding protein (G protein), gamma 11
Chr:7q32 CALU calumenin
Chr:7q32.3 CHCHD3 hypothetical protein FLJ20420
Chr:7q36 ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2
Chr:7q36.3 DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6
Detailed aCGH analysis
Specific tumour cultures investigated by aCGH in this study have previously been 
studied by analogue CGH in our laboratory. All analogue CGH experiments referenced 
in this thesis are credited to Dr S Ward. Although it is well known that analogue CGH is 
less sensitive compared to aCGH, good correlation was seen between the analogue 
CGH and aCGH profiles completed on the same tumour samples. Figures 5.44-5.46 
illustrate these correlations for tumour culture IN699. Figure 5.36 illustrating 
chromosome 13, highlights the sensitivity of aCGH compared to analogue CGH.
Figure 5.44 Correlation of analogue CGH and aCGH profiles for chromosome 3 in tumour IN699.
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Figure 5.45 Correlation of analogue CGH and aCGH profiles for chromosome 9 in tumour IN699.
Figure 5.46 Correlation of analogue CGH and aCGH profiles for chromosome 13 in tumour IN699.
■ L i
When investigating CNAs on each chromosome only single clones that exceeded the 
cut-off threshold were put forward for further investigation. However when all 
chromosomes were analysed simultaneously for a specific tumour culture, additional 
changes that did not cross the cut-off threshold became apparent. Figure 5.47 illustrates 
the aCGH profile for tumour culture IN 179. This patient is male and clear loss of 1 copy 
of chromosome X, with clones exceeding the cut-off threshold, can be seen on the far 
right of the profile.
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Figure 5.47 Tumour IN 179 aCGH profile for all chromosomes.
IN179
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Chromosome Linear Location
The single clones on each chromosome are represented by a spot, the spots for each chromosome are coloured and are ascending from left to right with the X chromosome on 
the far right. The cut-off threshold for clone gains and losses is represented by the dotted red line.
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The alterations documented in Table 5.12 can also be seen in the profile including, gain 
of 1 copy of chromosome 7, gain of possibly 2 copies of chromosome 9, gain of 1 copy 
of 17q and gain of 1 copy of 21. Moreover, there is a clear shift in the clones located on 
chromosome lp, 3, 16, 18 and 22 away from the ratio of 0 towards the cut-off threshold. 
As these clones have not crossed the threshold they have not been investigated further. 
However, this profile suggests that alterations of these chromosomes may be present in 
a proportion of IN 179 tumour cells and are a reflection of tumour heterogeneity 
(Snijders et al., 2001). This may also be due to non-tumorigenic cell contamination 
within the culture population. Further investigation of this profile with fluorescent in 
situ hybridisation (mFISH) would be necessary to confirm these results. The only other 
profile that exhibited this shifting of clones located on specific chromosomes was 
tumour culture IN 1523 (Figure 5.38), although it was not as clear as tumour culture 
INI 79.
The log2 ratio of the X chromosome was investigated in each sample analysis and the 
average log2 ratio of each X chromosome was compared to that of the male/female 
control using a Students t-test. The mean log2 ratio for the X chromosome in the 
male/female control of this study was ±1.41 ±0.15 SD. In 12 tumours, the X 
chromosome average log2 ratio was significantly different from the control (Table 5.14).
In 9 tumour cultures, the significant difference was though to be due to cross­
hybridisation between some X chromosome genes and homologous sequences on 
autosomes and was not considered to be true gain or loss of the X chromosome (Pollack 
et al., 1999). Tumour culture IN1419 is from a patient diagnosed with Turners 
Syndrome (loss of 1 copy of the X chromosome). This X chromosome loss can clearly 
be seen in the chromosome profile of this tumour in which the X chromosome log2 ratio 
is approximately 0 and is significantly different from the normal (Supplementary Data). 
In tumour cultures IN380 and IN I523 the X chromosome average log2 ratios were 0.327 
and 0.291 respectively and significantly different from the male/female control. In these 
tumours, the X chromosome loss appears to be in a proportion of tumour cells, 
consequently the X chromosome average log2 ratios are not approximately 0, as seen in 
tumour IN1419. As the X chromosome loss was only thought to occur in a proportion of 
tumour cells, differential gene expression on the X chromosome was not directly
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investigated in these tumours. This may also be due to non-tumorigenic cell 
contamination in the cell culture sample.
Table 5.14 The X chromosome log2 ratio averages and SD for 12 tumours that showed 
a significant difference from the male/female normal control.
Tumour Significance X chromosome average 
log2 ratio and SD
INI419 p<  0.001*** 0.053 ±0.212
IN 1524 p < 0.05 -0.554 ±0.206
IN 1520 p < 0 .0 1 ** -0.559 ±0.214
IN 1262 p <  0 .0 0 1 *** -0.560 ±0.209
IN380 p<  0.001*** 0.327 ±0.203
IN2591 p < 0.05* 0.554 ±0.2122
IN3013 p < 0.05* -0.554 ±0.220
IN 1869 p < 0 .0 1 ** 0.557 ±0.241
IN 1566 p <  0 .0 0 1 ** 0.591 ±0.219
INI 163 p < 0 .0 1 ** -0.560 ±0.242
IN2017 p < 0 .0 1 ** -0.555 ±0.230
IN1523 p<  0.001*** 0.291 ±0.163
Results shown in bold suggest true X chromosome alterations.
DISCUSSION
Array technology has been used to define genomic aberrations and generate gene 
expression profiles of paediatric astrocytoma short-term cell cultures with the main aims 
of correlating differential gene expression and genomic aberrations in paediatric 
astrocytoma and characterising disrupted cellular pathways that could be involved in 
tumour development and growth. Genomic gain and loss has been shown as a 
mechanism that can disrupt gene expression and play a significant role in the 
development of tumours.
The review of tumour diagnoses in this Chapter, according to 2007 WHO grading 
scheme, revealed some unexpected results. Two tumours, IN I930 and IN3032, 
previously diagnosed as DAII were re-graded as AAIII and all remaining DAII were re­
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graded as PAI. In the experience of the pathologists involved in this review, paediatric 
astrocytoma are rarely classified as DAII. In this study, it was not sensible to analyse 
the tumour cultures by pathological grade due to the clustering patterns seen, 
highlighting the difficulties of analysing paediatric astrocytoma by pathological grade. 
The 2007 WHO grading scheme, does show a higher correlation with the 3 tumour 
Groups seen here, with Groups 1 and 2 consisting of predominately PAI cultures and 
Group 3 consisting of mostly high-grade tumour cultures. Furthermore, this suggests 
that two sub-groups of PAI do exist as seen by Wong et al. (2005), although different 
genes in this study characterise the sub-groups, as seen by the investigation of Groups 1 
and 2. However, the tumour samples of this study are short-term cultures compared to 
biopsies used by Wong et al. (2005) and this may explain why different genes 
characterise the two PAI sub-groups in each study. Moreover, the PA biopsies 
investigated in Chapter 3 do not show clear sub-groups, but the tumours that cluster 
furthest apart do show characteristics of each sub-group identified by Wong et al. 
(2005). Additional biopsy samples maybe need to be added to this cohort to distinguish 
any subgroups.
Differential gene expression and cell signalling pathways in paediatric astrocytoma 
short-term cell cultures
In total, 4682 probe sets showed a 2-fold and significant change in expression between 
the 3 tumour culture Groups and normal controls, k-means clustering allowed the 
grouping of genes according to expression profile similarity and identified molecular 
signatures that could define each tumour culture Group. Sets 7 and 10 of the clustering 
approach identified genes that were expressed at a low level in all Groups compared to 
the controls and may be characteristic of astrocytoma. Clusters sets 4, 5 and 6  were 
differentially expressed in Groups 2 and 3 compared to Group 1 and controls and could 
be used to distinguish these tumour culture clusters. Sets 3 and 8  were differentially 
expressed in Group 1 and 2 tumour cultures compared to Group 3 and the controls and 
could distinguish Group 1 and 2 tumour cultures. Sets 2 and 9 were differentially 
expressed in Group 2 tumour cultures only and set 1 was differentially expressed in 
Group 3 tumour cultures only. These sets could be used to characterise these specific 
tumour culture clusters. Overall each tumour Group has a specific molecular signature 
that distinguishes the clusters and the controls. This is most relevant with respect to 
Group 3 tumour cultures that show increased CNAs (discussed later in this Chapter).
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The cluster stets of this k-means approach were too large to investigate by data mining, 
consequently Onto-tools was used to identify biological processes and pathways that 
were significantly altered in each tumour Group.
The characterisation of the biological pathways significantly disrupted in the different 
clusters of paediatric astrocytoma, highlighted that the tumour cultures of Group 3 show 
a larger number of differentially expressed genes compared to Groups 1, 2 and the 
controls. Overall, only the biological process antigen processing and presentation was 
significantly altered in all 3 Groups. Cell motility, cell growth, angiogenesis, cell 
adhesion and phosphate transport were altered in Groups 1 and 2 and ER to golgi 
vesicle transport, attachment of glycophosphatidylinositol (GPI) anchor protein, 
electron transport and barbed-ended actin filament capping were altered in Groups 2 and 
3. Protein biosynthesis was found to be altered in Group 3, with specific biosynthesis 
processes, such as glutathione biosynthesis, also showing alterations in the tumours of 
Group 1. Furthermore, cell differentiation was only significantly altered in Group 1 
tumour cultures.
Although the up-regulation of genes involved in immune response has been reported in 
PAI compared higher grade astrocytomas as discussed in Chapter 4 (Hunter et al., 2002; 
Huang et al., 2005), reduced staining of immune response genes have also been reported 
in high-grade astrocytoma compared to normal brain (Facoetti et al., 2005). Further 
investigation of immune response genes in paediatric astrocytoma is necessary to fully 
understand this pathway. The majority of significantly altered biological processes 
common to Groups 2 and 3 are characteristic of tumour development. However, several 
of the processes unique to Group 3 are not well characterised in paediatric astrocytoma. 
Glycosyl-phosphatidylinositol (GPI) anchor protein up-regulation has been linked to 
increased tumourigenesis and invasion in breast cancer (Wu et al., 2006). Furthermore, 
GPI anchor attachment protein 1 (GPAA1), located at 8q24.3, was found to be 
frequently up-regulated in hepatocellular carcinomas (Ho et al., 2006). Moreover, the 
control of barbed-ended actin filament capping regulates actin filament polymerisation 
and lamellipodia formation influencing cell migration (Carlier et al., 2003). Cell 
differentiation was also identified as a significantly altered biological process in PAI by 
Wong et al. (2005).
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The impact of differential gene expression on cellular pathways was assessed by Onto- 
tools for each cluster Group. The ranking of the focal adhesion and ECM-receptor 
interaction pathways as 1 or 2 in each tumour culture cluster is most likely a reflection 
of the samples being derived short-term cell cultures. All ranked pathways showed 
variations between the 3 tumour culture Groups, with the Wnt signalling and the cell 
cycle pathways illustrating differential gene expression in all Groups previously 
associated with tumour development (Figures 5.3 and 5.4). The hypothesis stating that 
the disruption of the cell cycle and Wnt signalling through differential gene expression 
in each Group to different extents was true. With the number of differentially expressed 
genes being greater in the more malignant tumour cultures of Group 3.
Wnt signalling has a role in both embryological development and mature tissues 
controlling cell proliferation, fate and self-renewal. Three different pathways can be 
activated by Wnt signalling molecules, including the canonical Wnt signalling pathway, 
the Wnt/planar cell polarity pathway and the Wnt/calcium pathway. This report will 
focus on the canonical Wnt signalling pathway which influences the stabilisation of p- 
catenin transcription activity and is most relevant in cancer development.
Alterations in many genes of the Wnt signalling pathway have been identified in a wide 
variety of tumours and cancer (Table 5.15). Signalling in this pathway is tightly 
regulated and controlled by several interacting mechanisms. Inhibition can occur 
through sequestration of Wnt ligands from Frizzled receptors by WIF-1 or Cer-1 (Hsieh 
et al., 1999; Piccolo et al., 1999) or through LRP5 and LPR6 receptor inactivation by 
the Dickkopf (Dkk) family of proteins via endocytosis (Mao et al., 2001). Expression 
data was not available for WIF-1 or Cer-1. However up-regulation of LRP5 and LRP6 
as well as Dkk was seen in both Group 1 and 2 tumour cultures. Furthermore, Wnt 
ligands and frizzled receptors were down-regulated in each tumour Group.
Degradation of p-catenin through independent and dependent phosphorylation controls 
cellular protein levels. Degradation of p-catenin through dependent phosphorylation 
requires recruitment to a large complex consisting of Axin, APC, GSK3p, CKIa and 
PP2A, ultimately leading to ubiquitination and protein destruction by the proteasome 
system (Ciechanover, 1998; Hinoi et al., 2000). Independent degradation involves TP53 
induction of Siahl which forms a complex with p-catenin and APC, promoting
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ubiquitination of p-catenin without GSK3p phosphorylation (Liu et al., 2001). 
Furthermore, pathway receptor activity is propagated through the dishevelled protein 
that inhibits GSK3P activity preventing p-catenin degradation.
Table 5.15 Wnt associated genes previously reported in other types o f tumour and cancer with 
differential expression and/or mutation. Taken from Ilyas., (Ilyas, 2005).
NSCLC=non-small cell lung cancer; HNSCC=head and neck squamous cell carcinoma; CLL=chronic 
lymphatic leukaemia; BCObasal cell carcinoma; GOF=gain of function; LOF=loss o f function
Most p-catenin gene (CTNNB1)  mutations are found in exon 3, leading to the loss of the 
GSK3p recognition motif. This prevents phosphorylation and degradation leading to 
increased protein concentration (Morin et al., 1997). Mutations of A PC  or Axin 
inhibiting P-catenin degradation have also been documented suggesting loss of p- 
catenin regulation is selective for mutations in proteins involved in degradation 
(Segditsas and Tomlinson, 2006). GSK3fi and PP2A  were expressed at normal levels in 
all tumour Groups; up-regulation of Axin was seen in all tumour Groups and CKIa in 
Groups 2 and 3. The down-regulation of the dishevelled  gene (D v l)  was also found in 
tumour Groups 2 and 3 as well as Siah-1 down-regulation in Group 3 tumour cultures. 
Moreover, the up-regulation of CTNNB1 and down-regulation of APC  was only found 
in the tumour cultures of Group 3 suggesting increased pathway activity. Increased p-
Cancer Type
Wnts Over-expression NSCLC, CLL, Gastric cancer, HNSCC,
WIF-1
LRP5
Frizzled
sFRPs
Down-regulation 
Down-regulation 
Over-expression 
Down-regulation 
Over-expression 
Over-expression 
Over-expression 
Over-expression 
GOF mutation
Colorectal, Ovarian, BCC 
Breast
Breast, Bladder, Mesothelioma, Colorectal 
Prostate
NSCLC, Prostate, Breast, Lung, Bladder 
Osteosarcoma
Prostate, HNSCC, Colorectal, Ovarian, Oesophageal, Gastric
Dishevelled Prostate, Breast, Mesothelioma, Cervix
Fratl
CTNNB1
Pancreatic, Oesopahgeal, Cervical, Breast, Gastric 
Gastric, Colorectal, Intestinal carcinoid, Ovarian, Pulmonary 
adenocarcinoma, Endometrial, Hepatocellular, Hepatoblastoma,
Medulloblastoma, Pancreatic, Thyroid, Prostate,
Melanoma, Pilomatricoma, Wilms tumour, Pancreatoblastoma,
Liposarcoma, Juvenile nasoparyngeal angiofibromas,
APC
Axin
LOF mutation 
LOF Mutation
Desmoia, Synovial sarcoma 
Colorectal, Melanoma, Medulloblastoma, Desmoid 
_______ Hepatocellular, Medulloblastoma_______
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catenin immunoreactivity has previously been linked to increased astrocytoma grade 
and poor prognosis (Utsuki et al., 2002).
To activate transcription, p-catenin is translocated to the nucleus where it complexes 
with members of the LEF/TCF family of proteins. These proteins serve as a p-catenin 
DNA binding domain as P-catenin itself can not directly bind DNA (Behrens et al.,
1996). Members of this transcription family were up-regulated in all tumour culture 
Groups.
The disruption of Wnt signalling through elevated levels of CTNNB1 results in constant 
activation or inhibition of a large number of target genes that may affect cellular 
processes linked to tumour development (Figure 5.48). In this study, target genes KLF4 
and CD44 were up-regulated in all tumour cultures; PLAUR was down-regulated in 
tumour culture Groups 1 and 2; PPARD  was down-regulated in tumour culture Groups 
2 and 3; and survivin was up-regulated in Group 3 tumour cultures. Over-expression of 
survivin has been correlated with poor prognosis in high-grade astrocytoma and 
inhibition of gene expression has been shown to induce caspase-dependent apoptosis 
(Blum et al., 2006; Saito et al., 2007).
Disruption of Wnt signalling has a huge impact on cellular function. Moreover, with 
Group 3 tumour cultures showing both up-regulation of CTNNB1 and down-regulation 
of APC, it is possible to suggest that disruption of the Wnt signalling pathway in these 
tumours promotes tumour development. Although Groups 1 and 2 tumour cultures do 
not demonstrate differential expression in as many genes of the Wnt signalling pathway 
as Group 3 tumour cultures, pathway signalling is still altered influencing tumour 
development.
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c-myc 8q24.21 (He et al., 1998)
Cyclin D1 11 q 13 (Tetsu and McCormick, 1999) 
PPARdelta 6p21.2-p21.1 (He et al 
Gastrin 17q21 (Koh et al., 2000)
Fas Ligand lp23 (Sansom et al., 2C 
Caspase 3 4q24 (Chen et al., 2003)
Clusterin 8p21-pl2 (Paoni et al., 2(
Survivin 17q25 (Zhang et al., 2001 
Cyclooxygenase-2 Iq25.2-q25.3 (Howe 
Fra-1 11 q l3 (Mann et al., 1999)
Osteopontin 4q21-q25 (Paoni et al., 
uPAR 19ql 3 (Mann et al., 1999)
Claudin-1 3q28-q29 (Miwa et al., 2001)
CD44 1 lp l3 (Wielenga et al., 1999) 
MMP-7/9/11/14/16 (Paoni et al., 2003) 
IGFBP-4 17ql2-q21.1 (Paoni et al., 2003)
Met 7q31 (Boon et al., 2002a)
Integrin p7 12ql3.13 (Sansom et al., 2004) 
Alpha e integrin 17pl3 (Sansom et al., 2004) 
BMP4 14q22-q23 (Kim et al., 2002a)
Hathl 4q22 (Leow et al., 2004)
FABP2 4q28-q21 (Paoni et al., 2003)
Muc2 1 lp l5.5 (Batlle et al., 2002)
KLF4 9q31 (Batlle et al., 2002)
Carbonic Annhydrasell (Batlle et al., 2002) 
EphrinBl Xql2(Batlle et al., 2002)
Muc3 7q22 (Paoni et al., 2003)
Sox9 17q24.3-q25.1 (Blache et al., 2004)
Histone deacetylase 2 (Paoni et al., 2003) 
Histocompatability 2, Ql (Paoni et al., 2003) 
P2-microglobulin 15q21-q22.2 (Paoni et al., 2003)' 
VEGF 6pl2 (Zhang et al., 2001b)
Inappropriate stem cell 
phenotype
Evasion of apoptosis
Tissue invasion and 
metastasis
Self sufficiency of 
growth signals
Insensitivity to growth 
inhibitors
Failure of terminal 
differentiation
Evasion of immune 
response
Sustained angiogenesis
Figure 5.48 This Figure illustrates genes that are affected by elevated P-catenin levels through disrupted 
Wnt signalling causing continuous expression or inhibition. These genes affect a large number of cellular 
processes that can be associated with tumour development and progression. Up-regulated genes are 
shown in red and down-regulated genes are shown in blue. Adapted from Ilyas., (Ilyas, 2005).
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Disruption of cell cycle regulators has been well documented in tumour and cancer 
development including TP53. Group 2 and 3 tumour cultures showed a 9.45 and 25.53- 
fold increase in TP53 expression respectively compared to normal controls and Group 1 
tumour cultures. Moreover, the majority of differentially expressed genes in the cell 
cycle of Group 3 tumour cultures show up-regulation suggesting that TP53 over­
expression is not halting cell cycle progression as expected. This implies increased 
TP53 transcription but lack of TP53 translocation, prolonged protein half-life, or 
reduced degradation. Both latter scenarios are linked to mutant TP53 proteins, which 
have been the focus of many studies investigating the complex interactions between 
wild-type and mutant TP53 and cancer or tumour development.
Missense mutations have been found in every central region residue of the TP53 protein 
encoded by 600 nucleotides, with some residues being targeted by one or more 
mutations in various cancers (Soussi, 2007). The most common TP53 mutations are 
missense leading to the synthesis of a stable protein that lacks specific DNA-binding 
activity and accumulates in the cell nucleus (Kato et al., 2003). Rare missense mutations 
as well as nonsense and frame shift mutations result in stable proteins with 
heterogeneous DNA-binding activity, that have partial activity on some or all target 
genes (Soussi et al., 2005).
The investigation of mutant TP53 with oncogenic properties has shown that transfection 
of mutated TP53 genes into cells without wild-type TP53 increases cell carcinogenicity. 
Furthermore, specific mutations gave cells an enhanced tumorigenic potential (Dittmer 
et al., 1993; Strano et al., 2007). Recent microarray studies have begun to identify gene 
targets of oncogenic mutant TP53 that have a role in tumour and cancer development 
(Weisz et al., 2004; Scian et al., 2004; Tepper et al., 2005; Zalcenstein et al., 2006; 
Weisz et al., 2007). Moreover, a KEGG TP53 signalling pathway has now been 
recognised (released date; 24 July 2007). Unfortunately, the Onto-Tools software is yet 
to include this pathway in the analysis programme and consequently this pathway was 
not involved in the investigations completed in this study (Figure 5.49).
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IFigure 5.49 The KEGG TP53 signalling pathway
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In this study, the cell cycle genes of Group 2 tumour cultures are down-regulated 
compared to Group 1 tumour cultures and normal controls suggesting that in these 
tumour cultures the TP53 protein is functional or is a mutant protein that is able to exert 
effects on the cell cycle. The cell cycle of Group 3 tumour cultures does not appear to 
be influenced by TP53. One possible explanation for this is that these tumours have a 
mutant TP53 protein that is no longer able to affect the cell cycle and may have 
oncogenic properties. This is an over-simplification but given the diverse function and 
mutations of this protein, is possible.
Cell cycle control is dependent on the degradation of regulatory proteins by the 
ubiquitin-proteasome system (Baker et al., 2007). Three enzymes are involved in this 
complex process including the multiprotein E3 ligase known as the anaphase promoting 
complex/cyclosome (APC/C). This enzyme plays a role in mitotic progression and cell 
cycle exit (Castro et al., 2005). In this study, components of APC/C  were found to be 
down-regulated in Group 2 tumour cultures and up-regulated in Group 3 tumour 
cultures compared to normal controls and Group 1 tumour cultures. This may be a 
reflection of cell cycle activity but deregulation of APC/C proteins has been associated 
with cancer and tumour development. The association of APC/C with different activator 
proteins at different times during the cell cycle is controlled by phosphorylation and 
ultimately governs specific cell cycle check points (Kraft et al., 2003). The two main 
co-activators are Cdc20 involved in metaphase regulation and Cdhl responsible for late 
metaphase control (Kramer et al., 2000). C dhl was expressed at normal levels in all 
tumour groups compared to normal controls, but no reliable data was available for 
Cdc20. APC/C and co-activator Cdc20 are involved in the spindle assembly check 
point, ensuring correct separation of mitotic chromosomes by inhibiting anaphase until 
each kinetichore has attached to the mitotic spindle (Rieder et al., 1994; Yu, 2002).
Other proteins involved in this check point include Bubl, BubRl, Bub3, Madl and 
Mad2, which bind to unattached kineticores and APC/C and cdc20 to generating a 
‘stop’ signal that inhibits anaphase (Sudakin et al., 2001). Bub3, M adl and M ad2 were 
up-regulated in Group 3 tumour cultures compared to normal controls, Group 1 and 
Group 2 tumour cultures. This is contradictory to the up-regulation of APC /C  and the 
overall increased cell cycle activity seen in this Group, suggesting that the spindle check 
point is failing to halt cell cycle progression.
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Dysfunction of the spindle checkpoint has been proposed as a cause of chromosome 
instability resulting in aneuploidy (Cahill et al., 1998). Mutations in mitotic checkpoint 
genes themselves have been identified as a mechanism of checkpoint impairment in 
human tumour cells (Ohshima et al., 2000; Ru et al., 2002). Furthermore, some 
aneuploid cell lines do not show mutations in spindle check point genes but do show 
alterations in gene expression (Bharadwaj and Yu, 2004). M ad2 haploinsufficiency in 
mice correlated with a 30% reduction in protein level that lead to spindle check point 
deficiencies and a high incidence of lung tumours (Michel et al., 2001). It is clear that 
small alterations in the expression of spindle checkpoint genes or mutations can disrupt 
the check point influencing chromosome stability and aneuploidy. Although still to be 
discussed in detail, the tumour cultures of Group 3 showed increased whole 
chromosome CNAs providing further evidence for spindle check point disruption in this 
tumour group.
DNA replication involves the precise duplication of the entire genome once per cell 
cycle. Each chromosome contains starting points of replication or origins of replication. 
These origins are tightly regulated, only becoming active during the S phase of the cell 
cycle (Tachibana et al., 2005). Minichromosome maintenance proteins (MCMs 2-7) are 
involved in origin activation by binding to or ‘marking’ DNA for replication. 
Phosphorylation of these proteins during replication displaces them from the DNA, 
consequently the DNA is no longer marked ensuring replication is not repeated (Bell 
and Dutta, 2002).
MCM proteins have been used as biomarkers of cell cycle state as they are highly 
expressed in all phases of the cell cycle and degraded on cycle exit (Stoeber et al.,
2001). Furthermore, in normal stratified epithelium MCM protein expression is only 
found in the basal proliferative compartment and not in the terminally differentiated 
keratinocytes. Pre-invasive lesions cause the expansion of the proliferative compartment 
and resulting neoplastic cells found on the surface of the epithelium are positive for 
MCM proteins (Freeman et al., 1999). MCM proteins have been found to be highly 
expressed in a variety of malignant cancers and pre-cancerous cells (Lei, 2005). In this 
study MCM proteins 2, 4, 5 and 6 were found to be over-expressed in Group 3 tumour 
cultures compared to normal controls and Group 1 and 2 tumour cultures suggesting 
disruption of DNA replication mechanisms. Moreover, the over-expression of MCM
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protein 2 in meningiomas correlated with an increased risk of recurrence (Hunt et al.,
2002), and over-expression in oligodendroglioma correlated with increased tumour 
grade and poor prognosis (Wharton et al., 2001).
Differential expression of TP53, APC/C  and M CM  play crucial roles in the disruption of 
cell cycle regulation and DNA replication in the astrocytomas of this study. It is 
possible that these alterations lead to increased proliferation, decreased apoptosis and 
disrupted DNA replication causing chromosome copy number alterations.
Comparison of adult GBMIV and paediatric astrocytoma short-term cell culture 
expression profiles
The clustering of adult and paediatric astrocytoma short-term cell cultures and the 
expression profiles of these tumour cultures revealed some unexpected findings. The 
clustering of 5 of the adult tumour cultures with the 3 paediatric cultures that show 
alterations of whole chromosomes or arms, suggests that these paediatric tumours may 
have a genotype more comparable to that of adult astrocytoma than other paediatric 
astrocytoma. Moreover, the clustering of IN2675 and IN 1566 that showed no whole 
chromosome alterations suggests that the expression profile of these tumours is similar 
to that of adult astrocytoma but the mechanisms involved in tumour development are 
different. Furthermore, GBMIV cultures IN2675, IN I566, IN699, IN I523 and IN I79 
are from paediatric patients that are 14, 6.4, 15, 10 and 13 years of age respectively, 
suggesting that a sub-group of GBMIV in older paediatric patients are more comparable 
to adult GBMIV than other paediatric GBMIV patients of a similar age or younger 
GBMIV patients. The remaining paediatric GBMIV tumours, IN2087 and INI 163, that 
cluster separately from those previously mentioned are tumours are from patients aged 3 
and 15.9 years at diagnosis.
The investigation of genes commonly differentially expressed in adult astrocytoma in 
the adult and paediatric short-term cell cultures studied here reveal some consistent 
patterns, but no correlations with tumour grades or short-term cell culture cluster 
Groups were identified. The integration of the adult and paediatric short-term cell 
culture samples when completing this clustering approach also suggests that the impact 
of cell culture may influence gene expression, the majority of which are involved in the 
cell cycle, promoting integration.
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The cluster of 94 gene probe sets that showed over-expression in the sub-group of 
Group 3 tumour cultures correlated with 53 probe sets that characterised the paediatric 
short-term cell culture Groups. The remaining 41 probes, representing 38 genes, were 
only found in the 4870 gene probe set that characterise the Groups when the adult short­
term cell cultures are added (Table 5.9).
The function of these 38 up-regulation genes may provide astrocytoma cells with 
selective advantages. These genes encode proteins that are mostly involved in the cell 
cycle, proliferation and chromosome instability. Those genes found to be over­
expressed that have been shown to promote cell proliferation include CCNB2, CCNB1 
and CDC6. Furthermore, a large number of genes have functions linked to mitosis, 
spindle formation and DNA replication including BUB IB, AURKB , NUSAP1, CENPF, 
RCF4, HMMR, CKAP2, MCM3 and PTTG1. Several genes were also associated with 
chromosome structure including NASP, LBR and A URKB.
Of the remaining genes with known functions RRM1 has been shown to be involved in 
chemoresistance, RAD21 is thought to play a role in DNA repair and MELK inhibits 
specific pro-apoptotic signals. Moreover, the gene coding for the Ki-67 antigen is used 
to establish the mitotic index of malignancies and up-regulation is associated with more 
aggressive tumours.
From this analysis it is clear that the tumour cultures of the Group 3 sub-group show 
additional differential gene expression that can be linked to an aggressive malignant 
phenotype. As this sub-group of Group 3 consists of adult and paediatric GBMIV short­
term cell cultures, the differential gene expression of these genes in paediatric tumours 
may suggest a tumour that is more similar adult GBMIV.
Genomic CNAs in paediatric astrocytoma short-term cell cultures
In total, 37 clones were found to be altered in 16% of tumour cultures or more. In the 
majority of cultures these were single clone alterations, but in specific cases clone 
alterations were part of whole chromosome or arm gains or losses. These included, loss 
at 6q25.1-6q25.3 in IN2044, loss of 7p21 in IN2012, gain of clones located on 
chromosome 7 in tumours IN3032, IN2017, IN I523, IN I79 and IN699, loss of 2q21- 
2q22 and 4ql3-4ql3 in IN1523, loss of 6q25.3 in IN699 and gain of 5pl5.2, 9q32-
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9q33.3, Ip34.3-lp36.11 and Ip31.1-lp31.3 in IN699. In total, 21 of the 37 clones were 
found in regions of LCV in the normal population, suggesting that a number of these 
alterations may either predispose individuals to tumour development or are not involved 
in tumour development. O f the clones not located in regions of LCV, a large number 
were located on 7q (25%), a region linked to astrocytoma development.
O f the clones that showed alterations of 2-4 adjacent clones several over-lapped with 
the single clones. These included a region at 16pl 1.2 altered in tumour cultures IN3013, 
IN2591, IN2017 and IN179, a region at 7ql 1.23 altered in cultures IN I523, IN179 and 
IN699, a region at 6ql2 altered in culture IN2110 and a region at 2ql4 altered in culture 
IN3013.
When investigating the number of individual clones altered in each tumour culture, 
IN 1523 showed the most clone gains and losses (1031). However, IN699 does show the 
most chromosome alterations. This is in part due to IN 1523 showing several alterations 
of whole chromosomes compared to regions in IN699, but also the number of clones 
that were accepted as reliable during experimental analysis. The aCGH experiment 
investigating tumour culture IN699 had a high number of clones, 34%, that were 
deemed unreliable. This ranged from 2-45% in the remaining cultures investigated and 
explains the large difference in single clones altered in each culture case (refer to the 
Supplementary Data CD for clones deemed unreliable for each individual aCGH 
experiment).
Copy number alterations and astrocytoma predisposition
Specific germline gene mutations have long been associated with an increased risk or 
predisposition to disease including TP53 mutations and the risk of Li-Fraumeni 
Syndrome and BRAC1 mutations in breast cancer (Frebourg, 1997a; Gilmore et al.,
2003). The characterisation of frequent LCVs involving gain or loss of hundreds of 
kilobases of genomic DNA in phenotypically normal individuals has suggested that 
some regions of LCV maybe involved in disease predisposition (Iafrate et al., 2004). A 
recent study that investigated the risk of cancer in 2561 patient with constitutional 
chromosome deletions found that an increased risk of renal cancer was seen in patients 
with 1 lp  loss, an increased risk of eye cancer was found in patients with loss of 13q and
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loss of l l q  increased the risk of vulval and vaginal cancer and anogenital cancers 
(Frebourg, 1997b; Gilmore et al., 2003; Swerdlow et al., 2008).
Few studies have investigated germline genomic alterations in adult or paediatric 
astrocytoma patients. Diaz de Stahl et al. (2005) identified a small gain on chromosome 
22q in both germline and adult GBMIV DNA in 28% of patients investigated. This 
region included the genes TOP3B , involved in DNA replication, and TAFA5. No CNA 
in this region were identified in the tumours of this study. The study by Braude et al. 
(2006) concluded the CNA at 14ql2 present in 50% of chronic myeloid leukaemia 
(CML) and paediatric solid tumours compared to an incidence of 10% in somatic DNA 
of healthy controls suggested that DNA alterations at this site may predispose 
individuals to tumour development. This region needs further investigation in paediatric 
astrocytoma as discussed in this Chapter and Chapter 4. Furthermore, a study 
investigating cancer incidence in women with Turner syndrome found that the risk of 
CNS tumours, specifically meningioma and childhood brain tumours, was significantly 
increased in this patient cohort. Moreover, the patient in this study with tumour IN1419 
had been diagnosed with Turner syndrome and showed no other CNAs aside from loss 
of 1 copy of chromosome X. Gain of 7q was the most frequent large CNA found in the 
short-term cultures of this study but has not previously been associated with 
predisposition to astrocytoma. However, this alteration has been linked to tumour 
development and progression as discussed later in this Chapter.
Somatic mutations in cancer candidate genes have also been identified in patients with 
GBMIV including TP53 located at 17p l3.1, NF1 located at 17ql 1.2, EPHA3 located at 
3p ll.2 , MLL3 located at 7q36.1, TECTA located Ilq22-q24, FBXW7 located at 
4q31.3, and OBSCN  located at lq42.13 (Thiel et al., 1995; Fulci et al., 2002; 
Balakrishnan et al., 2007). No alterations in these regions were identified in the tumours 
of this study. However, larger regions encompassing these loci, most likely to be 
involved in tumour development and/or progression rather than predisposition, were 
found including 17p l3.1 gained in IN699, 7q36.1 gained in 4 tumours including 
IN2017, IN3032, IN I79 and IN I523, chromosome 4 was lost in IN I523 and IN699 and 
lq32-lpter was lost in IN699. Any of the 21 loci identified by single clone alterations in 
this study and located in regions of LCV common in the normal population, could be
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investigated further, to establish if these are germline alterations and may predispose 
individuals to tumour development.
Correlation of CNAs with differential gene expression in paediatric astrocytoma 
short-term cell cultures
Reliable expression data was not available for the majority of single clone alterations 
investigated. The most frequently altered clone was located at Ipl3.3-lp21.1 and a 
cluster of amylase genes, including a-amylase, mapped to the clone location. No 
reliable expression data was available for these genes, but reduced expression of a- 
amylase has been found in AAIII and GBMIV compared to normal brain (Kotonski et 
al., 2001). The gene COL11A1 is adjacent to the clone at Ipl3.3-lp21.1 and was found 
to be under-expressed in all astrocytoma cultures. Down-regulation can be explained by 
clone loss at l p l 3.3-lp 2 1.1 in 60% of cultures. An additional mechanism such as 
promoter hypermethylation is likely to be involved in the down-regulation of COL11A1 
in the remaining 40% of tumour cultures.
CNAs were seen in 47% of cultures at 14ql2 and were randomly distributed between 
the 3 tumour culture Groups. In total, 28% of cultures showed gain and 19% showed 
loss, compared to 82% of PAI biopsies that displayed loss in Chapter 4. As previously 
discussed, 14ql2 is a region of LCV in the normal population and alterations at this site 
have been associated with solid tumours in children (Braude et al., 2006). A cluster of 
genes including RPL26P , BTF3P3 and LOC387978  map to the exact clone location at 
14ql2, but no reliable expression data was available. The gene FOXG1B  is adjacent to 
the clone at 14ql2 and was found to be under-expressed in all PAI biopsies investigated 
in Chapter 4. Moreover, FOXG1B  expression was shown to be down-regulated in 91% 
of the paediatric astrocytoma cultures studied here; IN699, INI 523 and IN I79 showed 
up-regulation. A recent study identified loss at 14ql2 in 75% of hepatoblastoma but 
over-expression of FOXG1B  in 81% of cases. This was suggested to be the result of 
errors in duplication/deletion in adjacent regions at 14ql2 (Adesina et al., 2007). CNAs 
at this site and the involvement of FOXG1B  in paediatric astrocytoma require further 
investigation.
A clone located a lOq 11.22 was found to be lost in ten tumours that were randomly 
distributed between the 3 tumour culture Groups. This correlated with down-regulation
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of ANXA8 in all tumours. This gene is a calcium-dependent phospholipid-binding 
protein previously identified as a blood anticoagulant (Hauptmann et al., 1989). Up- 
regulation o f ANXA8 has been found in acute promyelocytic leukaemia and breast 
cancer as a marker or poor prognosis (Sarkar et al., 1994; Stein et al., 2005).
The up-regulation of EPHA2 located at Ip35.1-p36.21 has been associated with 
aggressive malignancies and tumour progression (Fang et al., 2005). This is 
contradictory to this study, which found under-expression of this gene seen in all 
tumour cultures compared to normal controls and clone loss at Ip35.1-p36.21 in 8 
cultures. Furthermore, the up-regulation of ephrin-Al in U251 adult GBMIV cells and 
consequent down-regulation of EPHA2 inhibits migration, cell proliferation, and 
adhesion-independent growth highlighting a key role for EPHA2 in tumourigenesis (Liu 
et al., 2007). This suggests that while the down-regulation of EPHA2 may inhibit 
tumourigenesis in adult astrocytoma, the role of this gene in paediatric astrocytoma 
needs further investigation. It may be that the down-regulation of EPHA2 in low-grade 
astrocytoma does inhibit tumour growth but that in high-grade astrocytomas alternative 
mechanisms promote tumour development.
TJP1 located at 15 q l3.1 was found to be over-expressed in Group 2 and 3 tumour 
cultures and correlated with gain of clone AC 102941.9 in 7 cultures. In contrast to the 
expression profile, 5 of the 7 cultures that showed gain of clone AC 102941.9 cluster in 
Group 1. This gene encodes a protein located on the cytoplasmic membrane surface of 
intercellular tight junctions and is involved in signal transduction at cell-cell junctions. 
Altered expression of TJP1 has been associated with the differentiation of liver 
metastases and colorectal cancer. Furthermore, the up-regulation of this gene has been 
shown to contribute to melanoma ontogenesis (Kaihara et al., 2003; Smalley et al.,
2005).
ARFHGEF4 was down-regulated in all paediatric astrocytoma cultures and is located at 
2q21-q22, a region found to be lost in 5 tumour cultures. The protein of this gene (also 
known as APC stimulated guanine nucleotide exchange factor (Asef)), is a key regulator 
of APC and actin cytoskeleton reorganisation. Mutant APC binds Asef constitutively 
activating the protein and increasing cellular migration (Kawasaki et al., 2003). 
Furthermore, adenoma cells of APC knock-out mice have a similar proliferation rate to
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normal crypt epithelium, but the cells lack direction suggesting that aberrant migratory 
behaviour may be important for tumour formation as well as progression and invasion 
(Oshima et al., 1997; Akiyama and Kawasaki, 2006). The evidence does suggest that 
the down-regulation of A se f  may contribute to paediatric astrocytoma development 
through disruption of cytoskeleton organisation.
COL8A2, located at Ip34.3-lp36.11, was up-regulated in Group 2 tumour cultures, G10 
(BUD31), located at 7q21.1-7q21.1, was up-regulated in Group 2 and 3 tumour cultures 
and SHCBP1, located at 16p 11.1-16p 11.1, was up-regulated in Group 3 cultures. Roles 
for these genes in tumour development have not been characterised. However, COL8A1 
from the same protein family as COL8A2 was found to be up-regulated in 
gastrointestinal stromal tumours and has been linked to malignant tumours with an 
increased risk of recurrence (Koon et al., 2004).
TRIP6, located at 7q21.1-7q21.1, was up-regulated in Group 2 and 3 tumour cultures. 
The protein of this gene functions as a coactivator for AP-1 and NF-kB, acting as a 
molecular platform for transcription factors (Kassel et al., 2004). This is a key signalling 
cellular pathway often disrupted in tumour development, suggesting a role for this gene 
in tumourigenesis.
ARPC1A, located at 7q21.1-7q21.1, was up-regulated in Group 3 tumour cultures. The 
protein encoded by this gene is a subunit of the Arp2/3 complex. This complex is 
involved in the organisation of the actin cytoskeleton. Moreover, this complex was 
found to be enriched in the lamellipodia of fibroblasts on stimulation with PDGF, 
suggesting that this protein may be involved in cell motility (Machesky et al., 1997).
The genes SGCE  and SLC25A13 were up-regulated in all paediatric astrocytoma 
cultures and are located at 7q22.1, which showed gain in 5 tumour cultures. Mutations 
in SLC25A13 have been characterised in adult-onset citrullinemia (type II, CTLN2), a 
disease associated with a high incidence of hepatocellular carcinoma (Tsai et al., 2006). 
This suggests that disruption of this gene may be involved in tumourigenesis. The 
SGCE  gene encodes the epsilon member of the sarcoglycan family of proteins and is 
highly expressed in the brain (Nishiyama et al., 2004). A role for this gene in tumour 
development remains to be determined.
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Although no reliable expression data was available for the genes located at 19pl3.2, this 
region has been identified as a cancer susceptibility locus in breast cancer. The over­
expression of ICAM1 in this region strongly correlates with breast tumourigenesis 
(Rosette et al., 2005). Moreover, 5 tumour cultures showed gain of a single clone at 
19pl3.2. Other regions of CNAs that could not be correlated with differential gene 
expression have shown alterations in other types of cancer including 16pl 1.2 in small 
cell lung carcinoma and breast cancer, 19pl3.2 in ependymoma, 7p21 in ependymoma 
and prostate cancer, and 7q 11.23 in prostate cancer and cholangiocarcinoma (Levin et 
al., 1994; Ichikawa et al., 2000; Chariyalertsak et al., 2005; Modena et al., 2006; Stange 
et al., 2006). Furthermore, loss of a region at 7qll.23  was also found 7 PAI biopsies 
investigated in Chapter 4
Individual tumour cultures showed alterations of multiple adjacent clones ranging from 
2 to 218 (Table 5.12). The investigation of these clones in individual cultures showed 
correlation with differential gene expression in the same regions. Of the differentially 
expressed genes that correlated with adjacent clone alterations in specific cultures, 5, 
including ARFHGEF4, have functions that may promote tumour development or 
provide the specific tumour with a selective advantage. CASP6 is a member of the 
cysteine-aspartic acid protease (caspase) family. Caspase activation plays a central role 
in the initiation of cell apoptosis, consequently the down-regulation of this gene in 
tumour IN2122 may inhibit apoptosis. Reduced CASP6 expression has been found in 
approximately 50% of gastric cancers, as well as mutations, although at a low frequency 
(Yoo et al., 2004; Lee et al., 2006). Caspase-8, -3 and -6 have also been shown to 
directly proteolyse p-catenin in vitro (Van de Craen et al., 1999).
Previously, 4q32-34 has been characterised as a susceptibility locus for familial 
pancreatic cancer. PALLD, a gene located in the region that encodes a component of the 
cytoskeleton that controls cell shape and motility, was found to be mutated in all 
affected family members but not the unaffected members. Furthermore, over-expression 
of PALLD  was reported in the tissues from precancerous dysplasia and pancreatic 
adenocarcinoma in both familial and sporadic disease. Transfection of wild-type and 
mutant PALLD  gene constructs into HeLa cells, initiated several phenotypic effects. The 
cells expressing the mutant construct exhibited cytoskeletal changes, abnormal actin 
bundle assembly and an increased migration. This suggests that PALLD  over-expression
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may contribute to cell invasion and migration in tumour IN2110 (Pogue-Geile et al.,
2006).
PDIA2 is specifically up-regulated in response to hypoxia/brain ischemia in astrocytes. 
Furthermore, the over-expression of this gene in neurons protects against apoptotic cell 
death induced by hypoxia/brain ischemia. The up-regulation of PDIA2 in neuronal cells 
significantly inhibited hypoxia-triggered DNA fragmentation. This was not seen when 
the DNA fragmentation was induced by nitric oxide or staurosporine. This suggests that 
PDIA2 is a crucial regulatory protein involved in cell death and therefore up-regulation 
may result in tolerance against ischemic stress in tumour IN I78 (Ko et al., 2002).
Multidrug resistance can be caused by ATP-binding cassette (ABC) transporters that 
function as drug efflux pumps. The over-expression of ABCA3 was found in 42 
samples from children with acute myloid leukaemia. Furthermore, the median 
expression of ABC A3 was higher in 21 patients who did not achieve remission after the 
first course of chemotherapy. Incubation of leukaemia cell lines with a number of 
different cytostatic drugs increased ABCA3 expression. Moreover, the down-regulation 
of ABCA3 by small interfering RNA sensitized cells to specific chemotherapeutic 
agents (Steinbach et al., 2006). This suggests that the up-regulation of this gene in 
tumour IN I78 may increase drug resistance in this tumour.
In all tumor cultures except IN699, 40-68% of differentially expressed genes that 
correlated with CNAs involving more than 2 clones were involved in the profile of the 
4682 probe sets used to characterise the clustered tumour culture Groups. In culture 
IN699 this was reduced to 0-55%. Figure 5.50 illustrates a significant difference 
between the mean percentage of differentially expressed genes located in regions of 
alteration and also involved in the profile of the 4682 probe sets for culture IN699, 
culture IN 1523 and the regions altered in the remaining cultures that were larger than 4 
adjacent clones. Regions of alteration involving 4 clones or less were not included in 
this approach as only a small number of genes in these regions showed differential gene 
expression. A significant difference in the mean number of these 3 Groups was 
established using a 1-WAY-ANOVA (p = 0.0003). This suggests that CNAs are 
influencing differential gene expression involved in a common tumorigenic profile as 
well as additional genes that may provide individual tumours with selective advantages,
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promoting tumour development. The lower percentage of differentially expressed genes 
in culture IN699 that correlate with the common tumorigenic profile suggests an 
increase in the number of differentially genes that are specific to this tumour and may 
provide a selective advantage.
Figure 5.50 This Figure illustrates the significant difference between the mean percentages of 
differentially expressed located in regions of CNA and involved in the profile of the 4682 probe sets for 
tumour IN699, tumour IN 1523 and other tumours.
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As an example of relationship between CNAs and differentially expressed genes 
common to the tumorigenic profile and those specific to an individual tumour, the 
expression profile of 53 differentially expressed genes that correlated with gain of 2q21- 
q31.2 in IN699 is illustrated in Figure 5.51. The top profile shows 19 genes that 
correlate with the 4682 differentially expressed probe sets used to characterise the 
culture clusters. The bottom profile illustrates the 34 differentially expressed genes in 
IN699 only (the genes showed a 2-fold up-regulation in IN699 compared to the 
remaining tumours). The gene expression profile of the 34 genes shows a constant 
expression in all tumours (variations in specific tumours can be seen) and up-regulation 
in IN699, compared to the profile of the 19 genes that shows a continuous increase in 
expression from Group 1 to 3 tumour cultures.
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Figure 5.51 The expression profile of 53 differentially expressed genes that correlated with gain of 2q21- 
q31.2 in IN699.
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The top profile (a) illustrates the 19 genes also found in the 4682 genes characterising the tumour clusters. 
The bottom profile (b) illustrates the 34 differentially expressed genes in IN699.
To establish whether or not the genes up-regulated in IN699 may provide the tumour 
with a selective advantage, the functions of 34 genes showing up-regulation in IN699 
only were studied in detail. Table 5.16 illustrates the fold change and functions as 
described by the National Centre for Biotechnology Information (NCBI) web site 
Entrez Gene (www.ncbi.nlm.nih.gov/entrez) of 16 characterised genes from the 34 that 
showed a 2-fold up-regulation in tumour culture IN699 only. The functions of these 
genes are linked to cellular processes and mechanisms that if disrupted could promote
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tumour development. Furthermore, several of these genes have already been associated 
with various cancers.
Table 5.16 The fold change and functions for 16 o f the 34 genes differentially expressed in tumour 
culture IN699 that correlated with gain o f 2q21-q31.2 (as described by the NCBI web site Entrez Gene).
Fold
Change
Common
Name
Description according to NCBI Locus Link
8.47
2.76
179.86
11.71
33.00
2.79
3.57
2.78
147.93
2.28
AD024
ATF2
CHRNA1
DLX2
GAD1
GORASP2
HOXD4
HOXD9
ITGA6
MTX2
This gene encodes a protein that may be involved in kinetochore-microtubule 
interaction and spindle checkpoint activity.
This gene encodes a transcription factor that is a member of the leucine zipper 
family o f DNA binding proteins. The protein forms a homodimer or 
heterodimer with c-Jun and stimulates CRE-dependent transcription. The 
protein is also a histone acetyltransferase (HAT) that specifically acetylates 
histones H2B and H4 in vitro; thus it may represent a class of sequence- 
specific factors that activate transcription by direct effects on chromatin 
components.
The muscle acetylcholine receptor consists of 5 subunits of 4 different types: 2 
alpha isoforms and 1 each of beta, gamma, and delta subunits. This gene 
encodes an alpha subunit that plays a role in acetlycholine binding/channel 
gating.
Members o f the Dlx gene family contain a homeobox that is related to that of 
Distal-less (Dll), a gene expressed in the head and limbs of the developing 
fruit fly. The Distal-less (Dlx) family o f genes comprises at least 6 different 
members, DLX1-DLX6. The DLX proteins are postulated to play a role in 
forebrain and craniofacial development.
This gene encodes one of several forms o f glutamic acid decarboxylase, 
identified as a major autoantigen in insulin-dependent diabetes. A pathogenic 
role for this enzyme has been identified in the human pancreas since it has 
been identified as an autoantigen and an autoreactive T cell target in insulin- 
dependent diabetes. This gene may also play a role in the stiff man syndrome. 
Deficiency in this enzyme has been shown to lead to pyridoxine dependency 
with seizures.
The Golgi complex plays a key role in the sorting and modification o f proteins 
exported from the endoplasmic reticulum. The protein encoded by this gene is 
involved in establishing the stacked structure o f the Golgi apparatus.
This gene belongs to the homeobox family o f genes that encode a highly 
conserved family o f transcription factors. These transcription factors play an 
important role in morphogenesis in all multicellular organisms. Mammals 
possess four similar homeobox gene clusters, HOXA, HOXB, HOXC and 
HOXD, located on different chromosomes, consisting of 9 to 11 genes 
arranged in tandem.
As HOXD4
The ITGA6 protein product is the integrin alpha chain alpha 6. Integrins are 
integral cell-surface proteins composed of an alpha chain and a beta chain 
which are known to participate in cell adhesion as well as cell-surface 
mediated signalling.
The protein encoded by this gene is highly similar to the metaxin 2 protein 
from mouse, which has been shown to interact with the mitochondrial 
membrane protein metaxin 1. Because o f this similarity, it is thought that the 
encoded protein is peripherally associated with the cytosolic face of the outer 
mitochondrial membrane and be involved in the import of proteins into the 
mitochondrion.
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3.89 PDKl Pyruvate dehydrogenase (PDH) is a mitochondrial multienzyme complex that
catalyzes the oxidative decarboxylation o f pyruvate and is one of the major 
enzymes responsible for the regulation o f homeostasis of carbohydrate fuels in 
mammals. The enzymatic activity is regulated by a 
phosphorylation/dephosphorylation cycle.
2.85 POHl POH1 (pad one homolog-1) is a component of the 26S proteasome, a
multiprotein complex that degrades proteins targeted for destruction by the 
ubiquitin pathway.
4.03 RBMS1 This gene encodes a member of a small family of proteins which bind single
stranded DNA/RNA. The proteins o f this family have been implicated in the 
diverse functions o f DNA replication, gene transcription, cell cycle 
progression and apoptosis. Several isforms o f this gene were isolated by virtue 
o f their binding to either strand of an upstream element of c-myc (MSSPs), or 
by phenotypic complementation o f cdc2 and cdcl3 mutants of yeast (scr2), or 
as a potential human repressor o f HIV-1 and ILR-2 alpha promoter 
transcription (YC1).
2.07 SSB La is involved in diverse aspects o f RNA metabolism, including binding and
protecting 3-prime UUU(OH) elements o f newly RNA polymerase Ill- 
transcribed RNA, processing 5-prime and 3-prime ends of pre-tRNA 
precursors, acting as an RNA chaperone, and binding viral RNAs associated 
with hepatitis C virus.
3.03 TANK The TRAF (tumor necrosis factor receptor-associated factor) family of
proteins associate with and transduce signals from members of the tumor 
necrosis factor receptor superfamily. The protein encoded by this gene is 
found in the cytoplasm and can bind to TRAF1, TRAF2, or TRAF3, thereby 
inhibiting TRAF function by sequestering the TRAFs in a latent state in the 
cytoplasm. For example, the protein encoded by this gene can block TRAF2 
binding to LMP1, the Epstein-Barr virus transforming protein, and inhibit 
LMP1 -mediated NF-kappa-B activation.
2.96 WASPIP This gene encodes a protein that plays an important role in the organization of
______________________ the actin cytoskeleton._________________________________________________
The involvement of ATF2 in MAPK signalling and tumour cell invasion has previously 
been investigated in breast tumour and GBMIV cells (Song et al., 2006; Dziembowska 
et al., 2007). A central role for the cholinergic receptor, nicotinic, alpha 1 (muscle) 
(CHRNA1) in the regulation of growth factor-induced endothelial cell migration 
provides evidence that this gene is involved in tumour development (Ng et al., 2007). 
The differential gene expression of HOXD4 and HOXD9 has been associated with acute 
lymphoid malignancies and esophageal squamous cell carcinomas respectively. The up- 
regulation of ITGA6 may be involved in increased Akt signalling in breast cancer (Shen 
and Falzon, 2006).
The investigation of differential gene expression that correlated with gain of 2q21-q31.2 
in tumour IN699 provided evidence that CNAs may influence differential gene 
expression of genes involved in a common tumour profile as well as specific genes in 
individual tumours. Moreover, it has been shown that differentially expressed genes in a
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region of CNA in one tumour are also part of a common tumourigenesis profile in other 
tumours that do not show CNA in the same region.
Gain of part or all of chromosome 7 and correlation with gene expression in 
paediatric astrocytoma short-term cell cultures
Gain of part or all o f chromosome 7 was the most common chromosome alteration 
found in the paediatric astrocytoma short-term cell cultures studied here. Furthermore, 
all 5 cultures with this CNA clustered in Group 3 including the PAI, IN2017. Of the 5 
patients with tumours showing chromosome 7 alterations, four died due to their tumour 
and 1 remains alive (IN2017).
In total, 16 genes located on chromosome 7 showed a 2-fold and significant up- 
regulation in expression in tumours with gain of part or all of chromosome 7. 
Furthermore, all o f these genes correlate with the 4682 probe sets that were used to 
characterise the tumour culture clusters. The profile of these genes in Figure 5.42 shows 
a continuous increase in expression between Group 1 and 3 tumour cultures. Moreover, 
5 of these genes have functions previously linked to cancer or tumour development 
including astrocytoma.
The over-expression o f calcium binding protein SRI has recently been described as a 
marker of GBMIV (Yokota et al., 2006) Furthermore, the over-expression of the SRI 
protein in multi-drug resistant (MDR) leukaemia cells lines led to reduced cytosolic 
calcium levels and increased resistance to apoptosis through the up-regulation of Bcl-2 
and decreased level o f Bax. This suggests that SRI plays a role in MDR via the 
regulation of apoptosis pathways (Qi et al., 2006).
PBEF1 encodes a protein that is involved in the biosynthesis of nicotinamide adenine 
dinucleotides. In addition, to functions promoting vascular smooth muscle cell 
maturation and inhibition of neutrophil apoptosis, PBEF1 has been shown to promote 
angiogenesis via activation of mitogen-activated protein kinase ERK-dependent 
pathway in adypocytes (Kim et al., 2007). Furthermore, this protein has been shown to 
activate migration, invasion and tube formation in human umbilical vein endothelial 
cells (Kim et al., 2007). Differential expression of PBEF1 was also shown between drug 
resistant and sensitive blasts in acute myeloid leukaemia (Eisele et al., 2007).
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The protein encoded by CAPZA2 is the alpha subunit of the barbed-end actin binding 
protein Cap Z. By capping the barbed end of actin filaments, Cap Z regulates the growth 
of the actin filaments. Furthermore, this gene is located in a gene cluster found to be 
amplified on chromosome 7 in more than 20% of GBMIV investigated (Mueller et al.,
1997).
The protein encoded by the ABCF2 gene is a member of the superfamily of ATP- 
binding cassette (ABC) transporters. ABC proteins transport various molecules across 
extra- and intracellular membranes. Copy number gains of this gene have been 
associated with a drug resistant phenotype in a variety of cancers (Yasui et al., 2004). 
Up-regulation of ABCF2 has also been found in clear cell adenocarcinomas of the ovary 
and the uterine corpus (Nishimura et al., 2007).
Gain of chromosome 7 has previously been associated with reduced survival in adult 
DAII, AAIII and GBMIV (Kunwar et al., 2001; Wessels et al., 2002; Arslantas et al.,
2004). It has been suggested that the gain of chromosome 7 accumulates with age in 
GBMIV (Zuber et al., 2002) and gain of 7q has been proposed as an early event in the 
initiation of adult astrocytoma (Schrock et al., 1996). Furthermore, radiation resistant 
adult GBMIV cells showed gain o f 3 regions on chromosome 7 (Misra et al., 2006). 
Part of one of these regions (7q21.1-7q22.1) showed gain in all 5 of the paediatric 
astrocytoma short-term cell cultures with alterations on chromosome 7 studied here, 
suggesting that resistance to radiation may also be linked to up-regulation of genes on 
chromosome 7.
In this tumour cohort, 5 patients with tumour cultures showing gain of part or all of 
chromosome 7 and 2 patients with tumours that showed alterations of 6q and 7p were 7 
years of age or above, suggesting that whole chromosome or arm alterations may be 
more common in tumours of older children. However, this was not found to be 
significant when comparing the number of children above 7 years of age with tumour 
cultures that showed whole chromosome or arm alterations (two-sided Fisher’s Exact 
Test p = 0.0721).
254
Further discussion of paediatric astrocytoma short-term cell culture Groups 1, 2 
and 3
The tumour cultures with multiple whole chromosome or arm alterations all clustered in 
Group 3. Figure 5.53 illustrates the significant difference between the number of tumour 
cultures with whole chromosome or arm alterations in Group 3 compared to Groups 1 
and 2 and this is independent of tumour grade (Chi-square test p = 0.0387). However, 
this may be due to the small number of tumours with whole chromosome alterations and 
the small number of AAIII in this study.
Figure 5.53 This graph illustrates the significant increase in tumours with whole chromosome
or arm alterations in Group 3
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In this study, paediatric astrocytoma cultures cluster in 3 clear Groups, each with a 
specific expression profile. The profiles of Group 1 and 2 tumour cultures appear to be 
characteristic of predominantly low-grade tumours with the profile of Group 3 tumour 
cultures being associated with predominantly high-grade tumours. The expression 
profile is a reflection of CNAs, in that the majority of tumour cultures with multiple
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whole chromosome or arm alterations cluster in Group 3, suggesting that gene dosage of 
multiple genes is influenced by CNAs in these tumours. The expression profile of the 
remaining tumour cultures in Group 3 that show only a small number of single 
alterations, may be due to alternative mechanisms other than CNAs or CNAs that are 
smaller than 1MB and undetectable by aCGH. Tumour short-term cultures that cluster 
in unexpected groups can be explained to a certain extent by specific tumour 
characteristics, including the GA variant of tumour IN3032; the single clone CNAs 
found in IN1495, IN1419, IN178 and IN1262 and the gain of chromosome 7q in tumour 
IN2017.
The clustering o f these tumour short-term cultures predominately by grade does suggest 
that these cultures are representative of the tumour of origin with some of high-grade 
cultures showing large and more frequent CNAs. As discussed in the introduction the 
majority of paediatric astrocytomas previously investigated (>70%) have a normal 
karyotype (Bhattachaijee et al., 1997), therefore only small number of tumours were 
expected have abnormal complex karyotypes. However, as the short-term cultures were 
derived from tumour biopsy tissue, this approach may have introduced non-tumorigenic 
cells into the culture or generated a mixed clonal population as discussed in Chapter 3. 
This may also explain the expression profiles and clustering of tumour cultures IN 1495, 
IN1419, IN178 and IN 1262. However, given that previous cytogenetic studies have 
only identified a small number o f abnormal karyotypes in paediatric astrocytoma and 
the differential expression profiles o f all tumour cultures here, this is unlikely and it is 
probable that alternative mechanisms are influencing gene expression or that CNAs 
smaller the 1KB are present in these short-term tumour cultures and undetectable by the 
approach used here.
It is also important to recognise that the tumour cluster Groups may be a representation 
of tumour heterogeneity. This study involved short-term cell cultures of passage 8 or 
less and consequently the expression profile, although influenced by short-term cell 
culture, has not undergone the changes associated with long-term culture or that of cell 
lines. The profiles may not be representative of the majority clone within each tumour 
and it is also possible that less common clones capable of growing in an in vitro 
environment were grown during culture. Moreover, it is also feasible that the tumour 
Group expression profiles are a reflection of tumour region representing the tumour
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periphery or a more central area of the tumour mass. These are two scenarios outside the 
scope of this study as it was not possible to know exactly which region of the tumour 
mass a sample was taken from or the exact clonal composition of the tumour sample.
In conclusion the author feels that the paediatric astrocytomas short-term cell cultures 
used in this study are representative of the tumour of origin as shown by the clustering 
of the cultures into 3 Groups, Groups 1 and 2 consisting of predominantly low grade 
tumours and Group 3 high-grade tumours. This is also strengthened by the increased 
number of CNA found in the cultures of Group 3, specifically the gain of chromosome 
7. The significantly disrupted profiles of each Group and to a greater extent in Group 3, 
has allowed the identification and characterisation of pathways and genes that maybe 
involved in tumour development in paediatric astrocytoma.
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CHAPTER 6 
SUMMARY AND CONCLUSIONS
Paediatric astrocytoma are the most common form of solid tumour in children and are 
classified by WHO guidelines into 4 grades of malignancy. PAI are most common in 
patients below 15 years of age, with the majority being located in the cerebellum. The 
10-year survival rate of children diagnosed with astrocytoma is approximately 90% for 
patients with grade I tumours, compared to only 15% for patients with malignant 
tumours. Current treatment regimes are not adequate for those patients with high-grade 
tumours and new more effective approaches are needed.
Little is known about the genetics of paediatric astrocytoma compared to their adult 
counterparts. This study has involved the characterisation of differential gene 
expression in paediatric astrocytoma, to further understand the genetics involved in 
tumour development. Clustering of paediatric PAI biopsies, according to expression 
profile similarity, showed that these tumours are significantly different from normal 
brain. Furthermore, clustering of paediatric astrocytoma short-term cell culture samples 
of various grades demonstrated that paediatric astrocytoma could be grouped into low 
and high-grade tumours by molecular signature. The tumours clustered into 3 clear 
Groups with Groups 1 and 2 consisting of predominately low-grade tumours and Group 
3 comprising mostly high-grade tumours. Furthermore, the tumours of Group 3 were 
also associated with increased CNAs, specifically gain of part or all of chromosome 7q 
and this was independent of tumour grade. However, only 20% of tumours showed 
whole chromosome or arms CNAs and this may have influenced this result, as well as 
the small number of AAIII.
The assessment of tumour biopsies and short-term cell cultures identified a large 
number of differentially expressed genes, which were further characterised according to 
GOs and cellular pathways. Pathways including the cell cycle, Wnt signalling, MAPK 
signalling and PI3K signalling were shown to be disrupted in paediatric astrocytoma. 
Key genes involved in these pathways and the role they could play in tumour 
development was also defined.
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Unsupervised hierarchical clustering of paediatric and adult short-term cell cultures 
revealed surprising results. A cluster of paediatric GBMIV integrated with the adult 
GBMIV, suggesting that these paediatric tumours may be more similar to their adult 
counter parts compared to other paediatric astrocytoma. Investigation of the expression 
profile identified a number of differentially expressed genes unique to this paediatric 
and adult astrocytoma cluster, which may be used to distinguish paediatric astrocytoma 
with a similar molecular profile to adult astrocytoma.
The most challenging part of this study was the use of both biopsy and short-term cell 
culture samples in the investigation of paediatric astrocytoma. It is the majority opinion 
that tumour tissue is the preferred material in the analysis of any tumour or cancer, 
however many functional studies require short-term cell cultures and cell lines. It is 
therefore important that the differences and similarities of tumour tissue and derived 
cells in culture are clear and understood. Cell culture does have an overall effect on 
gene expression without a doubt. However, short-term cell cultures do have a molecular 
profile that represents the tumour of origin. The results in this study using paediatric 
astrocytoma short-term cell cultures demonstrate that astrocytoma cells derived from 
tumours of various grades can generally be distinguished. The impact of in vitro cell 
culture influences all derived cells and therefore the molecular profiles from specific 
grades maintain a relationship similar to that expected when using astrocytoma biopsies. 
This is an over simplification to a certain extent, as tumour heterogeneity and the 
isolation of specific cell sub-populations during culture do impact the molecular profile. 
This study also highlighted that cell culture conditions influence adult GBMIV derived 
short-term cell culture expression profiles to a lesser extent than paediatric PAI short­
term cell culture profiles, but that the derived short-term cell cultures could be 
distinguished from the other by molecular profile.
The impact of cell culture on gene expression also means that biopsy and short-term cell 
cultures cannot be combined in the same experiment as biological or technical replicates 
of paediatric astrocytoma. The tumour samples can only be investigated and compared 
to other samples of the same source and controls unique to each sample source must be 
used. Furthermore, direct comparisons between the biopsy and derived short-term cell 
cultures from the same tumour are not possible, due to the impact of cell culture on gene 
expression. Moreover, because of the variation and difficulties encountered with
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controls and experiment analysis approaches in this study, comparisons between the 
differentially expressed genes identified in the biopsy and short-term cell culture 
experiments were felt to be inappropriate. This does not mean to say that any one 
experiment is better than the other, but that comparisons between the two are not 
feasible. It would be extremely valuable to carry out a parallel study generating 
expression profiles of both paediatric astrocytoma tissues and derived cell lines. This 
would allow more appropriate comparisons to be made between paediatric astrocytoma 
biopsy and short-term cell cultures of various grades.
Several aspects of this study have demanded careful attention and thought. The use of 
specific control samples in microarray experiments is usually dictated by the availability 
and access to controls sources. Appropriate controls should be investigated for each 
tumour or cancer type. However, lack of published studies in this area hinders control 
choices. The use of uniform standard controls for studies involving specific tumours or 
cancer would allow more comparisons to be made between studies. The controls chosen 
for the analysis of paediatric astrocytoma biopsies and short-term cell cultures in this 
study have dictated experimental design and to some extent the differentially expressed 
genes identified in paediatric astrocytoma. The use of controls in the identification of 
differently expressed genes, between so called ‘normal’ and ‘tumour’ samples has a 
direct influence on the generated gene list, as shown by Zom et al. (2003). All possible 
efforts were made in this study to obtain the best controls and where doubts were cast 
over controls, experimental analysis was adjusted.
The use of adult normal total brain as a control for PAI biopsy analysis was done so 
with some confidence. The controls showed reduced gene expression variability, 
associated with individuals, due to pooling and originated from young adults. 
Comparisons and justifications were carried out for the use of this control, with the only 
better alternatives being normal brain from a child or from the tumour patient. Two 
options which realistically are not possible. It has been suggested that astrocytes would 
be a suitable control for this type of analysis. However, with this approach the control 
would consist of a uniform cell population, a feature that is uncommon in any tumour.
As the pooled adult normal total brain control was compared to PAI biopsies that 
clustered tightly together and no other biopsies were available from other astrocytoma
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grades, it was felt appropriate to normalise the experiment to the control samples. This 
approach clearly highlights those genes that are differentially expressed compared to the 
controls.
It was felt to be inappropriate to compare astrocytoma short-term cell culture samples to 
normal brain tissue that had not been exposed to artificial cell culture conditions. 
However, the only alternative to this was cultured foetal astrocytes. Although this 
control has been exposed to artificial culture conditions, other sample parameters cause 
some concerns. This control is of foetal origin and as described when investigating the 
biopsy controls, the characteristics of foetal tissue, such as increased proliferation and 
reduced cell death are also associated with tumour growth and development. Moreover, 
only 2 sources of foetal astrocytes were available for this study.
As the foetal control was used in the investigation of paediatric astrocytoma short-term 
cell cultures with some caution, the experiment was not normalised directly to the 
controls. This allowed any comparisons made between tumour groups or grades, to be 
done so without the direct influence of controls, but also allowed comparisons to be 
made between the tumours and controls where appropriate. Moreover, the controls were 
effectively used as a baseline for some comparisons.
Another challenging aspect of this study was the analysis of 22000 gene expression 
results for every sample. Although tools in GeneSpring® can identify global gene 
expression profiles for each sample, isolate differentially expressed genes and cluster 
genes and samples accordingly; correlating these changes with tumour parameters and 
biologically significant patterns is still predominately determined by the investigator.
This requires a vast amount of database mining to characterise gene ontologies,
•  •  • functions and pathways. Furthermore, many of the analysis approaches in GeneSpring
correlate expression patterns of hundreds of genes, a number that cannot be reliably
investigated by database mining. Consequently in this study, differentially expressed
genes were investigated by pathway or GOs to focus the analysis and where appropriate,
key genes were further characterised by database mining. This allowed biologically
relevant differential gene expression to be characterised in paediatric astrocytoma.
Moreover, a molecular profile could not be linked to tumour or patient parameters,
which is often the hypothesis in many studies.
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It is understood that this not the only way to investigate this data set and in the hands of 
a different investigator, other biologically significant pathways or gene expression 
patterns may have been identified. Moreover, from this aspect, this data can be re­
analysed at any time with an alternative hypothesis. This is also a positive feature of this 
technology and future expression patterns or genes, identified as significant in paediatric 
astrocytoma development, can be investigated in this sample cohort. It is also important 
to note that no software programme exists that can identify differential gene expression, 
define gene function, chromosome location and relevant information, accurately predict 
pathway involvements and alterations, highlight common biological processes and 
correlate all of this information into an overall result. Furthermore, CNAs or any other 
mechanism that may be relevant, also needs to be taken into consideration by any 
analysis software. Whilst this information is still correlated by the investigator it will be 
extremely difficult to understand the overall picture.
CNAs were extensively investigated in the paediatric astrocytoma of this study. All 
tumours showed single clone alterations, with specific tumours exhibiting multiple 
alterations of large chromosomal regions. Many of the single clone alterations were 
located in regions of known LCV in the normal population. Correlation of differential 
gene expression in these small regions of alteration was not always possible due to lack 
of reliable gene expression data. However, several candidate genes in regions of 
alteration in PAI biopsies were identified including, BCL7B at 7q 11.23; SH3GL2 at 
9p21.2-p23; BCL7A at 12q24.33; DRD1IP at 10q26.3; FOXG1B at 14ql2; and TUBG2 
and CNTNAP1 at 17q21.31. In the short-term cell cultures comprised of all astrocytoma 
grades, candidate genes including COL11A1 at l p l3.3; FOXG1B at 14ql2; IDI1 at 
1 Op 15.3; EPHA2 at lp35.1 and ANXA8 at lOq 11.22 were identified in 10 or more 
tumours. Although no reliable expression data was available for the genes located at 
19pl3.2; 16pll.2; 7p21; and 7ql 1.23, these regions have previously been associated 
with CNAs in other types of cancer. Moreover, single clone alterations at 14ql2 and 
7q 11.23 were identified in both paediatric astrocytoma biopsy and short-term cell 
culture samples.
The detection of a large number of single clone alterations in specific tumours at regions 
of LCV, does suggest that these alterations may not be linked to tumour development. 
Moreover, if  the alterations occur in a region of LCV at a higher frequency than that of
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the normal population, this suggests that some LCV may predispose individuals to 
tumour development, such as alterations at 14ql2.
In the biopsy and short-term cell culture studies investigating paediatric astrocytoma 
CNAs, the different grades involved in each experiment may have influenced the clone 
alteration frequencies. For example, loss at 14ql2 was found in 82% of paediatric PAI 
biopsy samples, compared to gain in 28% and loss in 19% of paediatric astrocytoma 
short-term cell cultures of various grades. If biopsy samples had been available from 
additional grades, 14ql2 alterations may have occurred at different in this experiment.
The resolution of aCGH has also been questioned with the theoretical sensitivity being 
estimated at 2.65Mb, the single-copy sensitivity being estimated at 2.65Mb and 
breakpoint precision being estimated at 4.55Mb (Coe et al., 2007). Essentially single 
copy alterations of approximately 50kb are detected in 15% of cases using the 
SpectralChip 2600, compared to alterations of approximately 500kb that are detected in 
50% of cases. This is due to the BAC clone size and distribution along the genome, 
which is not uniform. Oligonucleotide based approaches are more sensitive detecting 
both 50kb and 500kb alterations in approximately 95% of cases (Coe et al., 2007). 
Recent experience in our laboratory has suggested that aCGH does not efficiently detect 
small regions of alteration in specific samples and that SNP arrays may be a more useful 
technique if small regions of alteration need to be clearly defined.
The dye swap approach completed in each aCGH experiment does provide confidence 
in single clone alteration detection in the paediatric astrocytoma samples of this study. 
However, it is essential that these alterations are validated using a different technique, 
such as SNP arrays or fluorescent in situ hybridisation (FISH), before any further 
investigations are completed.
Alterations of between 2 and 4 clones were identified in specific tumours and correlated 
with differential gene expression. From these results, it was hypothesised that 
differential gene expression at these loci may provide specific tumours with selective 
advantages. In total, 7 tumours showed whole chromosome and arm alterations in the 
paediatric astrocytoma short-term cell cultures. The majority of these tumours clustered 
in Group 3. Furthermore, differential gene expression that correlated with large CNAs
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could be divided into two groups. Firstly, a large number of the differentially expressed 
genes correlated with the signature of 4682 probe sets that could distinguish the 3 
tumour culture Groups. Secondly, those genes differentially expressed that did not 
correlate, had functions associated with tumour development and/or a function that 
could provide a specific tumour with a selective advantage, such as chemoresistance. 
This highlights tumour heterogeneity and a mechanism through which it may occur.
The most common whole chromosome or arm alteration seen in the tumours of this 
study was gain of part or all of 7q. This correlated with differential gene expression 
previously linked to tumour development, including astrocytoma. Moreover, gain of 
part or all of chromosome 7q has been previously associated with reduced patient 
survival.
The use of the reference control in the aCGH experiment has raised one question. The 
sex mismatch approach was recommended by the manufacturer for aCGH, in which the 
opposite sex DNA to the sex of the tumour patient is used as the reference control. 
However, it was felt that this may have hindered the investigation of sex chromosome 
alterations in the paediatric astrocytoma of this study and that it may have been more 
appropriate to adopt the sex paired approach, in which the same sex DNA to the sex of 
the tumour patient is used as the reference control. By using the sex mismatch approach 
the X chromosome was always shown as gained or lost. Whilst this was helpful for 
experimental analysis, it did not allow analysis of single clone or small regions of 
alteration that may have been present on the X chromosome, with the analysis 
approaches used here.
The large amount of unreliable gene expression results generated by the Affymetrix 
GeneChip® U133A was also very frustrating. Ultimately this reduced the number of 
correlations that could be made with CNAs. Technology has improved since the start of 
this project and the Affymetrix GeneChip® Plus 2 array is now available investigating 
approximately 50,000 gene sequences, in the future correlations between differential 
gene expression and CNAs may be more efficient. To ultimately determine whether 
gene expression is influenced by CNAs, all genes must be investigated along with every 
base pair in the genome, a tall order.
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Affymetrix GeneChip® technology is designed to investigate global gene expression 
patterns and whilst reliable, this technology relies on experimental design. The 
investigation of brain tumours using this technology would only reach its full potential 
if multiple and repeated tumour sampling could be completed. This approach may be 
used to monitor tumour molecular changes associated with malignant progression or 
growth and tumour responses to treatment that may aid treatment regimes. Overall, 
multiple sampling of tumours would also improve characterisation of tumour regions, 
molecular profiles linked to astrocytomas in specific age groups and rare astrocytomas 
associated with unusual characteristics such as prolonged or reduced prognosis.
The survival data for patients in this study is some what compromised. Tumours 
involved in this study have been collected over a period of approximately 25 years. This 
has lead to significant variations in tissue collection procedures, patient diagnosis, 
patient treatment regimes and overall prognosis. Consequently, the survival data was 
not directly used in this study for statistical. Another tumour parameter significantly 
affected by the tumours being collected over a number of years is the grade at diagnosis. 
The review of tumour initial diagnosis according to the 2007 WHO grading scheme, re­
graded 39% of the cases investigated. This did not affect the paediatric astrocytoma 
biopsy experiment, as all these tumours were PAI. However, in the paediatric short-term 
culture experiment, all reviewed DAII were re-graded as PAI and additional specific 
changes were also seen. Moreover, the new diagnoses according to the 2007 WHO 
grading scheme does correlate better with the tumour clusters according to molecular 
profile. Furthermore, a study in 2000, established that tumour diagnosis concordance 
between various neuropathologists was as low as 40% (Prayson et al., 2000). This raises 
the question of human error in tumour diagnosis and whether molecular profiling would 
be more efficient. However, there are undoubtedly difficulties in this approach on a 
global scale including, tumour sampling, tissue processing, experiment standardisations, 
characterisation of molecular profile features associated with various tumour and patient 
parameters and essentially cost.
Overall, these data remain descriptive with the aims of identifying novel candidate 
target genes and characterizing cellular pathways that are involved in paediatric 
astrocytoma development and growth. Future functional studies are needed to evaluate
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these findings in paediatric astrocytoma but as discussed, evidence supports a role for 
these candidate genes and pathways in tumourigenesis.
The overall conclusions of this study are that paediatric astrocytoma biopsies and short­
term cell cultures can be used in the investigation of this tumour, but they cannot be 
directly compared and specific controls for each experiment must be used. Young adult 
normal total brain is a reliable control for the biopsy experiment although if a paediatric 
normal total brain sample was available this may be more appropriate. Foetal astrocytes 
were an acceptable control for the short-term cell culture experiment, but comparisons 
between other culture controls such as adult astrocytes would have strengthened this 
control choice.
It was not possible to identify expression profiles or molecular signatures of any tumour 
or patient parameters, mainly because of the sample numbers. When tumour location or 
patient age was investigated, no molecular profile could be identified with confidence 
that distinguished sub-groups within these parameters. Correlations between grade and 
molecular profile were improved after diagnoses review.
Molecular pathways involved in paediatric astrocytoma development could be clearly 
identified, with pathway alterations in Group 3 characterising a more malignant tumour. 
CNAs were identified in paediatric astrocytoma that did correlate with differential 
expression and could be a mechanism disrupting gene expression. However, gene 
promoter methylation was not found to be involved in differential gene expression.
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CHAPTER 7 
FUTURE WORK
To expand this study investigating paediatric astrocytoma validation of CNAs and 
differential gene expression in regions of interest would first need to be completed. 
Moreover, this approach may also include genes in regions of CNA that did not have 
reliable expression data. Gene expression validations could be completed by Q-PCR 
analysis and CNAs through SNP arrays, FISH or m-FISH (multiplex fluorescent in situ 
hybridisation) analysis. SNP arrays have a higher resolution compared to aCGH and use 
an oligonucleotide based approach (Coe et al., 2007). This technique may also define 
the regions of interest further.
FISH is a physical mapping approach that uses fluorescent tags to detect the 
hybridization of probes with metaphase chromosomes. In this case, specific probes 
complementary to regions of CNAs of interest would be used. Furthermore, m-FISH 
can be used to identify simple and complex translocations, interstitial deletions and 
insertions, chromosomal aneusomies and double minutes. The technique uses 
combination labelling with between 1-5 fluorochromes for each chromosome, providing 
every chromosome with a specific spectral signature. Both latter approaches allow 
single cell analysis, compared to total sample analysis adopted by aCGH or SNP arrays 
and may highlight tumour heterogeneity as well as common alterations.
Aspects of this study may need to be refined for future work in order to reduce 
variability between tumour samples and also generate a wider picture of tumour 
molecular profiles. Multiple biopsies of a single tumour have been used to investigate 
variations in tumour molecular profile at different tumour sites, including tumour core 
and periphery (Van et al., 2006). The same approach has also been used to investigate 
variations in gene mutations within tumour regions, including the frequency and 
variability of TP53 mutations in a single tumour (Watanabe et al., 1997a). 
Unfortunately, this approach requires imaging and surgical approaches that may be 
difficult to implicate, given that material currently received is surplus to diagnosis.
Microdissection is another approach previously used to investigate histophorically 
different tumour regions, as well as specific regions such as proliferating stromal blood 
vessels, within a given sample. This technique allows the selection of tumour cells by
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region or type prior to investigation with further techniques such as aCGH or FISH. 
This allows the exact location/frequency of specific alterations within individual tumour 
regions or cells to be characterised (Romeike et al., 2001; Kulla et al., 2003; Wemmert 
et al., 2006).
A large number of single clone alterations in the tumours of this study were found in 
regions of LCVs that occur in the normal population. It was not possible to determine 
whether the CNAs found within the tumours, where also somatic alterations. Paired 
patient blood DNA is available for the majority or tumours investigated and it would be 
valuable to identify those clones that are altered in the tumour only compared to germ 
line controls, as well as alterations that occur in both tumour and germ line DNA at a 
higher frequency than the normal population. This may identify DNA variants in the 
normal population that could predispose individuals to tumour development, such as the 
CNA identified at 14ql2 (Braude et al., 2006). A similar approach has been carried out 
in GBMIV (Balakrishnan et al., 2007).
3D cell culture models are being investigated as a more appropriate approach to 
studying tumour cell behaviour in vitro. It has been suggested that cells cultured in a 3D 
environment are more representative of tumour cells in vivo. The paediatric astrocytoma 
short-term cell cultures studied here are a valuable resource and the use of 3D culture 
environments could be an essential step in the study of these tumours, given the limited 
availability of biopsy material. This approach has already been described using 
malignant breast epithelial cells (Lee et al., 2007a).
A limiting factor in this study is the number of tumours available for investigation. This 
is a reflection of the rarity of this tumour, preventing the analysis of parameters such as 
patient age or tumour location and specific molecular signatures. Furthermore, 
validation of the tumour clusters seen here could not be completed on an independent 
tumour group as the samples and funding were not available. Guidelines for array 
experiments with respect to platform and controls would allow more comparisons 
between tumours of different studies, although this would be difficult to implement. 
Moreover, it would be particularly valuable if this study could be on-going and include 
any newly diagnosed paediatric astrocytoma. Overtime, this would increase experiment 
numbers allowing a more detailed analysis and validation of initial conclusions.
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Tumour grade was a difficult parameter to investigate in this study. The initial grading 
criteria used to diagnose these tumours, was outlined by the WHO prior to 2003. 
However, due to the new WHO grading scheme released in 2007 the initial diagnosis of 
the majority of tumours was reviewed in August 2007. A large proportion of the initial 
diagnoses were altered to correlate with the new grading scheme. This raises several 
questions regarding tumour grading according to histological criteria and how to 
approach the continuous review of the criteria used to define each astrocytoma grade. 
This also highlights the need for a tumour molecular profile based diagnostic approach, 
in conjunction with histopathological grading and current immunohistochemical 
staining. From the experience gained during this report, all tumour diagnoses should be 
reviewed prior to the start of a study and when new guidelines are issued. Changes are 
inevitable that may influence analysis approaches and conclusions.
Many of the tumours investigated in this study showed only single clone alterations, 
suggesting that additional mechanisms are involved in the development of specific 
paediatric astrocytoma. MSP was used to investigate specific genes commonly 
methylated in other tumour types. However, promoter region methylation was not 
identified in any of the astrocytomas investigated here. Furthermore, the methylation 
status of MGMT has been linked to treatment response to temozolomide, highlighting 
this significant mechanism in tumour growth and development. To fully investigate this 
mechanism in paediatric astrocytoma, a combined approach of pharmacologic inhibition 
of DNA methylation and histone deacetylation involving 5-aza-2'-deoxycytidine and 
trichostatin A treatment, coupled with expression microarrays, could identify global 
methylation patterns distinct to normal controls. This is already being investigated in 
adult GBMIV (Kim et al., 2006).
To continue the work compiled in this study, genes with strong evidence that suggests a 
role in tumour development, could be investigated further in expression manipulation 
studies. This may define cellular response and clarify the role of specific genes in 
paediatric astrocytoma with the aim of generating therapeutic targets. Candidates for 
investigation would include genes differentially expression in regions of CNAs, genes 
showing large changes in expression compared to controls and differentially expressed 
genes involved in a large number of pathways. Similar studies have already been 
completed including the use of retroviral constructs and adenoviral expression
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constructs to investigate the influence of tyrosine kinase pyk2 on GBMIV cell migration 
(Lipinski et al., 2005). Furthermore, siRNA directed against the unique exon 1/exon 8 
junction sequence of the most frequently occurring EGFR mutation in astrocytoma 
efficiently suppresses the expression of the mutant receptor in rodent fibroblasts and 
two human glioblastoma cell lines. siRNA-mediated depletion of the mutant EGFR led 
to reduced levels of phosphorylated Akt in glioma cells, that was associated with 
increased apoptosis and partial cell cycle arrest in the G2M phase (Fan and Weiss, 
2005).
Overall, the multiple CNAs and differential gene expression identified in this study 
suggest that many relevant pathways are involved in tumour predisposition and 
development, although establishing the exact role of each CNA or differentially 
expressed gene identified was beyond the scope of this study. Moreover, the 
characterisation of a larger number of differentially expressed genes and CNAs in the 
tumour cultures of Group 3, which consists predominately of high-grade cultures, may 
suggest that multiple sequential alterations have occurred in these tumours compared to 
the tumours of Group 1 and 2. This is also seen in the progression of adult astrocytoma 
from DAII to GBMIV with the accumulation of specific alterations and differential 
expression (Figure 1.8).
A nation wide study of somatic DNA from patients diagnosed with a paediatric 
astrocytoma could identify and confirm the role of specific LCVs in astrocytoma 
predisposition. This approach would also validate the role of CNAs at 14ql2 and the 
resulting differential expression of FOXG1B, suggested in this study, in the 
predisposition of paediatric astrocytoma. No doubt distinct alterations predispose 
different individuals to tumour development. Multiple biopsy samples taken from 
patients at diagnosis and at multiple time points thereafter would allow CNA and 
differential expression to be investigated as the tumour develops. This would establish 
which CNA and gene expression alterations are involved in early tumour development 
compared to the latter stages. Additional studies including those previously mentioned 
investigating methylation status and epigenetic disruption would define the involvement 
of these mechanisms in tumour development at specific stages. This approach is not 
novel and was initially investigated by Cavenee et al. (1991). However, this approach
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would need to be carried out routinely and encompass a large number of patients to 
establish significant alterations at specific stages of tumour development.
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APPENDIX I
Reagents and buffers
M edia
The cell culture media was made up in batches of 9, 500ml volumes of Hams F10 
nutrient mix with 10% FCS. Initially, 9 Hams F10 bottles were labelled A-I and allowed 
to reach room temperature. Universals were also labelled A-I and FCS. 5ml of FCS was 
pipetted into the correct universal. In turn 55ml of FCS was pipetted into a bottle of 
Hams F10, the bottle mixed and 10ml transferred to the correct universal. The media 
was then stored at 4°C until needed. The universals were incubated at 37°C for 3 days to 
ensure no contamination had occurred.
Antibiotics
The final concentration of antibiotics required per ml of media was as follows; 
penicillin/Streptomycin lOOU/lOOpg per ml, kanamycin 50pg/ml, amphotericin 
2.5pg/ml. To a 1.5ml tube, 0.5ml of the penicillin/Streptomycin original solution 
(10,000U/10mg per ml), 25pi of the amphotericin original solution (5mg/ml) and 
0.25ml of kanamycin original solution (lOmg/ml) were added. The antibiotic mix was 
stored in at -20°C. When needed the mix is added to 50ml of media to reach the correct 
concentration
Biopsy tissue collection media
Media without FCS containing antibiotic at the previous concentration described was 
used to collect the biopsy samples from theatre. Therefore, 1 tube of antibiotic mix 
(previously described) was added per 50ml of FCS free media.
Agilent -d y e  preparation
To prepare the gel-dye mix, 0.4ml of gel mix was placed in the provided filter and 
centrifuged at 4000rpm for 10 minutes. From the elution, 1 30jlx1  was add to 2 p i  of 
concentrated RNA dye and vortexed thoroughly. The gel-dye mix was used within 1 
week and the gel mix was used within 1 month as recommended by the manufacturer.
D EPC-treated w ater
lml of diethylpyrocarbonate (DEPC) was added to 1L of water. This was then shaken 
vigorously, autoclaved and stored at room temperature.
NaCL
1M = 58.44g/L
For 3M NaCL and 5M NaCL, 17.53g and 29.22g were dissolved in 100ml DEPC- 
treated water respectively. The solutions were then autoclaved and stored at room 
temperature.
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0.5M Na2EDTA Stock
186.12g o f disodium ethyenediaminetetraacetate was dissolved in 800ml DEPC-treated 
water. The pH was adjusted to pH8.0 with NaOH and the total volume made up to 1L. 
This was autoclaved and stored at room temperature.
50x TAE buffer
242g o f Tris was added to 500ml of DEPC-treated water. 100ml of 0.5M Na2EDTA and 
57.1ml of glacial acetic acid was added and the total volume adjusted to 1L. This was 
autoclaved and stored at room temperature.
Ethidium brom ide stock
The stock solution concentration was lOmg/ml. This was made by adding lg of 
ethidium bromide to 100ml of DEPC-treated water. This was stirred until the dye 
dissolved and stored in the dark at room temperature.
DNA loading dye
Prepared in DEPC-treated water; 50% glycerol, 0.25% xilene cyanol, 0.25% 
bromophenol blue and 1% SDS. This was stored at -20°C.
RNA loading dye
Prepared in DEPC-treated water; 50% glycerol, 0.4% bromophenol blue and ImM 
Na2EDTA . This was then stored at -20°C.
Qiagen kit buffers
The majority o f Qiagen buffers were already prepared. However, buffer RPE was 
supplied as a concentrate and the correct volume of absolute ethanol was added before 
use. This amount depended on the kit being used, p-mercaptoethanol was added to 
buffer RLT before use at lOpl per 1ml.
Buffer Cl (cell lysis buffer)
1.28M sucrose; 40mM Tris-Cl; 20mM MgCl2; 4% Triton X-100.
Initially, 438.14g sucrose, 406g MgCl2 and 4.84g Tris base was dissolved in 680ml 
DEPC-treated water and 42g of Triton X-100 (100%) added. The pH was adjust to pH 
pH7.5 and the volume made up to 1L with DEPC-treated water.
Buffer G2 (digestion buffer)
800mM guanidine-HCl; 30mM Tris-Cl; 30mM EDTA; 5% Tween-20; 0.5% Triton X- 
100.
Initially, 76.42g guanidine-HCl, 11.17g Na2EDTA and 3.63g Tris base was dissolved in 
600ml DEPC-treated water and 250ml of 20% Tween-20 solution and 50ml of 10% 
Triton X-100 solution was added. The pH was adjusted to pH 8 and the volume made 
up to 1L with DEPC-treated water.
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Buffer QBT (equilibration buffer)
750mM NaCl; 50mM MOPS; 15% isopropanol; 0.15% Triton X-100.
Initially, 43.83g NaCl and 10.46g MOPS was dissolved in 800ml DEPC-treated water. 
The pH was adjusted to pH 7 and 150ml of pure isoprpanol and 15ml of 10% Triton X- 
100 added. The volume was then made up volume to 1L with DEPC-treated water.
Buffer QC (wash buffer)
1M NaCl; 50mM MOPS; 15% isopropanol.
Initially, 58.44g NaCl and 10.46g MOPS was dissolved in 800ml DEPC-treated water. 
The pH was adjusted to pH 7 and 50ml of pure isopropanol added. The volume was 
made up to 1L with DEPC-treated water.
Buffer QF (elution buffer)
1.25M NaCl; 50mM Tris-Cl; 15% isopropanol.
Initially, 73.05g NaCl and 6.06g Tris Base were dissolved in 800ml DEPC-treated 
water. The pH adjusted to pH 8.5 and 150ml pure isopropanol added. The volumewas 
made up to 1L with DEPC-treated water.
Sample clean-up module buffers
The majority o f Sample Clean-up Module buffers were already prepared. However, 
cDNA binding buffer was supplied as a concentrate and 24ml of absolute ethanol was 
added before use.
lO M N aO H
Initially, 4g o f NaOH was dissolved in 10ml DEPC-treated water. For 1M, lOOpl of the 
10M solution was added to 900pl of DEPC-treated water. For 3M, 150|al of the 10M 
solution was added to 350pl of DEPC-treated water.
1 OmM Hydroquinone
Initially, 0.220g was dissolved in 20ml of DEPC-treated water.
3M  sodium bisulfite
Initially, 3.183g o f sodium bisulfite was dissolved in 9.5ml of DEPC-treated water and 
360pl NaOH added before making the final volume up to 10ml.
10XM SP buffer
This was made up according to the Table below._________
_______________ Volume (ml) IPX Stock
1M Ammonium Sulfate 8.3 16.6mM
1M Tris/HCL 33.5 67mM
1M MgCL2 3.35 6.7mM
p-Mercaptoethanol (14.3M) 0.35 lOmM
Total Volume 50
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12.5mM NTP
This was made up according to the Table below.
Volume (pil)
lOOmM dATP 12.5
lOOmM dCTP 12.5
lOOmM TTP 12.5
lOOmM GTP 12.5
DEPC-treated water 50
Total Volume 100
12X MES stock buffer
64.61 g of MES hydrate and 193.3g of MES sodium salt were added to 800ml of DEPC- 
treated water. The pH was checked to ensure that it was between pH6.5-6.7 and the 
volume adjusted to 1L. This was then stored at 4°C.
2X  hybridisation buffer
8.3ml of 12X MES stock buffer was added to 19.9ml of DEPC-treated water. 17.7ml of 
5M NaCL was then added followed by 4ml 0.5M EDTA and 0.1ml of 10% Tween-20 to 
give a final volume of 50ml. This was then stored out of direct sunlight at 4°C.
Wash buffer A: non-stringent wash buffer
For a 1L final volume, 300ml of 20X SSPE was added to 699ml of DEPC-treated water 
and 1ml of 10% Tween-20. This was then stored out of direct sunlight at 4°C.
Wash buffer B: stringent wash buffer
For a 1L final volume, 41.7ml of 12X MES stock buffer was added to 910.5ml of 
DEPC-treated water along with 5.2ml 5M NaCL, and 1ml of Tween-20. This was then 
stored out of direct sunlight at 4°C.
2X  stain buffer
For a final volume of 250ml, 41.7ml of 12X MES stock buffer was added to 113.3ml of 
DEPC-treated water, along with 92.5ml of %M NaCL and 2.5ml of 10% Tween-20. 
This was then stored out of direct sunlight at 4°C.
lOmg/ml G oat IgG  stock
50mg of goat IgG was resuspended in 5ml of 150mM NaCL and stored at 4°C.
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Antibody solution
The antibody solution was made up as shown in the table below and used the same day.
Components Volume Final Concentration
2X Stain Buffer 300pl IX
50mg/ml BSA 24pl 2mg/ml
lOmg/ml Goat IgG Stock 6pl 0.1 mg/ml
0.5mg/ml Biotinylated Antibody 3.6pl 3pg/ml
DEPC-Treated Water 266.4pl -
Total Volume_________________600pl
SAPE stain solution
Streptavidin Phycoerythrin (SAPE) solution was made up as shown in the table below, 
stored at 4°C foil wrapped and used the same day.
Components Volume Final Concentration
2X Stain Buffer 600pl IX
50mg/ml BSA 48pl 2mg/ml
1 mg/ml SAPE 12pl lOpg/ml
DEPC-Treated Water 540pl -
Total Volume 1200pi
Assays-On-Dem and -  A pplied  Biosystems
CCNAEHs 00171105_ml 
SPINT2: Hs 00173936_ml 
MAPK1: Hs 00177066_ml 
MATK: Hs 00176738_ml 
TIM PEHs 00171558 m l 
M CLEH s 00172036_ml
2OX SSC (saline-sodium -citrate buffer)
Initially, 175.3g of sodium chloride and 88.23g of tri-sodium citrate was dissolved in 1L 
of DEPC-treated water.
0.2XSSC
50ml of 20X SSC was added to 450ml DEPC-treated water.
2XSSC, 0.5%  SDS
Initially, 2.5g of SDS (sodium dodecyl sulphate) was dissolved in 12.5ml DEPC-treated 
water. This was added to 437.5ml DEPC-treated water and 50ml 20X SSC.
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2XSSC, 50% deionised formamide
250ml of deionised formamide was added to 200ml DEPC-treated water and 50ml 20X 
SSC.
2XSSC, 0.1%  igepal
Initially, 1ml o f igepal was dissolved in 4ml DEPC-treated water. 2.5ml of this solution 
was added to 447.5ml DEPC-treated water and 50ml 20X SSC.
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Supplier information
Product
Plastics
Chemicals 
Total RNA Samples 
Total RNA Samples
Total RNA Samples
Normal Human Astrocytes 
RNase AWAY 
RNeasy Column Kits
TRIzol
QIAamp® DNA Mini Kit 
Proteinase K 
Protease
Supplier
Scientific Laboratory Supplies, Wilford Industrial
Estate, Nottingham, NG11 7EP. UK
www.scientific-labs.com
Triple Red Ltd, Unit D4 Drakes Park, Long
HP 18 9BA. UK www.triplered.com
Sigma Aldrich, Fancy Rd, Poole, Dorset, BH12 
4QH. UK www.sigmaaldrich.com
ams Biotechnology, 63B Milton Park, Abingdon, 
Oxon, 0X14 4RX. UK www.amsbio.com
United States Biological, P.O. Box 261, 
Swampscott, Massachusetts 01907.
www.usbio.net
BD Biosciences Clontech, 1020 East Meadow 
Circle, Palo Alto, CA 94303-4230. 
www.bdbiosciences.com
Cambrex Bio Science, Rockland, ME USA. 
www.cambrex.com
Molecular BioProducts Inc. San Diedo, CA 
www.mbpinc.com
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9 A. UK
www.qiagen.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9A. UK
www.qiagen.com
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9A. UK
www.qiagen.com
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9A. UK
www.qiagen.com
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Qiagen Genomic-tips 100/G
Hams F10 Nutrient Mix
Foetal Bovine Calf Serum
Trypsin EDTA
Ispton II
Coulter Counter
Glass Pasteurs 
Primers
Taq Polymerase
Ultrapure dNTP set
Filter Pipette Tips
(RNase/DNase free)
Thermal Cycler 
T7 Oligo(dT) Primer
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9A. UK 
www.qiagen.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Beckman Coulter Counter Ltd, Kingsmead 
Business Park, High Wycombe, HP 11 1JU. UK 
www.beckmancoulter.com
Beckman Coulter Counter Ltd, Kingsmead 
Business Park, High Wycombe, HP 11 1JU. UK 
www.beckmancoulter.com
Fisher Scientific UK, Bishops Meadow Rd, 
Loughborough, LEI 1 5RG. UK www.fisher.co.uk
Amersham Bioscience, Amersham Place, Little 
Chalfont, Bucks, HP7 9NA. UK
www5 .amershambiosciences.com
Promega, Delta House, Enterprise Rd, Chilworth 
Research Centre, Southampton, S09 1BG. UK 
www.promega. com
Amersham Bioscience, Amersham Place, Little 
Chalfont, Bucks, HP7 9NA. UK
www5 .amershambiosciences.com
Fisher Scientific UK, Bishops Meadow Rd, 
Loughborough, LEI 1 5RG. UK www.fisher.co.uk
Genetic Research Instrumentation (GRI) Ltd, 
Gene House, Queensborough Lane, Braintree, 
Essex, CM7 8TF. UK www.gri.co.uk
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
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Superscript Choice System
GeneChip Sample Cleanup Module
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
GeneChip® Human Genome U 133A Affymetrix Inc, 3380 Central Expressway, Santa
Clara, CA. www.affymetrix.com
GeneRuler™100bp DNA Ladder MBI Fermantas, (Helena Biosciences Europe), 
Colima Avenue, Sunderland Enterprise Park, 
Sunderland, SR5 3XB. UK www.fermantas.com.
Enzo Bioarray High Yield RNA 
Transcript Labeling Kit
RNA Centaury Marker
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
Ambion Ltd, Ermine Business Park, Spitfire 
Close, Huntingdon, Cambridgeshire. PE29 6XY. 
UK www.ambion.com
QuantiTect Reverse 
Transcription Kit
Assays-on-Demand™
Herring Sperm DNA
GeneChip Eukaryotic
Hybridisation Control Kit
R-Phycoerythrin Streptavin
Phosphate Buffered Saline
Mineral Oil
20X SSPE
Qiagen, Boundard Court, Gatwick Rd,
Crawley, West Sussex, RH10 9A. UK 
www.qiagen.com
Applied Biosystems, 850 Lincoln Centre Drive, 
Foster City, CA. 94404.
www.appliedbiosystems.com
Promega, Delta House, Enterprise Rd, Chilworth 
Research Centre, Southampton, S09 1BG. UK 
www.promega. com
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
Molecular Probes, (Invitrogen Ltd), 3 Foundation 
Drive, Inchianan, Renfrewshire, PA9 9FR. UK 
www.probes.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www. invitrogen. com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
Cambrex Bio Science, Rockland, ME USA. 
www.cambrex.com
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Goat IgG, Reagent Grade
Anti-streptavidin Antibody (Goat) 
Biotinylated.
Fluidics Station 450
GeneChip scanner 3000.
GeneSpring version 6.1
Plasmocin™
Myco Alert™
Kanamycin 
Amphotericin 
Penicillin/Streptomycin 
Polyclonal Rabbit anti-GFAP 
Polyclonal Goat anti-Rabbit 
Vectastin® ABC method
3,3’-diaminobenzidine (DAB) 
HistClear
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
Vector Laboratories Ltd, 3 Accent Park, Bakewell 
Road, Orton Southgate, Peterborough, PE2 6XS. 
UK www.vectorlabs.com
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
Affymetrix Inc, 3380 Central Expressway, Santa 
Clara, CA. www.affymetrix.com
Silicon Genetics, 2601 Spring Street, Redwood 
City, CA 94063 www.silicongenetics.com
Autogen Bioclear UK Ltd, Holly Ditch Farm, Mile 
Elm Caine, Wiltshire, SN11 OPY. UK 
www.autogenbioclear.com
Cambrex Bio Science, Rockland, ME USA. 
www.cambrex.com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
DakoCytomation, Produktionsvej 42, DK-2600, 
Denmark www.dakocytomation.com
DakoCytomation, Produktionsvej 42, DK-2600, 
Denmark www.dakocytomation.com
Vector Laboratories Ltd, 3 Accent Park, Bakewell 
Road, Orton Southgate, Peterborough, PE2 6XS. 
UK www.vectorlabs.com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
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D.P.X
Centrifuge (Biofuge Pico)
Centrifuge (Wifug 500E)
Class II Laminar Flow Cabinet 
Fume Cabinet (Astecair 500E) 
Luminometer (Mediators PhL)
0.5M EDTA
Superfrost slides
Wizard® DNA Clean-Up System
PureLink™ Quick Gel 
Extraction Kit
Sequnencing and Reaction Buffer
Montage™ PCR Centrigugal 
Filter Devices
Spectrophotometer (GeneQuant)
Sigma Aldrich, Fancy Rd, Poole, Dorset BH12 
4QH. UK www.sigmaaldrich.com
DJB Labcare, 20 Howard Way, Interchange 
Business Park, Newport Pagnell, Bucks, MK16 
9QS UK www.djblabcare.co.uk
DJB Labcare, 20 Howard Way, Interchange 
Business Park, Newport Pagnell, Bucks, MK16 
9QS. UK www.djblabcare.co.uk
Valeant Plaza, 3300 Hyland Drive, Costa Mesa, 
California 92626. USA www.valeant.com
Bioquell UK Ltd, 34 Walworth Road, Andover, 
Hants, SP10 5AA. UK www.bioquell.com
Aureon Biosystems GmbH, Simmeringer 
Hauptstr. 24 A-1110 Vienna / Austria
www.aureonbio.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Fisher Scientific UK, Bishops Meadow Rd, 
Loughborough, LEI 1 5RG. UK www.fisher.co.uk
Promega, Delta House, Enterprise Rd, Chilworth 
Research Centre, Southampton, S09 1BG. UK 
www.promega. com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Applied Biosystems, 850 Lincoln Centre Drive, 
Foster City, CA. 94404.
www.appliedbiosystems.com
Millipore, 290 Concord Road Billerica, MA. 
01821
USA. www.millipore.com
Pharmacia Biotech, Amersham Bioscience, 
Amersham Place, Little Chalfont, Bucks, HP7 
9NA. UK www5.amershambiosciences.com
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SpectralChip™ 2600 arrays
Cy3-dCTP and Cy5-dCTP
Spectral Hybridisation Buffers
Bioprime Labelling Kit
Dessiccator
Hybridisation Chamber 
22X60mm Coverslips
Axon 4000A Scanner
Gene PixPro version 6.1
Formatter Software
Human Genomic DNA
GE Healthcare UK Ltd, Amersham Place, Little 
Chalfont, Buckinghamshire, HP7 9NA. UK.
www.gehealthcare.com
GE Healthcare UK Ltd, Amersham Place, Little 
Chalfont, Buckinghamshire, HP7 9NA. UK.
www.gehealthcare.com
GE Healthcare UK Ltd, Amersham Place, Little 
Chalfont, Buckinghamshire, HP7 9NA. UK.
www.gehealthcare.com
Invitrogen Ltd, 3 Foundation Drive, Inchianan, 
Renfrewshire, PA9 9FR. UK
www.invitrogen.com
Nalge Company, A Subsidiary of Sybron 
Corporation, P.O.Box 20365, Rochester, NY, 
14602-0365. USA.
Coming Life Sciences, Koolhovenlaan, 12 NL- 
1119, NE Schiphcl-RIJK, The Netherlands.
Electron Microscopy Sciences, P.O.Box 550, 1560 
Industry Road, Hatfield, PA, 19440. USA 
www.emsdiasum.com
Molecular Devices Corporation, 1311 Orleans 
Drive, Sunnyvale, CA, 94089-1136, U.S.A. 
www.moleculardevises.com
Molecular Devices Corporation, 1311 Orleans 
Drive, Sunnyvale, CA, 94089-1136, U.S.A. 
www.moleculardevises.com
Digital Scientific UK, Sheraton House, Castle 
Park, Cambridge, CB3 OAX. UK 
www. digital scientific .co. uk
Promega, Delta House, Enterprise Rd, Chilworth 
Research Centre, Southampton, S09 1BG. UK 
www.promega. com
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APPENDIX II
Patient treatment regimes and survival for the paediatric astrocytoma of this
study.
IN1 Treatment2 Survival3
1350 Macroscopic removal Unknown
1520 Partial excision, radiotherapy DIS 112(A)
1524 Macroscopic removal, VP shunt 13(A)
1591 Craniotomy, partial excision 60 (D)
1740 Macroscopic removal 160(A)
2017 Macroscopic removal 124(A)
2110 Macroscopic removal DIS 125 (A)
2122 Partial excision, radiotherapy, VP shunt DIS 78 (A)
2356 Macroscopic removal 142 (A)
2368 Macroscopic removal DIS 87 (A)
2524 Macroscopic removal DIS 39 (A)
2604 Unknown Unknown
2631 Surgery 21(A)
2674 Macroscopic removal 112(A)
2688 Craniotomy, macroscopic removal 55 (A)
2788 Macroscopic removal 45 (A)
2825 Surgery x2, cranial radiotherapy 104(A)
2921 Macroscopic removal, LGG (wait & see) 48 (A)
2940 Macroscopic removal, LGG (wait & see) 74 (A)
2969 VP shunt, Macroscopic removal, LGG (wait & see) 57(A)
3013 Craniotomy, subtotal removal, LGG (wait & see) 58(A)
3017 Craniotomy, sub total removal, LGG (wait & see) 59(A)
3115 VP shunt, debulking, LGG (wait & see) 33 (A)
3126 Subtotal Removal (x3), Radiotherapy, craniotomy (x2) 31(A)
3156 Surgery 1(A)
380 Macroscopic removal, radiotherapy 92 (D)
1145 Macroscopic removal 60 (A)
1751 Craniotomy, macroscopic removal, VP shunt, radiotherapy 63(A)
1869 Craniotomy, partial excision, radiotherapy 139 (A)
1930 Temporal lobectomy 53 (A)
2012 Partial excision, radiotherapy 145 (D)
2044 Craniotomy, macroscopic removal DIS 18(A)
2102 Partial excision, radiotherapy 67 (A)
3032 Partial excision, radiotherapy, VP shunt, craniotomy for debulking 12(D)
2003* Macroscopic removal, craniotomy 117(A)
2591* Radiotherapy 117(A)
178” Unknown 3(D)
179” Unknown 3(D)
699 Stereotactic biopsy Unknown
1163 Craniotomy, macroscopic removal DIS 153 (A)
1262 Removal (extent unknown), radiotherapy 12(A)
1419** Partial excision, radiotherapy 12(D)
1495 Removal (extent unknown) 80 (A)
1523 Unknown 33 (D)
1566 Partial removal 7(A)
2087 Craniotomy, partial excision, cranial radiotherapy (D)
2675 Craniotomy, partial excision, chemo (combined), cranial radiotherapy 16(D)
3046 Partial excision, radiotherapy 14(D)
2435 Unknown Unknown
2731 Unknown Unknown
2810 Unknown Unknown
1760 Unknown 12(D)
1265 Unknown 15(D)
1528 Unknown 7(D)
2234 Unknown Unknown
IN1: Institute o f  Neurology assigned number; Treatment2: LGG = low-grade glioma protocol; BB = baby 
brain protocol (Appendix II); Survival3; survival in months from the data o f diagnosis, A = alive; D = 
deceased. DIS = Patient has been discharge; * and “ = tumours from the same patient; ** = patient 
diagnosed with Turners Syndrome (partial or complete loss o f  chromosome X).
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Clinical Protocols for the treatment of patients in this study.
Baby brain pro toco l (UKCCSG CNS 9204)
This protocol was used to treat patients below 3 years of age with malignant 
astrocytoma. After surgery, patients received vincristine, carboplatin, methotrexate, 
cyclophosphamide and cisplatin over a 43 day cycle with a maximum of 7 cycles, a total 
treatment time of 379 days.
Dose schedule: Vincristine
Carboplatin 
Methotrexate 
Cyclophosphamide 
Cisplatin
Low-grade gliom a study 
This protocol was used to treat patients with low-grade astrocytoma. After surgery 
patients underwent one of two arms of treatment in this study. The first arm was the 
“wait and see” arm, in which patients only had further treatment if they had residual 
bulky disease, initial symptoms were not relieved by surgery or if recurrence or tumour 
progression occurred. The second arm o f the study was the “treatment” arm, in which 
patients received carboplatin and vincristine. Initial treatment lasted 10 weeks with 
administration of vincristine on the first day of each week and carboplatin in weeks 1, 4, 
7 and 10. After a 2 week recovery period, vincristine and carboplatin were administered 
together in weeks 13, 17, 21, 25, 29, 33, 37, 41, 45 and 49. Doses were reduced by 33% 
for patients 6 months of age or less.
Dose schedule: Carboplatin
Vincristine
550mg/m2 x 1 
1.5mg/m2 x 1
1.5mg/m x 1 
550mg/m2 x 1 
8g/m2
1500mg/m2 x 1 
40mg/m2 x 1
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Additional Protocols
M etaphase spread  preparation
From a stock solution of lOpg/ml, 42pl of colcemid was added to a 75cm3 flask of 80% 
confluent cells and incubated at 37°C for 2-3 hours. The flask content was pipetted into 
a sterile universal and centrifuge at 1500rpm for 5 minutes to collect the pellet. Initially, 
the flask was trypsinised as previously described, the 10ml of media containing the cells 
added to the pellet and the universal was centrifuged at 1500rpm for 5 minutes. The 
supernatant was removed, the pellet transferred to a falcon tube and 10ml of 0.3% 
sodium chloride (NaCL) added. This solution was incubated at room temperature for 30 
minutes.
Once incubated, the flacon tube was centrifuged at 1500rpm for 5 minutes, the 
supernatant removed, 10ml of fix (75% methanol, 25% acetic acid) added and the 
solution incubated for 5 minutes. The mixture was centrifuged at 1500rpm for 5 minutes 
and the step repeated twice with an incubation of 30 minutes. The final pellet was 
resuspended in 1ml of fix. Superffost slides (Fisher Scientific, UK) were placed in 
absolute alcohol for a minimum of 2 minutes, removed, allowed to air dry and labelled. 
One drop of the fix/cell solution was dropped onto the centre of the slide, the slide 
flooded with fix after 10 seconds and allowed to dry.
Giemsa Stain (Sigma Aldrich) was used to stain the slide involving a 10 minute 
incubated at room temperature. The slide was rinsed using distilled water and allowed to 
air dry. Metaphase spreads were evaluated using light microscopy. Any remaining 
fix/cell solution was stored at -20°.
Glial fib rilla ry  acidic protein  staining
Cells were grown on coverslips in 24 well plates until confluent. The cells were then 
fixed in para for 30 minutes, followed by two 5 minute washes in IX phosphate 
buffered saline (PBS) in preparation for staining. The fixed coverslips were washed 
with IX PBS and 0.1% Triton for 15 minutes, followed by blocking in IX PBS, 3% 
normal goat serum and 5% powdered milk for 1 hour. The coverslips were washed 
twice with IX PBS and 0.1% triton for 5 minutes, and with IX PBS for a further 5 
minutes. The primary anti-body (polyclonal rabbit anti-GFAP, DakoCytomation) was 
applied to the coverslips over night at a dilution of 1:100 in IX PBS. The coverslips
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were washed twice as previously described. The secondary-biotinylated antibody 
(polyclonal goat anti-rabbit, DakoCytomation) diluted 1:100 in IX PBS, was applied to 
the coverslips and incubated for 2 hours. The coverslips were incubated in standard 
ABC solution for 1 hour (Vectastin® ABC method, Vector Laboratories) followed by 3 
washes with IX PBS each for 5 minutes. To stain the coverslips, 3,3’-diaminobenzidine 
(DAB) solution (SIGMAFAST™ DAB tablets, Sigma Aldrich) was applied and removed 
as soon as brown colouration was observed. The coverslips were washed 3 times with 
IX PBS for 5 minutes, washed consecutively in 70% alcohol, 90% alcohol and twice in 
absolute alcohol. Two final washes were carried out in HistClear (Sigma Aldrich) for 2 
minutes, before the coverslips were removed from the 24 well plates and mounted on 
clean slides using D.P.X (Sigma Aldrich). The extent of cell staining was evaluated 
using light microscopy.
This Figure illustrates the staining of GFAP in GP-9, a sample of foetal astrocytes.
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APPENDIX III
The genes found in Figure 3.7 of Chapter 3 in dendrogram order.
The green lines are in the same place as those shown on the dendrogram o f Figure 3.7.
Gene Nam e Description Chromosome
Location
ABL1 v-abl Abelson murine leukaemia viral oncogene homolog 1 9q34.1
PPP1R15A protein phosphatase 1, regulatory subunit ISA 19ql3.2
TGFB1 transform ing growth factor, beta 1 19ql 3.2
PPP6C protein phosphatase 6, catalytic subunit 9q34.11
RHOQ ras-like protein TC10 2p21
CDC23 CDC23 (cell division cycle 23, yeast, homolog) 5q31
KPNA2 karyopherin alpha 2 17q23.1-q23.3
CHC1 chrom osome condensation 1 lp36.1
FLJ42280 Deleted in split-hand/split-foot 1 region 7q21.3-q22.1
KPNA2 karyopherin alpha 2 17q23.1-q23.3
KIAA0010 ubiquitin-protein isopeptide ligase (E3) 7q36.3
TP53 tum or protein p53 (Li-Fraumeni syndrome) 17pl3.1
CDCA4 cell division cycle associated 4 14q32.33
CUL5 cullin 5 11q22-q23
PLEKHC1 mitogen inducible 2 14q22.1
IRF1 interferon regulatory factor 1 5q31.1
NBL1 neuroblastom a, suppression o f  tumorigenicity 1 Ip36.3-p36.2
NEK 9 N IM A  (never in mitosis gene a)- related kinase 9 14q24.2
FGF2 fibroblast growth factor 2 (basic) 4q26-q27
AHR aryl hydrocarbon receptor 7pl5
CDC37L1 H sp90-associating relative o f  Cdc37
LTBP2 latent transforming growth factor beta binding protein 2 14q24
MN1 m eningiom a (disrupted in balanced translocation) 1 22ql2.1
UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 20ql3.2
M APK6 mitogen-activated protein kinase 6 15q21
NHP2L1 N HP2 non-histone chromosome protein 2-like 1 22ql3.2-ql3.31
SH3BP4 SH3-domain binding protein 4 2q37.1-q37.2
EXT2 exostoses (multiple) 2 1lp l2 -p l 1
UBE2V1 ubiquitin-conjugating enzyme E2 variant 1 20ql3.2
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, C ip l) 6p21.2
RECK reversion-inducing-cysteine-rich protein with kazal motifs 9 p l3 -p l2
PLEKHC1 mitogen inducible 2 14q22.1
HK2 hexokinase 2 2pl3
CDK7 cyclin-dependent kinase 7 5ql2.1
PPP6C Homo sapiens protein phosphatase 6, catalytic subunit 9q34.11
MAPK7 m itogen-activated protein kinase 7 17pl 1.2
SRPK1 SFRS protein kinase 1 6p21.3-p21.2
CDC16 CDC16 cell division cycle 16 homolog 13q34
S100A6 S I00 calcium binding protein A6 1 q 2 1
PLAGL1 pleiomorphic adenoma gene-like 1 6q24-q25
CPR8 cell cycle progression 8 protein
7q21.3ASNS asparagine synthetase
QSCN6 quiescin Q6 lq24
EXT1 exostoses (multiple) 1 8q24.1 l-q24.13
MARS DNA-damage-inducible transcript 3 12q 13.1 -q 13.2
CDC16 CDC16 cell division cycle 16 homolog (S. cerevisiae) 13q34
CHFR checkpoint with forkhead and ring finger domains 12q24.33
PTEN phosphatase and tensin homolog 10q23.3
GAK cyclin G associated kinase 4 p l6
RPS4X ribosomal protein S4, X-linked Xql3.1
RFP2 ret finger protein 2 13ql 4
FH fumarate hydratase lq42.1
AXL AXL receptor tyrosine kinase 19q l3.1
STAT1 signal transducer and activator o f  transcription 1, 91kDa 2q32.2
CPR8 cell cycle progression 8 protein 15q21.1
TCF7L2 transcription factor 7-like 2 10q25.3
ANKHD1 FLJ20288 protein 5q31.3
FHIT fragile histidine triad gene 3pl4.2
BIN1 bridging integrator 1 2ql4
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ATM ataxia telangiectasia mutated (includes complementation groups A, C and D) Ilq22-q23
NHP2L1 NHP2 non-histone chromosome protein 2-like 1 22ql3.2-q 13.31
BCL2 B-cell CLL/lym phoma 2 18q21.3
PNUTL2 peanut-like 2 (Drosophila) 17q22-q23
BTG2 BTG family, member 2 lq32
KIAA1009 KIAA 1009 protein 6ql5
CDC10 CDC10 cell division cycle 10 homolog 7pl4.3-pl4.1
PARD6A par-6 partitioning defective 6 homolog alpha 16q21
CUL3 cullin 3 2q36.3
RAN RAN, m em ber RAS oncogene family 6p21
HDAC4 histone deacetylase 4 2q37.2
Homo sapiens p58/GTA protein kinase mRNA, complete cds.
CDKN2C cyclin-dependent kinase inhibitor 2C ( p i8, inhibits CDK4) lp32
GAS7 growth arrest-specific 7 17p
RGC32 RGC32 protein 13ql3.3
CSK c-src tyrosine kinase 15q23-q25
CDC7 CDC7 cell division cycle 7-like 1 (S. cerevisiae) lp22
RALGDS ral guanine nucleotide dissociation stimulator 9q34.3
CEB1 cyclin-E binding protein 1 4q22.1-q23
ANKHD1 FLJ20288 protein 5q31.3
CCND3 cyclin D3 6p21
ANKRD15 kidney ankyrin repeat-containing protein 9p24.3
PCAF p300/CBP-associated factor 3p24
TERF2 telom eric repeat binding factor 2 16q22.1
CTCF C CCTC-binding factor (zinc finger protein) 16q21-q22.3
TERF1 telomeric repeat binding factor (NIMA-interacting) 1 8q 13
CDK2AP1 CDK2-associated protein 1 12q24.31
RGS2 regulator o f  G-protein signalling 2, 24kDa 1 q31
RALGDS ral guanine nucleotide dissociation stimulator 9q34.3
AIF1 allograft inflammatory factor 1 6p21.3
NME1 non-m etastatic cells 1, protein expressed in 17q21.3
M CM 5 M CM 5 minichromosome maintenance deficient 5 22ql3.1
DUSP6 dual specificity phosphatase 6 12q22-q23
CCND2 cyclin D2 12pl3
R BI retinoblastoma 1 (including osteosarcoma) 13ql4.2
GPR21 rab6 GTPase activating protein 9q34.11
RBBP6 retinoblastom a binding protein 6 16pl2-pl 1.2
GSPT1 G1 to S phase transition 1 16p 13.1
NRAS neuroblastom a RAS viral (v-ras) oncogene homolog lp l3 .2
PCNA proliferating cell nuclear antigen 20pter-pl2
M CM2 M CM 2 minichromosome maintenance deficient 2, mitotin 3q21
M CM6 M CM 6 minichromosome maintenance deficient 6 2q21
CCNB2 cyclin B2 15q21.2
MELK maternal embryonic leucine zipper kinase 9p 13.1
CCNB1 cyclin B 1 5ql2
UBE2C ubiquitin-conjugating enzyme E2C 2 0 q l3 .1 1
MAD2L1 M AD2 mitotic arrest deficient-like 1 4q27
F2R coagulation factor II (thrombin) receptor 5ql3
CDK2 cyclin-dependent kinase 2 12ql3
CHEK1 CHK1 checkpoint homolog (S. pombe) Ilq24-q24
CENPF centromere protein F, 350/400ka (mitosin) Iq32-q41
HIRA H IR histone cell cycle regulation defective homolog A 22ql 1.21
CDC5L Homo sapiens KIAA0432 mRNA, partial cds. 6p21
PPAT phosphoribosyl pyrophosphate amidotransferase 4 q l2
PKMYT1 tyrosine- and threonine-specific cdc2-inhibitory kinase 16pl 3.3
MCC m utated in colorectal cancers 5q21-q22
PRKDC protein kinase, DNA-activated, catalytic polypeptide 8ql 1
TOPBP1 topoisom erase (DNA) II binding protein 3q22.1
RAD21 RAD21 homolog (S. pombe) 8q24
RBBP8 retinoblastom a binding protein 8 18ql 1.2
GMNN geminin, DNA replication inhibitor 6p22.1
ORC5L origin recognition complex, subunit 5-like (yeast) 7q22.1
MCM3 MCM3 minichromosome maintenance deficient 3 6pl2
MCM7 M CM 7 minichromosome maintenance deficient 7 7q21.3-q22.1
CDC10 CDC10 cell division cycle 10 homolog 7 p l4 .3 -p l4 .I
PDGFA platelet-derived growth factor alpha polypeptide 7p22
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 8q 11.1
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APPENDIX IV
Presentations and pending publications 
Awards
I was awarded additional funding in the 3 rd year of my PhD from the Arthur and 
Mildred Slater Award UCL.
Conference Presentations
Queen Square Symposium -  Institute of Neurology, 12th March 2004
♦ Poster presentation -  Identification of aberrantly expressed genes in different 
grades of paediatric astrocytoma.
British Neuro-Oncology Society Conference -  Telford, 23rd-25th June 2004
♦ Poster presentation -  Identification of aberrantly expressed genes in different 
grades of paediatric astrocytoma.
>  Awarded runner up for best scientific presentation.
tliQueen Square Symposium - Institute of Neurology, 15 March 2005
♦ Poster presentation - Reduced survival of paediatric patients with atypical low 
grade astrocytoma is associated with a gain in chromosome 7q.
>  Awarded top 8 position for scientific presentation.
thBritish Neurosurgical Research Group Meeting -  NHNN, London, 17 March 2005
♦ Oral presentation - Reduced survival of paediatric patients with atypical low 
grade astrocytoma is associated with a gain in chromosome 7q.
World Federation of Neuro-Oncology Conference -  Edinburgh, 4th-8th May 2005
♦ Poster presentation -  Genes that promote cell growth are aberrantly expressed in 
pilocytic astrocytoma. The abstract was published in Neuro-oncology.
Queen Square Symposium - Institute of Neurology, 14th March 2006
♦ Poster presentation - Down-regulation of PRDM2, SPINT2, DAPK1, CCNA1, 
REPR1MO and CDKN1C  is not caused by promoter hypermethylation in paediatric 
pilocytic astrocytoma.
British Neuro-oncology Society Meeting -  Institute of Child Health London, 21st -23rd 
June 2006.
♦ Poster presentation - Down-regulation of PRDM2, SPINT2, DAPK1, CCNA1, 
REPRIMO and CDKN1C  is not caused by promoter hypermethylation in paediatric 
pilocytic astrocytoma.
♦ Oral presentation - Identification of aberrantly expressed genes in different 
grades of malignancy in paediatric astrocytoma.
Society for Neuro-oncology — Orlando Florida, 16th -19th November 2006.
♦ Poster presentation - Abnormal gene expression can be linked to chromosome 
gains and losses in a number of paediatric astrocytomas.
Pending Publications
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As a result of the work I have completed during my PhD I have 1 manuscript that has 
been accepted for publication in Neoplasia entitled:
• Genomic deletions correlate with under-expression of novel candidate genes at 6 
loci in paediatric pilocytic astrocytoma
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